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Abstract 
Metastasis and drug resistance present as major problems to patients during cancer 
chemotherapy.  The research outlined in this thesis aims to further our knowledge about the 
molecular mechanisms involved in these processes and the relationship between drug resistance 
and cancer invasion and/or metastasis.   
One explanation for the link between resistance and metastasis is that resistance facilitates 
tumour progression and invasion into both surrounding and distal tissues.  Investigations were 
conducted on a clonal sub-population of poorly differentiated human lung squamous carcinoma 
cells (DLKP).  These were pulsed with mitoxantrone and the resulting cell populations 
extensively characterised.  Two sub-lines emerged: SQ-Mitox-BCRP and SQ-Mitox-MDR cell 
lines.  These two cell lines typically exhibited resistance to the selecting agent (ranging approx. 
210 to 320-fold).  This occurred as an early event during the pulsing process.  The two sublines 
differed in their morphology and pattern of gene expression.  In addition, BCRP was significantly 
increased in one population (SQ-Mitox-BCRP) while P-gp was significantly increased in the 
other population (SQ-Mitox-MDR).   
A crucial step in human lung cancer progression appears to be the acquisition of invasiveness.  
The population of cells arising from the 4th drug pulse remained noninvasive but had acquired a 
high level of drug resistance.  However, after two additional drug pulses, all cell lines acquired 
invasiveness.  The invasive, drug resistant BCRP and MDR cell line variants were characterised 
in depth and microarray analysis was used to find functionally significant changes in the 
transition from the preinvasive to the invasive phenotype.  Functional and cellular signaling 
analyses were performed on the cell lines using pharmacological inhibitors, function-blocking 
antibodies, and gene silencing by RNA interference.   
The DLKP cell line appears to contain at least three morphologically distinct sub-populations of 
cells with different levels of invasiveness.  Microarray analysis generated gene lists that were 
specific to an invasive phenotype, identifying possible genetic markers for invasion.  Proteins 
(including the cell adhesion molecules, N-cadherin and ALCAM and the axon guidance molecule 
SLIT2) were also identified as possible and alternative markers capable of distinguishing 
between the different cell line clones.   
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CHAPTER 1 
 
A comprehensive literary review.   
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1.1  Lung cancer 
1.1.1  Lung Cancer:the clinical problem 
Unfortunately, lung cancer is the most common cause of cancer-related death in Ireland and 
indeed the world.  Lung cancer was the single most common cause of cancer death in Ireland in 
2011, with a total of 1,848 deaths, just over one-fifth of all cancer deaths1.  In the United States 
in 2007, there were 203,536 people diagnosed with lung cancer and of this number, 158,683 
people died from the disease2.  Despite the advances in platinum-based chemotherapy3, lung 
cancer remains the most frequent cause of cancer-related mortality worldwide4 and has a 5-year 
overall survival (OS) rate of just 16% for all stages.   
 
1.1.2  Pathogenesis and classification 
Lung cancer is a disease characterised by un-controlled cell growth in the tissues of the lung.  If 
left untreated, this growth can spread beyond the lung in a process called metastasis into nearby 
tissues or more distally to other parts of the body.  Most cancers that arise in the lung, known as 
primary lung tumours, are carcinomas that derive from epithelial cells.  Lung cancers can be 
histologically classified into two main groups, non small cell lung cancer (NSCLC) and small 
cell lung cancer (SCLC) – with 80% of cases falling into the first group and the remaining 20% 
into the second group5.   
The most common cause of lung cancer is long-term exposure to tobacco smoke, which causes 
80 – 90% of all incidences6.  Nonsmokers account for 10 – 15% of lung cancer cases, and these 
cases are often attributed to a combination of genetic factors, exposure to radon gas, asbestos 
fibres (in the rare case of mesothelioma), and air pollution, including second-hand smoke7.  Since 
only approximately 20% of smokers develop lung cancer6, it is believed that some people are 
more susceptible to the carcinogens in tobacco than others.  Lung cancer, it may be argued, is one 
of the easiest cancers to prevent, but remains one of the most difficult to treat.   
In small-cell lung carcinoma (SCLC), the cells contain dense neurosecretory granules (vesicles 
containing neuroendocrine hormones), which give this tumour an endocrine/paraneoplastic 
syndrome association5.  These tumours are normally centrally located and are strongly associated 
with smoking.  Relapse is very common, even after an initial, successful response to treatment8.  
They grow quickly and spread early in the course of disease.  Sixty to seventy percent of patients 
typically have metastatic disease at clinical presentation.   
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There are three main subtypes of non small cell lung cancer (NSCLC) – (1.) adenocarcinoma, 
(2.) squamous-cell lung carcinoma, and (3.) large-cell lung carcinoma9 (figure 1-1).  Nearly 55% 
of lung cancers are adenocarcinoma, which usually originates in peripheral lung tissue9.  Most 
cases of adenocarcinoma are associated with smoking; however, among people who have 
smoked fewer than 100 cigarettes in their lifetimes ("never-smokers"), adenocarcinoma is the 
most common form of lung cancer10.  A subtype of adenocarcinoma, the bronchioloalveolar 
carcinoma (BAC), is more common in female never-smokers and eastern Asians, and may have a 
better long term survival11 relative to other forms of non-small cell lung cancer, especially when 
it is caught early and only one tumour is present.   
 
 
 
Figure 1-1:  Small cell carcinoma is usually the most aggressive type of lung cancer with the poorest 
prognosis. Thus, often patients are told they have small cell carcinoma or non-small cell carcinoma, 
combining the three non-small cell types together, as they are relatively less aggressive.  The only way 
to distinguish between these types of lung cancer is by a tissue biopsy.   
 
Squamous cell carcinomas account for approximately 30% of all lung cancers and they are 
typically centrally located12,13.  They are very common in Europe, and are often accompanied by 
the late development of distant metastasis9.  Generally, NSCLC is associated with a poor 
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prognostic outcome and, despite surgery being the first line of treatment, approximately 70% of 
patients present with unresectable disease14.   
 
1.1.3  Treatment of lung cancer 
The objective in cancer treatment is to control or eradicate the tumour and prevent its spread.  
Treatment for lung cancer can involve surgical removal, chemotherapy, or radiation therapy, as 
well as combinations of all these treatments.  Despite huge developments in cancer treatment in 
the last few years, the outcome for many patients with advanced disease is still not promising.   
Surgical removal of the tumour is generally performed for limited-stage (stage I or sometimes 
stage II) NSCLC and is the treatment of choice for cancer that has not spread beyond the lung9.  
About 10% to 35% of lung cancers can be removed surgically, but removal does not always 
result in a cure, since the tumours may already have spread and can recur later.  Among people 
who have an isolated and slow-growing lung cancer removed, 25% to 40% are still alive 5 years 
after diagnosis.   
 
1.1.3.1  Chemotherapy in the management of lung cancer 
Many single anti-cancer agents have activity against NSCLC and these include cisplatin, 
carboplatin, paclitaxel, docetaxel, vinorelbine and gemcitabine; however, a modest increase in 
response rates is seen with combinations of these drugs with platinum derivatives to form the 
standard care15.  Paclitaxel or docetaxel in combination with cisplatin have been recommended as 
an option in the first-line treatment of advanced NSCLC.  However, response rates are often low 
due to the increasing development of resistance to the cytotoxicity of these drugs by the tumour 
cells being targeted.   
Chemotherapy is the treatment of choice for most SCLC since these tumours are generally 
widespread in the body when they are first diagnosed.  Only half of the people who present with 
SCLC survive for greater than four months without chemotherapy.  With chemotherapy, their 
survival time is increased up to four- or five-fold.  Several drugs are primarily used for the 
treatment of SCLC and include; cisplatin, carboplatin VP-16, cyclophosphamide, adriamycin, 
vincristine, lomustine and ifosfamide.  Although combination therapy has shown good response 
rates, the median survival time of SCLC patients remains low.  The most frequent combination 
therapy in the treatment of SCLC is etoposide and cisplatin8,14,16.   
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Despite progress in the development of drugs that target unique cancer-specific pathways, 
traditional chemotherapeutics still yield significant survival advantages in many instances and so 
continue to be the tools that form the first line of defence used in the clinic.   
 
1.1.3.2  Novel therapies in the management of lung cancer NSCLC 
Modern treatment strategies focus on the pathological classification of NSCLC, which includes 
the assessment of protein expression by immunohistochemistry (IHC) to identify the presence of 
cell differentiation markers such as TTF1 and p63 (the splice variant p40).  Also involved is the 
detection of molecular predictive markers, including validated driver mutations in genes 
associated with cell growth and survival17 (figure 1-2).  However, lung cancer is a heterogenous 
disease and it can display a great number of genetic aberrations within different tumours18.  Lung 
cancers develop through a multistep process involving development of multiple genetic and 
epigenetic alterations, particularly activation of growth promoting pathways and inhibition of 
tumour suppressor pathways19.   
 
Figure 1-2:  Evolving genomic classification of NSCLC.  Li et al., (2013)20.   
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Characterisation of the molecular changes in lung cancer is becoming increasingly well-defined, 
helped by the continued advancement of both clinical and genomic tools.  Figure 1-3 shows the 
major signalling pathways implicated in lung cancer21.  These stimulatory signalling pathways 
are led by oncogenes, which drive cells towards a malignant phenotype, promoting proliferation 
and escape from apoptosis.  Mutated oncogenic proteins cause an “addiction” of tumour cells to 
their abnormal functions, a concept referred to as “oncogene addiction”22.   
 
 
Figure 1-3:  A major signalling pathway implicated in lung cancer is the EGFR pathway which 
signals to both the AKT/PI3K pathway (green) and the MAPK pathway (red) which regulate cell 
growth, proliferation and cell death.  There is significant cross-talk between these pathways and their 
downstream effectors, which may be classified into six pathways for simplicity to account for 
differences in treatment modalities.  The additional four pathways are: EGFR (blue), KRAS (yellow), 
EML4-ALK (orange), and P53/BCL (purple).  It is thought that the RAS/RAF/MEK/MAPK pathway 
may be constitutively activated by the EML4-ALK fusion oncogene.  The complex relationship 
between this pathway and EML4-ALK is indicated with a dashed line.  (From West et al., 201221) 
 
It has been shown that EGFR overexpression is most frequent in squamous (84%), large cell 
(68%) and adenocarcinoma (65%) with very little expression in SCLC23.  Mutations and 
amplification of EGFR are common in non-small-cell lung cancer and provide the basis for 
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treatment with EGFR-inhibitors.  The Ras/mitogen-activated protein kinase and PI3K/Akt 
pathways are major signalling networks linking EGFR activation to cell proliferation and 
survival.  Activation of the RAS/RAF/MEK/MAPK pathway occurs frequently in lung cancer, 
most commonly via activating mutations in KRAS which occur in ~20% of lung cancers, 
particularly adenocarcinomas 24, 25.  In lung cancer, 90% of mutations are located in KRAS (80% 
in codon 12, and the remainder in codons 13 and 61), with HRAS and NRAS mutations being 
only occasionally documented18.   
Mutation results in constitutive activation of downstream signalling pathways, such as PI3K and 
MAPK, rendering KRAS mutant tumours independent of EGFR signaling and therefore resistant 
to EGFR TKIs as well as chemotherapy.  KRAS mutations are mutually exclusive with EGFR 
and ERBB2 mutations and are primarily observed in lung adenocarcinomas of smokers18.   
Lung cancer mutations have also been identified in BRAF and the parallel phosphatidylinositol 
3-kinase (PI3K) pathway oncogenes and more recently in MEK and HER2 while structural 
rearrangements in ALK, ROS1 and possibly rearranged during transfection (RET) provide new 
therapeutic targets.  The roles of tumour suppressor genes are increasingly recognised with 
aberrations reported in TP53, PTEN, RB1, LKB11 and p16/CDKN2A.  Identification of 
biologically significant genetic alterations in lung cancer that lead to activation of oncogenes and 
inactivation of tumour suppressor genes has the potential to provide further therapeutic 
opportunities19.   
Genetic instability: Chromosomal aberration and loss of heterozygosity 
Cells possess checkpoint pathways important for genome stability and preventing cancer.  Like 
many solid tumours, genomic instability is a hallmark of lung cancer.  Amplification is a 
mechanism for the activation of oncogenes such as MET in adenocarcinoma, fibroblast growth 
factor receptor 1 (FGFR1) and discoidin domain receptor 2 (DDR2) in squamous cell carcinoma 
(SCC).  Intriguingly, many of these genetic alternations are associated with the smoking status of 
a population and also with particular racial and gender differences, which may provide further 
insights into the mechanisms of carcinogenesis and the role for various host factors in the 
development of lung cancer and its progression26.  Chromosomal damage can lead to a loss of 
heterozygosity, i.e. a gross chromosomal event that results in the loss of the entire gene and the 
surrounding chromosomal region.  This can cause inactivation of tumour suppressor genes.  
Damage to chromosomes 3p, 5q, 13q, and 17p are particularly common in small-cell lung 
carcinoma.  Additionally, genetic alterations in several genes have been implicated in the 
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development of lung cancer and include the activation of MYC, RAS, EGFR, NKX2-1, ERBB2, 
SOX2, BCL2, FGFR2, and CRKL as well as inactivation of RB1, CDKN2A, STK11 and 
FHIT318.   
P53 
The many roles of the protein p53 as a tumour suppressor include the ability to induce cell cycle 
arrest, DNA repair, senescence, and apoptosis, to name only a few27.  In humans, the TP53 gene 
is reported to be mutated in approximately 50% of non-small-cell lung cancer cases and more 
than 70% of small-cell lung cancers28.  The majority of these mutations are missense, resulting in 
the expression of a full-length p53 protein which is compromised in its ability to bind directly to 
DNA and activate anti-proliferative and pro-apoptotic target genes.  Tobacco smoke is one of the 
best-known and studied mutagen mixtures involved in lung carcinogenesis, and TP53 mutational 
patterns differ between smokers and nonsmokers, with an excess of G to T transversions in 
smoking-associated cancer29,30.  These particular transversions, which are uncommon in most 
cancers with the exception of hepatocellular carcinoma (HCC), is found to be associated with 
specific carcinogenic agents.  The most prominent carcinogens in tobacco smoke, polycyclic 
aromatic hydrocarbons (PAHs) and especially benzo(a) pyrene, were found to be able to form 
DNA adducts in the coding region of the TP53 gene.  In addition, there is a correlation between 
the mutational hotspots of TP53 in lung cancer (at codons 154, 157, 158, 245, 248, and 273) and 
the hotspots of adducts formation by PAHs in tobacco smoke.   
Targeted lung cancer treatments in current use 
More recently, targeted therapies have shown promise in the treatment of NSCLC (table 1-1).  
The drugs erlotinib (Tarceva) and gefitinib (Iressa) are so-called targeted drugs, which may be 
used in certain patients with NSCLC who are no longer responding to chemotherapy31.  Targeted 
therapy drugs more specifically target cancer cells, resulting in less damage to normal cells than 
general chemotherapeutic agents.  Erlotinib and gefitinib target the epidermal growth factor 
receptor.  Cetuximab, a monoclonal antibody added to first-line chemotherapy has been shown to 
improve survival in patients with high epidermal growth factor receptor (EGFR) expression in 
their tumours32.   
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Table 1-1. Current molecular targets in adenocarcinoma 
Target  Prevalence (%) Therapeutic agents 
EGFR Asians ∼40;  
Caucasians ∼10 
Erlotinib, gefitinib, afatinib 
ALK < 5 Crizotinib 
HER2 < 3 Afatinib, neratinib, dacomitinib 
PIK3CA < 5 GDC-0941, XL-147, BKM120 
BRAF < 5 Vemurafenib, GSK2118436 
MEK ∼1 AZD6244 
ROS1 ∼2 Crizotinib 
RET ∼2 Sunitinib, sorafenib, vandetanib, cabozantinib 
MET 1–11 Onartuzumab, rilotumumab, cabozantinib, tivantinib, crizotinib 
FGFR1 ∼3 AZD4547, S49076, ponatinib, brivanib 
PTEN < 10 Vandetanib 
PD-1/PD-L1 ∼30 Nivolumab, MPDL3280A 
NaPi2b ∼70 DNIB0600A (early development) 
ALK, anaplastic lymphoma kinase; EGFR, epidermal growth factor receptor; FGFR1, fibroblast growth factor receptor 1; PD-
L1, interaction of programmed death ligand 1; PIK3CA, phosphatidylinositol 3-kinase, catalytic subunit alpha.  From Shames 
and Wistuba 201433 
 
Other attempts at targeted therapy include drugs known as anti-angiogenesis drugs, which block 
the development of new blood vessels within a tumour.  Without adequate blood vessels to 
supply oxygen-carrying blood, the cancer cells will die.  In this regard, the VEGF pathway has 
become an important therapeutic target in lung cancer.  The antiangiogenic drug bevacizumab 
(Avastin) which targets VEGF has also been found to prolong survival in advanced lung cancer 
patients when it is added to the standard chemotherapy regimen34.  This demonstrates the use of 
VEGF as a target for therapy.   
Crizotinib also shows benefit in a subset of non-small cell lung cancer that is characterised by the 
EML4-ALK fusion oncogene, found in some relatively young, never or light smokers with 
adenocarcinoma35.   
 
1.1.4  Chemotherapy resistance 
A major obstacle in the use of chemotherapy for cancer treatment is the development of 
resistance.  Consequently, a better understanding of the mechanisms of drug resistance would 
help to overcome this obstacle.  Intrinsic and acquired drug resistance are believed to result in 
treatment failure in over 90% of patients with metastatic cancer36.  Resistance constitutes a lack 
of response to drug-induced tumour growth inhibition; it may be inherent in a subpopulation of 
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heterogeneous cancer cells or be acquired as a cellular response to drug exposure.  Principal 
mechanisms include: (1) altered membrane transport involving the P-glycoprotein product of the 
multidrug resistance (MDR) gene as well as other associated proteins; (2) altered target enzyme 
(e.g. mutated topoisomerase II); (3) decreased drug activation; (4) increased nuclear receptor 
activation; (5) increased drug metabolism and elimination due to altered expression of 
cytochrome P450 enzymes; (6) drug inactivation due to conjugation with increased glutathione; 
(7) subcellular redistribution; (8) drug interaction; (9) enhanced DNA repair and (10) failure to 
apoptose as a result of mutated cell cycle proteins such as p53.  Treatment with one agent can 
often lead to associated resistance to a number of unrelated agents.  The development of 
resistance to a variety of unrelated chemotherapeutic drugs is called multiple drug resistance 
(MDR).  MDR is caused by a variety of changes in the cancer cells and is almost always 
multifactorial.   
 
1.1.4.1  P-gp and Multiple Drug Resistance.   
The mechanism of multi-drug resistance was originally described in the 1970s when cells 
selected with just one agent, showed resistance to the cytotoxic effects of multiple unrelated 
agents.  Cells treated with actinomycin D showed resistance to mithramycin, vinblastine, 
vincristine, puromycin, daunomycin, demecolcine and mitomycin C37.  The protein responsible 
was identified as P-glycoprotein or P-gp, a 170kDa plasma membrane glycoprotein encoded by 
the MDR1 gene present on chromosome 7q21 38.  In addition to the cross-resistance of agents, a 
decreased intracellular concentration of the target drugs was also noted37.  This was attributed to 
the active efflux of the agent from the cells 39,40,41.  Gottesman et al., 42 showed that P-gp is an 
ATP-dependent drug pump involved in the transport of a broad range of structurally unrelated 
compounds.  Bellamy et al., 43 identified that P-gp also confers taxane resistance and can cause 
intracellular redistribution of the drug.  The list of compounds now known to interact with this 
transporter is well in excess of 30044,45.  Many of the “new generation” anticancer compounds 
(e.g., kinase inhibitors) are also substrates for transport by P-gp46,47 (table 1-2).   
P-gp is a member of a family of ATP-dependent transporters found in all living organisms that 
are called ABC (for ATP-binding cassette) transporters.  It is expressed in many distinct types of 
cancer as well as numerous normal tissues48.  In the human, there are 48 such transporters, and 
many are involved in the transport of lipophilic substances, such as cholesterol and 
phospholipids, into cellular organelles and out of the cell49.   
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Table 1-2:  Substrates and inhibitors of ATP-binding cassette transporters. a. Overlapping substrate specificities of 
the human ATP-binding cassette (ABC) transporters confering drug resistance to cancer cells.  A single drug can be 
exported by several ABC transporters (rows), and each ABC transporter can confer characteristic resistance patterns 
to cells (columns).  To determine which ABC transporters are involved in multidrug resistance (MDR), two different 
experimental procedures are common.  Cells could be selected in increasing concentrations of a cytotoxic drug, 
which could result in the increased expression of a specific ABC transporter (see green boxes representing drug–
gene pairs in which an ABC transporter was found to be overexpressed in cell lines selected for resistance to the 
respective drug).  Resistant cells overexpressing a single ABC transporter often show characteristic cross-resistance 
to other, structurally unrelated, drugs (red boxes).  b. The ability of ABC transporters to alter cell survival, drug 
transport and/or drug accumulation can be inhibited or altered by various modulators (yellow boxes).  As in a, white 
boxes denote unexplored or absent drug–gene relationships.  *The transport of these drugs by ABCG2 is dependent 
on an amino acid variation at position 482 (wild type is R; variants include R482G and R482T). Numbers in boxes 
refer to references. AZT, azidothymidine; 5-FU, fluorouracil; PMEA, 9-(2-phosphonylmethoxyethyl)adenine.  
(Adapted from Szakacs et al., 200650).   
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P-gp is synthesized as a 140-kDa polypeptide precursor that is later N-glycosylated to a final 
molecular weight of 170 kDa51.  Glycosylation of P-gp was not found to be necessary for its 
drugtransport activity52,53 but was shown to be important for the proper control of P-gp in the 
endoplasmic reticulum54 and transport of P-gp to the plasma membrane52.  It is made up of two 
homologous halves, which contain six transmembrane domains and an ATP-binding domain, 
separated by a linker protein (figure 1-4).  P-gp is an energy dependent pump, capable of 
transporting hydrophobic compounds out of the cell55.   
The ABCB1 (mdr1) gene is also up-regulated in response to a range of chemotherapeutic drugs56 
as well as to diverse stress stimuli, such as the alteration of oxygen supply or deregulation of 
intracellular pH57.  In addition, there are several nuclear receptors which are known to be 
modulators of mdr1 gene transcription:   
1. The Pregnane X Receptor (PXR), which is also known as the steroid and 
xenobiotic receptor.  PXR is most often described as being involved in P-gp 
transcriptional control.  This receptor is characterised by its interaction and 
activation by a large spectrum of ligands and represents an example of a 
promiscuous xenobiotic sensor.  PXR is also known to regulate transcription of 
other very important players in cell resistance, i.e., cytochrome P450, particularly 
the CYP3A subfamily.  The substrates and inhibitors of P-gp overlap considerably 
with those of CYP3A isoenzymes.  For this reason P-gp expression may be 
enhanced upon application of a substance that is not a substrate of P-gp but is a 
ligand of PXR.  For example, cisplatin, which cannot be transported by P-gp, 
frequently enhances the expression of P-gp as a side effect in both normal and 
cancer cells.  Cisplatin is a known PXR ligand, and this transcription factor is 
involved in the mechanisms of cellular protection against this substance56.   
2. The Constitutive Androstane Receptor (CAR) is also recognised as a xenobiotic-
sensor which can up-regulate the functional expression of drug transporters, such 
as P-glycoprotein (P-gp)58.  . 
3. Vitamin D receptor (VDR) identified as a positive regulator of P-gp expression in 
rat brain capillaries59.   
4. Thyroid hormone receptor (TR).  Nishio et al., suggest that thyroid hormone 
induces P-gp expression in a tissue-selective manner60,61.   
5. Peroxisome Proliferator Activated Receptors (PPARs).  PPARs are ligand-
activated transcription factors that regulate genes involved in fat and glucose 
metabolism, and inflammation.  Activation of PPAR signaling is also reported to 
regulate ABC gene expression62.   
14 
 
P-gp is frequently overexpressed in post-chemotherapy tumours where it hinders the cytotoxic 
response to drugs thus desensitising the cancerous cells.  It is most likely to be associated with 
clinical multidrug resistance in cancer, including multiple myeloma, certain types of leukemia, 
breast cancer and ovarian cancer49.  Overexpression of P-gp is associated with decreased cellular 
uptake of a drug, which allows cells to survive in the presence of higher drug concentrations 
originating from the vasculature.  This drug transport can happen against a concentration 
gradient.  Drug enters the cells via a non-energy dependent mechanism and leaves via this active 
ATP pump63.   
 
 
 
Figure 1-4:  Assembly of P-gp in the plasma membrane.  Both transmembrane domains (TMD1 and 
TMD2) of P-gp consist of six transmembrane α-helical spans (1-6 and 7-12) that form an active pore 
in the plasma membrane.  Both nucleotide binding domains (NBD1 and NBD2) are oriented toward 
the cytoplasm.  The glycosylation site (GS), which is located on the first external loop, is oriented 
toward the extracellular space and includes asparagines 91, 94 and 99.  Phosphorylation sites (PS) 
for protein kinases A and C are oriented toward the cytoplasm and correspond to serines 669 and 
681 of the linker region of murine P-gp, which is encoded by the mdr1b gene.  Other symbols: PB, 
phospholipid bilayer; out, extracellular space; in, intracellular space.  From Breier et al., 201356   
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1.1.4.2  BCRP 
Breast Cancer Resistant Protein (BCRP), also called ABCG2, and MXR (mitoxantrone resistance 
protein) or ABCP (placental ABC protein), is also another member of the ATP-binding cassette 
(ANC) transporter superfamily.  The ABCG2 gene was cloned independently from both drug-
selected model cell lines and human cDNA libraries in 199864,65 and 199966.  BCRP mRNA 
encodes a 655-amino acid, 72kDa protein with a single nucleotide-binding domain (NBD) and 
six transmembrane domains (TMD).  Because of its half size nature, ABCG2 has been thought to 
exist and work as a homo-dimer67,68 (figure 1-5).  However, emerging evidence suggests that 
ABCG2 may exist as a higher order of homo-oligomers on plasma membranes69.  BCRP 
undergoes N-linked glycosylation at asparagine 596, and formation of an intramolecular disulfide 
bond between cysteines 592 and 608 which maintain its protein stability.  Mature, oligomeric, 
fully glycosylated BCRP is degraded mainly via the lysosome, while underglycosylated, 
misfolded BCRP or BCRP without the intramolecular disulfide bond is targeted to the 
proteasome for degradation70.   
 
Figure 1-5:  Membrane topology model of BCRP (ABCG2).  The schematic topological model was 
constructed on the basis of sequence analysis and the available experimental data.  Nucleotide-
binding domain (NBD), membrane-spanning domain (MSD), transmembrane (TM) segments, and 
extracellular loop 3 (ECL3) are indicated.  The cysteine residues and N-linked glycosylation sites in 
ECL3 are also shown.  From Mo & Zhang 201271   
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There may be multiple functions for the ABCG2 protein (BCRP), depending on the cellular 
context.  For example, the expression of BCRP in several different tissues (including the 
placenta, colon, large and small intestine, sebaceous glands, islets and acinar cells of the 
pancreas) suggests a physiologically protective role.  Jonker et al., 72,73 have suggested that the 
protein may be responsible for either the transport of compounds in the foetal blood supply or the 
removal of toxic metabolites.  In addition, ABCG2’s different functional roles are potentially 
reflected in its transcriptional control (figure 1-6).  ABCG2 expression has been shown to be up-
regulated by the aryl hydrocarbon receptor74, suppressed by DNA methylation75 and, with 
specific respect to hepatobiliary cancer, up-regulated by Oct476.   
 
 
Figure 1-6:  Schematic representation of transcriptional regulation of BCRP expression.  Transcription 
factors that bind to cis elements upstream of the BCRP E1B/C promoter with subsequent activation or 
repression of the promoter are depicted diagrammatically.  Signaling pathways and extracellular stimuli 
that stimulate binding of the transcription factors are also shown.  The position of the various 
experimentally verified BCRP cis regulatory elements in relation to the transcription start site of the 
BCRP E1B/C first exon are also shown.  (From Natarajan et al., 201270). 
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The upstream region contains functional oestrogen77 and hypoxia78 response elements, consistent 
with its expression in mammary glands and a role in haemopoietic stem cell protection.  Various 
other potential transcriptional control points have been identified in the ABCG2 promoter, 
including putative Sp1, AP1 and AP2 binding sites79.   
BCRP has been detected in various in vitro cancer models, particularly following exposure to 
mitoxantrone.  Mutant forms of BCRP in which amino acid arginine at codon 482 is substituted 
with threonine or glycine have been reported in various cancer cells when cells were selected 
with a BCRP substrate chemotherapeutic drug such as doxorubicin80.  So far, expression of these 
mutants has not been reported in clinical specimens81-83.   
While the P-gp substrates vinblastine, paclitaxel and verapamil are not substrates of BCRP, 
BCRP does transport a variety of dyes (e.g. Hoechst 33462), chemotherapeutics such as 
flavopiridol topotecan, irinotecan and its active metabolite SN-38 as well as the tyrosine kinase 
inhibitors erlotinib, imatinib and gefitinib69 (table 1-2 ).  Both the R482G and R482T mutants 
and the wild-type ABCG2 are able to efflux mitoxantrone, topotecan, SN38 and Hoechst 33342 
84.  However, the R482G and R482T mutants have higher affinity with anthracyclines, including 
doxorubicin, daunorubicin, epirubicin.  Only the wild type ABCG2 can effectively transport 
methotrexate (MTX)85.  These data suggest that amino acid 482 may be a ‘hot spot’ for mutation 
and this mutation affects the substrate specificity of ABCG286.   
 
1.1.4.3  MRP family 
Multidrug resistance-associated proteins (MRPs) are ATP-binding cassette, transmembrane 
transporter proteins.  MRP1 is the most characterised member of the group.  The MRP1 gene 
encodes a 190kDa transmembrane protein whose structure is somewhat homologous to P-
gp/MDRl.  Although P-gp and MRP-1 share only 15% sequence homology, both function in an 
energy-dependent drug efflux system which reduces the intracellular accumulation of drug. It is 
located in the plasma membrane and endoplasmic reticulum of drug-resistant cells.  While there 
is significant overlap with the substrate specificity of P-gp, MRP1 transports a broader range of 
xenobiotics used as antineoplastic or therapeutic agents, including folate-based antimetabolites, 
anthracyclines, vinca alkaloids, antiandrogens, and numerous glutathione (GSH) and 
glucuronide-conjugates of these compounds as well as organic anions and heavy metals.  MRP1 
also transports diverse physiological substrates such as folates, GSH and GSH disulfide (GSSG) 
as well as sulphate-, GSH- and glucuronide- conjugates of steroids, leukotrienes and 
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prostaglandins87.  MRPs are often over-expressed in NSCLC88.  MRP1 expression has also been 
shown to be predictive of poor response to chemotherapy in SCLC89,90.  Other members of the 
ABC family of transporters include MRP2, MRP3, MRP4, MRP5 and BCRP.  These family 
members are also involved in drug efflux, however, they are not as extensively studied as P-gp 
and MRP1.   
 
1.1.4.4  Reversal of MDR 
A large number of studies have focussed on blocking the function of multidrug resistance pumps, 
in an attempt to reverse MDR.  Some non-toxic compounds can inhibit drug transport by acting 
as competitive or non-competitive inhibitors or by preventing ATP binding.  Non-steroidal anti-
inflammatory drugs (NSAIDS) such as sulindac and indomethacin have been shown to increase 
the cytotoxic effects of commonly used chemotherapy drugs in cells which have become 
resistant91.  Early studies in this area observed that P-gp inhibitors such as verapamil and 
cyclosporin A were efficient in vitro but were poor inhibitors in vivo92,93 (table 1-2b).  This led to 
the development of second-generation P-gp inhibitors such as alspodar (PSC 833), dexverapamil, 
and dofequidar fumarate.  However, these second generation inhibitors inhibit drug metabolism 
enzymes and ABC transporters, which results in impaired drug metabolism and elimination94-96.  
The third generation of P-gp inhibitors, which are currently undergoing clinical trials, include 
zosuquidar (LY335979), elacridar (GF120918)97,98, CBT-1, and XR957699-102.  Several of these 
later-generation inhibitors act on multiple ABC transporters.  Biricodar (VX-710) and GF-
120918 for example, bind P-gp as well as MRP1 and ABCG2103.  These generations of inhibitors 
have been examined in preclinical and clinical studies; however to date these trials have largely 
failed to demonstrate an improvement in therapeutic efficacy104.   
 
1.1.4.5  Mitoxantrone 
Mitoxantrone, a Pgp substrate, is a synthetic anthracenedione which was developed based on the 
anthracycline structure, in an attempt to find anthracycline analogues with decreased 
cardiotoxicity while being able to maintain the same antitumour efficacy105.  However, various 
reports showed that mitoxantrone causes chronic cardiotoxicity106-108.  Unlike the anthracyclines, 
mitoxantrone is not active against a wide spectrum of tumours.  Instead, it is used specifically for 
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the treatment of advanced breast cancer, non-Hodgkins lymphoma, non-lymphocytic leukemia 
and melanoma109.   
The structure of mitoxantrone is shown in figure 1-7.  It has a planar heterocyclic ring, 
substituted with two positively charged nitrogen containing side chains.  The anticancer 
mechanisms of mitoxantrone are believed to be related to its capacity to bind DNA and inhibit 
DNA topoisomerase II in the nuclear compartment of cells110,111.  In addition, the action of its 
metabolites in the intracellular cytosolic compartment may also contribute to its antineoplastic 
activities112.   
 
 
Figure 1-7:  Chemical formula of mitoxantrone 
 
1.1.4.6  Drug resistance in lung cancer 
Most lung cancers already exhibit an intrinsic resistance to chemotherapy by the time of 
diagnosis.  Most SCLCs are chemotherapy sensitive at diagnosis, but any recurrence of the 
disease usually displays acquired drug resistance.  NSCLC, on the other hand, are predominantly 
intrinsically resistant to chemotherapy.  It is likely that both acquired and intrinsic resistance 
share common factors, such as the expression of drug transporters, modulation of internal 
regulatory pathways, upregulation of defense pathways and the promotion of an antiapoptotic 
environment.   
Drug transporters involved in the efflux of chemotherapeutic drugs   
Studies have shown a large expression of P-gp in lung tumours, notably higher in NSCLCs than 
in SCLCs.  Other studies have shown that lung tumour cell lines that were resistant to vincristine 
demonstrated cross-resistance to doxorubicin113.  Molecular analysis revealed that these drug-
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resistant cell lines had a higher expression of both P-gp and the MDR1 gene than did the parental 
cell lines.  In addition, in vitro studies have also demonstrated higher expression of P-gp in 
NSCLC cell lines derived from smokers114.   
A further role for MDR1 in drug resistance was demonstrated by gene array studies where the 
expression of various genes were analysed in paclitaxel sensitive (NCI-H460) and resistant (NCI-
H40/PTX250) human large-cell lung carcinoma cell lines.  The results indicated a 1,092 fold 
increase in the expression of MDR1 observed in the paclitaxel resistant cell line 115.   
Although P-gp has been shown to play a major role in drug resistance, other non-P-gp mediated 
mechanisms attributed to proteins such as MRP1 have also been implicated in NSCLC drug 
resistance.  To date, seven isoforms of MRP have been identified (MRP1-MRP7).  The major 
isoforms that have been shown to play a role in drug resistance are MRP1, MRP2, MRP3 and 
MRP5.  Comparative studies performed with a panel of 30 lung cancer cell lines showed that 
NSCLC cell lines expressed higher levels of MRP3, MRP1 and MRP2 protein than in SCLC cell 
lines88.   
Other ABC transporters may also be involved in the pathogenesis of cancer, including 
ABCC10/MRP7116.  A higher expression of ABCC10/MRP7 was demonstrated in 12 out of 17 
lung cancer vinolrelbine resistant cell lines thereby demonstrating the involvement of other ABC 
transporter proteins other than MDR-1 in drug resistance116.  Zhao et al., recently suggested that 
ABCC3 expression may serve as a marker for MDR and multidrug resistance in NSCLC117.  
Another study reported the involvement of a non-ABC transporter protein, RLIP, in contributing 
to vinolrelbine resistance118.  RLIP76 is a transporter involved in catalysing energy-dependent 
efflux of various chemotherapeutic drugs, such as doxorubicin119.  Thus resistance to a 
chemotherapeutic drug may not only be due to one particular ABC transporter protein but may 
also be due to a defect in multiple transporter proteins.   
Other pathways and mechanisms involved in drug resistance in lung cancer 
Although drug efflux is a major mechanism associated with drug resistance, another mechanism 
by which cancer cells avoid drug cytotoxicity is by conjugation of the drug with sulphur-
containing macromolecules such as metallothioneins (MTs) and glutathione (GSH).  
Furthermore, antioxidants such as, superoxide dismutase (SOD) have also been shown to be 
implicated in drug resistance114.  The MTs are low molecular-weight intracellular proteins with a 
high cysteine content that can bind to several heavy metal ions.  MTs can also bind to drugs such 
21 
 
as cisplatin, thereby leading to decreased sensitivity in lung cancer and other cancer types120-122.  
There was also a correlation found between MT expression and doxorubicin in NSCLC123.  
However, there are conflicting studies concerning MT expression and drug resistance in lung 
cancer120,124.  MT expression was also found to be higher in tumours with high metastatic and 
proliferative potential125.   
The glutathione-S-transferases (GSTs) are another group of enzymes that are often up-regulated 
in drug-resistant cell lines.  The GSTs are a family of phase II detoxification enzymes which 
ordinarily protect the normal cells from reactive endogenous and exogenous electrophiles, such 
as prostaglandins, aromatic hydrocarbons, and chemotherapy agents, by conjugating those 
compounds to the sulphur containing macromolecule glutathione-S-hydroxylase (GSH), thus 
detoxifying them114.  The same may be described for cancer cells, so conferring on them 
resistance to chemical stress imposed by antineoplastic agents.  The GSTs have two distinct roles 
in drug resistance – drug detoxification and MAPK pathway inhibition.  Many chemotherapeutic 
drugs that form electrophilic moieties are detoxified through the GSH mechanism, thereby 
leading to resistance.  Numerous drugs used in lung cancer treatment, such as cisplatin, kill 
tumour cells by inducing apoptosis arising from the activation of the JNK/MAPK pathway.  
Inhibition of this pathway by GSTs leads to decreased cisplatin-induced apoptosis, thereby also 
conferring resistance to the drug114.   
Another mechanism by which cancer cells develop resistance is by overexpression of 
antioxidants that protect cells from chemotherapy-induced oxidative stress and cell death. 
Numerous chemotherapeutic drugs such as epirubicin cause oxidative damage by generation of 
superoxide and hydrogen peroxide moieties, thereby leading to cancer cell death.  However, 
overexpression of antioxidant systems such as SOD and GSH can neutralise the drug-induced 
oxidative stress, thereby leading to drug resistance114.   
Drug resistance and DNA repair 
The primary target for most lung cancer chemotherapeutic agents is cancer cell DNA.  For 
instance, cisplatin induces apoptosis primarily by forming DNA–platinum adducts and by 
introducing oxidising agents, thus causing oxidative damage to the DNA of cancer cells126.  
Dealing with resistance to DNA repair enzymes is a challenge as there are many different DNA 
repair pathways and enzymes and each tumour has its own unique genetic profile of 
overexpressed repair enzymes.   
22 
 
1. The nucleotide excision-repair (NER) pathway which is involved in platinum-based 
drug resistance127.  The ERCC1 removes the DNA adducts so that DNA 
polymerase can repair and/or synthesise new DNA, and the tumour cell can divide 
normally again114,128.   
2. Mismatch-repair pathway (MMR) which repairs base–base and insertion–deletion 
mismatches generated during DNA replication or recombination of DNA.  MMR is 
usually a cancer-preventing pathway that helps to maintain genomic stability, but it 
can also lead to resistance against certain chemotherapeutic agents such as 5-
Fluorouracil129.  The MMR pathway does not appear to play a major role in 
chemotherapy resistance in lung cancer114.   
3. Base excision–repair (BER) pathway which uses DNA glycosylase to recognise 
and catalyse the removal of damaged DNA bases and the gaps are then repaired 
which prevents the apoptotic affects of chemotherapy-induced DNA damage130.   
4. Non-homologous endjoining (NHEJ) pathway, is the major pathway used for 
repairing double-strand breaks (DSBs) in human DNA.  It leads to resistance of 
cancer cells to multiple chemotherapy drugs and ionizing radiation by repairing 
DNA damage and stopping apoptosis.  It involves the Ku protein which is a 
heterodimer composed of two polypeptides, Ku70 (XRCC6) and Ku80 (XRCC5).  
The Ku protein acts as a molecular scaffold which helps in binding of other 
proteins involved in DNA repair114.  The drug doxorubicin also induces more 
apoptosis in cancer cells when those cells are deficient in DNA ligase IV or 
DNAPKcs; two of the integral proteins in the NHEJ pathway131.   
5. Homologous-recombination (HR) pathway which can repair the same kind of 
DNA-platinum adducts that occur in the NER pathway.  This pathway begins with 
the recruitment of proteins to form the M/R/N complex (consisting of Mre11, 
Rad50, and NBS1) together with recruitment of replication protein A (RPA), which 
is a single-stranded DNA-binding factor. These bind the broken ends of the DNA 
strands together and begin the process of homologous DNA pairing for which the 
HR mechanism is named.  This enables cancer cells to have two separate pathways 
for resisting the damage caused by alkylating agents114.   
 
Drug resistance and apoptosis 
Failure to activate the process of programmed cell death or apoptosis represents an important 
mode of drug resistance and survival in cancer cells.  Even though drugs such as cisplatin and 
carboplatin induce tumour cell death by damaging DNA, the final result is usually the activation 
of the apoptotic pathways.  The loss of apoptotic control will eventually lead to tumour cell 
survival and progression of the cancer by enabling the cells to be more resistant to 
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chemotherapy114.  Drugs such as cisplatin, taxol, etoposide and gemcitabine induce tumour cell 
death by activation of the intrinsic and extrinsic apoptotic pathways.  A defect in either of these 
pathways can also lead to drug resistance.  For example, drugs such as paclitaxel which can 
induce cell death by regulating cellular microtubule dynamics, kill cells in a Fas/Fas ligand 
(FasL)-dependent manner132.  Furthermore, overexpression of Bcl-2 causes resistance to 
chemotherapeutic drugs in SCLC128.  In addition, drugs such as cytarabine, doxorubicin, and 
methotrexate, which activate the apoptotic pathways, reportedly can confer resistance to cancer 
cells if their caspases are defective114.  Thus, many factors appear to be involved in order to 
establish the drug resistance phenotype (figure 1-8).   
 
 
Figure 1-8:  Drug-resistance mechanisms in tumour cells.  Broad-based drug resistance, either intrinsic 
or acquired, exists in tumours and is believed to result from a multitude of factors.  Various tissue 
culture studies have consistently shown that MDR in most cultured cancer cells involves ATP-binding 
cassette (ABC) transporters in the human such as P-glycoprotein (P-gp, ABCB1), multidrug resistance 
protein (MRP, MRP-1/ABCC1) breast cancer resistant protein (BCRP, ABCG2), lung resistant protein 
(LRP), bcl-2, p53, and Topoisomerase II (TopoII).  Taken from Oh et al., 2009133.   
 
Drug-resistance in the Microenvironment of tumours 
Oh et al., (2009)133 suggest drug resistance due to the microenvironment of tumours is one of the 
most important obstacles to tumour treatment (figure 1-9).  In clinical tumours, a poorly 
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organised vasculature where cells are located far from blood vessels gives rise to a hypoxic 
region resistant to chemotherapy because drug penetration into this region is very limited.  Since 
tumour cells in this hypoxic region are non-proliferating or slowly proliferating with increasing 
distance from tumour blood vessels, most anticancer drugs are less active.  Such regions may 
encourage the elevation of anti-apoptosis proteins to prevent cell death and up-regulate growth 
factors for cell survival.  Indeed, several growth factors such as epidermal growth factor (EGF), 
fibroblast growth factor (FGF), insulin-like growth factor (IGF), and hepatocyte factor (HGF), all 
have important functions in regards to MDR, cell proliferation, metastasis, and angiogenesis.   
 
 
Figure 1-9:  Drug-resistance mechanisms (such as soluble growth factors, ECM-based drug resistance, 
cell-cell interaction, and hypoxia-induced drug resistance) in the tumour microenvironment.  Taken 
from Oh et al., 2009133.   
 
As shown in figure 1-9, binding of EGF, FGF, and IGF to their receptors leads to up-regulation 
of anti-apoptotic proteins (bcl-2 family members such as bcl-2, bcl-XL, and LAPs), resulting in 
inhibition of apoptosis.  In addition, binding of FGF to its receptor mediates obstruction of p53 
pathways while HGF binding to its receptor enhances DNA repair functions.  Altered expression 
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of extracellular matrix (ECM) components (such as fibronectin, collagen, tenacin, laminin, and 
hyalurona) contributes to protecting tumour cells from anticancer drugs, by activation of MAPKs 
and PI3K/AKT survival signaling, decreasing TopoII level, and arresting cell proliferation due to 
the increased cyclin-dependent kinase (CDK) inhibitor p27/Kip1 protein.  In addition, cadherins, 
selectins, and cell adhesion molecules (CAMs) can make cell-cell contact and exhibit further 
drug-resistance.   
 
1.1.5  Invasion and metastasis 
1.1.5.1  Key molecular mechanisms in cancer invasion and metastases 
Around 90% of all cancer deaths are the result of metastases, rather than through the effects of 
the primary tumour134.  The majority of patients with lung cancer are diagnosed at late stages, 
when they are already beyond the possibility of treatment by surgery or radiotherapy – due to the 
extent of local invasion or distal metastases.   
Nevertheless, the processes of invasion and metastasis are still insufficiently understood.  In fact, 
there are currently no effective treatments available that target invading tumour cells.  For 
example, the question is still unanswered, why some cancers, such as melanomas, tend to 
metastasize, whereas others, such as squamous carcinomas of the skin, scarcely form secondary 
tumours.  Bissell et al., 135 suggest that the micro-environment surrounding the tumour may 
provide tumour-suppressive signals as long as the architecture or the tissue homeostasis is 
essentially controlled and maintained.  However, once tissue homeostasis is lost, the altered 
microenvironment can itself become a potent tumour promoter.   
A tumour which has not yet reached an invasive phenotype is often referred to as ‘carcinoma in 
situ’.  Invasiveness does not only mean the ability to thrust aside adjacent tissues, but also to 
actively invade and, therefore destroy these tissues at the contact borders.  Metastasis refers to 
the capability to leave a primary tumour site, travel via the circulation to a distant tissue site, and 
there, form a secondary tumour136.   
Most deaths from cancer are due to metastasis that are resistant to conventional therapies.  
Current therapies fail to eradicate metastasis for three major reasons.  Firstly, when initially 
diagnosed, most tumours are well advanced and metastasis has already occurred.  Secondly, the 
specific organ environment can modify the response of a metastatic tumour cell to systemic 
therapy and alter the efficiency of anticancer agents.  The third reason, and the greatest obstacle 
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to the success of therapy, is the heterogeneous composition of tumours, where highly metastatic 
cells can escape from the effect of therapeutic agents.   
Micro-metastases can remain in the body of a cancer patient after successful chemotherapy or 
radiotherapy.  It is possible that these remaining tumour cells start to proliferate uncontrollably 
years after the patient is thought to be cured of the primary disease, leading to the redevelopment 
of a new cancer.   
Fortunately, metastasis is thought to be an inefficient process, a phenomenon which is often 
referred to as ‘metastatic inefficiency’137 and animal modeling suggests that less than 0.02% of 
tumour cells in circulation can survive to form metastases138.  Up to one million cells per day can 
leave a primary mouse tumour of only 1g mass (~109 cells), and enter the invasion metastasis 
cascade.  In direct contrast, the amount of micro-metastases which evolve into clinically relevant 
secondary tumours is negligible136.  This is because tumour cells often encounter significant 
obstacles as they attempt to reactivate their growth machinery at metastatic sites.  In 1889, 
Paget139 concluded that metastasis occurred only when certain favoured tumour cells (the “seed”) 
had a special affinity for certain specific organs (the “soil”).   
The formation of metastases requires the interaction of the right cells with the compatible organ 
environment.  More recently, a number of genes whose expression facilitates the metastatic 
colonisation of breast cancer cells, specifically to either bone, lung, brain or liver, have been 
identified.  These genes seem to dictate organ-specific metastatic tropism due to their ability to 
compensate for and overcome incompatibilities between the intrinsic growth programs of the 
disseminated carcinoma cells and the demands imposed by the particular foreign tissue micro-
environment around them140.   
The cascade of events in lung cancer metastasis all require the participation of fundamental 
mechanisms such as cellular motility (which is an early event in metastasis) angiogenesis, 
degradation of matrix barriers, disruption of cell-cell and cell-matrix adhesion (figure 1-10) 141.  
Genes that regulate functions like unlimited growth potential, survival, genomic instability, 
angiogenesis, epithelial to mesenchymal transition (EMT) and apoptosis evasion, are involved in 
giving lung cancer tumours invasive and metastatic competence141.   
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1.1.5.2  The epithelial-mesenchymal transition 
To begin, lung tumour cells undergo a transformation known as the epithelial-mesenchymal 
transition, or EMT142.  EMT is regulated by growth factors and cytokines including transforming 
growth factor (TGF)-beta and can be deregulated in cancer cells during tumour progression 
resulting in invasiveness with metastatic characteristics.   
Carcinomas can invade as cohesive multi-cellular units through a process termed “collective 
invasion” but individual tumour cells may also invade via two distinct programs: the protease-, 
stress-fiber-, and integrin-dependent “mesenchymal invasion” program or the protease-, stress- 
 
 
Figure 1-10:  The cascade of events in lung cancer metastasis include: (1) Detachment of tumour cells 
from the extracellular matrix (ECM) and degradation of the ECM by several proteolytic enzymes.  (2) 
Invasion of neighboring tissues and basement membrane.  (3) Intravasation into the blood stream or 
lymphatic vessels, by attachment on the endothelial cells with adhesion molecules, infiltration of the 
vessels, survival and transport through the blood stream.  (4) Arrest and extravasation at a distal site 
and formation of a metastatic lesion.  (From Fidler, 2003143) 
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fiber-, and integrin-independent, Rho/ROCK-dependent “amoeboid invasion” program140.  It is 
believed that tumour cells interconvert between these various invasion strategies in response to 
changing microenvironmental conditions140.  To achieve this, carcinoma cells may use a cell-
biological program known as EMT, which is a differentiation program essential for 
morphogenesis during embryo development.   
EMT features include loss of cell polarity, reorganisation of the cytoskeletal architecture, 
redistribution of the intracellular organelles, upregulation of fibroblast markers and increased 
motility144.  Cells that undergo EMT assume a spindled shape, lose desmosomes and adherence 
junctions, and secrete increased amounts of enzymes to degrade the ECM144,145.   
EMT is driven by a network of transcription factors including Snail1, Snail2, and Snail3, ZEB1 
and ZEB2 (zinc-finger E-box binding factor), Twist, and others.  The general features of EMT 
include the downregulation of epithelial markers in adherence junctions, tight junctions and 
cytoketarin filament network (for example, E-cadherin, occludins, claudins, desmoplakin, type 
IV collagen, laminin 1, cytokeratins, catenins, ZO-1 and mucin1) and upregulation of 
mesenchymal markers, such as N-cadherin, vimentin, α5β1 and αVβ6 integrins, tenascin C, 
laminin β1 and 5, type I and VIα collagen, fibronectin, fibroblast specific protein 1 and α-smooth 
muscle actin141.   
Loss of expression of the cell cell adhesion molecule E-cadherin is a key characteristic trait of 
EMT and in the progression of epithelial tumours to become invasive, metastatic cancers.  The 
loss of E-cadherin is generally seen to coincide with a gain of expression of the mesenchymal 
cadherin, N-cadherin in many cancer types; this 'cadherin switch' is thought to be necessary for 
tumour cells to gain invasive properties and is also a characteristic of EMT.  N-cadherin has an 
affinity to stroma cells and upregulation of N-cadherin enhances migration towards the stroma136.  
Interestingly, the expression of N-cadherin promotes tumour cell metastasis irrespective of E-
cadherin status of a given cell146.  Interestingly Marsen et al., 2014147 suggest that the acquisition 
of a mesenchymal morphology is the end-point of EMT but the routes towards that end-point 
might differ between conditions and cells.  They identified a set of core invasiveness genes, the 
expression of which was associated with epithelial-mesenchymal transition in breast cancer cell 
lines and in human tissue samples but were unable to demonstrate a link between the core 
invasiveness gene signature and enhanced metastatic potential147. 
The transcription factors Slug, Snail, Goose-coid, Twist, and ZEB1, which are highly expressed 
by metastatic cells, have been suggested to have a role in inducing epithelial-mesenchymal 
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transitions148.  However, the central EMT regulator is TGFβ.  In non-small cell lung cancer, 
TGFβ inhibits tumour growth in early stages, whereas in late stages the same pathways promote 
tumour invasiveness and metastasis.  TGFβ also activates Erk and p38 MAPKs, PI3K and Ras 
and Rho GTPases.  All these signalling pathways end up promoting EMT by regulating genes 
that control cell proliferation, apoptosis, differentiation, motility and migration149.   
MicroRNAs (miRNAs) are also involved in regulating EMT and tumour metastasis.  miRNAs 
are a class of small non-coding RNAs that negatively regulate gene expression at the post 
transcriptional level by blocking translation and inducing mRNA degradation150.  The miR-200 
family has been identified as potent negative regulator of EMT in lung adenocarcinoma, by 
controlling ZEB1 and ZEB2 and thus leading to increased E-cadherin expression151.  MiR-126 
has been shown in squamous cell lung cancer to downregulate Crk protein, reducing invasive 
potential151.  Other regulatory circuits including the epigenetic machinery and post-translational 
control are also crucial in enabling cancer cells to maintain a defined cellular state or switch 
between the epithelial and mesenchymal states in response to stromal cues152,153.   
 
1.1.5.3  Invasion/Metastasis 
The process of EMT is followed by invasion which initiates the metastatic process.  Invasiveness 
involves entry of cancer cells that have resided within a well-confined primary tumour, across 
tissue boundaries and through host cellular and extracellular matrix barriers.  The ‘stroma’ 
consists of fibroblasts, vasculature, immune cells and interstitial ECM.  In order to invade the 
stroma, carcinoma cells must first breach the ECM, which plays a vital role in organising 
epithelial tissues, in part by separating their epithelial and stromal compartments.  Components 
of this ECM contain proteinases, growth factors molecules and cytokines, which can be activated 
and released by the invading cells.  Moreover, the ECM also plays crucial roles in signalling 
events within carcinoma cells via pathways initiated by integrin-mediated cell-matrix adhesions, 
leading to alterations in cell polarity, proliferation, invasiveness, and survival135.  The controlled 
tissue architecture of normal epithelium serves as an intrinsic barrier to invasiveness that must be 
overcome by incipient metastatic carcinoma cells before they can develop into overt 
malignancies140.   
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1.1.5.4  Cell adhesion molecules 
Numerous adhesion molecules mediate the tumour cell-ECM adhesion process.  The cell 
adhesion molecules (CAMs) can be divided into four major families: the immunoglobulin 
superfamily, the integrins, selectins and the cadherins154.  Cadherins, whose main function is 
cell–cell adhesion, are well studied for their role in cell signaling during critical processes such as 
epithelial-to-mesenchymal transition (EMT), cell migration and gene regulation through catenins, 
especially the β-catenin/Wnt signling pathway155.   
Selectins and immunoglobulin superfamily (IgSF) members are mainly involved in the wound 
healing (recruiting platelets and leukocytes) process and the immune response (communication 
between immune cells and other constituents of the inflammatory process as well as among 
components of the immune system).  Among other roles, they are ‘traffic regulators’ in the 
lymphatic system and attract immunocompetent cells to the site of inflammation154.   
Integrins are transmembrane receptors that mediate the attachment between a cell and its 
surroundings, such as other cells or the ECM itself.  During signal transduction, integrins pass 
information about the chemical composition and mechanical status of the ECM into the cell.  So, 
in addition to transmitting mechanical forces across otherwise physically vulnerable membranes, 
integrins are involved in cell signaling and the regulation of cell cycle, shape, and motility.  
Many studies suggest that various integrin subunits can contribute either positively or negatively 
to the transformed cell phenotype.  Although cell-type-dependent changes in integrin signalling 
make it impossible to rigidly assign each of the integrins to the 'anti-neoplastic' or the 'pro-
neoplastic' category, present evidence indicates that α2β1 and α3β1, at least in some cases, 
suppress tumour progression, whereas αvβ3, αvβ6 and α6β4 often promote it156. 
This family of proteins can form at least 25 distinct pairings of its 18 α and 8 β subunits, with 
each integrin consisting of a noncovalently linked α- and β-subunit, with each subunit having a 
large extracellular domain, a single membrane-spanning domain and a short, non-catalytic 
cytoplasmic tail157.  Integrins also induce the expression of different ECM degrading proteases, 
especially members of the MMP family which can cleave ECM components to remodel the 
overall ECM structure, thereby promoting cell migration.  The interplay between integrins and 
the matrix metalloproteinases may be one of the key phenomena in the invasion process.   
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1.1.5.5  MMPs 
MMPs are a family of structural and functional related endopeptidases.  They are, with the 
exception of MMP-11, secreted as inactive zymogens and activated outside the cell by other 
activated MMPs or serine proteases (e.g trypsin, plasmin, kallikrein).  Proteolytic removal of the 
propeptide-domain is required for their activation.  This enables access to the catalytic site of the 
MMPs.  The cleavage of the ECM by activated MMPs facilitates the invasion of tumour cells as 
well as the release of ECM bound growth factors (e.g. insulin like growth factors and fibroblast 
growth factors).  MMPs degrade fibronectin, collagen, laminin and proteoglycans.  They also 
affect tumour neoangiogenesis and also break cell–cell and cell-ECM connections by cleaving 
adhesion molecules such as E-cadherin and CD44158,159.   
MMPs can thus change the structural and mechanical properties of the ECM160.  MMP-1, MMP-
2 and MMP-9 have all been correlated with increased risk of metastasis in human lung 
cancer161,162.  However, MMP activity is held in check by the the TIMPs (tissue inhibitors of 
metalloproteinases) which prevent excessive ECM degradation and the resulting tissue instability 
that would ensue.  Current thinking stresses the importance of the balance between TIMPs and 
MMPs, considering this to be of vital importance for invasion and metastasis163.  At present, 
greater than 20 distinct MMPs are known: collagenases (MMP-1/8/13/18), gelatinases (MMP-
2/9), stromalysines (MMP-3/10/11), matrilysines (MMP-7/26), membrane-bound MMPs (MMP-
14/15/16/ 17/24/25) and other MMPs, which do not fit into the listed groups164. 
 
1.1.5.6  Evasion of apoptosis 
In order for a cancer cell to migrate, it needs not only motility, but also the ability to evade 
apoptosis.  Apoptosis is regarded as the central mediator of programmed cell death and is often 
defective or simply ineffective in cancer cells.  Apoptosis is stimulated by a broad range of 
conditions and signals.  The main mechanisms of cancer resistance to apoptosis are the loss of 
p53 activity and the overexpression of the Bcl2/BclxL165,166 that play important roles in inhibiting 
mitochondria-dependent extrinsic and intrinsic cell death pathways.  The anti-apoptotic proteins 
(Bcl-2, Bcl-xL) function to preserve mitochondrial integrity and prevent the loss of 
mitochondrial membrane potential and cell death by interfering with the action of Bax and Bak.  
Mitochondrial p53 can complex with Bcl-2 and Bcl-xL resulting in cytochrome c release and 
apoptosis.  However, p53 mutants found in tumours are often defective in their binding to Bcl-xL 
implying that inhibition of p53-mediated apoptosis may contribute to the continued survival of 
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tumour cells.  The pro-proliferative function of mortalin (mot-2, a member of the Hsp 70 – heat-
shock protein 70 family, predominantly present in mitochondria) has been demonstrated by 
several studies including its overexpression resulting in lifespan extension of normal human 
fibroblasts and the malignant transformation of mouse and human immortal cells167,168.  The pro-
proliferative effects of mortalin in cancer cells have been assigned, at least in part, to its binding 
with the tumour suppressor protein, p53 that results in its retention in the cytoplasm and 
inhibition of its transcriptional activation and control of centrosome duplication function169,170.  
Overexpression of mortalin overrides the p53-dependent suppression of centrosome duplication 
and abnormal amplification of centrosomes, commonly found in human cancer, is the major 
cause of mitotic defects and chromosome instability in cancer cells.   
Specific types of apoptosis in normal cells are also induced by integrin detachment resulting in 
the loss of cell adhesion to neighbouring cells or the ECM (anoikis) or loss of the internal cell 
cytoskeletal architecture (amorphosis).  Anchorage independent growth is a critical step in the 
tumourigenic transformation of cells.  Breaching the anoikis barrier disrupts the normal cell's 
defenses against transformation141.  Evasion of anoikis is mainly regulated by integrins171.  
Integrins protect the cell from anoikis, and so also do several kinases activated by integrins, like 
SRC, FAK and ILK172,173.  Altered integrin receptors or elevated levels of integrin-activated 
kinases are found in tumour cells, facilitating survival and metastasis174.  Apoptosis evasion is 
also associated with EMT, since downregulation of E-cadherin175 and activation of Snail and 
Twist lead to anoikis suppression141.   
 
1.1.5.7  Intravasation, circulation and extravasation 
The circulation of the blood plays a significant role in determining where cancer cells travel.  
This is facilitated by the creation of new blood and lymph vessels that not only provide the 
primary tumour with all it needs in order to grow, but also reduce to a minimum the distance that 
metastasising cells need to move in order to enter the vasculature176.  Therefore, angiogenesis is a 
fundamental step in the transition of tumours from a benign state to a malignant one.  Normal 
angiogenesis is regulated by the balance of a vast range of activators and inhibitors177.  The most 
important regulators include cytokines, acidic and basic fibroblast growth factor (aFGF and 
bFGF), vascular endothelial cell growth factor (VEGF), the CXC chemokines, the angiopoietin/ 
TIE ligand–receptor system, peptides including angiostatin, endostatin, tumstatin and 
thrombospondin 1, platelet-derived growth factor (PDGF), epidermal growth factor (EFG) and 
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hypoxia-inducible factors (HIF1A, HIF2A)178.  In lung cancer, angiogenesis has mainly been 
associated with VEGF, bFGF and the CXC chemokines family179.   
Cancer cells usually become trapped in the first set of capillaries they encounter downstream 
from their point of entry.  Frequently these sites are in the lungs, since deoxygenated blood 
leaving many organs is returned first to the lungs for re-oxygenation before being distributed 
throughout the rest of the body.  Once in a new site, the cells must again penetrate the basement 
membrane of the blood vessel and establish themselves in the new tissue141.   
 
1.1.5.8  Drug resistance, metastasis and cancer stem cells  
Cancer stem cells are cancer cells (CSC, found within tumours or haematological cancers) that 
possess characteristics associated with normal stem cells, specifically the ability to give rise to a 
multitude of different cell types.  It is well established that CSCs can drive primary, metastatic 
and recurrent tumourigenesis in many malignancies.  They are also believed to play a role in 
metastasis and the development of resistance to chemo- or radiotherapy180.  Small populations of 
cells with properties similar to stem cells have been reported in small cell lung cancer181 and non-
small cell lung cancer182.  Several studies have identified CD133, CD44, ALDH (aldehyde 
dehydrogenase) and ABCG2 (ATP-binding cassette sub-family G member 2) as lung cancer stem 
cell markers183,184.  These markers also happen to be validated CSC markers in multiple other 
cancer types.  Embryogenesis signaling pathways, such as the hedgehog, wnt and notch pathways 
have also been implicated as determinants of the lung CSC phenotype.  With a central role for 
CSCs in tumour recurrence, metastasis and drug-resistance, targeting CSC markers and/or 
signaling pathways to eradicate lung cancer and enhance patient outcome is an attractive clinical 
approach184.   
 
1.1.6  MDR and invasion and metastasis 
The major causes of treatment failure in cancer are the development of metastases and drug 
resistance.  For more than two decades, these two important but not clearly understood aspects in 
the biology of cancer have been extensively studied.  An important goal of cancer research is to 
determine whether a common factor exists that activates two sets of genes or pathways, one 
responsible for drug resistance, and the other responsible for increased tumour cell invasion and 
metastasis.  Although direct evidence linking ABC transporters to metastasis is currently lacking, 
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roles are emerging for these proteins in cell migration and invasion.  Research indicates that there 
is a change towards a more malignant phenotype indicating cancer progression 185,186,187,188,189,190.   
Role of ABC transporters in cell migration 
Several ABC transporters have roles in the migration of normal cells.  Induced migration of 
peripheral dendritic cells to lymph nodes is greatly reduced in Abcc1–/– mice191, and Abcc1- 
deficient dendritic cells also have markedly attenuated chemotactic responses in vitro.  However, 
exogenous addition of the ABCC1 substrates leukotriene C4 (lTC4) and lTD4 overcame the 
absence of the transporter in vivo and in vitro191, suggesting a role for ABCC1 in autocrine 
signalling in mouse dendritic cell migration.  Other ABC transporters might also have a role, as 
ABCB1-specific neutralising antibodies and the inhibitor verapamil prevented the migration of 
dendritic cells from human skin explants 192.  However, comparison of these results across 
species is complicated by differences in the roles of various family members.  In human dendritic 
cells, ABCC4 seems to have a more prominent role than ABCC1 in migration, with ABCC4 
knockdown or pharmacological inhibition by sildenafil preventing their migration from human 
skin explants193.   
The apparent roles of ABC transporters in dendritic cell migration are also reflected in cancer 
cell lines.  The original work by Meyers and Biedler194 in highly resistant multidrug-resistant 
(MDR) cell lines suggested that P-glycoprotein overexpression leads to decreased 
tumourigenicity.  Moreover, the expression levels of a panel of metastasis- and drug resistance-
related genes were analysed in a study carried out on a human prostate carcinoma cell line (PC-
3M) and its variants with different metastatic ability.  Highly metastatic cells growing in culture 
expressed higher levels of mRNA for b-FGF, IL-8, MMP-2, MMP-9, and Pgp than poorly 
metastatic cells and parental cells.  This suggests a possible correlation between metastasis and 
Pgp-mediated drug resistance195.  Tumour cells selected for resistance to chemotherapeutic drugs 
often become more invasive relative to sensitive parental cells196 and it has been observed that 
secondary metastatic tumours are in some cases more resistant to chemotherapy than primary 
tumours197.  Studies on the human nasal carcinoma cell line, RPMI- 2650, indicate that pulse-
selection with taxol, while leading to an increase in drug resistance, does not promote in vitro 
invasiveness in the human nasal carcinoma cell line.  However, selection with the anticancer 
agent melphalan appears to increase in vitro invasiveness198.  Furthermore, mitoxantrone, 5-FU, 
methotrexate, BCNU, cisplatin and chlorambucil all induce an invasive phenotype in the human 
lung cancer cell line DLKP196.   
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A doxorubicin-selected, multidrug-resistant human melanoma line expressing high levels of 
ABCB1 showed a more invasive phenotype than the parental cell line199.  Although it is possible 
that other genetic changes contributed to this phenotype, knock down of ABCB1 by siRNA 
substantially reduced the invasiveness of this cell line in vitro.  Also, reduction of ABCB1 levels 
by siRNA reduced the migration of MCF-7 breast cancer cells in transwell migration and 
matrigel invasion assays.  Expression of ABCB1 in the canine kidney cell line MDCK also 
stimulated increased migration, and inhibition of ABCB1 reduced migration of the rat brain 
endothelial cell line RBE4 200.   
Drugs that interfere with the function of P-glycoprotein also interfere with the cell's motility and 
invasion.  Nokihara et al. 201 confirmed the importance of P-glycoprotein in metastatic changes 
when they showed that the rate at which metastatic sites were formed by MDR human small cell 
lung cancer cells (SBC-3/ADM, P-glycoprotein positive) was higher than that produced by the 
sensitive parental cells (SBC-3, P-glycoprotein negative) in SCID mice.  Bjornland et al.202 
observed that MDR hepatoma cells displayed an elevated capacity to migrate when compared 
with that of P-glycoprotein (−) parental cells.  Treatment of the MDR hepatoma cells with the P-
glycoprotein inhibitor PSC833 decreased their migration rate.   
Other studies make the connection between these two phenotypes more apparent.  Yang et al203,  
reported that the extracellular matrix metalloproteinase inducer (EMMPRIN), a cell membrane 
glycoprotein involved in invasion and metastases is overexpressed in MDR cells and not in drug-
sensitive parental cell lines204,205.  Miletti-González et al. 206,207 reported that the functional 
interaction between CD44 and P-glycoprotein (P-gp) was one step in a complex molecular 
organisation that results in the concomitant multidrug resistance (MDR) phenotype as well as 
increased cell migration, in vitro invasion, and metastasis.  The knockdown of MDR1 by short 
hairpin RNA (shRNA) impairs the migration and invasion abilities of tumour cells.  Misra et 
al.,208 reported that MDR in cancer cells could be regulated by the ubiquitous extracellular matrix 
component, hyaluronan, a major ligand for the metastases-related CD44 receptor.  Zhang et al., 
209 also showed that Anxa2 was up-regulated in multidrug-resistant MCF-7/ADR cells and might 
play essential roles in modulating MDR-induced tumour invasion/metastasis.  More recently 
Zhang et al., showed that P-gp interacts with Src, a tyrosine kinase upstream of Anxa2210.  They 
suggest that P-gp may promote the invasion of MDR breast cancer cells by modulating the 
tyrosine phosphorylation of Anxa2.   
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ABC transporters and metastasis in vivo 
Although it remains to be determined whether ABC transporters contribute to metastasis in vivo, 
several studies indicate such a link.  For example, Slotman et al., 211 found an increased incidence 
of haematogenous metastases with induction chemotherapy for patients with advanced head-and-
neck squamous carcinomas, compared to patients receiving only surgery and radiotherapy.  They 
also found an increase in metastases at sites other than the usual pulmonary site211.  Stefani and 
coworkers reported that the use of hydroxyurea in combination with radiotherapy for the 
treatment of head and-neck cancer yielded no benefit in terms of response rate or survival, but 
rather increased the incidence of distant metastases from 8% to 23% 212.  The administration of a 
single drug dose may be sufficient to induce spontaneous metastasis213.  In another study it was 
found that MDR1 gene expression can be rapidly activated in human tumours after transient in 
vivo exposure to doxorubicin214.  In a breast cancer study, ABCC1 expression was higher in 
metastatic lymph nodes than in the corresponding primary tumour215, and in melanoma, ABCC1 
and ABCC4 were more highly expressed in cell lines derived from metastases than in those 
derived from primary tumours216.   
 
Role of EMT in drug resistance and metastasis 
One of the early steps in the invasion-metastasis cascade includes the epithelial–mesenchymal 
transition.  There are many studies on the role of EMT in cancer progression, in terms of drug 
resistance and metastasis217.  For example overexpression of some of the transcription factors 
associated with EMT such as Snail, Twist and Slug has also been associated with 
chemoresistance, although their depletion has been shown to increase drug sensitivity218-220.  
Saxena et al.221 investigated the role of EMT-inducing transcription factors in drug resistance 
mediated by ABC transporters in breast cancer cells.  They showed that the transcription factors 
that lead to EMT and invasion also orchestrate the overexpression of drug transporters by directly 
modulating their promoter activity, thus providing a novel molecular mechanism for the long-
standing association between invasiveness and drug resistance221.  Irradiation has also been 
shown to predispose breast cancer cells to EMT, i.e., the transition into the more immature and 
malignant mesenchymal phenotype128.   
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Therapy induced stress 
Huang et al., 2013222 suggest that progression toward a resistant tumour is not only due to the 
selection of cells that are genetic or epigenetic variants and “happen” to survive because they 
express a phenotype that is more drug-tolerant but may be also due to the therapy itself.  A 
frequent clinical observation is that metastasis correlates with therapeutic resistance.  It is 
hypothesised that metastatic competence and drug resistance are common traits of tumour stem 
cells223.  As indicated previously, there is increasing evidence in many cancers that enhanced 
tumourigenicity resides in a tumour cell population that exhibits stem cell-like properties such as 
self-renewal, differentiation, cell mobility and toxicity resistance, designated as cancer stem cells 
(CSC) or tumour initiating cells (TIC) 224,225.  There is evidence to indicate that therapy induces 
stemness or drug resistance.  For instance, irradiation induces stem cell-like behavior and drug 
tolerance in leukemic cells 226 and in hepatocarcinoma cells, including the expression of key 
pluripotency genes, such as Sox2 and Oct4227.  It was also been shown that the chemotherapy 
agent cisplatin which may cause a genome-wide response; can also induce the same response.  
Therapy-induced trauma caused by surgery, irradiation or cytostatic treatment can also increase 
or decrease oxygen and nutrient levels and activate the production of chemokines and growth 
factors by stromal cells.  Multiple pathways are then activated that may boost cancer cell 
invasion, metastasis, and resistance responses228.   
 
Joint pathways to resistance and invasion 
Evidence is accumulating that cancer invasion and drug resistance are interconnected228.  
Molecular changes in different signalling pathways including apoptosis signalling or cell cycle 
regulation may be involved in cancer cell chemoresistance and increased malignancy185,190,229.  
Table 1-3 summarises the molecules important in resistance and invasion.  Figure 1-11 
summarises the overlap between migration-inducing and pro-survival pathways – particularly 
those concerning PI3K, Akt, Ras and Rho GTPases, integrins, cadherins and p53.  Strategies to 
target these pathways have been explored in both preclinical and clinical studies228.  For example, 
the tumour suppressor transcription factor TP53 is dysfunctional in many cancer types and 
controls many genes including the DNA checkpoint kinases and apoptosis regulators, so allowing 
unlimited growth.  As a result it is a master regulator of cell susceptibility to cytotoxic stimuli, 
the constitutive deregulation of which supports resistance228.   
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Unlimited growth is also mediated by mutations within RAS (H-RAS, K-RAS, and N-RAS) which 
activates the mitogen activated kinases (MAPKs;MEK.ERK, JNK, and p38), PI3K/Akt, and 
mammalian target of rapamycin (mTOR), thereby favouring cell cycle progression228.  Active 
Ras proteins also contribute to invasion regulation as direct and indirect upstream activators of 
Rho GTPases and enhance motility and invasion through PI3K, mTOR, the Rac1-activating 
guanine-nucleotide exchange Tiam, and the MAPKs p38 and JNK.  Ras pathways also activate 
the integrin-mediated focal adhesion and growth factor receptor signaling that interact with the 
MAPK and ERK pathways and results in regulation of the expression of the MMPs228.   
Preclinical animal models are necessary to detect tumour cell and stromal cell responses to 
therapy at a cellular level.  In addition, investigation of gene transcription and protein expression 
profiles in the invasion and resistance pathways should be carried out on patient tumour cells, 
stroma and circulating tumour cells.  There is a substantial redundancy involved in cancer cell 
survival in response to therapy and multipathway targeting is necessary for cancer treatment228.   
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Table 1-3:  Molecules important in resistance and invasion.  Taken from Alexander & Friedl, 2012228. 
 Factor, molecule, 
or pathway 
Alteration Function in survival and resistance Function in cytoskeletal control, 
invasion and metastasis 
Classical 
tumour 
suppressors 
and 
oncogenes 
p53 (transcription 
factor) 
LOF mutation Defective cell cycle arrest after DNA 
damage (abortive p21 expression / 
activation); impaired apoptosis response 
(via downregulated death receptors and 
Bax) 
Enhanced mesenchymal and amoeboid 
migration in vitro (via Rho GTPases); 
increased ECM degradation (via MMP2 
upregulation); EMT induction (via Slug, 
Twist) 
GOF mutation Impaired DNA repair (via Mre11/ATM) 
and apoptosis response (via inhibition 
of p63/p73 and Notch signaling) 
EMT induction (via Twist); increased 
invasion in vitro and metastasis in vivo 
(via TAp63 inhibition) 
Ras superfamily 
(N-ras, H-ras, K-
ras) 
GOF mutation Increased cell proliferation (via 
Ras/MAPK, PI3K, mTOR); inhibition 
of apoptosis (via PI3K/Akt, mTOR) 
Increased motility [via PI3K/Tiam (Rac), 
mTOR (RhoA/Rac)]; increased 
expression of c-Met, K-ras (via p38/JNK) 
Growth factors 
and their receptors 
Amplification, 
overexpression, 
GOF mutation, 
constitutive 
activation 
EGFR: increased cell proliferation (via 
Ras, PI3K/Akt, JAK/STAT); decreased 
apoptosis (via PI3K/Akt) 
EGF/EGF-receptors: increased migration, 
chemotaxis (via PI3K, Src; STAT3; 
PKCδ) 
  FGFR: increased cell proliferation (via 
Ras, PI3K); decreased apoptosis (via 
PI3K/Akt) 
FGF/FGFR: increased migration/invasion, 
chemotaxis (via PI3K) 
  c-Met: increased cell proliferation (via 
CD44/Ras, PI3K, JAK/STAT), 
decreased apoptosis (via PI3K/Akt) 
HGF/c-Met: increased invasion, 
chemotaxis (via CD44/Ras, Src, PI3K) 
  TGFβ/EMT: increased survival (via 
Ras, MAPK, PI3K/Akt, Src, STAT, 
Smad and Notch) 
TGFβ/TGFR: increased invasion, 
chemotaxis (via PI3K/Cdc42/Rac, 
Smad/RhoA); TGFβ/EMT: expression 
regulation of N-cadherin, Rho GTPases, 
integrins, MMPs and GFRs 
Cell 
adhesion 
receptors 
Integrins Constitutive 
expression and 
ligation to ECM 
Enhanced survival (via Src/Grb2/Ras, 
FAK/PI3K); chemoresistance and 
radioresistance (via PINCH, STAT3, 
GSK3) 
Adhesion to ECM, actin dynamics and 
mechanotransduction (via talin, vinculin, 
FAK); control of migration mode 
CD44 and 
variants 
Upregulation 
(cancer stem 
cells); alternative 
splicing 
Prosurvival signaling (via Ras as 
coreceptor for GFRs; via Src and 
ROCK activation of PI3K/Akt); 
multidrug resistance (via MDR1 
upregulation) 
Interaction with ECM; EMT induction 
(via c-Met interaction); putative role in 
mechanotransduction 
Cadherins Altered 
expression 
pattern; 
downregulation 
Prosurvival signaling (via β-cat/Wnt, 
p120-cat/Rac/Cyclin D1; coengagement 
of integrins 
Control of cell–cell cohesion and 
detachment; supports collective invasion; 
EMT (E-cadh via integrins; N-cadh via 
p120-catenin) 
Classical 
drivers of 
invasion 
Rho superfamily 
members 
Rac (Rac1) 
activation / 
overexpression 
Increased proliferation (via MAPK, 
PI3K, JNK, NFκB, PAK, Cyclin D1); 
apoptosis inhibition (via Bad) 
Promotes actin assembly and branching 
(via WAVE/Scar/Arp2/3); required for 
lamellipodia formation and invasion 
Rho (RhoA, 
RhoC) 
overexpression 
Increased proliferation [via Cyclin D1, 
LIMK2 (RhoC)] 
Controls actomyosin contraction required 
for migration/invasion (via ROCK and 
myosin II); supports roundish/amoeboid 
migration 
Cdc42 
overexpression 
Increased proliferation and decreased 
apoptosis (via PI3K, PAK, EGFR 
signaling, NFκB, STAT3), oncogene 
Controls actin assembly (via WASP) and 
cell protrusion formation (filopodia, 
invadopodia) 
Chemokines/ 
cytokines and 
their receptors 
CXCL12/CXCR4: 
enhanced release 
Increased proliferation (via Ras); 
increased resistance (via PI3K/Akt) 
Promotion of invasion and chemotaxis 
(via PI3K/Cdc42, FAK, Pax) 
IL-6/IL-6R: 
enhanced release 
Increased cell proliferation (via Ras, J 
AK/STAT); increased resistance (via 
PI3K) 
Promotion of invasion and chemotaxis 
(via MAPK, STAT) 
MMPs Upregulation Increased growth factor/chemo-
/cytokine release and signaling (via 
ectodomain shedding, ECM 
degradation) 
Tissue degradation underlying tissue 
invasion and remodeling; control of 
migration mode 
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Figure 1-11:  Signalling pathways controlling tumour cell growth, survival and invasion. The pathways of p53, Ras GTPase, small Rho 
GTPases, integrins, growth factor receptors and cadherins with a dual role in controlling cell growth and survival (upper row), as well as cell 
migration and invasion (lower row). Migration effectors are marked in red; survival effectors in purple; and signaling hubs in bright green.  
Arrows indicate signaling direction.  Transcription factors are shown bound to DNA. Some abbreviations: a-act., aactinin; cat, catenin; Cdc42, 
cell division cycle 42; CREB, cAMP response element-binding; CyclD1, Cyclin D1; eIF, eukaryotic initiation factor; ERK, extracellular signal-
related kinase; ETS, erythroblast transformation specific (transcription factor); FAK, focal adhesion kinase; GEF, guanine nucleotide exchange 
factor; GFR, growth factor receptor; GRB2, growth factor receptor-bound protein 2; ILK, integrin-linked kinase; Integ., integrin; JNK, Janus 
kinase; MEK, mitogen-activated protein kinase/extracellular signalregulated kinase kinase; MEKK, MEK kinase; mTOR, mammalian target of 
Rapamycin; MLC, myosin light chain, etc.  Taken from Alexander & Friedl, 2012.   
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1.2  Background to techniques   
1.2.1  Gene expression microarrays   
Microarray-based gene expression profiling refers to the analysis of thousands of genes in a 
single experiment, where the labelled target (ie sample RNA, cRNA or cDNA) is interrogated 
with probes that are immobilized to a solid matter (eg fibrous mesh membrane, glass slide, 
beads).  Through biostatistical and bioinformatics methods, the relative expression levels of each 
gene represented by a probe in the microarray can be obtained.  After obtaining these values, 
numerous approaches and algorithms to interrogate microarray data can be applied230.   
The core principle behind microarrays is hybridization between two DNA strands, the property of 
complementary nucleic acid sequences to specifically pair with each other by forming hydrogen 
bonds between complementary nucleotide base pairs.  A high number of complementary base 
pairs in a nucleotide sequence means tighter non-covalent bonding between the two strands.  
After washing off non-specific bonding sequences, only strongly paired strands will remain 
hybridized.  Fluorescently labeled target sequences that bind to a probe sequence generate a 
signal that depends on the hybridization conditions (such as temperature), and washing after 
hybridization.  Total strength of the signal, from a spot (feature), depends upon the amount of 
target sample binding to the probes present on that spot.  Microarrays use relative quantization in 
which the intensity of a feature is compared to the intensity of the same feature under a different 
condition, and the identity of the feature is known by its position.   
The microarray experiments carried out in our study employed the Affymetrix GeneChip system. 
Affymetrix probes are designed using publicly available information.  The sequences, from 
which the probe sets were derived, were selected from GenBank, dbEST, and RefSeq.  The 
sequence clusters were created from the UniGene database (Build 133, April 20, 2001) and then 
refined by analysis and comparison with a number of other publicly available databases, 
including the Washington University EST trace repository and the University of California, Santa 
Cruz Golden-Path human genome database (April 2001 release).  Sequences from these 
databases were collected and clustered into groups of similar sequences.   
The probes are manufactured on the chip using photolithography (a process of using light to 
control the manufacture of multiple layers of material), which is adapted from the computer chip 
industry.  Each GeneChip contains approximately 1,000,000 features.  Each probe is spotted as a 
pair, one being a perfect match (PM), and the other with a mismatch (MM) at the centre.  These 
probe pairs allow the quantitation and subtraction of signals caused by non-specific cross-
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hybridisation.  The differences in hybridisation signals between the partners, as well as their 
intensity ratios, serve as indicators of specific target abundance.  Each gene or transcript is 
represented on the GeneChip by 11 probe pairs.  The probe sets are given different suffixes to 
describe their uniqueness and/ or their ability to bind different genes or splice variants.   
“_at” describes probes set that are unique to one gene. 
“_a_at” describes probe sets that recognise multiple transcripts from the same gene. 
“_s_at” describes probe sets with common probes among multiple transcripts from separate 
genes.   
The “_s_at” probe sets can represent shorter forms of alternatively polyadenylated transcripts, 
common regions in the 3‟ ends of multiple alternative splice forms, or highly similar transcripts. 
Approximately 90% of the _s_at probe sets represent splice variants. Some transcripts will also 
be represented by unique _at probe sets.   
“_x_at” designates probe sets where it was not possible to select either a unique probe set or a 
probe set with identical probes among multiple transcripts.  Rules for cross-hybridisation are 
dropped in order to design the _x_at probe sets.  These probe sets share some probes identically 
with two or more sequences and therefore, these probe sets may cross-hybridise in an 
unpredictable manner.   
A sample must be registered and an experiment defined in GCOS (GeneChip Operating 
Software) before processing a probe array in the fluidics station or scanning.  Once the array is 
scanned, an image file is created called a “.dat” file.  The software then computes cell intensity 
data (“.cel” file) from the image file.  It contains a single intensity value for each probe cell 
delineated by the grid (calculated by the Cell Analysis algorithm).  The amount of light emitted 
at 570nm from stained chip is proportional to the amount of labelled RNA bound to each probe. 
Each spot correspond to individual probe (either perfect match or mismatch).  The probes for 
each gene are distributed randomly across the chip to nullify any region specific bias.  Following 
this, data analysis algorithms combine the probes to the respective intensity of individual 
transcripts.   
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1.2.2  2D-DIGE MALDI-TOF MS   
Two-dimensional difference gel electrophoresis (2D-DIGE) is a high performance proteomic 
technology, allowing quantitative protein expression profiles across many clinical specimens in a 
reproducible, sensitive and high-throughout manner.  Originally introduced in 1975, Farrell and 
Klose231 demonstrated the ability to separate proteins based on their isoelectric points and 
molecular weights by 2-DE on polyacrylamide gels.  Proteins in a 2D gel are separated by two 
separate unrelated elements.  In the first dimension, proteins are separated according to their 
isoelectric point (pi) called isoelectric focusing.  In the second dimension proteins are separated 
according to their molecular weights in SDS-PAGE.   
2D-DIGE technology involves prelabelling the protein samples with different spectrally-
resolvable fluorescent dyes so they can be mixed together, co-separated and visualised on a 
single 2-DE gel.  The CyDye DIGE Fluor dyes (Cy2, Cy3 and Cy5) are matched for mass and 
charge, but possess distinct excitation and emission spectra.  During labelling, the dyes undergo a 
nucleophilic substitution reaction with the s-amino group of lysine residues on protein resulting 
in the formation of an amide bond.  The dye: protein ratio is optimised so that only 5% o f the 
protein sample is labelled (where the protein is abundant). This method ensures that only proteins 
with a single dye molecule are visualised and those containing multiple dye molecules are 
minimised.  Consequently, the same protein labelled with any of the dyes will migrate to the 
same position on the 2D gel.  By using different dyes to separately label proteins isolated from 
normal and diseased tissues, multiple samples (up to three) can be co-separated and quantitated 
by three different set of wavelengths (figure 1-12).  The inclusion of a pooled internal standard 
(Cy2), containing every protein from all samples is used to match protein patterns across gels.  
This feature, counteracts inter-gel variation, allows normalisation of individual experiments and 
accurate quantification of differences between samples with significance232 233.   
The fully optimised system (including CyDye fluorescent dyes, imager, and DeCyder 
Differential Analysis Software) offers increased throughput, ease of use, reproducibility, and 
accurate quantitation of protein expression differences.  Reduced system variability enables 
accurate study of protein expression differences against a baseline of biological variation.  
DeCyder biological variation analysis (BVA) processes multiple gel images, performs gel-gel 
spot matching and quantatively compares protein abundance across gels.   
Mass spectrometry identifies the proteins corresponding to any spots observed by 2D-DIGE and 
utilises the gene and literature database to interpret the proteomic data.   
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Figure 1-12  Outline of 2D-DIGE system where three CyDye DIE Fluor minimal dyes are separated 
in one gel   
 
Matrixassisted Laser Desorption/Ionisation (MALDI) developed by Karas and Hillenkamp234 
involves the deposition of sample molecules with an excess of matrix material (α-cyano-4-
hydroxycinnamic acid or dihydroxybenzoic acid) in a solvent.  The water in the solvent 
evaporates and the sample proteins are surrounded by the matrix, which forms a crystal lattice. 
The precipitant is then bombarded with laser pulses that imparts energy.  The matrix materials 
have absorbances at the wavelength of the laser, and are subject to desorption and ionisation, 
accompanied by fragmentation.  The MS measures the mass-to-charge ratio (m/z) of the protein, 
peptide or peptide fragments (figure 1-13).  The time-of-flight (TOF) analyser measures the time 
it takes for the ions to fly from one end of the analyzer to the other end and strike the detector.  
The smaller ions possess higher velocity relative to larger/heavier ions.  Separated ion fractions 
arriving at the end of the drift tube are detected by an appropriate recorder that produces a signal 
upon impact of each ion group.  The TOF mass spectrum is a recording of the detector signal as a 
function of time.  This peptide mass fingerprint can then be used to search databases to identify 
the protein235.   
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Figure 1-13  A schematic diagram of MALDI-TOF-MS. 
 
1.2.3  siRNA and shRNA   
The discovery of RNAi, a powerful tool to induce loss-of-function phenotypes through the 
posttranscriptional silencing of gene expression, has provided new possibilities for cancer 
therapy236-238.  RNA interference (RNAi) is the mechanism for RNA-guided regulation of gene 
expression, in which the introduction of double-stranded RNA (dsRNA) into a diverse range of 
organisms and cell types causes degradation of the complementary mRNA.  Small interfering 
RNA (siRNA) is also known as short interfering RNA or silencing RNA (figure 1-14).  It is a 
class of 20-25 nucleotide-long double-stranded RNA molecules.  In the late nineties RNA 
silencing was discovered in plants during the course of transgenic experiments that eventually led 
to the silencing of the introduced transgene and, in some cases, of homologous endogenous genes 
or resident transgenes239 (Matzke et al., 1989; Linn et al., 1990; Napoli et al., 1990; Smith et al., 
1990; van der Krol et al., 1990).  However, this approach could not be used in mammalian cells 
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as the long double-stranded RNAs (dsRNAs) triggered a cytotoxic reaction leading to cell death 
(Hunter et al., 1975).  Further studies in plants and invertebrates demonstrated that the actual 
molecules that led to RNAi were short dsRNA oligonucleotides, 21 nucleotides in length, 
processed internally by an enzyme called “Dicer”.  It was then demonstrated in 2001, that siRNA 
could directly trigger RNAi in mammalian cells without evoking nonspecific effects.  RNAi 
technology takes advantage of the cell’s natural machinery, facilitated by short interfering RNA 
molecules, to effectively knock down expression of a gene of interest.  There are several ways to 
induce RNAi, synthetic molecules, RNAi vectors, and in vitro dicing.   
 
1.2.3.1  Mechanism of action   
Long double-stranded RNAs (typically >200 nt) can be used to silence the expression of target 
genes in a variety of organisms.  Long double-stranded RNA (dsRNA) enters a cellular pathway 
that is commonly referred to as the RNA interference (RNAi) pathway.  The dsRNA triggers a 
two-step reaction.  During the initiation stage, dsRNA is processed by a ribonuclease (RNase) III 
enzyme, called Dicer, into small interfering RNAs (siRNAs)240; mediated by type III RNase 
Dicer enzyme.  RNase III family members are among the few nucleases that show specificity for 
dsRNAs241 and are evolutionarily conserved in worms, flies, fungi, plants, and mammals242.  
Complete digestion by RNase III enzymes results in dsRNA fragments of 20-25 base pairs243.  
During the effector stage, the siRNAs assemble into endoribonuclease-containing complexes 
known as RNA-induced silencing complexes (RISCs).  siRNAs undergo unwinding before being 
incorporated into a high-molecular-weight protein complex called RISC244.  Dicers are part of the 
RISC complex, which includes several different proteins such as the Argonaute gene family 
members and an ATP-dependant RNA helicase activity that unwinds the two strands of RNA.  
Functional RISCs contain only single stranded siRNA245.  The siRNA strands subsequently guide 
the RISC to complementary RNA molecules, where base pairing takes place between the 
antisense strand of the siRNA and the sense strand of the target mRNA. This leads to 
endonuclease cleavage of the target RNA246,247.   
 
1.2.4  microRNA   
MicroRNAs (miRNAs) are a class of naturally occurring small non-coding RNA molecules (21-
25 bases in length) that regulate a variety of developmental and physiological processes248.  They 
control gene expression by mRNA cleavage, mRNA destabilization, or inhibition of 
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translation249.  The discovery of let-7 in Caenorhabditis elegans in 2000 as a regulator of 
developmental cellular fate250 and discovery of let-7-related genes in multiple species indicated 
the importance of these miRNAs251.  Since then, miRNA research has revealed multiple roles in 
negative regulation (transcript degradation and sequestering, translational suppression) and 
possible involvement in positive regulation (transcriptional and translational activation).  By 
affecting gene regulation, miRNAs are likely to be involved in most biological processes252.   
Almost half of miRNAs reside in clusters and are transcribed as polycistronic precursor 
miRNAs253.  Other miRNAs, located in intergenic regions, are transcribed by their own 
promoters, and those present in intronic regions are likely under the control of the host 
genes’promoters254.  There are currently approximately 2,600 unique mature miRNAs in human 
(miRBase version 20)255.  Almost 50% of these are located at fragile sites on chromosomes 
known for having common alterations (i.e. amplification, deletion, and rearrangements) in 
cancer256.  Roles of miRNAs in cellular processes like cell cycle progression, proliferation, 
metabolism, apoptosis, and stress resistance cannot be overlooked as more than 60% of human 
protein coding genes are predicted to be under selective pressure to be regulated by 
miRNAs257,258.   
The uncapitalized "mir-" refers to the pre-miRNA, while a capitalized "miR-" refers to the 
mature form. miRNAs with nearly identical sequences except for one or two nucleotides are 
annotated with an additional lower case letter.  For example, miR-123a would be closely related 
to miR-123b.  Pre-miRNAs that lead to 100% identical mature miRNAs but that are located at 
different places in the genome are indicated with an additional dash-number suffix.  For example, 
the pre-miRNAs hsa-mir-194-1 and hsa-mir-194-2 lead to an identical mature miRNA (hsa-miR-
194) but are located in different regions of the genome.  Both strands of a pre-microRNA may be 
processed into two mature microRNAs, with similar efficiencies which are discriminated by -5p 
and -3p, or with one dominantly processed and the recessive one star-labeled (*), which function 
differently against different target genes.  For example, miR-123 and miR-123* would share a 
pre-miRNA hairpin, but more miR-123 would be found in the cell259,260.   
 
1.2.3.1  microRNA transcription and function   
miRNA genes are usually transcribed by RNA polymerase II (Pol II).  The first step in miRNA 
maturation is the nuclear cleavage preformed by the Drosha RNase III endonuclease to give an 
approximately 60–70 nt stem loop intermediate, having a 5’ phosphate and an approximately 2 nt 
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3’overhang (figure 1-14).  This pre-miRNA is actively transported from the nucleus to the 
cytoplasm by Ran-GTP and the export receptor Exportin-5.  The nuclear cut by Drosha defines 
one end of the mature miRNA, and the other is processed in the cytoplasm by Dicer, which 
recognizes the double-stranded portion of the pre-miRNA and cuts about two helical turns away 
from the base of the stem loop.  This eliminates the loop itself and leaves the 5’ phosphate and 
approximately 2nt 3’ overhang characteristic of the RNase III products.  This process results in a 
mature miRNA, and siRNA-like imperfect duplex ready for RISC.  Once loaded on RISC, there 
is no substantial difference between miRNA and siRNA toward the target messenger RNA.  Both 
of them are capable of undertaking two possible post-transcriptional mechanisms: mRNA 
cleavage, translational repression.  The choice is determined by the degree of complementarity 
with the target.  A total identity between siRNA or miRNA and mRNA will specify cleavage, 
while partial complementarity of any of the two RNAs in the 30-untranslatable (30-UTR) region 
of the messenger will induce translational repression261.   
 
 
Figure 1-14:  (a) siRNA and (b) miRNA (From Izquierdo et al., 2005261). 
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1.2.5  Methylation analysis   
Methylation has been shown to play a vital role in numerous cellular processes, including 
embryonic development, genomic imprinting, X-chromosome inactivation, and preservation of 
chromosome stability262.  DNA methylation occurs at the cytosine bases of eukaryotic DNA, 
which are converted to 5-methylcytosine by DNA methyltransferase (DNMT) enzymes.  The 
altered cytosine residues are usually immediately adjacent to a guanine nucleotide, resulting in 
two methylated cytosine residues sitting diagonally to each other on opposing DNA strands.  
Different members of the DNMT family of enzymes act either as de novo DNMTs, putting the 
initial pattern of methyl groups in place on a DNA sequence, or as maintenance DNMTs, 
copying the methylation from an existing DNA strand to its new partner after replication263.   
In mammals, methylation is found sparsely but globally, distributed in definite CpG sequences 
throughout the entire genome, with the exception of CpG islands, or certain stretches 
(approximately 1 kilobase in length) where high CpG contents are found.  The methylation of 
these sequences can lead to inappropriate gene silencing, such as the silencing of tumour 
suppressor genes in cancer cells (figure 1-15).   
 
Figure 1-15: DNA methylation and cancer.  The diagram shows a representative region of 
genomic DNA in a normal cell.  The region shown contains repeat-rich, hypermethylated 
pericentromeric heterochromatin and an actively transcribed tumour suppressor gene (TSG) 
associated with a hypomethylated CpG island (indicated in red).  In tumour cells, repeat-rich 
heterochromatin becomes hypomethylated and this contributes to genomic instability, a hallmark of 
tumour cells, through increased mitotic recombination events.  De novo methylation of CpG islands 
also occurs in cancer cells, and can result in the transcriptional silencing of growth-regulatory genes.  
These changes in methylation are early events in tumourigenesis (From Robertson, K. DNA 
methylation and human disease. Nature Reviews Genetics 6, 598262).   
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Currently, the mechanism by which de novo DNMT enzymes are directed to the sites that they 
are meant to silence is not well understood.  However, researchers have determined that some of 
these DNMTs are part of chromatin-remodeling complexes and serve to complete the remodeling 
process by performing on-the-spot DNA methylation to lock the closed shape of the chromatin in 
place.  The global pattern of methylation in mammals makes it difficult to determine whether 
methylation is targeted to certain gene sequences or is a default state, but the CpG islands tend to 
be near transcription start sites, indicating that there is a recognition system in place263.   
 
1.2.5.1  Bisulfite modification   
A major advance in DNA methylation analysis was the development of a method for sodium 
bisulfite modification of DNA to convert unmethylated cytosines to uracil, leaving methylated 
cytosines unchanged264.  Bisulfite modification of genomic DNA was first employed for the 
detection of varying methylation patterns in individual strands of particular genomic 
sequences264.  Incubation of target DNA with sodium bisulfite, results in conversion of 
unmethylated cytosine residues into uracil, leaving methylated cytosines unchanged.  This allows 
one to distinguish methylated from unmethylated DNA via PCR amplification and analysis of the 
PCR products.  During PCR amplification, unmethylated cytosines amplify as thymine and 
methylated cytosines amplify as cytosine (figure 1-16).   
In this reaction, a bisulfite ion is added to the 5-6 double bond of the cytosine molecule, which is 
converted to a uracil-bisulfite derivative by hydrolytic deamination.  The final alkali treatment of 
the DNA removes the sulphonate group to give uracil 265-267.  Under these conditions, 5-
Methylcytosine (5-mC) remains unchanged.  During PCR amplification, with primers designed 
to anneal with bisulfite-converted DNA only, all uracil and thymine nucleotides are amplified as 
thymine, whereas only 5-mC is amplified as cytosine (figure 1-16).  
 
1.2.5.2  Methylation sensitive PCR (MSP)   
Methylation sensitive PCR (MSP) is a rapid and very sensitive technique to screen for 
methylation.  First reported in 1996 by Herman et al.,268, MSP has become a widely used 
technique that is good for a “yes or no”indication concerning methylation of CpG sites.  MSP 
primer-based methods include MethyLight269, SYBER green-based quantitative MSP270, 
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sensitive melting analysis after real-time MSP (SMART-MSP)271, and methylation-specific 
fluorescent amplicon generation (MS-FLAG)271.   
 
 
Figure 1-16: Sodium bisulfite conversion. Sodium bisulfite modifies the sequence of genomic DNA 
by converting unmethylated cytosines to uracils while leaving methylated cytosines unmodified.  PCR 
amplification results in the replacement of uracil residues by thymines. Bisulfite conversion destroys 
the self-complementarity of the original genomic DNA, so that two different PCR products can be 
generated: one derived from the top strand, and one derived from the bottom strand.(From 
SpringerImages.com).  
 
 
The design of primers is essential for reliable results; ideally, the ‘methylated’ and 
‘ummethylated’ primer sets should be designed for the same CpG sites and include multiple CpG 
sites at the 3’ ends272.  Following bisulfite modification, PCR is performed using two sets of 
primers designed to amplify either methylated or unmethylated alleles.  The methylated primer 
set assumes the CpG’s are fully methylated and thus the primer will have all four bases in the 
sequence.  The unmethylated primer set anneals to gDNA that is not methylated in the (same) 
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primer binding site, and therefore will have a T in place of C in the primer sequence.  It is 
important to test the primer sets with a control gDNA of known methylation status.  The properly 
designed methylated primer set will only amplify the control methylated gDNA, and not the 
unmethylated gDNA, and the unmethylated primer set will only amplify the unmethylated 
gDNA.   
 
1.2.5.3  Quantitative methylation specific PCR   
Eads and colleagues first introduced the high-throughput technology known as MethyLight or 
quantitative methylation specific PCR (QMSP) for the analysis of DNA methylation that utilises 
fluorescence-based real-time PCR (TaqMan®) technology269 (figure 1-17).  The use of three 
oligonucleotides (forward and reverse primers, and interpositioned probe) in MethyLight, any 
one or more of which can be used for methylation discrimination, allows for a high degree of 
specificity, sensitivity, and flexibility in methylation detection273.  Figure 1-17 (application C) 
illustrates the primer design strategy for a quantitative version of MSP where the probe is 
designed to avoid covering CpG dinucleotides.  A greater degree of methylation discriminatory 
capability can be achieved by designing the probe to include CpG dinucleotides in addition to the 
forward and reverse primers and this is the most commonly used application of MethyLight 
(figure 1-17, application D).  The design of primers and probe that do not overlap CpG 
nucleotides  (figure 1-17, application A) results in a reaction without any methylation 
discriminatory capability and serves as a control reaction for the amount of input DNA.  The 
inclusion of methylation discrimination only in the probe (figure 1-17, application B) provides a 
quantitative method for determining the relative amounts of various permutations of methylation 
within the sequence covered by the probe.   
A disadvantage of the MethyLight technique is that it cannot quantify methylation at the 
individual nucleotide level; rather, it can assess methylation levels at the primer sites and/or a 
probe site as a whole.  These assays were designed to detect completely methylated or 
unmethylated alleles, but do not detect partial allelic methylation.  In contrast, bisulfite-
sequencing, such as bisulfite-pyrosequencing274 can achieve resolution at the individual 
nucleotide level.  More recently mass spectrometry has been widely used in methylation 
analyses275.   
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Figure 1-17:  Schematic of the theoretical basis of MethyLight technology.  Genomic DNA is first 
chemically modified by sodium bisulfite.  This generates methylation-dependent sequence differences 
at CpG dinucleotides by converting unmethylated cytosine residues (locations indicated by white 
circles) to uracil, while methylated cytosine residues (locations indicated by black circles) are retained 
as cytosine.  Fluorescence-based PCR is then performed with primers that either overlap CpG 
methylation sites or that do not overlap any CpG dinucleotides.   
Sequence discrimination can occur either at the level of the PCR amplification process or at the level 
of the probe hybridisation process, or both.  Sequence discrimination at the PCR amplification level 
requires the primers and probe (application D), or just the primers (application C), to overlap potential 
methylation sites (CpG dinucleotides).  The MethyLight assay can also be designed such that 
sequence discrimination does not occur at the PCR amplification level.  If neither the primers nor the 
probe overlap sites of CpG dinucleotides (application A), then no methylation-dependent sequence 
discrimination occurs at the PCR amplification or probe hybridisation level.  This reaction represents 
amplification of the converted genomic DNA without bias to methylation status, which can serve as a 
control for the amount of input DNA. When just the probe overlaps methylation sites (application B), 
then sequence discrimination can occur through probe hybridisation.  The design of separate probes 
for each sequence variant resulting from different methylation patterns (22 = 4 probes in the case of 
two CpGs, as illustrated) can potentially serve as a quantitative version of the MethyLight 
technology269.   
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1.2.6  Sequenom Oncogenotype Mutational Analysis   
The Sequenom MassARRAY® system is a DNA analysis platform that efficiently and precisely 
measures the amount of genetic target material and/or variations and is suitable for a variety of 
research applications including Somatic Mutation Profiling, Genotyping, Methylation Analysis, 
Molecular Typing and Quantitative Gene Expression (QGE).  Detection by MALDI-TOF mass 
spectrometry (MS) offers high sensitivity and accuracy.   
The assay is based on primer extension and offers two levels of specificity.  First, a locus-specific 
PCR reaction takes place, followed by a locus-specific primer extension reaction (iPLEX assay) 
in which an oligonucleotide primer anneals immediately upstream of the polymorphic site being 
genotyped.  The PCR primers are designed in a region of approximately 100 base pairs around 
the SNP of interest and an extension primer is designed immediately adjacent to the SNP.  In the 
iPLEX assay, the primer and amplified target DNA are incubated with mass-modified 
dideoxynucleotide terminators (figure 1-18).  The primer extension is made according to the 
sequence of the variant site, and is a single complementary mass-modified base.  Through the use 
of MALDI-TOF mass spectrometry, the mass of the extended primer is determined.  The 
primer’s mass indicates the sequence and, therefore, the alleles present at the polymorphic site of 
interest.  Sequenom supplies software (SpectroTYPER) that automatically translates the mass of 
the observed primers into a genotype for each reaction276.   
Figure 1-19 outlines the steps involved in the iPLEX assay.  Firstly, the DNA needs to be 
amplified by PCR prior to performing an extension reaction of the SNP of interest.  Sequenom’s 
MassARRAY Designer software automatically designs PCR and extension primers (probes) for 
each SNP to be investigated.  All oligos for PCR and iPLEX reactions are unmodified, with 
standard purification.  The goal of an optimal multiplex PCR reaction is to evenly amplify many 
individual loci of DNA with minimal nonspecific byproducts.  Purified amplicons are then used 
as templates for the primer extension reaction.  Following the PCR, treatment with shrimp 
alkaline phosphatase (SAP) is performed in order to remove remaining, nonincorporated dNTPs 
from amplification products.  SAP dephosphorylates unincorporated dNTPs by cleaving the 
phosphate groups from the 5′ termini.   
After PCR amplification of the region of interest from genomic DNA, a genotyping primer is 
annealed adjacent to the polymorphic site in the presence of DNA polymerase and a mixture of 
dNTPs and ddNTPs.  During the iPLEX reaction, the primer is extended by one mass-modified 
nucleotide depending on the allele and the design of the assay.  Such a reaction mixture generates 
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allele specific products of different lengths, which allows easy interrogation by MALDI-TOF-
MS.   
The primer extension reaction is then desalted, as cations are known to interfere with MALDI.  
This cleanup step is important to optimize mass spectrometry analysis of the extended reaction 
products.  A slurry of resin is added directly to primer extension reaction products to remove 
salts such as Na+, K+, andMg2+ ions.  If not removed, these ions can result in high background 
noise in the mass spectra.   
The DNA/RNA analyte mixture is transferred to a SpectroCHIP® Array.  The SpectroCHIP® 
Array is coated with a matrix which allows crystallization of the PCR product on its surface.  The 
chip is placed into the mass spectrometer and a laser is fired at the crystal which ionizes the 
molecules.  These ions travel through a vacuum tube to an ion detector based on their mass.  
Smaller molecules travel faster than larger ones.  Time of flight measures the difference in time 
different molecules hit the detector and the software calculates the mass of the fragments.  
MALDI-TOF can resolve mass differences of 16 Daltons.   
 
 
Figure 1-18:  Single-base primer extension 
assay.  In the iPLEX assay, the primer and 
amplified target DNA are incubated with mass-
modified dideoxynucleotide terminators.  The 
primer extension is made according to the 
sequence of the variant site, and is a single 
complementary mass-modified base.  Through 
the use of MALDI-TOF mass spectrometry, 
the mass of the extended primer is determined.   
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Figure 1.19  iPLEX Assay (The scheme depicts a single assay).  The starting point of the iPLEX 
assay is PCR amplification, followed by the addition of Shrimp Alkaline Phosphatase (SAP) to 
inactivate remaining nucleotides in the reaction.  Following a brief incubation, the primer mixture is 
added and conducted using a standardised cycling programme, placed on a SpectroChip and analysed 
by MALDI-TOF MS (diagram taken from Oeth et al, 2006, Sequenom Application Note Doc. No. 
8876-006).   
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1.3  Introduction and Aims of thesis   
The DLKP cell line has great potential for studying human lung cancer phenotypes for several 
reasons.  First of all, although it is sensitive to most chemotherapeutic drugs, resistant variants 
can be readily generated196,277.  Secondly, it is itself quite poorly invasive in vitro, but highly 
invasive variants can be readily generated196,278,279.  Thirdly, it has been shown to contain at least 
three clonal subtypes which can interconvert through one of the clonal types only, and which 
have marked differences in invasiveness, adhesiveness, migration and anoikis resistance in 
vitro280,281.  Finally, having been established from a tumour biopsy in our laboratory, it is 
available at early passage number, close to the patient tumour.   
In the work described in this thesis, I have exploited the availability of clonal populations to 
investigate the time course and mechanism of development of resistance to a chemotherapeutic 
drug (mitoxantrone) and development of in vitro invasiveness and to investigate some aspects of 
the mRNA and protein expression changes associated with these changing phenotypes.   
 
Aims   
The aims of this thesis were as follows:  
1. To examine the temporal relationship between emergence of drug resistance and 
invasiveness in a human lung carcinoma cell line model of mitoxantrone resistance 
development in order to better understand the link between multidrug resistance and 
cancer invasion.   
2. To characterise the resistant phenotype of mitoxantrone resistant lung cancer cell 
lines – using toxicity assays, gene copy number assays, methylation assays, 
microarray expression analysis and proteomic analysis.   
3. To use microarray analysis to search for changes which may be functionally 
significant in the transition from preinvasive to invasive phenotype in the newly 
developed lung cancer cell line models of mitoxantrone resistance.   
4. To explore the association between the expression of ABC transporter proteins and 
cell signalling pathways.   
5. To characterise, at the molecular level, three distinct clonal subpopulations of the 
lung cancer cell line DLKP which display different levels of in vitro invasiveness, 
and to identify reliable protein markers which could characterise these clones in a 
mixed cell population.   
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CHAPTER 2  
 
Materials and methods 
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2.1  Cell lines and reagents 
Table 2-1 outlines details and sources of the human lung tumour cell lines and their media 
components and serum concentrations used in this thesis.  All cells were maintained under 
standard culture conditions, 5% CO2 at 37°C.  Cell culture procedures were strictly adhered to as 
outlined in NICB SOP.  All cell lines were determined to be mycoplasma free; testing was 
carried out in-house.  Table 2-2 outlines the chemotherapeutic drugs and inhibitors used in this 
project.   
Table 2-1 Cell lines used in this thesis 
Cell Line Source Media Cell Type 
DLKP parent NICB ATCC + 5% FCS Human poorly differentiated lung 
carcinoma 
DLKP-SQ 
McBride et al., 1998280) 
NICB ATCC + 5% FCS Intermediate Sub-Population  
Cloned from DLKP  
DLKP-I 
(McBride et al., 1998280) 
NICB ATCC + 5% FCS Intermediate Sub-Population  
Cloned from DLKP  
DLKP-M 
(McBride et al., 1998280) 
NICB ATCC + 5% FCS Intermediate Sub-Population  
Cloned from DLKP  
SQ-Mitox-BCRP-4P NICB  ATCC + 5% FCS Mitoxantrone selected variant of DLKP-
SQ 
SQ-Mitox-BCRP-6P NICB  ATCC + 5% FCS Mitoxantrone selected variant of DLKP-
SQ 
SQ-Mitox-BCRP-6P 
(Isolate 1) 
NICB  ATCC + 5% FCS Mitoxantrone selected variant of DLKP-
SQ 
SQ-Mitox-MDR-4P NICB ATCC + 5% FCS Mitoxantrone selected variant of DLKP-
SQ 
SQ-Mitox-MDR-6P NICB ATCC + 5% FCS Mitoxantrone selected variant of DLKP-
SQ 
DLKP-A 
(Heenan et al., 1997277) 
NICB ATCC + 5% FCS Adriamycin selected of DLKP 
DLRP (Law et al., 
1992282) 
NICB ATCC + 10% FCS Human poorly differentiated lung 
carcinoma 
Limbal stromal 
(O’Sullivan and 
Clynes283) 
NICB DMEM + 10% FCS Corneal epithelia 
NICB: National Institute for Cellular Biotechnology, DCU, Dublin, Ireland.  ATCC (Hams F12/DMEM 1:1)   
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Table 2-2 Chemotherapy drugs and inhibitors used in this project 
Drug Storage Source 
Mitoxantrone Room temperature in dark SVUH 
Taxol Room temperature in dark SVUH 
Epirubicin 4°C in dark SVUH 
Vinblastine 4°C in dark SVUH 
Irinotecan -20°C SVUH 
Cisplatin Room temperature in dark SVUH 
VP16 Room temperature in dark SVUH 
5FU Room temperature in dark SVUH 
Elacridar (GF120918) -20°C Sequoia 
PD98059 -20°C Promega 
U0126 -20°C Promega 
AZD6244 -20°C Selleck 
 
2.2  In vitro proliferation assays   
Cells in the exponential phase of growth were harvested by trypsinisation.  Cell suspensions 
containing 1×104 cells/ml were prepared in cell culture medium.  To each well of a 96 well plate 
100 μl of the cell suspension was added (Costar, 3599).  Plates were agitated gently in order to 
ensure even dispersion of cells over the surface of the wells.  Cells were incubated overnight.  
Cytotoxic drug dilutions were prepared at 2× their final concentration in cell culture medium.  A 
volume of 100 μl of drug dilution was added to each well.  Plates were mixed gently as above.  
Cells were further incubated for 6 – 7 days until the control wells had reached approximately 80-
90% confluency.  Assessment of cell survival in the presence of drug was determined by the acid 
phosphatase assay (section 2.2.2).  The concentration of drug which caused 50% cell kill (IC50 of 
the drug) was determined by using Prism software from GraphPad Software (section 2.16).  
Results were graphed as percentage survival (relative to the control cells) versus cytotoxic drug 
concentration.   
2.2.1  Combination toxicity assays 
DLKP cells (2000 cells/well) were seeded into 96 well plates and incubated overnight as 
described in 2.2.  Cytotoxic drug dilutions and MAPK kinase inhibitors (PD98059 and U0126) 
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were prepared at 2× their final concentration in cell culture medium.  Elacridar (GF120918) was 
used as a control and prepared at 2× final concentration in cell culture medium.  A volume of 100 
μl of the final drug dilutions were added to each well and mixed gently.  Cells were incubated for 
48 hours.  Assessment of cell survival in the presence of drug was determined by the acid 
phosphatase assay (section 2.2.2).   
 
2.2.2  Assessment of cell number - Acid Phosphatase assay   
Following the incubation period, media was removed from each plate/well.  Each well on a plate 
was washed with 100 μl PBS.  This was removed and 100 μl of freshly prepared phosphatase 
substrate (10 mM p-nitrophenol  phosphate (Sigma 104-0) in 0.1 M sodium acetate (Sigma, 
S8625), 0.1% triton X-100 (BDH, 30632), pH 5.5) was added to each well.  The plates were 
wrapped in tinfoil and incubated in the dark at 37°C for 2 hours.  The enzymatic reaction was 
stopped by the addition of 50 μl of 1 M NaOH to each well.  Plates were read in a dual beam 
plate reader at 405 nm with a reference wavelength of 620nm.   
 
2.3  Extracellular matrix studies 
2.3.1  In vitro invasion assays 
Matrigel (BD Biosciences, 354234) was diluted to a working stock of 1 mg/ml in serum- free 
DMEM.  Aliquoted stocks were stored at -20oC.  Invasion assays were performed using the 
method of Albini et al. (1987)284.  A volume of 100 μl of matrigel was placed into each insert 
(BD Biosciences, 353097) (8.0μm pore size, 24 well format) and kept at 4 oC for 24 hours.  The 
insert and the plate were then incubated for one hour at 37 oC to allow the proteins to polymerise.  
Cells were harvested and resuspended in culture media containing 5% FCS at 1×106 cells/ml.  
Excess media/PBS was removed from the inserts, and they were rinsed with culture media.  A 
volume of 100 μl of the cell suspension was added to each insert.  A further 100 μl of culture 
media was added to each insert and 500 μl of culture media containing 5% FCS was added to the 
well underneath the insert.  Cells were incubated for 24 hours.   
To investigate the effect of MMP-2 (Millipore MAB13405) and MMP-10 (R&D Systems 
MAB9101) blocking antibodies on cell invasion, cells were seeded in culture media containing 
5% FCS and 5μg/ml blocking antibody MMP-2 or 10μg/ml MMP-10.   
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To investigate the effect of the MAPK kinase inhibitor U0126 (Promega U0126 V112A) on cell 
invasion, cells were seeded in culture media containing 5% FCS and either 5μM or 10μM and 
500 μl of culture media containing 5% FCS and either 5μM or 10μM was added to the well 
underneath the insert.   
After the 24 hour incubation, the inside of the insert was wiped with a cotton swab dampened 
with PBS, while the outer side of the insert was stained with 0.25% crystal violet for 10 minutes 
and then rinsed in distilled water (dH2O) and allowed to dry.  The inserts were viewed and 
photographed under the microscope.  The invasion assays were quantified by counting cells in 10 
random fields within a grid at 20× objective and graphed as the total number of cells invading at 
200× magnification.  A minimum of 2 inserts were used per sample tested.   
 
2.3.2  Motility assay  
Motility assays were carried out as described in section 2.3.1, without the addition of 
extracellular proteins. 
 
2.3.3  Adhesion assay 
The CytoMatrix SCREEN kit (Chemicon Millipore, ECM205) contains five individual 96-well 
plates, one each for fibronectin, vitronectin, laminin, collagen I and collagen IV.  Each 96-well 
plate contains 12 × 8-well removable CytoMatrix Cell Adhesion Strips in a plate frame.  The 
wells in rows A – G have been coated with a human ECM protein.  Row H of each strip is coated 
with BSA which serves as a negative assay control.  Cells are seeded onto the coated substrate.  
Subsequently, adherent cells are fixed and stained.  Relative attachment was determined using 
absorbance readings.  The CytoMatrix SCREEN kit was used according to the manufacturerer’s 
instructions.   
 
2.3.4  Preincubation of cells with matrigel coated flasks  
Matrigel was coated onto flasks (1 ml/25 cm2) at a concentration of 1 mg/ml.  Flasks were shaken 
gently to ensure complete coverage of the bottom of the flask.  The coated flasks were then 
placed at 4oC overnight to allow the matrigel settle.  Before seeding flasks with cells, the flasks 
were placed into an incubator at 37oC for approximately 2 hours to allow the matrigel 
polymerise.  The excess media in the flasks was then removed and fresh complete media 
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containing the cell suspension was added.  Cells attached to the matrigel on the bottom of the 
flask and after 24 hrs were removed with 0.5 ml/25 cm2 dispase (BD Biosciences, 354235).  
Dispase is a bacillus derived neutral metalo protease that recovers cells cultured on matrigel.   
 
2.4  Zymography Assay   
2.4.1  Collection of Conditioned Media   
Cells were cultured until 50 – 60% confluent.  Cells were washed 3× in serum-free (SF) media. 
Cells were incubated in SF media (12 ml/T75 cm2 flask) for 60 min.  After this time, cells were 
washed again 3× in SF media.  A volume of 12mls of media was added to the cells and incubated 
for 72 hrs.  After such time, conditioned media was collected, centrifuged for 5 min at 1000rpm, 
filter sterilised through a low-protein binding 0.22μm filter, concentrated (to 10× of the starting 
volume of the conditioned media) in a Vivaspin concentrator (Vivaspin-20, cat VS2012) with a 5 
kDa cut-off and stored at –80°C.   
 
2.4.2  Zymography of Matrix Metalloproteinases 
Conditioned media supernatants were prepared in a 4× non-reducing loading buffer (Invitrogen, 
NP0007) before being separated on a 10% zymogram (gelatin) gel (Invitrogen, EC6175BOX) 
which allows for the visualisation of MMP-2 and MMP-9 or 12% zymogram (casein) gel 
(Invitrogen, EC6405BOX) which allows for the visualisation of MMP-10.  The gels were run at a 
constant voltage of 125V, 45mA for 90 minutes, or until the bromophenol blue dye front reached 
the end of the gel, in a 1× Tris-Glycine SDS running buffer (Biorad, 161-0732).  After 
electrophoresis, the gel was incubated with a 1× Zymogram Renaturing Buffer (Invitrogen 
Developing buffer (LC2671) containing 2.5% Triton-X100 (BDH, 30632), for 30 minutes at 
room temperature.  The Renaturing Buffer is decanted, and 1× Zymogram Developing Buffer 
(Invitrogen LC2671) was added, followed by an additional 30 minute incubation at room 
temperature.  Fresh Developing Buffer was added, and the gel incubated at 37°C overnight.  The 
gel was stained with Brilliant blue G Colloidal Coomassie (Sigma, B2025).  
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2.5  Immunohistochemistry   
2.5.1  Immunofluorescence studies on fixed cells   
Aliquots of 30 μl of 1×106 cells/ml from actively growing cultures were plated directly onto 10 
well, 7mm microscope slides (Erie Scientific Company, 465-68X).  Cells were allowed to attach 
overnight.  After such time, slides were washed 3× in PBS and allowed to air dry.  Slides were 
then foil wrapped and stored at -80oC until required.  Cells were later thawed and fixed in ice-
cold acetone for 5-10 minutes and allowed to air dry for 15 min prior to immunostaining.  The 
primary antibody (table 2-3) was added and incubated for 1 hr at RT.  Cells were washed 3× in 
PBS and secondary antibody, fluorescein isothicyanate-linked (FITC) anti-mouse IgG (Dako, 
F0261) which was diluted 1/40 was added for 30 min at RT.  Secondary antibody was removed 
and cells washed as outlined.  Slides were mounted with ProLong Gold mounting medium 
(P36930) and covered using a glass cover slip.  Cells were viewed and photographed using a 
Nikon phase contrast microscope fitted with an FITC filter.  Counterstaining was performed with 
propidium iodine nuclic acid stain (Invitrogen P3566).   
2.5.2  Immunohistochemistry   
All immunohistochemical (IHC) staining was performed using the DAKO Autostainer (DAKO, 
S3800) (table 2-4).  Deparaffinisation and antigen retrieval was performed using Epitope 
Retrieval 3-in-1 Solution (pH 6) (DAKO, S1699) or the Epitope Retrieval 3-in-1 Solution (pH 9) 
(DAKO, S2375) and the PT Link system (DAKO, PT101).  For epitope retrieval, slides were 
heated to 97°C for 20 minutes and then cooled to 65°C.  The slides were then immersed in wash 
buffer (DAKO, S3006).  On the Autostainer slides were blocked for 10 minutes with 200 μL 
HRP Block (DAKO, S2023).  Cells were washed with 1× wash buffer and 200 μL of antibody 
added to the slides for 20 minutes.  Slides were washed again with 1× wash buffer and then 
incubated with 200 μL Real EndVision (DAKO, K4065) for 30 minutes.  A positive control slide 
was included in each staining run.  Each slide was also run with Negative Control Reagent (1× 
TBS/0.05% Tween-20), to allow evaluation of non-specific staining and allow better 
interpretation of specific staining at the antigen site.  All slides were counterstained with 
haematoxylin (DAKO) for 5 minutes, and rinsed with deionised water, followed by wash buffer.  
All slides were then dehydrated in graded alcohols (2 x 3 minutes each in 70% IMS, 90% IMS 
and 100% IMS), and cleared in xylene (2 x 5 minutes), and mounted with coverslips using DPX 
mountant (Sigma, 44581).   
 
65 
 
Table 2-3:  Antibodies used in immunofluorescence analysis 
Primary Antibody Dilution Company 
N-cadherin 5 μg/ml ab19348 Abcam 
Piccolo, clone 4G3.3 1:300 Millipore 
Robo-2 10 μg/ml ab75014 Abcam 
MMP-2 1:50 MAB13405 Millipore 
MMP-10 1:50 MAB9101 R&D 
Systems 
ALCAM 1:150 ab109215 Abcam 
 
Table 2-4:  Antibodies used in immunohistochemical analysis 
Primary 
Antibody 
Dilution Company 
BCHE 9 μg/ml AV44208 Sigma 
DSCAM 5 μg/ml       LS-B5787 LSBio 
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2.6  Western blot analysis 
2.6.1  Preparation of Protein Lysates   
2.6.1.1  Preparation of whole cell lysates   
Cells were grown to 80-90% confluency in culture flasks (T75cm2 flask), media was removed, 
cells were trypsinised, pelleted and washed twice in ice cold PBS.  All procedures from this point 
forward were performed on ice.  Cells were resuspended in 500μl (per T75cm2 flask) RIPA lysis 
buffer (Sigma, R0278) containing 1× protease inhibitor (Complete MiniTM, 04693124001, 
Roche Diagnostics, GmbH) (Sigma, R0278) and incubated on ice for 20 minutes.  Following 
centrifugation at 16,000 g for 5 minutes at 4°C the resulting lysate was stored at -80°C.  Protein 
concentration was quantified using the Pierce BCA Protein Assay Kit (Cat no. 23227).   
2.6.1.2  Preparation of membrane proteins   
Membrane proteins were isolated from cells using the ProteoExtract Native Membrane Protein 
Extraction Kit (Calbiochem, 444810) and used according to the manufacturerer’s instructions.   
 
2.6.2  Gel Electrophoresis   
Proteins for Western blotting were separated by SDS-PAGE gel electrophoresis (Laemmli et al., 
1970285), using 4-12% gradient gels (Invitrogen NP0335, NP0321).  Approximately 15μg of 
protein was applied to each well of the polyacrylamide gel.  Pre-stained molecular weight 
markers (Invitrogen, LC5800) were also loaded onto the gel for the determination of the 
molecular weight of the protein samples.  Gels were run at 200 volts and 250 milliamps for 1 - 
1.5 hours with 1× MOPS, Tris/ Glycine/ SDS running buffer (Invitrogen, NP0001).  When the 
dye front of the molecular weight markers had reached the end of the gel, electrophoresis was 
stopped.   
 
2.6.3  Enhanced chemiluminescence (ECL) detection   
Proteins were transferred to nitrocellulose membranes (Invitrogen, IB3010-01) using the iBlot 
transfer system (Invitrogen, IB1001).   Protein transfer was visually confirmed using Ponceau S 
staining (Sigma, P7170).  The membrane was blocked with 5% milk powder (170-6404, Biorad) 
in 0.1 % TBS-Tween (10× TBS, Sigma, T5912) at room temperature for 1 hour, then incubated 
overnight at 4°C in primary antibody (table 2-4) with 0.1 % TBS-Tween in 5 % milk powder.  
The membrane was washed three times with 0.5 % TBS-Tween and then incubated at room 
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temperature with secondary antibody (table 2-5) in 5 % milk powder with 0.5 % TBS-Tween for 
1 hour.  The membrane was washed three times with 0.5 % TBS-Tween followed by one wash 
with TBS alone.  Immunoblots were developed using ECL reagents (Amersham, RPN 2105), 
which facilitated the detection of bound peroxidase-conjugated secondary antibody.  Following 
the final washing membranes were incubated with ECL reagent and approximately 3 ml of a 
50:50 mixture of ECL reagent was used to cover the membrane.  The membrane was then 
exposed to Amersham HyperfilmTM, chemiluminescence film (GE Healthcare, 28906837) for 
various times (from 10 seconds to 30 minutes depending on the signal).  The exposed 
autoradiographic film was developed for 3 minutes in developer (Kodak, LX-24).  The film was 
then washed in water for 15 seconds and transferred to a fixative (Kodak, FX-40) for 5 minutes.  
The film was then washed with water for 5-10 minutes and left to dry at room temperature.   
 
Table 2-5:  List of primary, secondary antibodies and dilutions used in 
Western blot analysis 
Primary Antibody Dilution Company 
BCRP (BXP-21) 1:25 ALX-801-029 Enzo 
P-gp (C219) 1:50 ALX-801-002 Enzo 
Anti-EF1α, clone CBP-KK1 1:1000 05-235 Upstate-Millipore 
Anti-human Integrin 
αV/CD51 
1:1000 AF1219 R&D Systems 
PA2G4/EBP1 1 μg/ml LS-B6878 LSBio 
DSCAM 1 μg/ml LS-B5787 LSBio 
ALCAM 1:1000 ab109215 Abcam 
BCHE 1:800 AV44208 Sigma 
SLIT2 1:1000 ab134166 Abcam 
IGF1Rβ 1:200 IGF1Rβ (C-20):sc-713 
Santa Cruz 
pERK 1:1000 #9101 Cell Signaling 
tERK 1:1000 #4695 Cell Signaling 
GAPDH 0.05 μg/ml R&R Systems 
α-tubulin 1 μg/ml Sigma 
Swine Anti-Rabbit HRP  1/2000 P0399 Dako 
Goat Anti-Mouse HRP 1/2000 P0477 DAKO 
Goat Anti-Rabbit HRP 1/2000 P0448 DAKO 
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2.7  Human Phospho-MAPK array 
The Human Phospho-MAPK array (catalog number ARY002B) was used to show the effect of 
the MAPK kinase inhibitor, U0126 on specific pathways.  DLKP-I and DLKP-M cells were 
grown overnight on matrigel coated flasks (section 2.3.4).  After 24 hrs, one flask of each was 
treated with 10 μM of the MEK inhibitor U0126 for 1 hour (DMSO used as control).  Following 
the removal of the cells with dispase (section 2.3.4) the cells were rinced with PBS and 
solubilized at 1×107 cells/mL in Lysis Buffer 6.  The lysates were pipetted up and down to 
resuspend and then gently rocked at 4°C for 30 minutes.  They were then microcentrifuged at 
14,000 × g for 5 minutes, and the supernatant transferred into a clean Eppendorf.  Quantitation of 
sample protein concentrations was performed using the Pierce BCA Protein Assay Kit (Cat no. 
23227) and the arrays were incubated with 250 μg of lysate.   
 
2.8  RNA Analysis   
2.8.1  RNA Extraction   
RNA extraction was achieved using the Qiagen RNeasy mini kit (Qiagen, 74104), following the 
manufacturer’s instructions.  The RNA was then quantified spectrophotometrically at 260nm and 
280nm using the NanoDrop® (ND-1000 spectrophotometer).  The ND-1000 software 
automatically calculated the quantity of RNA in the sample based on an OD260 of 1 being 
equivalent to 40mg/mL RNA.  The software simultaneously measured the OD280 of the samples 
allowing the purity of the sample to be estimated from the ratio of OD260/OD280.  This was 
typically in the range of 1.8-2.0.  A ratio of <1.6 indicated that the RNA may not be fully in 
solution.  RNA samples were stored at -80 °C.   
 
2.8.2  Reverse Transcriptase Reaction 
To form cDNA, the following reagents (table 2-6) were mixed in a 0.5ml eppendorf (Eppendorf, 
0030 121.023) heated to 72°C for 10 min and then cooled to 37°C.  Added directly to this 
mixture was 4μl DEPC water and lμl Moloney murine leukaemia virus reverse transcriptase 
(MMLV-RT) (40,000U/μl) (Sigma, M-1302).  The RT reaction was carried out by incubating the 
eppendorfs at 37°C for 1 hour.  The MMLV-RT enzyme was inactivated by heating to 95°C for 5 
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min.  The cDNA was stored at -20°C until required for PCR reactions as outlined in Section 
2.8.3. 
Table 2-6  Reaction components for reverse transcriptase reaction 
Reaction Component Reaction volume 
25 mM MgCl2 (Sigma, M-8787) 1.2μl 
l0x PCR Buffer (Sigma, P-2317) 2μl 
Oligo (dT) primers (0.5ng/μl) 
(MWG/Sigma) 
2μl 
dNTP’s (10mM of each dNTP; Sigma, 
DNTP-100) 
0.4μl 
RNAsin (40U/μl) (Sigma, R-2520) 0.5μl 
total RNA (500ng/ul) 2μl 
DEPC water 6.9μl 
 
 
2.8.3  Real-Time PCR 
Taqman real time PCR was used for the mRNA quantification in this study.  Real-time PCR is 
the technique of collecting data throughout the PCR process as it occurs, thus combining 
amplification and detection into a single step.  Reactions are characterized by the point in time 
(or PCR cycle) where the target amplification is first detected.  This detection occurs when the 
quencher dye that is found in the 3’ end of the probe is separated from the fluorescent dye which 
is found in the 5’ end of the probe due to cleaving of the probe with the target.  This value is 
usually referred to as cycle threshold (Ct), the time at which fluorescence intensity is greater than 
background fluorescence.  Consequently, the greater the quantity of target DNA in the starting 
material, the faster a significant increase in fluorescent signal will appear, yielding a lower Ct286.  
Ct is defined as the fractional cycle number at which the fluorescence passes the fixed 
threshold287.   
RNA was extracted (Section 2.8.1) and cDNA synthesised as per Section 2.8.2.  The Taqman® 
Real Time PCR analysis was performed using the Applied Biosystems Assays on Demand PCR 
kits (TaqMan® gene expression assays) (table 2-7) on a 7900 fast real-time PCR instrument 
(Applied Biosystems).  A volume of 22.5μl of qPCR master mix was added to was added to the 
relevant wells of a 96-well PCR plate (cat no. 4366932).  A volume of 2.5μl of each cDNA 
sample was added to give a final reaction volume of 25μl.  Each cDNA sample was analysed in 
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triplicate for the separate measurement of target gene expression and endogenous control 
(GAPDH).  The components of the PCR were as follows are shown in table 2-8.  The plate was 
then covered with an optical adhesive cover and placed in the ABI 7500 Real Time PCR 
instrument.  The thermal cycling conditions were set using the default settings outlined in table 2-
9.  The sample volume was changed to 25μl and the run started.   
 
Table 2-7  TaqMan assays used in this study 
Gene TaqMan assay catalog number 
ABCB1 HS00184491_m1 
ABCG2 HS00242273_m1 
Actin HS00184979_m1 
 
Table 2-8  Components of Real Time PCR master mix 
Reaction 
Component 
Volume/well per 25μl 
reaction 
Final Concentration 
TaqMan universal 
PCR mastermix (2×) 
(Cat no. 4318157) 
12.5μl 1× 
20× assays on 
demand gene 
expression assay mix 
(primers) 
12.5μl 1× 
RNase –free water 8.75μl - 
cDNA 2.5μl  
 
Table 2-9  Thermal cycling conditions for TaqMan Gene Expression Assays 
Stage Temp 
(°C) 
Time 
(mm:ss) 
Hold 50 2:00 
Hold 95 10:00 
Cycle  
(40 cycles) 
95 
60 
0:15 
1:00 
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Each real time PCR run was analysed on the 7500 system software under Relative Quantification 
ddCt study.  A calibrator sample was selected and set to a value of one, allowing for the 
comparison of all other samples in relation to the calibrator.  For the analysis of target gene or 
endogenous control amplification, the baseline was set to average, normalised fluorescent signal 
before detectable increase (usually 3-15 cycles) and the cycle threshold was set in the exponential 
part of the curve.  The well information was then analysed. The Ct standard error was ideally less 
than +/-0.161. Ct errors with values greater than this were removed as outliers.  The endogenous 
control was used automatically to normalise the data.  When this was achieved for both the target 
and endogenous control, the relative quantity values for the run were generated and plotted 
relative to the calibrator sample.   
 
2.9  Copy number assignment using real time qPCR 
TaqMan Copy Number Assays are run simultaneously with a TaqMan Copy Number Reference 
assay in a duplex real-time polymerase chain reaction (PCR).  The copy number assay detects the 
target gene of interest, and the Reference Assay detects a sequence that is known to exist in two 
copies in a diploid genome.  In this study, the Reference Assay used is the RNase P H1 RNA 
gene.  The number of copies of the target sequence in each test sample is determined by relative 
quantitation (RQ) using the comparative Ct (ΔΔCt) method.  This method measures the Ct 
difference (ΔCt) between target and reference sequences, then compares the ΔCt values of test 
samples to a calibrator sample known to have two copies of the target sequence.   
Quantitative PCR analysis of ABCG2 and ABCB1 gene content was performed in the SQ-Mitox 
cell line DNA samples using commercially available, predesigned TaqMan Copy Number Assays 
(Assay IDs: Hs00670096_cn and Hs02314130_cn for ABCB1 and ABCG2, respectively, each 
consisting of a pair of unlabeled primers and a FAM labeled, MGB probe) and the RNase P Copy 
Number Reference Assay, with a VIC-labeled TAMRA probe (Applied Biosystems, Foster City, 
CA).  DNA was prepared using the Wizard SV Genomic DNA Purification System (Promega, 
A2360).  The PCR consisted of 20 µl reactions containing 4 µl DNA (20 ng total gDNA), 10 µl 
Taqman Genotyping Master Mix (Applied Biosystems) and 1.0 µl each of one target gene and 
reference CNV assay mixes (20× working stock) and 4 µl nuclease-free water.  Following the 
manufacturer's instructions, all qPCR reactions were run using four replicates on an ABI 7900HT 
instrument (Applied Biosystems) and thermal cycling conditions were 95°C, 10 min followed by 
40 cycles of 95°C for 15 s and 60°C for 1 min.   
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2.10  Affymetrix GeneChips® 
The microarray gene expression experiments carried out in this body of work were performed 
using Affymetrix GeneChips® Whole genome arrays (Affymetrix, 900470).  Affymetrix 
GeneChip probe microarrays are manufactured using photolithography and combinatorial 
chemistry.   
Table 2-10  Equipment required for microarray experiment 
Item Catalogue no. Supplier 
20× SSPE US51214 Cambrex 
Anti-Strep Biotinylated Ab (Goat) BA-0500 LABKEM 
Wheaton 1L sterile bottles 219980 Scientific 
Herring sperm DNA  D1811 MSc 
10% Tween 20 28320 MSc 
BSA 15561-020 Biosciences 
R-Phycoerythro Streptavidin S-866 Biosciences 
GeneChip Human Genome U133 Plus 2.0 Array 900470 Affymetrix 
Test3 Array 900341 Affymetrix 
One-Cycle Target Labelling Kit 900493 Affymetrix 
Two-Cycle Target Labelling Kit 900494 Affymetrix 
0.5M EDTA E7889 Sigma 
MES Free Acid Monohydrate M5287 Sigma 
MES Sodium Salt M5057 Sigma 
DMSO D5879 Sigma 
Goat IgG 15256 Sigma 
Sodium Hypochlorite 42,504-4 Sigma 
20× SSPE 85637 Sigma 
5M NaCl, RNase-free, DNase-free  9760G Ambion 
1.5 ml eppys 12400 Ambion 
0.5 ml eppys 12300 Ambion 
Rnase Zap 9780 Ambion 
RNA ladder 7152 Ambion 
0.5M EDTA 9260G Ambion 
Rnase-free UHP 9932 Ambion 
5× Megascript T7 kit 1334 (or B1334-5) Ambion 
Rneasy Mini Kit 74104 Qiagen 
QIA Shredder 79656 Qiagen 
RNA 6000 Nano Labchip Kit 5065-4476 Carl Stuart Ltd. 
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Tens to hundreds of thousands of different oligonucleotide probes are synthesised and located in 
a specific area on the microarray slide, called a probe cell.  Each probe cell contains millions of 
copies of a given oligonucleotide and each feature size on the Affymetrix U133 plus 2.0 is 11 
microns.   
Microarray analysis was performed on RNA isolated from three biological repeat experiments 
(i.e. RNA was isolated from three independent stocks of the cells, each of which resulted in a set 
of data).  Table 2-10 lists the items used in the analysis.   
 
2.10.1  cDNA synthesis from total RNA   
RNA was prepared using the RNeasy Mini Prep Kit® (QIAGEN, 74104) (section 2.8.1).  The 
concentration of RNA was calculated using the Nanodrop (Nanodrop ND-1000, Labtech 
International, Ringmer, East Sussex, UK).  The Agilent Bioanalyser was used to assess RNA 
qualitatively after isolation.  cDNA was synthesised using the GeneChip® One-Cycle cDNA 
Synthesis Kit from l0 μg total RNA.  Total RNA (10 μg), diluted poly-A RNA controls and T7-
Oligo-dT) primer were mixed in a 0.2 mL PCR tube (table 2-2).  RNase-free water was added to 
a final volume of 11 μL.  The tube was gently flicked a few times to mix, and then centrifuged 
briefly to collect the reaction at the bottom of the tube.  The reaction was then incubated for 10 
minutes at 70°C.  The sample was cooled at 4°C for at least 2 minutes.  The tube was centrifuged 
briefly to collect the sample at the bottom of the tube.  The First-Strand Master Mix was prepared 
by mixing 4 μl 5× First Strand Reaction Mix, 2 μl DTT (0.1M) and 1 μl dNTP (10mM) for a 
single reaction.  A volume of 7 μl of First Strand Master Mix was added to each RNA/T7-Oligo 
(dT) Primer mix.  The tube was mixed thoroughly be flicking the tube a few times and 
centrifuged briefly and then incubated for 2 minutes at 42°C.  A volume of 2 μl of SuperScript II 
was then added to each RNA sample and the tube was mixed, centrifuged and immediately 
placed at 42°C for 1 hour and then cooled for at least 2 minutes at 4°C.   
The Second-Strand Master Mix was prepared as shown on table 2-12 (for a single reaction).  The 
tube was mixed and centrifuged.  A volume of 130 μl of Second-Strand Master mix was added to 
each first-strand synthesis sample for a total volume of 150 μl.  The tube was then mixed, 
centrifuged briefly and incubated for 2 hours at 16°C.  A volume of 2 μl of T4 DNA polymerase 
was added to each sample and the tube was incubated for 5 minutes at 16°C.  After incubation 
with T4 DNA Polymerase a volume of 10 μl EDTA (0.5M) was added. The double-stranded 
cDNA was then cleaned up using the GeneChip Sample Cleanup module (section 2.10.2).   
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2.10.2  Sample cleanup module cDNA cleanup   
Sample cleanup was carried out using GeneChip Sample Cleanup module (Affymetrix, 900371), 
following the manufacturer’s instructions.  Biotin-labeled cRNA was then prepared using the 
GeneChip IVT Labeling Kit (section 2.10.3).   
 
2.10.3  cRNA synthesis from cDNA IVT Amplification   
The components listed in table 2-11 were added into a 1.5 mL eppendorf.  The tubes were mixed 
centrifuged and then incubated at 16°C for 16 hours.  The labelled cRNA was stored at -20°C, or 
at -70°C if not purifying immediately.   
 
Table 2-11  cRNA synthesis from cDNA IVT amplification 
Component Volume (μl) 
Template cDNA (total RNA 8.1 to 15 μg) 6 
Water 14 
10× IVT labelling buffer 4 
IVT labelling NTP mix 12 
IVT labelling enzyme mix 4 
37°C overnight (16 hours)  
 
 
2.10.4  Biotin-Labeled cRNA Cleanup   
Sample cleanup was carried out using GeneChip Sample Cleanup module (Affymetrix, 900371), 
following the manufacturer’s instructions.  The sample was run on the Agilent Bioanalyser (1:1 
dilution) and concentration determined using the nanodrop (Read at A260, 1:50 dilution; in 
duplicate).  The cRNA was stored at -20°C, or at -70°C if not quantitated immediately.   
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Table 2-12  cDNA reaction for total RNA (10μg) 
Reaction Volume (μl) 
First strand cDNA synthesis: 
RNA + RNase free water 
Diluted poly-A RNA controls  
T7-Oligo(dT) Primer (50 μMol) 
70°C for 10 min 
Cooled to 42°C. 
5× 1st strand buffer buffer 
DTT (0.1 M) 
dNTP’s (10 mM) 
42°C for 2 min 
Superscript II 
42°C – 1 hr spin/ice 
 
7 
2 
2 
 
 
4 
2 
1 
 
2 
 
Second strand cDNA synthesis: 
(< 90 min on ice) 
RNase free water 
5× 2nd strand buffer 
dNTP’s (10mM) 
E. coli DNA ligase 
RNase H 
E. coli DNA polymerase I 
130 μl of second strand master mix was added to each of the first 
strand synthesis samples 
 
 
91 
30 
3 
1 
1 
4 
 
16°C for 2 hr (thermocycler) 
2 μl T4 DNA polymerase added 
16°C for 5 min. 
10μl 0.5M EDTA added to stop reaction. 
Spin/ice. 
 
 
 
2.10.5  Hybridisation of cRNA to chip   
The components listed in table 2-13 (fragmentation reaction) were added into a 0.5 mL 
Eppendorf.  The samples were incubated at 94°C for 35 minutes and then placed on ice.  A 
aliquot was saved for analysis on the Bioanalyzer.  Undiluted, fragmented cRNA samples were 
stored at -20°C or (-70°C for longer-term storage) until ready to perform the hybridisation.   
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The components listed in table 2-13 (hybridisation reaction for a single probe array) were added 
into a 1.5 mL Eppendorf.  Volumes were scaled up for hybridisation to multiple probe arrays.  
The probe array was equilibrated to room temperature immediately before use.  The hybridisation 
cocktail was heated to 99°C for 5 minutes in a heat block, transferred to a 45°C heat block for 5 
minutes and then centrifuged at maximum speed for 5 minutes to remove any insoluble material 
from the hybridisation mixture.  The array was pre-wet with 200 μl 1× Hybridisation Buffer and 
incubated at 45°C for 10 minutes with rotation.  This buffer was then removed from the probe 
array cartridge and 200 μl of the clarified hybridisation cocktail was added.  The probe arrays 
were then incubated at 45°C for 16 hours with rotation at 16 rpm.   
 
Table 2-13  Hybridisation of cRNA to chip   
Reaction Volume (μl) 
Fragmentation reaction: (15μg cRNA in 0.5ml Eppendorf) 
cRNA + water 
5× fragmentation buffer 
Incubate 35 min at 94°C 
 
15μg (1 to 24 μl) 
6 
 
 
Hybridisation reaction: 
Fragmented cRNA 
Control Oligonucleotide B2 (3 nM) 
20× Eukaryotic Hybridisation Controls 
Herring sperm DNA (10 mg/ml) 
BSA (50 mg/ml) 
2× Hybridisation buffer 
DMSO 
Water 
 
15 μg 
5 
15 
3 
3 
150 
30 
to final vol. of 300 μl 
Pre-wet chips 
Added 200μl 1× hybridisation buffer 
Rotated 15 min at 45°C, 60 rpm 
Removed buffer 
 
Hybridise chips 
Preheated hybridization solution – 5 min at 95°C 
45°C (for > 5min) 
Rotated overnight (16 hours) at 45°C, 60 rpm 
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2.10.6  Fluidics on chip   
The fluidics station was primed and the hybridisation solution was removed from the chips.  The 
chips were then filled with 200 μl non-stringent buffer.   
The SAPE and antibody solutions (tables 2-14 and 2-15) were added to the fluidics station and 
the fluidics protocol was run on the selected chips (EukGEvs450 for U133 Plus 2.0 chips).  The 
Affymetrix Genechip Operating Software (GCOS) managed the fluidics protocol.  All relevant 
data from the fluidics was stored in the Report file (*.RPT) for each chip.   
 
Table 2-14  Preparation of SAPE solution   
Reaction Volume (μl) 
SAPE solution (stains 1 & 3) 
2× stain buffer 
50 mg/ml BSA 
1 mg/ml SAPE 
Distilled water 
Total/chip 
 
600 
48 
12 
540 
1200 
 
Table 2-15  Preparation of antibody solution   
Reaction Volume (μl) 
Ab solution (stain 2) 
2× stain buffer 
50 mg/ml BSA 
10 mg/ml goat IgG stock 
0.5mg/ml biotinylated antibody 
Distilled water 
 
300 
24 
6 
3.6 
266.4 
 
 
2.10.7  Chip Scanning   
The chips were placed in the scanner and scanned.  The GCOS software was used to manage the 
scanning protocol.  The scan generated an initial image file (*.DAT) that contained the values for 
each gene probe.  As there were 11 probes for each gene (one probeset), these values were 
averaged out into another file that was generated automatically by GCOS (*.CEL).  The user then 
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gets GCOS to generate another file from the .CEL file which contains numerical values for each 
probeset (*.CHP).  Finally, a quality control report file (*.RPT) is generated which is used to 
check the reliability/QC of each sample.   
 
2.10.8  Microarray Data Normalisation   
The purpose of data normalisation is to minimise the effects of experimental and technical 
variation between microarray experiments so that meaningful biological comparisons can be 
drawn from the data sets and that real biological changes can be identified in microarray 
experiments.  Normalisation is the first step in the data analysis process.  The challenge of 
normalisation is to remove as much of the technical variation as possible while leaving the 
biological variation untouched.  Some of the common normalisation algorithms for Affymetrix 
arrays are MAS5288, RMA289 and dChip290.  MAS5 developed by Affymetrix uses a reference 
(baseline) chip which is used to normalise all the experimental chips.  The procedure is to adjust 
the intensity of each probe against the corresponding probes on the baseline chip; eliminate the 
highest 1% of probes (and for symmetry the lowest 1%), and fit a regression line to the middle 
98% of probes.  dChip uses an array with median overall intensity as the baseline array against 
which other arrays are normalised at probe level intensity.  Subsequently a subset of PM 
(“perfect match”) probes, with small within-subset rank difference in the two arrays (also known 
as invariant set), serves as the basis for fitting a normalisation curve.  RMA employs 
normalisation at probe level using the quantile method.  This normalisation method makes the 
chips have identical intensity distribution.   
 
2.10.9  Microarray QC   
The quality of the data generated with Affymetrix microarray chips was assessed based on 
different criteria including the scaling factor, background and noise levels, GAPDH 3′/ 5′ ratios 
and the %Present call.   
Scaling factor 
The scaling factor was the multiplication factor applied to each signal value on an array.  A 
scaling factor of 1.0 indicates that the average array intensity was equal to the target intensity.  
Scaling factors vary across different samples and so there were no set guidelines for any 
particular sample type.  However, Affymetrix advise that for replicates and comparisons 
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involving a relatively small number of changes, the scaling/normalisation factors (calculated by 
the global method) should be comparable among arrays.  Larger discrepancies among 
scaling/normalisation factors (e.g., three-fold or greater) may indicate significant assay 
variability or sample degradation leading to noisier data.   
 
Background and noise levels 
Although there are no official guidelines regarding background, Affymetrix has found that 
typical average background values range from 20 to 100 for arrays scanned with the GeneChip® 
Scanner 3000.  Arrays being compared should ideally have comparable background values.  A 
high background implies that impurities, such as cell debris and salts, are binding to the probe 
array in a non-specific manner, and that these substances are fluorescing at 570nm (the detection 
wavelength).  These non-specific binding causes a low signal-to-noise ratio (SNR), meaning that 
transcripts present at very low levels in the sample may be incorrectly called as “Absent”.  High 
background creates an overall loss of sensitivity in the experiment.  The noise is a measure of the 
pixel-to-pixel variation of probes cells on a GeneChip array.   
 
GAPDH 3′/ 5′ ratios 
β-actin and GAPDH are used to assess RNA sample and assay quality for the majority of 
GeneChip® expression arrays.  Specifically, the Signal values of the 3′ probe sets for -actin and 
GAPDH are compared to the Signal values of the corresponding 5′ probe sets.  The ratio of the 3′ 
probe set to the 5′ probe set is generally no more than 3 for the 1-cycle assay.  A high 3′ to 5′ 
ratio may indicate degraded RNA or inefficient transcription of ds cDNA or biotinylated cRNA.  
3′ to 5′ ratios for internal controls are displayed in the Expression Report (.rpt) file.   
 
% Present call 
The number of probe sets called “Present” relative to the total number of probe sets on the array 
is displayed as a percentage in the Expression Report (.rpt) file.  Percent present (%P) values 
depend on multiple factors including cell/tissue type, biological or environmental stimuli, probe 
array type, and overall quality of RNA.   
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Replicate samples should have similar %P values. Extremely low %P values are a possible 
indication of poor sample quality.   
 
Quality inspection 
The following Quality Controls were taken to estimate the quality of chip: 
1. Median Intensity: Median intensity is the median intensity of the un-normalized 
probe values. 
2. P call %: Calls indicate if the transcript is expressed or not. It can be ‘P’ for 
present, ‘M’ for marginally present and ‘A’ for absent. Total P calls in an array can 
vary widely based on the different nature of samples. 
3. % Signal outlier: The signal value greater than 80th percentile multiplied by 3 is 
taken as signal outlier and is represented as % signal outlier. 
4. % Array outlier: The array-outliers are the arrays whose probe pattern for selected 
probe set is different from the consensus probe pattern seen in most arrays. 
5. Warning: If the array outlier increases over 5%, the chip is marked as outlier chip 
and is marked by ‘*’, indicating potential image contamination or sample 
hybridisation problems of that array. 
 
In addition to the above parameters, a manual inspection was also performed to estimate the 
quality of individual chips.   
 
Hierarchical Clustering: Clustering is a way of finding and visualizing patterns in the data.  It 
allows the grouping of objects based on similarity.  In other words, it is the partitioning of a data 
set into subsets, so that the data in each subset share some common trait.  Hierarchical clustering 
is a mathematical technique, the measure for a common trait is defined before the clustering is 
performed and is often a distance metric defining the relative similarity among two or more 
objects.  The sample/genes with similar expression patterns are grouped together and are 
connected by a series of branches, which is called a dendrogram or clustering tree.  Hierarchical 
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clustering was used to see how well the replicate samples cluster, identify any sub-groups in the 
samples and identify correlated genes.   
 
2.10.10  Finding significant genes   
In general, a combination of filtration criteria was used to pick up the differentially-regulated 
genes. These criteria are discussed below.   
Fold change 
Fold change is the ratio of mean of experimental group to that of baseline. It’s a metric to define 
the gene's mRNA-expression level between two distinct experimental conditions. Fold change of 
1.2, 1.5 and 2 was used for different types of analysis.   
Difference 
The difference of Affymetrix expression units was also taken for finding differentially-regulated 
genes. Difference of 100 was taken for most of the comparisons.   
t-test 
The t-test assesses whether the means of two groups are statistically different from each other. 
The output of the t-test is the p-value. The p-value of less than 0.05 was taken as significantly 
different.   
Combination of parameters  
A combination of a fold-change of 1.2, difference of 100 and p-value <0.05 was taken for up 
regulated genes.  Similarly a combination of fold change of 1.2, difference of 100 and p-value < 
0.05 was taken for down-regulated genes.   
 
2.11  Proteomic analysis 
Studies have shown that differential mRNA expression does not always correlate with protein 
expression291,292.  Distinct changes may occur during the transformation of a healthy cell to a 
neoplastic cell that may not be apparent in gene changes.  In addition, there may be less that 40% 
agreement between protein and mRNA levels in cultured cells, less for regulatory proteins like 
tyrosine kinases.  The location, structure and function of proteins can also change dramatically 
within an organism due to malignant transformation, cell cycle and external/internal signalling.   
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2.11.1  Sample preparation   
Cells were grown to 60-70% confluency in 175cm2 flasks and trypsinised.  Cell pellets were then 
washed twice in ice cold PBS and twice in sucrose buffer and the resulting pellet was stored at -
80 oC.   
 
2.11.2  Total protein extraction   
All proteomic analysis detailed in this thesis was carried out by Dr. Paul Dowling.  Cell pellets 
were reconstituted with 1ml of the following complete lysis buffer: (4% w/v CHAPS, 7 M urea, 2 
M thiourea, 10 mM Tris-HCL, 5 mM magnesium acetate pH 8.5).  Immediately before use, 10μl 
of 100x stocks of DNase and RNase were added to 1ml of lysis buffer.  The lysate was then 
homogenised by passing through a 25-gauge needle 6 times.  The cell lysate was placed on an 
orbital shaker and shaken for 1 hour at room temperature.  The protein lysate was then 
transferred to an eppendorf and centrifuged at 14,000 rpm for 20 minutes at 10 oC to remove 
insoluble material.  The resulting supernatant was transferred to a fresh microcentrifuge tube and 
its pH was checked to ensure it was between pH 8.0-9.0 by spotting 3 μl onto a pH indicator 
strip.  The sample was then divided into smaller aliquots and stored at –80 oC.  The protein 
concentration was quantified using the Biorad method.  Biological replicates (n=3) of each cell 
line were prepared.  
 
2.11.3  Protein sample labelling   
2.11.3.1  Preparation of dye stock solution (1 nmol/μl)   
The three CyDye DIGE Fluor Minimal dyes (Cy3, Cy5 and Cy2 (GE Healthcare, 25-8010-65) 
were thawed from –20oC to room temperature for 5 minutes.  To each microfuge tube 
dimethylformamide (DMF) (Aldrich, 22,705-6) was added to a concentration of 1 nmol/μl.  Each 
microfuge tube was vortexed vigorously for 30 sec to dissolve the dye.  The tubes were then 
centrifuged for 30 sec at 14,000 rpm in a microcentrifuge.  The reconstituted dyes were stored at 
–20oC for up to two months.   
 
2.11.3.2  Preparation of 10 μl working dye solution (200 pmol/μl)   
On thawing, the dye stock solutions were centrifuged in a microcentrifuge for 30 seconds.  To 
make 10 μl of the three working dye solutions, 8 μl of DMF was added to 2 µl of 1 nmol/µl stock 
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of Cy2, Cy3 and Cy5 i.e. 200 pmol/µl working stock.  The dyes were stored at -20 oC in tinfoil in 
the dark for 3 months.   
 
2.11.3.3  Protein labelling   
Protein samples equivalent to 50 μg were placed into eppendorf tubes and labelled with the Cy3 
and Cy5 minimal dyes.  Each tube was mixed by vortexing, centrifuged and then left on ice for 
30 minutes in the dark.  The reaction was quenched  with a 50-fold molar excess of free lysine to 
dye for 10 minutes on ice in the dark. The labelled samples were stored at –80oC.  The Cy2 pool 
for each gel (50 μg) contained an equal concentration aliquot of each of the protein samples.  To 
this 1 µl of each dye (200 pmol/µl) was added to 50 µg of protein sample.  An equal volume of 
2× sample buffer (2.5 ml rehydration buffer stock solution (7 M urea, 2 M thiourea, 4 % 
CHAPS), pharmalyte broad range pH 4-7 (2%) (GE Healthcare, 17-6000-86), DTT  (2%) 
(Sigma, D9163)) was added to the labelled protein samples.  The mixture was left on ice for at 
least 10 minutes then applied to Immobiline DryStrips for isoelectric focussing.   
 
2.11.4  First dimension separation - isoelectric focussing  
2.11.4.1  Strip rehydration   
Immobiline 24 cm linear pH gradient (GE Healthcare, IPG) strips, pH 3-11 were rehydrated in 
rehydration buffer solution (7 M urea, 2 M thiourea, 4% CHAPS, 0.5% IPG buffer, 50 mM 
DTT).  Each strip was overlaid with about 3 ml IPG Cover Fluid (GE Healthcare, 17-1335-01) 
and allowed to rehydrate overnight (or at least 12 hours) at RT.   
 
2.11.4.2  Isoelectric focussing   
IEF was performed using an IPGphor apparatus (GE Healthcare).  The cover of the IPGphor unit 
was closed and the desired programme selected (40 kV/h at 20°C with resistance set at 50 mA).  
On completion of the IEF run, the strips were drained of the cover fluid and stored in glass tubes 
at –80oC or used directly in the second dimension.   
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2.11.5  Second Dimension – SDS polyacrylamide gel electrophoresis  
2.11.5.1  Equilibration of focussed Immobiline DryStrips   
Strips were equilibrated for 20 min in 50 mM Tris-HCL, pH 8.8, 6 M urea, 30% v/v  glycerol, 
1% w/v SDS containing 65 mM DTT and then for 20 min in the same buffer containing 240 mM 
iodoacetamide.  The 12.5 % acrylamide gel solution was prepared in a glass beaker 
(acrylamide/bis 40 %, 1.5 M Tris pH 8.8, 10 % SDS).  Prior to pouring, 10 % ammonium 
persulfate and 100 µl neat TEMED were added.  The gels were overlaid with 1 ml saturated 
butanol.  The gels were left to set for at least three hours at RT.  Equilibrated IPG strips were 
transferred onto 24 cm 12.5% uniform polyacrylamide gels poured between low fluorescence 
glass plates.  Strips were overlaid with 0.5% w/v low melting point agarose in running buffer 
containing bromophenol blue.  Gels were run at 2.5 W/gel for 30 min and then 100 W total at 
10°C until the dye front had run off the bottom of the gels.  All the images were collected on a 
Typhoon 9400 Variable Mode Imager (GE Healthcare).   
 
2.11.5.2  Scanning DIGE labelled samples   
The appropriate emission filters and lasers were then selected in the Typhoon Variable Mode 
Imager (GE Healthcare) for the separate dyes (Cy2 520 BP40 Blue (488), Cy3 580 BP30 Green 
(532) and Cy5 670 BP 30 Red (633)).  Gels were scanned at 100 pixel resolution, resulting in the 
generation of three images, one each for Cy2, Cy3 and Cy5.  Once the scanning was completed, 
the gel images were imported into the ImageQuant software.  All gels were cropped identically to 
facilitate spot matching in the Decyder BVA module (version 6.5).  
 
2.11.6  Analysis of gel images   
2.11.6.1  Differential in-gel analysis (DIA)   
The DIA module processes a triplet of images from a single gel.  The internal standard is loaded 
as the primary image followed by the secondary and tertiary image, derived from, for example, a 
control and treated sample.  Spot detection and calculation of spot properties were performed for 
each image from the same gel.  The software determined the margins of the spots, quantified the 
spot intensities and calculated the relative spot intensity as the ratio between the total intensity of 
the gel and the intensity of each individual spot.  The protein spots were then normalised using 
the in-gel linked internal standard.  The data from the first gel was XML formatted and exported 
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into the Biological Variation Analysis (BVA) software for further analysis.  This procedure was 
repeated for each gel in the experiment.   
 
2.11.6.2  Biological variation analysis (BVA)   
Once all gels from the experiment were loaded into the BVA module, the experimental design 
was set up and the images were assigned into three groups (standard, control and treated).  The 
spots on the gels were then matched across all gels in the experiment.   
This module detects the consistency of the differences between samples across all the gels.  The 
software standardises the relative spot intensity of the Cy5 image to that of the Cy3 image in the 
same gel.  The standardised spot intensity was then averaged across the triplicate gels.  The BVA 
module calculates the degree of difference in the standardized protein abundance between 2 spots 
from different groups and expressed these differences as average ratio.  The values by the 
software are displayed in the range of -∞ to -1 for a decrease in expression and +1 to + ∞ for an 
increase in expression.  For example, a two-fold increase and decrease is represented by +2 and-
2, respectively (not by 2 and 0.5).  The ‘average ratio’ has been termed as ‘fold change’ in this 
thesis.  The software also calculates the consistency of the differences between samples across all 
the gels and applies statistics to associate a level of confidence (p-value) for each of the 
differences.  The spots with statistically significant changes in protein expression (±1.2 fold with 
p-value ≤ 0.05) were considered as differentially expressed proteins.  A ±1.2 fold change was 
chosen with p-values less than 0.05 to look for even subtle changes in expression across the cell 
lines.   
The protein spots with statistically significant protein expression changes were designated 
“proteins of interest” and placed in a pick list.  Preparative gels for spot picking with 300 μg of 
protein/gel were focussed and run out on SDS-PAGE gels.  The gels were then stained with 
colloidal coomassie and deep purple (section 2.14.3, 2.14.4).  Spots that showed differential 
protein expression were picked with the ETTAN Spot Picker (section 2.14.3).   
 
2.11.6.3  Staining- Brilliant blue G Colloidal coomassie staining of preparative gels for spot 
picking   
After electrophoresis, the smaller lower plates with the gels attached were placed in the gel boxes 
containing fixing solution (7% glacial acetic acid in 40% (v/v) methanol (Aldrich, 200-659-6)) 
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for at least 1 hour.  During this step a 1× working solution of Brilliant Blue G colloidal 
coomassie (Sigma, B2025) was prepared by adding 800ml UHP to the stock bottle.  When the 
fixing step had nearly elapsed a solution containing 4 parts of 1× working colloidal coomassie 
solution and 1 part methanol was made, mixed by vortexing for 30 seconds and then placed on 
top of the gels.  The gels were  left to stain for 2 hours.  To destain, a solution containing 10% 
acetic acid in 25% methanol was poured over the shaking gels for 60 seconds.  The gels were 
then rinsed  with 25% methanol for 30 seconds and then destained with 25% methanol for 24 
hours.  Alternatively, after fixing solution, gels were washed 3 times in wash buffer (35 mM 
sodium hydrogen and 300 mM sodium carbonate in water) and further washed in water.  Deep 
purple stain (GE Healthcare, RPN6305) was then added to the gels, diluted 1/200 in water, and 
incubated for 1 hr.  Gels were destained in 7.5% (v/v) acetic acid in the dark for 15 min and 
repeated.  The glass surface was dried and two reference markers (GE Healthcare) attached to the 
underside of the glass plate before scanning.  The resulting image was imported into the 
ImageMaster software (GE Healthcare) and the spots were detected, normalised and the 
reference markers selected.  All spots of interest were manually selected.  The resulting image 
was saved and exported into the Ettan Spot Picker software.  
 
2.11.6.4  Spot picking   
The stained gel was placed in the tray of the Ettan Spot Picker (GE Healthcare, 18- 1145-28) 
with reference markers (GE Healthcare, 18-1143-34), aligned appropriately  and covered with 
UHP.  The imported pick list was opened, the syringe primed and the  system was set up for 
picking the spots from the pick list.  The spots were robotically picked and placed in 96-well 
plates (Greiner), which were stored at 4o C until spot digestion.   
 
2.11.6.5 Spot digestion   
The 96-well plate was placed in the Ettan Digester (GE Healthcare, 18-1142-68) to digest the 
protein.  The gel plugs were washed 3 times for 20 minutes each with 50µl 50mM ammonium 
bicarbonate (Sigma, A6141) in 50% methanol, followed by 3 × washes for 15 min with 50µl 
70% acetonitrile (Sigma, 34967).  The gel plugs were left to dry.  After drying, the individual gel 
pieces were rehydrated in 10µl digestion buffer (12.5ng trypsin (Promega, V5111) per µl of 10% 
acetonitrile, 40mM ammonium bicarbonate).  Exhaustive digestion was carried out overnight at 
37oC. A volume of 40µl of 0.1% trifluoroacetic acid (Sigma, 302031) in 50% acetonitrile was 
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added to the wells, mixed and left for 20 minutes.  A volume of 60µl of this solution was 
transferred to a fresh 96 well plate.  A volume of 30 µl of 0.1% trifluoroacetic acid in 50% 
acetonitrile was added to the wells, mixed and left for 20 minutes.  A volume of 50µl of this 
solution was transferred to the fresh 96-well plate.  The liquid in the plate was vacuum-dried in a 
Maxi dry plus (Speed Vac, MSC, Dublin).  After drying, the 96-well plate was placed in the 
Ettan Spotter (GE Healthcare, 18-1142-67) for spotting onto the target plates.  A volume of 3 µl 
of 0.5% trifluoroacetic acid in 50% acetonitrile was added to desiccated peptides and mixed 5 
times.  A volume of 0.3 μl of this mixture was spotted onto the target plate after which a volume 
of 0.3 μl matrix solution [7.5 mg/ml a-cyano-4-hydroxycinnamic acid (LaserBio labs, 28166-41-
8) n 0.1% trifluoroacetic acid in 50% acetonitrile] was added.   
 
2.11.6.6  Identification of proteins with MALDI-TOF  
The target plate was placed in the MALDI-ToF (GE Healthcare, 11-0010-87) instrument.  
Spectra were acquired by selective accumulation of 250 individual laser shots and processed 
using Ettan MALDI evaluation software.  The spectra were internally calibrated with trypsin 
enzyme autolysis peptide peaks at m/z 842.51 and m/z 2211.10, and externally calibrated with 
Pep4 mix with the five individual peaks covering the 500-3500 Da mass range and include 
bradykinin fragment 1-5 (573.315), angiotensin II human(1046.5424), neurotensin (1672.9176) 
and insulin Bchain oxidised (3494.6514).  Known contaminant peaks were removed from the 
resulting mass spectra and remaining sample-related peaks were used for database searching.  
The identification sequencing method were set for the mass range 0-300kDa, pI 1-14, missed 
cleavage 1.  The artificial modifications of peptides (carbamidomethylation of cysteines and 
partial oxidation of methionines) were also considered.  Protein identification was achieved using 
Ettan MALDI-ToF Pro evaluation software (GE Healthcare) incorporating the ProFound 
database search engine for peptide mass fingerprints.  The sequence database searched was the 
NCBI-nr database (2007/12/02) using subset species Homo sapiens and 
NR_NICB_Human070308.  Protein identifications were accepted if they could be established at 
greater than 99% probability and had at least 3 identified peptides.  The unidentified protein spot 
that had promising spectr um to get identification were desalted and concentrated using C-18 
Zip-Tips (Millipore) and were reanalysed by MALDI-ToF MS to get identification.  For this, the 
mixtures of tryptic peptides from individual samples were desalted using Millipore C-18 Zip-
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Tips (Millipore) and eluted onto the sample plate with the matrix solution (5 mg/mL CHCA in 
50% ACN/0.1% TFA V/V) and analysed with MALDI-ToF. 
 
2.12  Methylation analysis 
2.12.1  Bisulfite modification of genomic DNA 
DNA (2 μg) obtained from cell lines was submitted to bisulfite modification using the EpiTect 
Bisulfite Kit (Qiagen, 59104) following the manufacturer’s protocol.  Bisulfite-treated DNA was 
resuspended in 20μl elution buffer and was used in the MethyLight assay.  Since accurate 
quantification of DNA after bisulfite treatment was not possible due to its high degradation, the 
presence of amplifiable DNA was tested by real time PCR using a primer pair and a Taqman 
probe for the bisulfite converted sequence of a non-CpG-containing region of β-actin (section 
2.12.5).   
 
2.12.2  MethyLight assay 
MethyLight assays were done using established protocols according to the protocol of QIAGEN 
EpiTect MethyLight PCR kit (59496, QIAGEN).  Briefly, CpG island sequences were identified 
using the University of California Santa Cruz genome browser (http://genome.ucsc.edu/ 
webcite).  MethyLight primers were designed usung MethPrimer (section 2.10.3) and Taqman 
probes were designed manually inhouse.  Sequences of primers and probes are listed in table 2-
16 (PrimeTime Mini qPCR Assay, Integrated DNA Technologies, IDT).  DLKP-SQ and SQ-
Mitox-BCRP-4th pulse DNA was converted using EpiTect Bisulfite Kit (Qiagen).  For 
MethyLight, 1 µl of bisulfite-converted DNA solution was combined with 0.4 μM of each primer 
and 0.2 μM of probe in 1× EpiTect MethyLight master mix.   
Amplification was carried out at 95°C for 5 min, followed by 40 cycles at 95°C for 15s, 60°C for 
60s in an ABI 7500 Real-Time PCR cycler.  The EpiTect Control DNA set were used as 
methylation controls (59695, QIAGEN).   
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Table 2-16  MethylLight primer and probe sequences 
IDT primers/probes Gene Sequense Type 
Prime Time ABCG2-m ABCG2-m.p ACTTCCTAAACCGCGCTTCGAACTA Probe 
Prime Time ABCG2-m ABCG2-m.s ATTGCGTTTAGTTTTGGCG Primer 
Prime Time ABCG2-m ABCG2-m.as AACGAACTCAAACAACGCTA Primer 
Prime Time ABCG2-nm ABCG2-nm.p aAACTTCCTAAACCaCaCTTCaAACTATAAAC Probe 
Prime Time ABCG2-nm ABCG2-nm.s GGTTATTGTGTTTAGTTTTGGT Primer 
Prime Time ABCG2-nm ABCG2-nm.as AAACAAACTCAAACAACACTAAC Primer 
Prime Time ACTB-bis ACTB.p ACCACCACCCAACACACAATAACAAACACA Probe 
Prime Time ACTB-bis ACT-bis.s TGGTGATGGAGGAGGTTTAGTAAGT Primer 
Prime Time ACTB-bis ACT-bis.as AACCAATAAAACCTACTCCTCCCTTAA Primer 
m – methylated; nm – non methylated; bis – bisulfite; m.p – methylated probe; m.s – methylated sense; m.as – methylated antisense. 
 
2.12.3  MethyLight primer and probe sequences 
Three sets of inhouse PCR primers and probes, designed specifically for bisulfite converted DNA 
sequences were used: a set representing fully methylated and fully unmethylated DNA for the 
ABCG2 gene, and an internal reference set for the ACTB gene to control for input DNA.  The 
methylated and unmethylated primers and the probe were designed to overlap the CpG 
dinucleotide site of ABCG2.  The primer and probe sequences are listed above in table 2-16.  In 
all cases, the first primer listed is the forward PCR primer, the second is the TaqMan® probe and 
the third is the reverse PCR primer.   
The primer and probe sequences were designed using the web-based tool MethylPrimer Express 
(Applied Biosystems).  MethylPrimer Express is a program for designing PCR primers for 
primers for bisulfite sequencing (BSP) and/or for methylation-specific PCR (MSP).  The 
software searches DNA sequences for CpG islands, simulates bisulfite modification on the CpG-
containing sequences, then recommends primer pairs for MSP or BSP.  Primer design for either 
method can be adjusted to accommodate variation in experimental design.   
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2.12.4  Methylation Controls 
The EpiTect PCR Control DNA Set (59695, Qiagen) consists of three different types of human 
DNA.: 
 Amplified human genomic DNA (completely unmethylated) 
 Completely unmethylated human genomic DNA – bisulfite converted 
 Completely methylated human genomic DNA – bisulfite converted 
The unmethylated and unconverted human control DNA of the EpiTect PCR Control DNA Set 
allows us to check that primers designed for the specific detection of unmethylated and converted 
DNA (U-converted DNA), and for methylated, converted DNA (M-converted DNA) do not bind 
to untreated genomic DNA.  In case bisulfite conversion was not complete, leaving certain 
unmethylated C residues unconverted, false positives would result if the primer specific for M-
converted DNA binds to untreated gDNA.  This control DNA can also be used to check 
conversion efficiency during bisulfite treatment.   
 
2.12.5  MethyLight Primer/Probe Preparation 
The MethyLight assay utilises the TaqMan PCR principle which requires forward and reverse 
primers as well as an oligomeric probe which emits fluorescence only after it is degraded by the 
5’-3’ exonuclease activity of Taq polymerase.  Each PCR reaction uses the same basic reaction 
set-up – the choice of primer/probe sets is the only variable in these reactions.  All primer/probe 
sets used are diluted to the same stock concentrations to standardise the PCR reaction set-up as 
well as the running of the PCR program.   
Designing primers and probes to target and amplify small regions of fully methylated bisulfite-
modified DNA of the promoter CpG island of interest and analysing the ratio between this 
reaction and an endogenous control reaction (ACTB), which is impartial to methylation status, 
provides a measure for the frequency of methylated molecules at a given locus.   
 
2.12.6  Checking the specificity of primers and PCR conditions   
The presence of amplifiable DNA was tested by real time PCR using a primer pair and a Taqman 
probe for the bisulfite converted sequence of a non-CpG-containing region of β-actin.  The Ct 
values obtained when using control DNA and ACTB primer pairs are shown in table 2-17.   
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Table 2-17  Primer for unmethylated actin gene 
Sample Ct (Ct std err) 
Unmethylated control DNA Undetermined 
Unmethylated control DNA (bisulfite converted) 30.373 (0.366) 
Methylated control (bisulfite converted) 28.997 (0.407) 
No template control Undetermined 
 
2.12.7  5-Aza-2’ deoxycytidine (5-aza-dC) treatment of DLKP-SQ cells   
Cell viability was assessed using the acid phosphatase assay (section 2.2) and 5-Aza-dT 
concentrations up to 5μM were shown to have a minimal effect (approx. 10%) on cell viability.  
DLKP-SQ, Sq-Mitox-MDR and SQ-Mitox-BCRP cells were incubated in ATCC with 1μM of 
DNA methyltransferase inhibitor, 5-aza-2-deoxycytidine (5-aza-dC) (Sigma Chemical 
Company).  After culture for 24 hours, cells were treated with 1μM 5-aza-dC for 72 hours.  
Whole cell lystates were prepared as outlined in section 2.6.1.1 and 10μg of protein from each 
sample were separated by Western blotting as outlined in section 2.6.2.   
 
2.13  microRNA Expression Analysis   
Megaplex™ Pools (Table 2-18) are designed to detect and quantitate up to 380 microRNAs 
(miRNAs) per pool in either human, mouse, or rat species using Applied Biosystems real-time 
instruments.  The TaqMan® Array Human MicroRNA A card v2.0 contains 384 TaqMan 
microRNA Assays enabling quantitation of 377 human microRNAs.  Three TaqMan MicroRNA 
Assay endogenous controls are included to aid in data normalization and one TaqMan® 
MicroRNA Assay not related to human is included as a negative control.  The TaqMan® Array 
Human MicroRNA B Card v2.0 contains 290 TaqMan® MicroRNA Assays.  Megaplex Pools 
consist of matching primer pools and TaqMan® Arrays: 
 Megaplex™ RT Primers is a set of two predefined pools (Pool A and Pool B) of 
up to 380 stem-looped reverse transcription (RT) primers per pool that enable the 
simultaneous synthesis of cDNA for mature miRNAs.   
 Megaplex™ PreAmp Primers (Optional) is a set of two pools (Pool A and Pool 
B) of gene-specific forward and reverse primers intended for use with very small 
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quantities of starting material. The primers enable the unbiased preamplification 
of the miRNA cDNA target by PCR prior to loading the TaqMan®MicroRNA 
Array. These primers were used for this study even though large quantities of 
starting material were available as it gives a better signal.   
 TaqMan® MicroRNA Arrays is a set of two 384-well microfluidic cards (Array 
A and Array B) containing dried TaqMan primers and probes.  The array enables 
quantitation of gene expression levels of up to 380 miRNAs and controls without 
the need to use multi-channel pipettors to fill the card.  This is accomplished by 
loading the cDNA product (with or without preamplification) onto the array for 
PCR amplification and realtime analysis.   
 
Table 2-18 Materials for microRNA Expression Analysis 
Description Part No. 
TaqMan Human Micro RNA Array A 4398977 
TaqMan Human Micro RNA Array B 4398978 
MegaPlex RT & Preamp Human Pool Set 4401091 
M-Plex RT Primers Human Pool A 4399966 
M-Plex RT Primers Human Pool B 4399968 
M-Plex Preamp Primers Human Pool A 4399233 
M-Plex Preamp Primers Human Pool B 4399201 
TaqMan MicroRNA RT kit 4366596 
MirVanaTM miRNA isolation kit AM1560 
 
 
2.13.1  Overall workflow   
1. Isolate total RNA that contains small RNAs such as miRNA, siRNA, and snRNA. 
2. Convert miRNA to cDNA prior to real-time PCR quantitation. 
3. Dilute RT product.   
4. TaqMan® Universal Master Mix II is added to each sample and pipetted into the sample 
loading ports of a TaqMan® Array Card.   
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5. The Taqman array card is run, performing real-time PCR.  Resulting data analysed.   
 
2.13.2  Run Megaplex Pools with Preamplification  
2.13.2.1. Prepare the Megaplex RT Reaction 
The MegaPlex RT reverse transcription kit components were thawed on ice.  The dNTPs were 
vortexed after thawing.  The directions and volumes listed below were for a single sample and 
were scaled appropriately using 2.2× volumes.  A separate master mix was prepared for both M-
Plex RT Primers Human Pool A and M-Plex RT Primers Human Pool B.  The tube was inverted 
six times to mix, then the tubes were centrifuged briefly.  A volume of 3μl (300ng) total RNA (or 
3μL of water for the NoTemplate Control reactions) were placed into each tube containing the 
RT reaction mix.  The tubes were inverted six times and spun briefly.  The tubes were placed on 
ice for 5 mins.  The run method was set up as shown in table 2-19 for a total reaction volume of 
7.5 μL.  The thermal cycling conditions are documented in table 2-20.   
 
Table 2-19 Preparation of RT master mix 
Component Vol 1 × sample (μl) Vol 10 × samples  (μl) 
Megaplex RT Primers (10×) 0.80 9.00 
dNTPs with dTTP (100mM) 0.20 2.25 
MultiScribe™ reverse transcriptase, (50 U/μl) 1.50 16.88 
10X RT  Buffer 0.80 9.00 
MgCl2 0.90 10.12 
RNase inhibitor, 20U/μl 0.125 1.25 
Nuclease-free water 0.20 2.25 
Total 4.50 50.62 
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Table 2-20 Thermal–cycling conditions for Megaplex RT Reaction 
Stage Temp Time 
Cycle (40 Cycles, each of…)   (i) 16°C 2 min 
    (ii) 42°C 1 min 
    (iii) 50°C 1 sec 
HOLD 85°C 5 min 
HOLD 4°C ∞ 
 
2.13.2.2. Run the preamplification reaction. 
The PreAmp reaction mix was prepared in a 1.5 mL microcentrifuge tube as shown in table 2-21.  
The microcentrifuge tubes were capped and mixed gently.  The tubes were centrifuged to 
eliminate air bubbles from the mixture, and placed on ice.  The thermal cycling conditions are 
documented in table 2-22.  The tubes were then briefly centrifuged and a volume of 75 μl 0.1× 
TE pH 8.0 was added.   
 
Table 2-21  Preparation of PreAmp reaction mix 
PreAmp Reaction MixComponent Vol 1 × sample (μl) Vol 10 × samples  (μl) 
TaqMan® PreAmp Master Mix, 2× 12.5 140.62 
MegaplexTM PreAmp Primers (10×) 2.5 28.13 
Nuclease-free water 7.5 84.37 
Total 22.5 253.12 
 
Table 2-22 Thermal–cycling conditions for PreAmp reaction 
Stage Temp Time 
HOLD 95°C 10 min 
HOLD 55°C 2 min 
HOLD 72°C 2 min 
Cycle (12 Cycles, each of…) (i) 
    (ii) 
85°C 
60°C 
15 sec 
4 min 
HOLD 99.9 °C 10 min 
HOLD 4°C ∞ 
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2.13.2.3. Run the real-time PCR reaction   
The PCR reaction mix was prepared in a 1.5 mL microcentrifuge tube as shown in table 2-23.  
The tubes were inverted to mix and then centrifuged briefly.  The array was loaded and run as 
outlined in section 2.13.2.4.   
 
Table 2-23  Preparation of Real-Time PCR reaction 
Component Volume for One Array (μl) 
TaqMan Universal PCR Master Mix, No 
AmpErase UNG, 2× 
450 
Diluted PreAmp product 9 
Nuclease-free water 441 
Total 900 
 
 
2.13.2.4. Loading and running the Taqman Array.   
When the TaqMan array had equilibrated to room temperature, the card was carefully removed 
from the packaging, and placed foil side down on the lab bench.  A volume of 100 μl of the RT 
reaction-specific PCR reaction mix was loaded into the corresponding ports.  This was dispensed 
so that it went in and around the fill reservoir toward the vent port; the entire 100 μl was pipetted 
into the fill reservoir.   
The TaqMan Arrays were centrifuged and sealed according to the user bulletin: Applied 
Biosystems TaqMan® Low Density Array (P/N 4371129).   The set up and running of the plated 
document were carried out following the user bulletin: Applied Biosystems TaqMan® Low 
Density Array (P/N 4371129) and Applied Biosystems 7900HT Fast Relative Quantitation Using 
Comparative CT Getting Started Guide (P/N 4364016).  The analysis of the PCR reactions was 
carried out with reference to the SDS online help, 7900HT system user guide and troubleshooting 
using the Megaplex Pools Protocol (P/N 4399721).   
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2.14  Sequenom Oncogenotype Mutational Analysis 
The Sequenom oncogenotype mutational analysis carried out in this study was outsourced to 
Professor Bryan Hennessy’s laboratory, Department of Medical Oncology, Royal College of 
Surgeons in Ireland, Beaumont Hospital, Dublin 9.  The Sequenoms Mass-ARRAY® system is a 
mass spectrometry based technique aimed at evaluating single nucleotide polymorphisms 
(SNPs), which can facilitate rapid, high-throughput and cost-effective detection of hot-spot gene 
mutations.  Mutations were identified in the DNA isolated from the cell lines using the 
Sequenom Mass-ARRAY® system (See section 1.2.6).   
DNA extraction was achieved using the Qiagen QIAamp genomic DNA kit (Qiagen, 513304) 
and approximately 500 ng of each cell line was submitted at a concentration of 10 ng/μl.  The 
technique involves a PCR reaction which amplifies the region of the DNA to be sequenced, 
followed by a clean-up reaction where shrimp alkaline phosphatase (SAP) is added to remove 
excess nucleotides.  An iPLEX assay was then carried out, where the primer and amplified target 
DNA were incubated with dideoxynucleotide terminators which have a modified mass.  Using 
these terminators the DNA is extended by one base.  Prior to sequencing, 6mg of clean resin was 
added to each sample, and samples were spotted directly from the PCR plate onto a Sequenom 
Spectrochip using the Sequenom nanodispenser RS1000.  Transferred volumes were checked to 
ensure they were greater than 5nL and less than 20nL.  If the volume was less than or greater 
than this, the speed of the machine was adjusted until the target volume was achieved.  Spotted 
spectrochips were run on the MassArray Analyser Compact and through the use of MALDI-TOF 
mass-spectrometry the mass of the extended primer is determined.  The mass of the primer 
indicates the sequence and, therefore the alleles present at the polymorphic site of interest.  The 
mass of the observed primers can then be translated into a genotype for each reaction20.  The 
aquisition parameters were: Shots (number of laser shots attempted during processing)-15, 
maximum acquisitions-9, minimum good spectra (Number of spectra collected before starting 
analysis) -5, maximum good spectra (Acquisition stops after this number) -5.  The Sequenom 
panel used in this analysis offers parallel analysis of 284 mutations (Appendix 1).   
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2.15  RNA interference (RNAi) 
RNAi using small interfering RNA's (siRNAs) was carried out to silence specific genes.  The 
siRNAs used were chemically synthesised (Ambion Inc).  These siRNAs were 21-23 bps in 
length and were introduced to the cells via reverse transfection with the transfection agent 
siPORT NeoFXTM (Ambion Inc., 4511).   
 
2.15.1  Transfection optimisation 
In order to determine the optimal conditions for siRNA transfection, optimisation with kinesin 
siRNA (Ambion Inc., 16704) was carried out for each cell line.  There were a number of different 
parameters that had to be determined to establish an optimised protocol for the siRNA 
transfection of the DLKP cells.   
Cell suspensions were prepared at 1×105, 3×105 and 5×105 cells per ml.  Solutions of negative 
control and kinesin siRNAs at a final concentration of 30nM were prepared in optiMEM 
(GibcoTM, 31985047).  NeoFX solutions at a range of concentrations were prepared in optiMEM 
in duplicate and incubated at room temperature for 10 minutes.  After incubation, either negative 
control or kinesin siRNA solution was added to each NeoFX concentration.  These solutions 
were mixed well and incubated for a further 10 minutes at room temperature.  To each well of a 
6-well plate 100μl of the siRNA/NeoFX solutions was added.  A volume of 1 ml of the relevant 
cell concentrations were added to each well.  The plates were mixed gently and incubated at 
37°C for 24 hours.  After 24 hours, the transfection mixture was removed from the cells and the 
plates were fed with fresh medium.  The plates were assayed for changes in proliferation at 72 
hours using the acid phosphatase assay (Section 2.2.1).  Optimal conditions for siRNA 
transfection were determined as the combination of conditions, which gave the greatest reduction 
in cell number after kinesin siRNA transfection and also the least cell kill in the presence of 
transfection reagent.  The optimised conditions for the DLKP cell lines were 2μl NeoFx to 
transfect 30nM siRNA in a cell density of 2×l05 per well of a 6-well plate.   
 
2.15.2  Proliferation assays on siRNA transfected cells 
Cells were seeded using 0.2μl NeoFX to transfect 30nM siRNA in a cell density of 2.5×103 per 
well of a 96-well plate.  After 24 hrs, transfection medium was replaced with fresh media and 
cells were allowed to grow until they reached 80-90% confluency, a total of 5 days.  Cell number 
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was assessed using the acid phosphatase assay (section 2.2.1).  All experiments were carried out 
independently at least three times.   
 
2.15.3  Invasion analysis of siRNA transfected cells 
To assay for changes in invasive capacity, siRNA experiments in 6-well plates were set up using 
2 μl NeoFx to transfect 30nM siRNA in a cell density of 2×l05 per well of a 6-well plate.  
Transfection  medium was removed after 24hr and replaced with fresh growth medium.  The 
transfected cells were assayed for changes in invasion capacity at 72hr using the optimised in 
vitro invasion assay described in Section 2.3.1.   
 
2.15.4  Chemosensitivity assay on siRNA-transfected cells   
Assays were set up as described above (section 2.15.2).  24 hrs after addition of fresh media, 
appropriate concentrations (2×) of chemotherapeutic drugs were added to the wells in replicates 
of 4 and incubated for 3 days.  The plates were assayed for changes in proliferation at 96 hrs 
using the acid phosphatase assay (Section 2.2.1).   
 
Table 2-24  List of siRNAs used in this study 
Silencer ® Select target name Life technologies ID 
ABCG2 # 1 S18056 
ABCG2 # 2 S18057 
ABCB1 # 1 S10420 
ABCB1 # 2 S10418 
ITGAV # 1 S3685 
ITGAV # 2 S7568 
BCHE # 1 S1906 
BCHE # 2 S1907 
Negative Control No. 1 siRNA S4390843 
Kinesin AM4639 
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2.16  Statistical analysis   
Software: Prism, Instat and Excel 
IC50 values were calculated using GraphPad Prism (Version 5.01, GraphPad Software, Inc., 
USA).  GraphPad Instat (Version 3) allowed simple descriptive statistics and 1-way ANOVA.  
Excel 2010 was used for t-tests and simple graphs.   
Analysis of the difference of comparisons, as well as untreated versus siRNA treated mean 
invasion and percentage survival calculated, were performed using a student t-test (two-tailed 
with equal variance), on Microsoft Excel.   
 
Error bars were plotted using plus and minus the standard deviation on duplicate inserts 
interexperimentally.   
In the siRNA experiments, siRNA scrambled transfected cells were used as control compared to 
siRNA treated samples.  This was to ensure no ‘off-target’ effects of the siRNA transfection 
procedure.  Non-treated controls were used to ensure scrambled siRNA was having no effect and 
to normalise data.   
Significance may be assumed as follows:  
 
* A p value of ≤ 0.05 was deemed significant 
** A p value ≤ 0.01 was deemed more significant 
*** A p value ≤ 0.005 was deemed highly significant 
 
2.17  Bioinformatics   
Bioinformatics is the collection, organization and analysis of large amounts of  biological data, 
using networks of computers and databases.  Software packages are available to analyse 
microarray data e.g. Genespring and Spotfire.  The data analysis software used for the analysis of 
the microarray experiments reported in this thesis was dChip293.   
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2.17.1  dCHIP   
DNA-Chip Analyzer (dChip) is a software package implementing model-based expression 
analysis of oligonucleotide arrays 290 and several highlevel analysis procedures.  This model-
based approach allowed probe-level analysis on multiple arrays.  By pooling information across 
multiple arrays, it was possible to assess standard errors for the expression indexes.  In this 
normalisation procedure an array with median overall intensity was chosen as the baseline array 
against which other arrays were normalised at probe level intensity.  Subsequently a subset of 
PM probes, with small within-subset rank difference in the two arrays, served as the basis for 
fitting a normalisation curve.  This approach also allowed automatic probe selection in the 
analysis stage to reduce errors due to cross-hybridizing probes and image contamination.  High-
level analysis in dChip included comparative analysis and hierarchical clustering.  Gene filters 
employed for this analysis included a raw value difference of at least 100, and a fold change of at 
least 1.2.  After these filters are in place and the relevant genes have been removed, a T-test is 
carried out to generate pvalues for each probe.  Only p-values of less than 0.05 were accepted.  
This normalisation was downloaded from (http: //dchip. or g/) along with other data analysis 
modules.   
 
2.17.2  R   
The name “R” refers to the computational environment initially created by Robert Gentleman 
and Robert Ihaka, similar in nature to the “S” statistical environment developed at Bell 
Laboratories (http://www.r-project.org/about.html).  It has since been developed and maintained 
by a strong team of core developers (R-core), who are renowned researchers in computational 
disciplines.  R has gained wide acceptance as a reliable and powerful modern computational 
environment for statistical computing and visualisation, and is now used in many areas of 
scientific computation.  R is free software, released under the GNU General Public License; this 
means anyone can see all its source code, and there are no restrictive, costly licensing 
arrangements.  One of the main reasons that computational biologists use R is the Bioconductor 
project (http://www.bioconductor.org), which is a set of packages for R to analyse genomic 
data294.   
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2.17.3  David   
DAVID (the Database for Annotation, Visualization and Integrated Discovery) is a free online 
bioinformatics resource and was used for gene-term enrichment analysis.  
(http://david.niaid.nih.gov)295,296.   
 
2.17.4  Panther   
Genelists were analysed using PANTHER Classification System (available from 
www.pantherdb.org).  The PANTHER (Protein ANalysis THrough Evolutionary Relationships) 
Classification System is a unique resource that classifies genes by their functions, using 
published scientific experimental evidence and evolutionary relationships to predict function 
even in the absence of direct experimental evidence297.  In this thesis, PANTHER was used to 
define a list of enriched pathways that are represented by lists of genes.   
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CHAPTER 3 
 
Development of P-gp- and BCRP-mediated mitoxantrone resistant lung cancer cell lines 
using identical selection schedules.   
 
 
103 
 
3.1  Establishment of Mitoxantrone-resistant Cell Lines 
3.1.1  Introduction 
The resistance of tumours to cytotoxic drugs is a major cause of chemotherapy failure.  In one 
type of multidrug resistance (MDR), that is caused by overexpression of multidrug efflux pumps 
belonging to the ABC family, cells display resistance to a variety of structurally and functionally 
unrelated chemotherapeutic drugs.  The chemotherapeutic drugs to which the cells are resistant 
generally include the anthracyclines, vinca alkaloids, podophyllotoxins, peptide antibiotics and 
taxol, but usually exclude nucleotide analogues, metabolic inhibitors, alkylating agents and 
platinum analogues.   
The MDR phenotype may be an inherent property of the cells or acquired following exposure to 
one or more cytotoxic agents.  Studies with drug-selected model cell lines have repeatedly 
demonstrated that overexpression of some members of the ATP-binding cassette (ABC) 
transporter superfamily including P-glycoprotein (Pgp or ABCB1), breast cancer resistance 
protein (BCRP or ABCG2), and multidrug resistance associated protein 1 (MRP1 or ABCC1) as 
one of the major mechanisms responsible for MDR.  Therefore, blocking BCRP- and P-gp-
mediated active efflux may provide a therapeutic benefit for cancers.  Delineating the precise 
molecular mechanisms for BCRP and P-gp gene expression may lead to identification of a novel 
molecular target to modulate BCRP- and P-gp mediated MDR.   
It was previously demonstrated that exposure of the human lung carcinoma cell line, DLKP to 
mitoxantrone, an anthracenedione, can result in not only an MDR phenotype but also enhanced 
cell invasion in vitro196.  One aim of the work described in this chapter was to use an in vitro 
model of development of mitoxantrone resistance to investigate whether resistance and invasion 
emerge together or sequentially.  I also aimed to identify changes in gene expression associated 
with the selection of a mitoxantrone – resistant cell population.  In the present study, I established 
two mitoxantrone resistant cell lines from DLKP-SQ by sequential pulsing.  Although both cell 
lines showed resistance to mitoxantrone over 200 times more than the parent cells and cross-
resistance to other anticancer drugs, the mechanism of resistance was different.   
 
3.1.2  Choice of cell line and drug 
Liang et al 196, have previously demonstrated that exposure of the human lung carcinoma cell 
line, DLKP to mitoxantrone, an anthracenedione, can result in not only an MDR phenotype but 
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also enhanced cell invasion in vitro.  In addition, mitoxantrone is a substrate for both BCRP and 
P-gp.  The aim of this study was to establish an in vitro model of mitoxantrone resistance to 
identify changes in gene expression associated with the selection of a mitoxantrone – resistant 
cell population and to establish if the resistant and invasion phenotypes emerged at the same or at 
different times.  Selections can be performed on individual clones or on mass populations of 
cells.  In this study, DLKP-SQ, a clone of DLKP was chosen for the establishment of a 
mitoxantrone resistant cell line.  The strategy of deriving isogenic drug resistant cell lines from 
the DLKP-SQ clone eliminates variability due to intrinsic genetic differences between cell lines.   
 
3.1.3  Cell culture and establishment of DLKP-SQ-Mitox 
DLKP-SQ cells were cultured in ATCC containing 5% FBS, in a humidified incubator with 
atmosphere of 5% CO2. DLKP-SQ-Mitox variants were selected by a high mitoxantrone 
concentration (the final concentration was 5 ng/ml, IC90), for 4 hours and washed with drug-free 
medium.  Triplicate flasks were set up.  Medium was changed after 3 days to wash out dead cells. 
When the cells started growing exponentially they were pulsed with 5 ng/ml of mitoxantrone. 
The cells in one of the triplicate flasks died after one pulse.   
This cyclic treatment was repeated four times over a period of four months, generating the 
replicate DLKP-SQ-Mitox resistant sublines.   
 
3.1.4  Generation of mitoxantrone resistant cell lines 
In the process of pulse treatment using high-dose Mitoxantrone, most of the cells enlarged in cell 
volume and the cells gradually died and floated.  A few cells without drug treatment survived 
after a period of time (approximately 5%), and resumed to logarithmic growth.  The DLKP-SQ-
Mitox cell lines were established after four months and exhibited stable resistance to 
mitoxantrone.  SQ-Mitox (flask A, figure 3.1-1) cells acquired levels of resistance to 
mitoxantrone that was 210 fold higher than the DLKP-SQ parent cells. DLKP-SQ-Mitox cells 
(Flask B) acquired levels of resistance to mitoxantrone that was 320 fold higher than the parent 
cells. IC50 values for SQ-Mitox sublines (flask A and B) ranged from 16 ng/ml to 25 ng/ml, 
whereas the IC50 for DLKP-SQ was 0.08 ng/ml. 
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Figure 3.1-1: Flow diagram outlining the generation of the mitoxantrone resistant cell lines.  *These 
eflux pumps were later identified through microarray analysis and revealed to be overexpression of  
BCRP and P-gp in flasks A and B respectively.   
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3.1.5  Morphology of mitoxantrone resistant cell lines 
As described in the previous section, two independent mitoxantrone resistant cell lines were 
generated (Flask A and B, figure 3.1-1) and microarray analysis revealed that the two variants 
had completely different mechanisms of resistance.  The two replicate flasks contained cells with 
two different morphologies.  One replicate flask contained cells with a spindle like morphology 
(SQ-Mitox-BCRP) while the other flask contained cells with a more regular morphology and was 
closest to the parental cells (SQ-Mitox-MDR), figure 3.1-2.   
 
 
Figure 3.1-2: Cell morphology The DLKP-SQ cells are compact with distinct boundaries while the 
size of the Flask A cells were unequal and slightly larger (later shown to be BCRP overexpression). 
The morphology of the Flask B cells was irregular (later shown to be MDR1 overexpression) 
Magnification ×100, scale bar 200μm..  
 
A. B. 
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3.1.6  Invasion assays of mitoxantrone resistant cell lines 
As the the aim of this study was to establish if the resistant and invasion phenotypes emerged at 
the same or at different times, the differences in invasion between the mitoxantrone resistant SQ 
cells and poorly invasive SQ parent were monitored during the development of resistance as 
described in section 2.3.1.  Results show the trend that invasion was increased in the 6th pulse 
relative to the 4th pulse and the SQ parent in both the BCRP and P-gp over-expressing cells 
(figure 3.1-3).  High standard deviations were observed in these assays and may have been due to 
the instability of the invasive phenotype in these new drug resistant cells.  Interestingly, induction 
of invasion was independent of the type of transporter expressed.  Further investigations 
(microarray analysis) of these cell lines will be described in chapter 4.   
 
 
Figure 3.1-3: The invasive capacity of panel of DLKP-SQ-Mitox cells. The total number of invading 
cells was determined by counting the number of cells per field in 10 random fields, at 200× 
magnification. The average number of cells per field was then multiplied by a factor of 140 (growth 
area of membrane/field area viewed at 200× magnification (calibrated using a microscope graticule)). 
Error bars represent the standard deviation of triplicate invasion assay experiments (n=3).   
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3.1.7  Cross resistance drug profiles of mitoxantrone resistant cell lines 
When cells are repeatedly treated with a chemotherapeutic drug, the drug resistant variant, which 
is eventually produced, typically not only displays resistance to this singular drug, but also to 
different groups of drugs.  To determine if the SQ-Mitox-BCRP and SQ-Mitox- MDR cell lines 
similarly displayed cross-resistance to multiple pharmacological agents, a panel of drugs with 
differing structure and function were tested as described in section 2.2.  As observed in table 3.1-
1 below, the SQ-Mitox-MDR cells demonstrate a “typical” MDR phenotype which has been 
correlated with P-gp-mediated drug resistance and its associated cross-resistance to taxol, 
epirubicin, vinblastine, irinotecan and VP16.   
In contrast, the SQ-Mitox-BCRP cell line exhibited resistance to mitoxantrone and irinotecan, but 
not to taxol, epirubicin, vinblastine, VP16 or 5-FU. Irinotecan and its active metabolite SN-38 are 
substrates of BCRP298.   
 
3.1.8  ABCB1/P-gp and ABCG2/BCRP RNA and protein expression 
Significant differences confirmed between parent and resistant cell lines 
Having developed MDR variants overexpressing BCRP and P-gp, the gene expression profiles of 
these cell lines were compared using microarray analysis (section 3.1.10).  Significant 
differences in transcript levels from the microarray data were confirmed by qRT-PCR and 
Western blotting for BCRP and P-gp (figure 3.1-4).  DLKP-A, an adriamycin-selected variant of 
a human lung epithelial carcinoma cell line, was used in these studies as a positive control.  This 
cell line has previously been shown to overexpress P-glycoprotein277.  There was perfect 
concordance between the microarray and qRT-PCR results for significant changes in expression 
of the P-gp and BCRP.  Real Time PCR and Western blot analysis revealed that BCRP is highly 
upregulated in SQ-Mitox- BCRP and that P-gp is also highly upregulated in SQ-Mitox-MDR.  
Interestingly, Western blot analysis showed that BCRP and P-gp overexpression occurs early on 
in the pulsing process in the SQ-Mitox-BCRP and SQ-Mitox-MDR cell line respectively (as 
early as the 2nd pulse).   
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Table 3.1-1: IC50 and fold resistance of the DLKP-SQ Mitox resistant variants compared to the parental 
DLKP-SQ cell line (ng/ml).   
Drug DLKP-SQ error SQ-BCRP error SQ-Pgp error 
Mitox: 
 IC50 
 fold (n) 
 
0.08 
1 (3) 
 
0.01 
 
16.79 
209.87 (3) 
 
2.27 
 
25.59 
319.87 (3) 
 
3.27 
Taxol: 
 IC50 
 fold (n) 
 
1.65 
1 (2) 
 
0.647 
 
1.11 
0.67 (3) 
 
0.379 
 
501.2 
303 (2) 
 
40.58 
Epirubicin: 
 IC50 
 fold (n) 
 
10.39 
1 (3) 
 
1.49 
 
13.93 
1.34 (3) 
 
0.91 
 
1861 
179.1(3) 
 
208.59 
Vinblastine: 
 IC50 
 fold (n) 
 
0.63 
1 (2) 
 
0.36 
 
0.68 
1.07 (2) 
 
0.4 
 
81 
128 (2) 
 
1.41 
Irinotecan: 
 IC50 
 fold (n) 
 
337 
1 (3) 
 
67 
 
1359 
4.03 (3) 
 
207 
 
1948 
5.8 (3) 
 
432.7 
Cisplatin: 
 IC50 
 fold (n) 
 
731.8 
1 (2) 
 
136.33 
 
467.85 
0.63 (2) 
 
11.80 
 
582 
0.79 (2) 
 
75.51 
VP16: 
 IC50 
 fold (n) 
 
1.20 
1 (2) 
 
0.076 
 
1.51 
1.25(2) 
 
0.40 
 
2073.5 
1727.5 (2) 
 
57.27 
5FU: 
 IC50 
 fold (n) 
 
822.55 
1 (2) 
 
325.9 
 
1850 
2.25 (2) 
 
544.47 
 
1434 
1.74 (2) 
 
470.93 
error: standard deviation 
n value indicates the number of times each toxicity assay done.   
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Figure 3.1-4: (A.) Western blotting for P-gp (170kD) and BCRP (70kD) in the SQ-Mitox cells.  
DLKP-A served as a positive control (B. and  C).  Western blot shows that P-gp and BCRP 
overexpression occurs early on in the pulsing process (Pulse 2).  (D.)  Real time PCR shows MDR1 
mRNA relative expression levels and (E.)  BCRP mRNA relative expression levels.   
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3.1.9:  MDR and BCRP confer drug resistance to Mitoxantrone-selected DLKP-SQ 
Effect of ABCB1 siRNA on drug resistance  
To further evaluate if ABCG2 was conferring resistance to mitoxantrone in the BCRP and P-gp 
overexpressing cell line, we performed cytotoxicity assays in the presence and absence of 
elacridar, a specific inhibitor of ABCG2 and ABCB1 as described in section 2.15 and section 2.2).  
A concentration of 443nM Elacridar was chosen for the inhibitor experiment as previously used 
in this laboratory299.  With the addition of 443nM Elacridar, the ABCG2-mediated and ABCB1-
mediated resistance to mitoxantrone was reversed (figures 3.1-5 and 3.1-6).  The addition of 
elacridar resulted in an approximately 30% enhancement of the toxicity of mitoxantrone on the 
SQ-Mitox-BCRP and SQ-Mitox-MDR cells.  This indicates that the inhibition of BCRP 
(ABCG2) and P-gp (MDR1 or ABCB1) results in greater toxicity to mitoxantrone exhibited by the 
SQ-Mitox-BCRP and SQ-Mitox-MDR cells respectively.   
To confirm that BCRP was the ABC transporter conferring resistance to SQ-Mitox-BCRP, RNA 
interference (RNAi) studies were performed as described in section 2.15.  Standard 
characterisation analysis determined the degree of silencing mediated by a synthetic siRNA 
corresponding to BCRP.  Using 30nM siRNA, BCRP protein expression was found to be reduced 
(figure 3.1-7).   
Following validation, cytotoxicity assays were performed on cells treated with BCRP (ABCG2) 
siRNA or scrambled siRNA (the negative control).  The BCRP siRNAs induced a shift of the 
drug response curve down, below 50% cell survival, indicating less resistance to mitoxantrone 
(figure 3.1-5).  Together with the results from the elacridar cytotoxicity studies, this suggests that 
BCRP is critical for the drug resistance observed in the SQ-Mitox-BCRP cell line.   
To confirm that P-gp (MDR1/ABCB1) was the ABC transporter conferring resistance to SQ-
Mitox-MDR, RNA interference (RNAi) studies were also performed.  Standard characterisation 
analysis was conducted to determine the degree of silencing mediated by a synthetic siRNA 
corresponding to P-gp.  Using 30nM siRNA, P-gp protein expression was found to be reduced 
(figure 3.1-7).  Following validation, cytotoxicity assays were performed on cells treated with P-
gp siRNA or scrambled siRNA.  The P-gp siRNA induced a similar shift of the drug response 
curve below 50% in the case of P-gp siRNA1, indicating less resistance to mitoxantrone (Figure 
3.1-6).  Together with the results from the elacridar cytotoxicity studies, this suggests that P-gp is 
likewise critical for drug resistance in the SQ-Mitox-MDR cell line.   
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Effect of siRNA on drug sensitivity of SQ Mitox (BCRP) cells
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Figure 3.1-5  Evaluating the combination effect of small interfering RNA (siRNA) and mitoxantrone 
treatment in SQ-Mitox-BCRP cells.  Cells were treated first with BCRP siRNA or scrambled siRNA 
for 24 hours followed by mitoxantrone treatment at different concentrations.  72 hours after the 
mitoxantrone treatment, cell viability was evaluated by acid phosphatase assay.  The BCRP inhibitor 
Elacridar was used as a control.  Data shown is mean ± standard deviation (n=3). 
Effect of siRNA on drug sensitivity of SQ-Mitox (MDR1) cells
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Figure 3.1-6  Evaluating the combination effect of small interfering RNA (siRNA) and mitoxantrone 
treatment in SQ-Mitox-MDR cells.  Cells were treated first with P-gp siRNA or scrambled siRNA for 
24 hours followed by mitoxantrone treatment at different concentrations.  72 hours after the 
mitoxantrone treatment, cell viability was evaluated by acid phosphatase assay.  The P-gp inhibitor 
Elacridar was used as a control.  Data shown is mean ± standard deviation (n=3).   
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Figure 3.1-7:  Effect of BCRP and P-gp siRNA on drug resistance – Western blot analysis of BCRP 
expression in SQ-Mitox-BCRP cells treated with BCRP siRNA and P-gp expression in SQ-Mitox-MDR 
cells treated with P-gp siRNA.  (A.): Western blot showing knockdown of BCRP at 48 hours post-
transfection in SQ-Mitox-BCRP cells transfected with two independent siRNAs targeting BCRP relative 
to scrambled control siRNA transfected cells and untreated cells.  (B.) Western blot showing knockdown 
of P-gp at 48 hours post-transfection in SQ-Mitox-MDR cells transfected with two independent siRNAs 
targeting P-gp relative to scrambled control siRNA transfected cells and untreated cells.   
 
3.1.10  Gene Expression data analysis for DLKP-SQ and its mitoxantrone resistant variants 
In order to further elucidate the mechanism of resistance in the mitoxantrone resistant variants, 
gene-lists were generated from the raw array data that may potentially serve as a genotypic 
signature for drug resistance in the SQ-Mitox variants.  Changes in gene expression between 
DLKP-SQ parental cells and the derived drug resistant cell lines were generated using the 
statistical software environment R (www.r-project.org), section 2.17.2., and the aroma affymetrix 
package using the robust multichip average (RMA) algorithm300,301, with a P-value adjustment of 
p ≤ 0.05.   
 
3.1.10.1  Changes in gene expression associated with resistance by microarray analysis 
Two fold lists of probesets with significant changes in expression (p ≤ 0.05) in each cell line 
compared to the drug sensitive parental cell line were generated. The 2 fold list showed that 1623 
probesets (502 probesets over-expressed and 1121 probesets down-expressed) were significantly 
different in the SQ-Mitox- BCRP line, and 1313 probesets (296 probesets over-expressed and 
1017 probesets down-expressed) were significant in the SQ-Mitox-MDR cell line. 
A. B. 
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The top 10 over- and down-expressed genes, with their primary functions, are summarised in 
table 3.1-2.  ABCG2 was the top over-expressed gene in the SQ-Mitox-BCRP cell line. ABCB1 
was similarly the top over-expressed gene in the SQ-Mitox-MDR cell line.   
Since the BCRP (ABCG2) and MDR1 (ABCB1) genes were highly over-expressed compared to 
the fold changes for the other genes, it was decided to analysis the gene lists for over-represented 
categories of genes.  The online tool DAVID enabled functional annotation analysis using the 
BP_FAT category of Gene Ontology (GO).  Functional annotation analysis was conducted on 
probesets differentially expressed using gene ontology (GO) categories for biological processes.  
This allows for the discovery of overrepresented categories of genes.  Functional annotation 
analysis of probesets significantly different in the BCRP overexpressing cell line (table 3.1-3) 
revealed that the most significant GO categories were associated with the regulation of 
neurogenesis, intracellular signalling cascades and mRNA metabolic processes.  Functional 
annotation analysis of probesets significantly different in the MDR1 overexpressing cell line 
revealed that the most significant GO categories were associated with mRNA metabolic 
processes, mRNA processing and RNA splicing.   
 
3.1.10.2  Generation of gene lists associated with BCRP- and P-gp – mediated mitoxantrone 
resistance 
The mitroxantrone selection exclusively activated, and in parallel, a P-gp and a BCRP-related 
resistance mechanism.  There may be alternate exclusive pathways, activated randomly by drug 
exposure.   
The bioinformatics analysis had the following aims:   
 To identify the genes that change with drug exposure.   
 To identify the genes that change with drug resistance.   
 To identify the genes which differ between the BCRP and MDR1 overexpressing 
variants.   
Lists of probesets were generated using a 1.5-fold cutoff value for significant changes in 
expression levels (p ≤ 0.05) relative to the drug sensitive parental cell line.  These lists were 
overlapped using a Venn diagram to find genes that were significantly different in the two cell 
lines (figure 3.1-8).  The 1.5-fold list showed 1872 probesets were significantly different in the
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Table 3.1-2: Top ten gene transcripts significantly over- and down-expressed in SQ-Mitox-BCRP and SQ-Mitox-MDR relative to DLKP-SQ.   
DLKP-SQ vs DLKP-SQ-Mitox-BCRP  DLKP-SQ vs DLKP-SQ-Mitox-MDR 
Gene 
symbol 
Log ratio Main function  Gene 
symbol 
Log ratio Main function 
Up-regulated 
ABCG2 9.889 Nucleotide binding, transporter activity  ABCB1 10.106 Nucleotide binding, transporter activity 
SPP1 8.501 Ossification, cytokine activity  TMEM47 6.498 Plasma membrane, cell junction 
CDH10 6.318 Calcium ion binding  SH3BP4 5.624 Signal transducer activity 
SAMD5 6.204 Unknown  PCDH7 5.572 Calcium ion binding, cell adhesion 
PRSS12 5.514 Serine- type endopeptidase activity  ARL4C 5.131 Nucleotide binding, GTPase activity 
AMPH 4.566 Synaptic transmission  CAB39L 4.996 Protein binding 
DKK1 4.468 Signal transducer activity  ZIC2 4.415 Zinc ion binding, cell differentiation 
LOC440934 4.318 Unknown  CYP26A1 4.252 Retinoic activity 
HS6ST2 4.206 Sulfotransferase activity  COL23A1 3.911 Collagen catabolic process 
AUTS2 4.07 Neurodevelopment  SETDB2 3.621 DNA binding 
Down-regulated 
MALAT1 –7.244 Associated with metastasis  MALAT1 –7.11 Associated with metastasis 
CD36 –6.391 Positive regulator of cell matrix adhesion  CD36 –6.309 Positive regulator of cell matrix adhesion 
RBP7 -5.952 Retinol binding, transporter activity  RBP7 -5.954 Retinol binding, transporter activity 
KIF1A -5.408 Microtubule motor activity  KIF1A -5.394 Microtubule motor activity 
SERPINH1 -5.315 Serine type endopeptidase activity  SERPINH1 -5.315 Serine type endopeptidase activity 
MDK -9.467 Signal transduction  MDK -4.923 Signal transduction 
MYH10 -9.194 Microfilament motor activity  SEM3C -5.691 Neural cell crest migration 
THRAP3 -5.148 Mediator complex  THRAP3 -5.148 mRNA processing 
TRIM59 -5.115 Ubiquitin-protein transferase activity  LAYN -5.14 Carbohydrate binding 
QSER1 -5.022 Unknown  TFPI2 -5.069 Serine type endopeptidase activity 
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Table 3.1-3: The gene ontology (GO) identified by functional analyses – differentially expressed genes in SQ-
Mitox 
Go ID Go term Foreground 
Freq. 
Background 
Freq 
P-value Benjamini
-Hochberg 
FDR 
SQ-Mitox-BCRP: 
GO:0050767 Regulation of neurogenesis 28/933 166/209875 2.5E-5 0.0742 0.0443 
GO:0007242 Intracellular signalling 
cascade 
121/933 1256/206424 1.10E-4 0.1577 0.1975 
GO:00016071 mRNA metabolic process 46/933 370/226320 1.40E-4 0.1325 0.2452 
GO:00046907 Intracellular transport 71/933 657/226320 1.60E-4 0.1170 0.2862 
GO:0007049 Cell cycle 81/933 776/236620 1.60E-4 0.0971 0.2937 
GO:0022402 Cell cycle process 63/933 565/225818 1.70E-4 0.0853 0.3077 
GO:0006397 mRNA processing 41/933 321/226320 1.90E-4 0.0810 0.3398 
GO:0044265 Cellular macromolecule 
catabolic process 
76/933 725/226652 2.30E-4 0.0854 0.4107 
SQ-Mitox-MDR: 
GO:00016071 mRNA metabolic process  44/761 370/226320 4.6E-6 0.0128 0.0082 
GO:0006397 mRNA processing 39/761 321/226320 1.10E-5 0.0150 0.0192 
GO:0008380 RNA splicing 35/761 284/226320 2.50E-5 0.0227 0.0439 
GO:0050767 Regulation of neurogenesis 24/761 166/208850 5.40E-5 0.0373 0.0969 
GO:0045664 Negative regulation of 
neuron differentiation 
10/761 33/1569472 6.00E-5 0.0333 0.1080 
GO:0007242 Intracellular signalling 
cascade 
103/761 1256/206424 7.60E-5 0.0347 0.1348 
GO:0000398 nuclear mRNA splicing, via 
spliceosome 
22/761 153/226320 1.30E-4 0.0506 0.2312 
GO:0000377 RNA splicing, via 
transesterification reactions 
22/761 153/226320 1.30E-4 0.0506 0.2312 
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SQ-Mitox- BCRP line, and 1472 probesets were significant in the SQ-Mitox-MDR line.   
Approximately half the total number of probesets were identified as changed as a consequence of 
selection for drug resistance (55.91% for SQ-Mitox-MDR and 43.96% for SQ-Mitox-BCRP) and 
45-57% of changes in gene expression are unique in each cell line (figure 3.1-8).   
Functional annotation analysis of probesets, exclusively and differentially expressed (totalling 
1049) in the BCRP overexpressing cell line, revealed that the most significant GO categories 
were related to RNA processing, intracellular transport and cellular response to stress (table 3.1-
4).   
Functional annotation analysis of genes exclusively differentially expressed (totalling 649) in the 
P-gp overexpressing cell line revealed that the most significant GO categories were related to 
chromatin modification, embryonic morphogenesis and chromatin organization (table 3.1-4).  
Specific analysis of the common 823 probesets showed that the most enriched categories were 
mRNA processing and RNA splicing.   
 
 
Figure 3.1-8:  The generation of gene-lists may potentially serve as a gene signature for P-gp and 
BCRP expression.  A pairwise comparison was employed to identify unique and shared gene sets 
among the DLKP-SQ-Mitox resistant cell lines.  1.5 fold lists were generated which showed that 
1872 probesets were significantly different in the SQ-Mitox- BCRP line and 1472 probesets were 
significant in the SQ-Mitox-MDR line.  These lists were overlapped using a Venn diagram to 
identify 823 probesets in common between the two gene lists.  1049 probesets were specific to 
BCRP and 649 probesets were specific to MDR1.   
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Table 3.1-4: The gene ontology (GO) identified by functional analyses – exclusively 
differentially expressed genes in SQ-Mitox 
Go ID Go term Foreground 
Freq. 
Background 
Freq 
P-value Benjamini 
Hochberg 
FDR 
SQ-Mitox-BCRP: David analysis of 1049 probesets (Figure 3.1-8) 
GO:0006396 RNA processing 52/651 547/20192 4.10E-6 0.0106 0.0073 
GO:0046907 Intracellular transport 59/651 657/20349 4.9E-6 0.0006 0.0087 
GO:0033554 Cellular response to stress 53/651 566/21223 5.0E-6 0.0043 0.0089 
GO:0044265 Cellular macromolecule 
catabolic process 
61/651 725/22950 2.5E-5 0.0158 0.0043 
GO:0009057 Macromolecule catabolic 
process 
64/651 781/22950 3.3E-5 0.0168 0.058 
GO:0022403 Cell cycle phase 40/651 414/21309 4.5E-5 0.0193 0.08 
GO:0016071 mRNA metabolic process 36/651 370/22305 1.0E-4 0.0368 0.1794 
GO:0010605 Negative regulation of 
macromolecule metabolic 
process 
40/651 734/20336 1.2E-4 0.0379 0.2113 
SQ-Mitox-MDR: David analysis of 649 probesets (Figure 3.1-8) 
GO:0016568 omatin modification 23/404 274/218517 2.5E-5 0.0527 0.0429 
GO:0048598 Embryonic morphogenesis 24/404 307/235521 4.8E-5 0.0515 0.0839 
GO:0006325 Chromatin organization 25/404 278/218517 4.2E-4 0.2640 0.7266 
GO:0010629 Negative regulation of gene 
expression 
30/404 504/227069 5.5E-4 0.2598 0.9498 
GO:0051276 Chromosome organization 28/404 485/218517 1.4E-3 0.4578 2.3982 
GO:0010608 Postranscriptional regulation of 
gene expression 
16/404 211/1560817 1.7E-3 0.4554 2.8504 
GO:0048568 Embryonic organ development 14/404 172/235521 1.9E-3 0.4541 3.3054 
GO:0048706 Embryonic skeletal system 
development 
9/404 77/235521 2.0E-3 0.4256 3.4572 
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3.1.11  Proteomic analysis of  DLKP-SQ and SQ-Mitox-BCRP-4P by 2D-DIGE. 
3.1.11.1  Introduction 
The work outlined earlier resulted in the generation of SQ-Mitox-BCRP cells, a cell line 
model of mitoxantrone resistance, which over-expressed the drug resistance pump, BCRP.  
Little is currently known of the intracellular protein changes associated with BCRP 
overexpression.  Two-dimensional differential in-gel electrophoresis (2D-DIGE) analysis was 
employed to examine alterations in the levels of proteins in SQ-Mitox-BCRP-4P compared to 
DLKP-SQ parental cells.  Proteins of interest were identified by MALDI-ToF mass 
spectrometry.  Western blotting confirmed these changes.   
 
3.1.11.2  Generation of a list of significantly altered proteins 
To investigate proteins potentially involved in mitoxantrone resistance in this model for 
human lung cancer, we systematically analysed protein expression from DLKP-SQ and 
DLKP-SQ- Mitox using 2D-DIGE as described in section 2.11.  For this, three biological 
replicate samples from each cell line were prepared separately.  Samples from each cell line 
were differentially labelled with 2D-DIGE dyes (i.e. Cy3 and Cy5).  A pooled internal control 
containing a mixture of all biological replicate samples in the experiment was labelled with 
Cy2 dye.   
Proteins were initially defined as differentially regulated if the observed fold change was 
greater than 1.2 with p-values less than 0.05 to look for even subtle changes in expression 
across the drug-resistant variant and the parent.  Biological variation analysis of spots was 
significant, showing greater than 1.2-fold change in expression (t-test, p < 0.05), and revealed 
293 differentially expressed proteins between DLKP-SQ and DLKP-SQ-Mitox-BCRP 
(identified proteins are tabulated in table 3.1-5).   
 
3.1.11.3  Comparison of proteomic analysis with microarray analysis 
The list of alterations in the levels of -proteins in SQ-Mitox-BCRP-4P compared to DLKP-
SQ parental cell were compared with the significant differences in transcript levels from the 
microarray data.  There was concordance between the proteomic and microarray data for 
EEF1A1, β-tubulin, p47, Ku80 and galactin 1 (table 3.1-5).   
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Table 3.1-5:  Up- (↑) and Down-Regulated (↓) Proteomic Analysis and Microarray Analysis: DLKP-SQ vs SQ-
Mitox-BCRP-4P 
Protein 
Name 
Gene 
Symbol 
Accession 
Number 
Molecular 
Function 
SQ vs 4P 
Protein expression 
SQ vs 4P 
Microarray analysis 
Fold 
Change 
P-Value Fold change P-Value 
EF1a-like protein  gi|12006049| translation 2.55 << 1 × 10-4 1.8 << 1 × 10-4 
β-tubulin TUBB gi|338695| cytoskeleton constituent 2.16 << 1 × 10
-4 1.29 << 1 × 10-4 
α-tubulin TUBA gi|340021| cytoskeleton constituent 1.93 << 1 × 10
-4 na na 
Triosephosphate 
isomerase 1 TPI1 gi|17389815| glycolysis 1.84 ≈ 1 × 10
-4 na na 
Phosphoglycerate Mutase PGAM1 gi|67464305| glycolysis 1.76 < 1 × 10-2 na na 
Heat Shock 70kDa protein 
8, isoform 2 variant HSPA8 gi|62896815| stress 1.70 << 1 × 10
-4 na na 
Chaperonin containing 
TCP1; subunit 7 isoform b CCT7 gi|58331185| protein folding 1.53 << 1 × 10
-4 na na 
erbB3 binding protein EBP1 gi|4099506| cell proliferation 1.49 << 1 × 10-4 na na 
p47 NSFL1C gi|33150522| protein binding 1.40 < 1 × 10-2 2.52 < 1 × 10-2 
Nuclear Factor IV/Ku80 XRCC5 gi|35038| DNA repair 1.33 << 1 × 10-4 1.39 << 1 × 10-4 
Thioredoxin-like protein  gi|3646128|  1.29 << 1 × 10-4 na na 
Chaperonin containing 
TCP1; subunit 3, isoform a CCT3 gi|63162572| protein folding 1.26 < 1 × 10
-3 na na 
Peroxiredoxin 1 PRDX1 gi|55959887| apoptosis/redox 1.26 < 1 × 10-3 na na 
fatty acid binding protein 5 FABP5 gi|30583737| lipid metabolism 1.25 < 1 × 10-1 na na 
Thioredoxin Peroxidase B  gi|9955016|  1.25 << 1 × 10-4 na na 
CCT2 CCT2 gi|48146259| protein folding 1.24 << 1 × 10-4 na na 
Cl- intracellular channel 1 CLIC1 gi|55961618| Cl- ion binding 1.24 < 1 × 10-3 na na 
Glycyl tRNA synthetase GARS gi|3845409| nucleotide binding 1.22 << 1 × 10
-4 na na 
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Table 3.1-5:  Up- (↑) and Down-Regulated (↓) Proteomic Analysis and Microarray Analysis: DLKP-SQ vs SQ-
Mitox-BCRP-4P 
Protein 
Name 
Gene 
Symbol 
Accession 
Number 
Molecular 
Function 
SQ vs 4P 
Protein expression 
SQ vs 4P 
Microarray analysis 
Fold 
Change 
P-Value Fold change P-Value 
Tu translation elongation 
factor, mitochondrial TUFM gi|32425705| translation 1.21 << 1 × 10
-4 na na 
Putative protein product of 
Nbla10058 
Nbla 
10058 gi|76879893| glycolysis -1.6 << 1 × 10
-4 na na 
actin related protein 2/3 
complex, subunit 2, ARPC2 gi|7959903| actin binding -1.58 << 1 × 10
-4 na na 
Galectin-1 LGALS1 gi|56554352| apoptosis/redox -1.50 << 1 × 10-4 -1.35 << 1 × 10-4 
phosphoglycerate kinase1 PGK1 gi|48145549| glycolysis -1.41 < 1 × 10-3 na na 
Phosphoglycerate Mutase PGAM1 gi|67464305| glycolysis -1.34 < 1 × 10-2 na na 
Down syndrome cell 
adhesion molecule like-
protein 1b 
DSCAML
1 gi|23450945| 
cell junction 
organisation -1.28 < 1 × 10
-2 na na 
heat shock 70kDa protein 5 
(glucose-regulated protein, 
78kDa) 
BiP gi|1143492| anti-apoptosis /stress -1.23 < 1 × 10
-3 na na 
ATP synthase; H+ 
transporting; mitochondrial 
F1 complex 
ATP5B 
 
gi|50345982| ion binding -1.22 0.01 na na 
proteasome subunit; alpha 
type 1 PSMA1 gi|30582133| protein turnover -1.21 < 1 × 10
-2 na na 
ns, not statistically significant; na: not available 
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3.1.11.4  Western blot confirmation of changes in protein expression 
The following proteins were selected for validation by Western blotting as described in section 
2.6 – EEF1a1 (instead of EF1a-like protein, for which there was no available antibody at the time 
of analysis), DSCAM and EBP1 binding protein.  The proteomic results for these four proteins 
are shown in table 3.1-5.  In all cases, the results were consistent with proteomic analysis.  These 
proteins will be discussed further in section 6.2.6.   
 
3.1.11.4.1  EEF1A1 
Elongation factor 1-alpha 1 (eEF1a1) is a protein that in humans is encoded by the EEF1A1 
gene302.  This gene encodes an isoform of the alpha subunit of the elongation factor-1 complex, 
which is responsible for the enzymatic delivery of aminoacyl tRNAs to the ribosome.  Western 
blotting confirmed the increase in protein levels of EEF1A1 in SQ-Mitox-BCRP cells compared 
to DLKP-SQ-parent cells (figure 3.1-9).   
 
 
Figure 3.1-9: Western blotting for (A) DSCAM and (B) EBP1 in the DLKP-SQ (SQ), SQ-Mitox-BCRP-
4P (4P), SQ-Mitox-BCRP-6P (6P) and SQ-Mitox-MDR (MDR) cell lines. Western blotting for (D) 
EEF1A1 in the DLKP-SQ (SQ), SQ-Mitox-BCRP-4P (4P) and SQ-Mitox-BCRP-6P (6P) cell lines.  
GAPDH was used as an equal loading control.  SQ-Mitox-BCRP-6P (6P) is described in section 4.2.2 
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3.1.11.4.2  EBP1  
EBP1 encodes an RNA-binding protein that is involved in growth regulation.  Western blotting 
confirmed the decrease in protein levels in the SQ-Mitox-BCRP cell lines compared to the 
DLKP-SQ and SQ-Mitox-MDR cell lines (figure 3.1-9).  The differential expression of EBP1 in 
the BCRP over-expressing cells lines warrants further investigation.   
 
3.1.11.4.3  DSCAM 
DSCAM encodes a neural cell adhesion molecule belonging to the Ig superfamily that mediates 
homophilic binding303.  DSCAM and Dscam are both abbreviations for Down Syndrome Cell 
Adhesion Molecule 304.  The case difference between the two acronyms is significant as DSCAM 
refers to the gene that codes for the Dscam protein 305 and the DSCAM-like gene, DSCAMLl 
located on chromosome band 11q23, a locus associated with Gilles de la Tourette and Jacobsen 
syndromes306.   
DSCAML1 was identified from the proteomic data but DSCAM was investigated instead as a 
more likely candidate because of its role as a cell adhesion molecule associated with other 
diseases.  As little is known about the DSCAM protein, it was decided to investigate the 
expression of DSCAM in the SQ-Mitox cell lines.  As shown in figure 3.1-9, DSCAM was 
present in the DLKP-SQ parent and SQ-Mitox-MDR and decreased in the SQ-Mitox-BCRP cell 
lines.   
 
IHC analysis of DSCAM expression in human cancer 
Western blot analysis of DSCAM showed that it decreased with BCRP overexpression.  There 
have been a few reports on the association of DSCAM with cancer but its role in tumourigenesis 
and drug resistance remains to be understood307.  DSCAM expression in human cancer was 
investigated further (table 3.1-6).  A lung cancer tissue microarray (TMA) (Biomax, LC817) was 
immunohisto-chemically stained using primary antibodies specific for DSCAM.  The array 
contained 17 cases of squamous cell carcinoma, 16 adenocarcinoma, 1 bronchioloalveolar 
carcinoma and 6 small cell carcinoma.  There were single cores per case with matched lymph 
node metastasis for each, providing 40 cases for analysis of expression (total 80 TMA cores).  
TMA cores were scored semi-quantitatively, according to the intensity of the DSCAM 
immunoreactivity observed (weak, moderate, strong).  Membrane staining was observed in a 
124 
 
number of squamous carcinomas and adenocarcinomas.  In squamous and adenocarcinoma 
samples where immunoreactivity was observed in the primary tumour, staining was also 
observed in matched metastatic tumours derived from the same patients (figure 3.1-10).  Primary 
tumours from small cell carcinomas did not show any staining.  Interestingly, in metastatic 
tumours from these small cell carcinomas, weak staining was observed in 3 out of 6 even though 
the primary tumours were negative.  The potential role of DSCAM in cancer will be discussed 
further in section 6.2.6.   
Figure 3.1-10 illustrates that negligible staining for DSCAM is observed in normal lung tissue, 
while intense immunoreactivity is observed in high-grade adenocarcinoma, known particularly 
for their poor differentiation but aggressive growth and metastasis.  Likewise, a representative 
squamous cell carcinoma also shows immunoreactivity and intense immunoreactivity is also 
observed in an invasive ductal breast carcinoma.   
 
Table 3.1-6:  DSCAM Immunoreactivity in squamous, adeno and 
small cell lung primary tumours 
Tumour type DSCAM staining intensity 
17 squamous 8/17 - negative 
2/17 - weak 
5/17-  moderate 
2/17 - strong 
16 adenocarcinoma 5/16 - negative 
5/16 – weak 
3/16 – moderate 
3/16 - strong 
 
6 small cell carcinoma 
Lymph node metastatic small cell 
6/6 negative 
3/6 weak 
 
 
3.1.12  ABCB1 and ABCG2 expression in SQ-Mitox-MDR and SQ-Mitox-BCRP 
3.1.12.1  Introduction 
Several mechanisms have been previously described that facilitate transcriptional up-regulation 
of ABCG2 in different MDR cell line models: 1) ABCG2 gene amplification, 2) chromosomal 
rearrangements and 3) alternative 3′-untranslated-mediated mRNA stability308.  Until recently, 
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the most frequently occurring mechanism of ABCG2 overexpression in MDR tumour cell lines 
was ABCG2 gene amplification53,309,310.  Drug-induced epigenetic modulation of ABCB1 and 
ABCG2 gene expression has gained increasing focus in a number of recent publications311.  
Epigenetics is the term for regulation of gene expression, other than via changes in the DNA 
sequence.  Well-characterised modifications of DNA or histone scaffolding proteins include 
methylation, acetylation, phosphorylation, and ubiquitination.  The enzymes responsible for these 
modifications chemically alter genomic DNA and histones, as well as epigenetic chromatin 
remodeling factors and regulate chromatin accessibility and ultimately gene expression.   
The results presented earlier (table 3.1-1) have shown that SQ-Mitox-MDR and SQ-Mitox-BCRP 
cells were 174-fold and 313-fold resistant to mitoxantrone respectively and that this was 
attributed to the over-expression of the ABC transporters ABCB1 (P-gp) and ABCG2 (BCRP) 
(figure 3.1-7).  This presented an interesting question as to whether the drug resistant cells were 
pre-existing in the DLKP-SQ population or arose by DNA damage and mutation.  To further 
illucidate the mechanisms leading to this overexpression, gene copy number profiling and 
methylation analysis were performed.  Additionally, 5-Aza-2’ deoxycytidine (5-aza-dC) 
treatment of the SQ-Mitox cell lines was also carried out to look at the effects of methylation 
inhibition.   
 
3.1.12.2  Gene Copy Number profiling 
Genomic DNA was extracted from DLKP-SQ, SQ-Mitox-BCRP and SQ-Mitox-MDR cell lines.  
The Taqman real-time quantitative PCR (qPCR) method was used to test the copy number of 
BCRP and MDR1 in these cell lines according to the protocol of Applied Biosystems (see section 
2.9).  Relative quantitation analysis was performed by CopyCaller Software (version v1.0), using 
the known calibrator sample method.  In this study, limbal stromal cells were used as the known 
calibrator and were presumed to be diploid.  Limbal stromal cells are a stem cell population 
which were isolated from the limbus of the corneal epithelia of the eye283.  The MDR1 copy 
number of the DLKP-A cell line was also investigated.  The DLKP-A cell line is an adriamycin-
selected MDR cell line containing multiple clonal subpopulations which exhibit significantly 
different drug resistances277.  The CT values were at the upper limits of detection and as a result 
there were errors.  The minimum and maximum copy numbers are shown in table 3.1-7.   
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Figure 3.1-10:  IHC analysis of 
DSCAM expression in human 
cancer. Normal lung, squamous, 
adeno, small cell carcinoma and 
invasive ductal breast carcinoma   
were immunohisto-chemically 
stained using a primary antibody 
specific for DSCAM.  
Representative photomicrographs 
are shown  (A.) Negligible staining 
is observed in normal lung tissue.  
(B.) In contrast, intense DSCAM 
immunoreactivity is observed in 
invasive ductal breast carcinoma.  
(C.) High grade lung 
adenocarcinoma also shows 
marked staining for DSCAM.  (D.) 
Squamous cell carcinoma of the 
lung also shows distinct 
immunoreactivity. (Original 
magnification of all 
photomicrographs, 400×, scale bar 
= 100 μm).   
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The PCR investigation showed that no copy number changes were detected in either SQ-Mitox-
BCRP or SQ-Mitox-MDR cells using the primers to detect the BCRP genomic DNA target. 
(table 3.1-7).  A positive control for BCRP internal copy number was not available.  A copy 
number of 2 was detected in the SQ-Mitox-MDR cells, while a copy number of six was detected 
in the DLKP-A cells using the primers to detect genomic MDR1.  Surprisingly a copy number 
change of 3 was detected in the DLKP-SQ and the SQ-Mitox-BCRP cell line using the primers to 
detect genomic MDR1 DNA.   
 
Table 3.1-7: TaqMan Copy Number Assays. 
Cell Line BCRP min/max MDR1 min/max 
Limbal stromal 2 1-3 2 1-3 
DLKP-SQ 2 1-3 3 3-4 
SQ-Mitox-
BCRP 
2 1-4 3 2-5 
SQ-Mitox-
MDR 
2 1-3 2 1-4 
DLKP-A - - 6 5-6 
 
 
3.1.12.3  Methylation 
Introduction 
Chemotherapeutic drug-induced transcriptional up-regulation of BCRP and other methylated 
genes occurs as early as 12 hours after initial drug exposure, hence resulting in as much as a 55-
fold increase in BCRP (ABCG2) transcript levels within a single cell cycle312.  The lack of MDR1 
and BCRP gene amplification in the SQ-Mitox cell lines suggest the possibility that the dramatic 
upregulation of both genes observed in these drug-resistant cell lines may be due to a loss of 
transcriptional silencing.  To illucidate this further, a direct experiment examining the effects of 
inhibiting methylation on gene expression was performed using 5-azacytidine in DLKP-SQ cells 
(section 2.12.7).  5-azacytidine is one of many different chemical analogs for the nucleoside 
cytidine.  When these analogs are integrated into growing DNA strands, some, including 
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5-azacytidine, severely inhibit the action of the DNA methyltransferase enzymes that are 
responsible for DNA methylation.  Thus, methylation may be inhibited by flooding cellular DNA 
with 5-azacytidine, and cell lines can be compared before and after treatment to see what impact 
the loss of methylation has on BCRP and P-gp protein expression.   
Methylation analysis was performed for the BCRP promoter as it has only one CpG island and 
therefore is relatively easy to design primers and probes for a successful analysis.  In contrast, the 
MDR1 promoter has several CpG islands which make such an analysis more difficult.  Toward 
this end, the methylation status of the BCRP promoter in the DLKP-SQ cell line and its BCRP-
overexpressing counterpart was investigated.   
 
5-Aza-2’ deoxycytidine (5-aza-dC) treatment of DLKP-SQ cells 
DLKP-SQ and SQ-Mitox cells were incubated with 1µM concentration of the DNA 
methyltransferase inhibitor 5-aza-dC as described in section 2.12.7.  After treatment for 72 hours, 
whole cell proteins from these cell lines were obtained, and protein isolated for Western blot 
analysis of BCRP and P-gp.  The results confirmed little change between BCRP or P-gp protein 
in the DLKP-SQ or SQ-Mitox cell lines (figure 3.1-11).   
 
Semiquantitative MethyLight real-time PCR with methylation-specific primers 
For semiquantitative MethyLight analysis (as described in section 2.12), a dual-labeled probe is 
used together with a set of PCR primers that specifically binds to the methylation sites of interest.  
Bisulfite converted DNA requires a different primer sequence for methylated and unmethylated 
CpG sites, so the primers need to be specific to methylated, bisulfite converted DNA.  If the 
methylation-specific primer binds to the DNA, it will be elongated, and the 5' → 3' exonuclease 
activity of Taq DNA Polymerase will lead to the degradation of the primer and the release of the 
fluorophore.   
The Ct values obtained when using control DNA and a primer pair for the unmethylated BCRP 
gene (bisulfite converted) are shown in table 3.1-8.  The probe was located between primers that 
bound the sites under investigation.  Primers in this case are specific for unmethylated sequences,   
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Figure 3.1-11:  5-Aza dC treatment has no effect on DLKP-SQ and SQ-Mitox cells.  Western blots 
show BCRP and P-gp expression in DLKP-SQ, SQ-Mitox-BCRP and SQ-Mitox-MDR cells treated 
with 1µM 5-aza-dC.  (A.) BCRP protein migrated at approximately 70 kDa.  Lanes 1 and 2: DLKP-
SQ with and without treatment.  Lanes 3 and 4: SQ Mitox-MDR with and without treatment.  Lanes 5 
and 6: SQ –Mitox-BCRP with and without treatment.  (B.) P-gp migrated at approximately 170kDa. 
Lanes 1 and 2: DLKP-SQ with and without treatment.  Lanes 3 and 4: SQ Mitox-BCRP with and 
without treatment.  Lanes 5 and 6: SQ –Mitox-MDR with and without treatment.  GAPDH was used 
as an equal loading control in all blots.   
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annealing only to unmethylated DNA, and not to methylated DNA.  During the PCR extension 
step released fluorophore was quantitated through its fluorescence. Surprisingly, there was a Ct 
value of 34.845 observed using the methylated control DNA.  This value was quite high and 
perhaps there was some non-specific binding.  Despite this, it was decided to use these primers 
for the actual methylation analysis.   
Similarly, the Ct values obtained when using control DNA and a primer pair for the methylated 
BCRP gene (bisulfite converted) are also shown in table 3.1-8. The results indicated that these 
primers were suitable for use in detecting methylated stretches of DNA.   
Table 3.1-8:  Positive control results for methylation analysis using primers to detect 
methylated and unmethylated BCRP promoters 
Primer for unmethylated BCRP gene Primer for methylated BCRP gene 
Sample Ct value (Ct std err) Sample Ct value (Ct std err) 
Unmethylated control DNA Undetermined  Unmethylated control 
DNA 
Undetermined 
Unmethylated control DNA 
(bisulfite converted) 
25.762 (0.216) Unmethylated control 
DNA (bisulfite 
converted) 
Undetermined 
Methylated control 
(bisulfite converted) 
34.845 (1.103) Methylated control 
(bisulfite converted) 
26.373 (0.384) 
No template control Undetermined No template control Undetermined 
 
The Ct values obtained when using the DLKP-SQ and SQ-Mitox-BCRP cell line DNA and 
primer pairs are shown in table 3.1-9.  The first set of primers were specific for unmethylated 
BCRP sequences, annealing only to unmethylated DNA, and not to methylated DNA.  The 
second set of primers were specific for methylated BCRP sequences alone.  The results indicate 
that the BCRP promoter was unmethylated in both the DLKP-SQ and SQ-Mitox-BCRP cells.  As 
expected, the results also illustrate that the primer pair for detection of a methylated BCRP gene 
did not produce a signal (thereby also confirming no DNA methylation).  Future work examining 
the methylation state of the MDR1 promoter is also warranted.   
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Table 3.1-9:  Cell line DNA results for methylation analysis using 
primers to detect methylated and unmethylated BCRP promoters 
Sample Primer pair Ct value (Ct std err) 
DLKP-SQ ACTB 27.76 (0.253) 
SQ-Mitox-BCRP ACTB 28.653 (0.448) 
DLKP-SQ Primer for unmethylated 
BCRP gene (bisulfite 
converted) 
28.976 (0.123) 
SQ-Mitox-BCRP Primer for unmethylated 
BCRP gene (bisulfite 
converted) 
28.933 (0.177) 
DLKP-SQ Primer for methylated 
BCRP gene (bisulfite 
converted) 
Undetermined 
SQ-Mitox-BCRP Primer for methylated 
BCRP gene (bisulfite 
converted) 
Undetermined 
 
3.1.13  miRNA Expression Analysis of DLKP-SQ, SQ-Mitox-BCRP-4P and SQ-Mitox-
MDR-4P   
In order to further illucidate the mechanism of resistance in the mitoxantrone resistant variants, 
miRNA lists were generated from the raw Taqman Array data that may potentially reveal 
whether miRNAs are involved in the development of drug resistance in the SQ-Mitox variants.  
Changes in miRNA expression between DLKP-SQ parental cells and the derived drug resistant 
cell lines were generated using the data analysis tool, DataAssist software, with a P-value 
adjustment of p ≤ 0.05.  1.5  fold lists of miRNAs with significant changes in expression (p ≤ 
0.05) in each cell line compared to the drug sensitive parental cell line were generated.  Even 
though the TaqMan Human Micro RNA Array A enables quantitation of 377 human miRNAs, 
only 4 miRNAs with significant changes in expression in each cell line compared to the drug 
sensitive parental cell line were generated.  The differentially expressed miRNAs, with their 
primary functions, are summarised in tables 3.1-10 and 3.1-11.  These miRNAs will be discussed 
further in section 6.2.7.   
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Table 3.1-10: Significantly Up/Down regulated miRNAs in SQ-Mitox-BCRP vs 
DLKP-SQ 
Assay SQ-Mitox-BCRP vs 
DLKP-SQ 
Fold Change 
P-value Function 
hsa-miR-218-4373081 22.0117 1.00E-04 tumour suppressor 
hsa-miR-27a*-4395556 1.8303 0.0112 Activator of Wnt signaling 
pathway 
hsa-miR-639-4380987 -3.071253071 0.0071 Controls cell proliferation 
hsa-miR-335*-4395296 -8.196721311 0.0141 unknown 
 
Table 3.1-11: Significantly Up/Down regulated miRNAs in SQ-Mitox-MDR vs 
DLKP-SQ 
Assay SQ-Mitox-MDR vs 
DLKP-SQ 
Fold Change 
p-value Function 
hsa-miR-342-3p-4395371 1.6167 0.0119 tumour suppressor 
hsa-miR-935-4395289 -4.012841091 0.0032 unknown 
hsa-miR-524-3p-4378087 -2.569373073 0.0069 unknown 
hsa-miR-550-4395521 -2.112824847 0.0145 unknown 
 
3.1.14  Summary 
In summary, two mitoxantrone resistant cell lines with distinct P-glycoprotein and BCRP 
expression were established.  These two cell lines were selected from the same cell population 
and under identical conditions.  Microarray analysis was performed in DLKP-SQ-Mitox-BCRP 
(4th pulse) and DLKP-SQ-Mitox-P-gp (4th pulse).  Functional annotation analysis of probesets 
exclusively differentially expressed in the BCRP overexpressing cell line revealed that the most 
significant GO categories were related to RNA processing, the cellular response to stress and cell 
cycle control.  Functional annotation analysis of genes exclusively differentially expressed in the 
P-gp over-expressing cell line revealed that the most significant GO categories were related to 
chromatin organization, chromatin modification and embryonic morphogenesis.   
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Proteomic analysis of the DLKP-SQ and its drug resistant variant SQ-Mitox-BCRP revealed 
many intracellular protein changes including those involved in various processes such as 
glycolysis, protein turnover and translational elongation.  Interestingly, increased IHC staining of 
the cell adhesion molecule DSCAM was shown to be associated with aggressive, metastatic lung 
and breast carcinomas.  In contrast, Western blot analysis of SQ-Mitox-BCRP showed an 
absence of DSCAM.  However, the presence of DSCAM in the DLKP-SQ and SQ-Mitox-MDR 
cells was observed.   
miRNA analysis of the DLKP-SQ and its drug resistant variant SQ-Mitox-BCRP revealed 
differential expression of 4 miRNAs involved as tumour suppressors, in cell proliferation and 
Wnt signalling.  miRNA analysis of the DLKP-SQ and its drug resistant variant SQ-Mitox-MDR 
revealed differential expression of 4 miRNAs of unknown function.   
The gene copy number of ABCG2 and ABCB1 was investigated using qPCR.  While the DLKP-A 
cell line exhibited a ABCB1 gene copy number of 6, the SQ-Mitox-MDR cells exhibited no 
change in copy number.  Surprisingly the DLKP-SQ and the SQ-Mitox-BCRP cells exhibited an 
MDR1 gene copy number of 3.  The elevated expression of these genes cannot be solely 
explained by gene copy number.   
Treatment with 5-azacytidine of the DLKP-SQ, SQ-Mitox-BCRP and SQ-Mitox-MDR cells had 
no effect on BCRP or P-gp protein expression.  DNA methylation analysis of the BCRP over-
expressing cell line revealed that the promoter of BCRP was unmethylated in both the DLKP-SQ 
and SQ-Mitox-BCRP cells.   
Based on these results, this chapter provides a preliminary insight into new candidate genes 
associated with P-gp and BCRP-mediated resistance.  These sublines may also prove to be useful 
models for the study of new modulators of resistance aimed at improving the outcome of 
acquired drug resistance.   
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CHAPTER 4 
 
Characterisation of clonal subpopulations of DLKP and drug resistant variants.   
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Introduction 
Resistance to chemotherapy drugs is a major problem in cancer treatment.  Consequently, a better 
understanding of the mechanisms of drug resistance would help to overcome this problem.  
Intrinsic and acquired drug resistance are believed to cause treatment failure in over 90% of 
patients with metastatic cancer36.  Some tumours are initially sensitive to an anticancer agent and, 
over time, develop a resistance to it – this is referred to as acquired resistance.  Whereas, other 
tumours are resistant before treatment and this is known as intrinsic resistance.  Both intrinsic and 
acquired resistance lead to tumour progression and metastatic changes, making treatment difficult 
in such patients.   
As a result, the overall 5-year survival of patients diagnosed with some cancers, such as lung 
cancer, remains dismal and is less than 15%.  Mechanisms of lung cancer invasion and metastasis 
and the link with drug resistance has not been fully elucidated and a better understanding of these 
processes could contribute to better treatment of this disease.   
The work described in this chapter was undertaken to increase understanding of the molecular 
nature of invasion in human lung cancer cell lines using the following approaches:   
1. To characterise the morphologically distinct populations of the lung cancer cell line 
DLKP – extensive characterisation in the form of microarray analysis. 
2. To examine the temporal relationship between the emergence of drug resistance 
and invasiveness in a clone of the DLKP cell line model of mitoxantrone resistance 
development in order to better understand any links which may exist between 
multidrug resistance and cancer invasion. 
 
4.1 Characterisation of clonal subpopulations of DLKP 
4.1.1  Introduction 
Most human tumours are heterogenous at the morphological level and are a mix of different 
types of cells.  Lung cancer is a good example and it’s remarkable heterogeneity has become 
more apparent over the last decade.  Heterogeneity is important in terms of predicting the clinical 
behaviour of the tumour, therapeutic responses and also in trying to understand what sustains 
heterogeneity313.  In this section, I have exploited the availability of clonal populations of a 
human lung cancer cell line DLKP  to investigate the development of in vitro invasiveness and to 
investigate some aspects of the mRNA and protein expression changes associated with these 
changing phenotypes.   
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4.1.2  Investigation into clonal variation in sub-populations of DLKP 
In tumour progression, populations of cancer cells with different patterns of growth and invasion 
often arise within the same tissue and within individual neoplasms.  Previous studies280 have 
found that DLKP, a human lung cell line established from a tumour histologically diagnosed as a 
“poorly differentiated squamous carcinoma”, contains at least 3 morphologically distinct 
populations.  Three clones corresponding to these populations were established from the parental 
DLKP cells — DLKP-SQ (squamous), DLKP-M (mesenchymal like), and DLKP-I 
(intermediate), that are characterised by their morphologies and growth patterns 281,280.  On 
prolonged subculture, DLKP-SQ and DLKP-M can each interconvert with DLKP-I, but DLKP-
SQ and DLKP-M do not appear to interconvert.   
This panel of DLKP cell lines provides an in vitro model of invasion.  In addition, these cell lines 
differing in levels of invasiveness (but all derived from the same parent), offer a unique 
opportunity to study tumour heterogeneity.  To characterise the morphologically distinct 
populations of the human lung cancer cell line DLKP, an extensive characterisation in the form 
of microarray analysis and mutation profiling was performed.   
 
4.1.3   Morphology of DLKP clones 
The three clones are morphologically distinct (figure 4.1-1).  All grow as monolayers.  The 
DLKP-SQ clones are squamous in appearance with distinct cell boundaries.  The DLKP-I cells 
grow in colonies with indistinct cell boundaries, while the DLKP-M clone is of intermediate size 
with an irregular, fibroblastoid-like morpholgy and does not appear to form colonies280.   
 
4.1.4  Invasion assays of DLKP clones 
Degradation of the extracellular matrix (ECM) by cancer cells is an important event in the 
dissemination of cells and spread of disease314.  In this study, the invasive activity of the DLKP 
clones was examined using an in vitro invasion assay as described in section 2.3.1.  A visual 
analysis of the levels of invasion of the clones showed that the DLKP-M cells were more 
invasive than the DLKP-SQ or DLKP-I cell lines.  The relative invasiveness of the sub-lines 
compared to each other after 48 hours (shown in figure 4.1-1) remained constant.   
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Figure 4.1-1: Growth of DLKP clones on plastic (A, C and E) and visual analysis of the level of invasion of 
the DLKP clones.  Cells suspended in media were seeded in Matrigel invasion inserts.  After 48h in culture, 
cells that invaded the lower surface of the filters were recorded (B, D and F) (original magnification = 100×, 
scale bar = 200 μm).   
 
4.1.5  Adhesion assays of DLKP clones 
Many studies have suggested  a correlation between the metastatic potential and the expression of 
adhesion molecules and/or their receptors on tumour cell surface membranes315,316.  Thus, the 
expression of functional fibronectin, vitronectin, laminin and collagen IV and V receptors on the 
DLKP cells were investigated which included an adherence assay to determine the in vitro 
binding capability of the clones to these molecules (figure 4.1-2) (as described in section 2.3.3).  
Overall, the highest level of adhesion was observed through fibronectin and vitronectin for the 
cell lines DLKP-I and DLKP-M.  In contrast, no in vitro binding to collagens type IV and V was 
displayed by any of the clones.  The increase in adhesion to vitronectin could be explained by the 
increased expression of integrin αV in the DLKP-I and DLKP-M cell lines.   
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Figure 4.1-2. Adhesion of DLKP-SQ, DLKP-I 
and DLKP-M clones to extracellular matrix 
proteins.  Results are expressed as absorbance at 
570nm.  Data shown is mean ± standard 
deviation (n = 3).  Fibronectin: SQ vs M, p < 
0.05; Laminin: not significant (ns); Vitronectin: 
SQ vs I, p < 0.05, 1-way ANOVA.  Zymography 
confirms that there are higher levels of MMP-2 
in DLKP-I and higher levels of MMP-10 in 
DLKP-M.  The Western blot above displays 
integrin alpha V protein expression in DLKP 
clones.   
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4.1.6  Microarray analysis of DLKP clones 
The expression profiles of the DLKP clones were analysed and compared to each other using 
microarray analysis as described in section 2.10.  The invasion status of the DLKP clones are 
shown in the invasion assay results (figure 4.1-1).  The purpose of the microarray analysis was to 
compare invasive and non-invasive cell lines in order to identify genes and compare gene 
transcription profiles descriptive of invasion.   
 
4.1.6.1  Hierarchical clustering   
Before generating the gene lists, it was important to examine the relationship between different 
cell lines as observed by hierarchical clustering (figure 4.1-3).  In hierarchical clustering, genes 
with similar expression patterns are grouped together and are connected by a series of branches, 
which is called a clustering tree (or dendrogram) (see section 2.10.9).  Two way hierarchical 
cluster analysis (HCA) was carried out using Euclidean distance and the Ward clustering 
algorithm in the R statistical environment and applied to all probesets and filtered probesets.   
Generally, the data can be divided into two distinct groups, one consisting of all the DLKP-SQ 
and DLKP-I clones, and one consisting of the DLKP-M clone.   
All of the samples used in the experiment were run in triplicate, all three replicates of a particular 
sample were expected to cluster together, and all such clusters would be expected to be 
significantly differently from each of the other clusters.  This was not the case for one of the sets 
of samples (figure 4.1-3).  DLKP-I did not behave as expected and did not cluster with its 
replicates.  Two of the DLKP-I samples clustered with the DLKP-SQ samples and one clustered 
with the DLKP-M sample.   
 
4.1.6.2  Generation of gene lists 
The aim of the microarray analysis was to generate gene lists that: 
1. were specific to an invasive phenotype, in order to identify genetic markers for 
invasion,   
2. were specific to the DLKP-I and DLKP-M clone.   
Before generating these gene lists, it was important to examine the relationship between different 
cell lines as observed by hierarchical clustering (section 4.1.6.1).  As already mentioned, the 
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DLKP-I replicates did not behave as expected, and this was obvious from the way they clustered.  
Despite this, it was decided to remove the outlier and continue with the remaining samples.   
The purpose of initial comparisons (SQ vs I and SQ vs M) was to determine the number of genes 
changed between the baseline and experiment samples.  Gene filters employed for this analysis 
included a raw value difference (between baseline and experiment) of at least 100, and a fold 
 
 
 
 
 
Figure 4.1-3:  Hierarchical cluster analysis dendrogram of filtered probesets for DLKP-SQ, DLKP-I 
and  DLKP-M samples used in microarray analysis.  The tree represents relationships amongst genes 
in which branch lengths represent degrees of similarities.  (A.) All probesets for DLKP-SQ, DLKP-I 
and DLKP-M  samples.  (B.)  Dendrogram of filtered probesets for DLKP-SQ and DLKP-M cell 
lines.   
A. 
B. 
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change of at least 1.5.  After these filters were in place and the irrelevant genes were removed, a 
Welch modified two-sample t-test was carried out to generate p-values for each probe.  Only P-
values of less than 0.05 were accepted.  Gene list comparisons were made using dChip (section 
2.17.1) and are summarised in table 4.1-1.   
Comparison of DLKP-SQ (baseline) to DLKP-M (experiment) resulted in a list of 2746 genes.  
That is, the expression of 2746 genes was up- or down-regulated in DLKP-M (1753 genes up-
regulated and 993 genes down-regulated).  The top 15 over-expressed and under-expressed genes 
are shown in Table 4.1-1a.   
Comparison of DLKP-SQ (baseline) to DLKP-I (experiment) resulted in a list of 1319 genes. 
That is, the expression of 1319 genes was up- or down-regulated in DLKP-I (490 genes up-
regulated and 829 genes down-regulated).  The top 15 over-expressed and under-expressed genes 
are shown in tables 4.1-1b.   
 
4.1.6.3  Confirmation of differences in gene expression among the three DLKP clones 
To investigate whether the invasive potentials of the DLKP clones were associated with 
differential gene expression, seven genes that were previously shown to be differentially 
expressed in the invasive DLKP-M and DLKP-I and poorly invasive DLKP-SQ cell lines, were 
picked for analysis by Western blot and immunofluorescence.  These included genes that coded 
for proteins with a known role in invasion such as integrin αV.  Piccolo, a presynaptic 
cytoskeletal matrix protein was also analysed because of high expression change in DLKP-M 
(but absent from the DLKP-I list).  Olfactomedin 3 was previously shown to be highly expressed 
in the DLKP-SQ clone relative to the DLKP-I and DLKP-M clones281.  A Western blot 
investigation was carried out on integrin αV (figure 4.1-2), ROBO2/SLIT2 and ALCAM (figures 
4.1-6 and 4.1-7 respectively) as described in section 2.6.  Immunofluorescence was performed on 
Piccolo, N-cadherin, MMP-2 and MMP-10 as described in section 2.5.1.  Zymgraphy was carried 
out on MMP-2 an MMP-10 as described in section 2.4.  Integrin αV, N-cadherin, 
ROBO2/SLIT2, ALCAM and MMP-10 confirmed the trends indicated in the microarray analysis 
(i.e. increased expression relative to the SQ parent cell line).  These genes will be discussed 
further in section 6.4.3.   
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Table 4.1-1a:  Top fifteen over- and down-expressed genes 
 DLKP-SQ vs DLKP-M genelist: 
 Gene symbol Main function Fold change Gene symbol Main function Fold change
 Top 15 over-expressed genes Top 15 down-expressed genes 
01 VGLL3 transcription 321 OLFM3 protein binding -139 
02 PCLO calcium ion binding 204 HAPLN1 cell adhesion -127 
03 NELL2 Cell adhesion 165 CTCFL  gene regulation -66 
04 DDX3Y RNA helicase 149 HSP1A  member of heat shock 
protein 70 famiily 
-64 
05 LHX9 transcription factor  140 PMAIP1 pro-apoptotic member of 
Bcl-2 family 
-49 
06 SCN9A sodium ion transport 126 HTR2B  serotonin receptor -37 
07 ECRG4 G1 to G0 transition  121 LXN metalloendopeptidase 
inhibitor activity 
-32 
08 CADM2 Cell adhesion 107 PDE4B  3',5'-cyclic 
phosphodiesterase act. 
-31 
09 PLCB4 signal transducer activity 102 VCAN cell adhesion -21 
10 Camk2b calcium signalling 101 VCAN cell adhesion -28 
11 SLC6A15 amino acid transporterer 100 PMAIP1 promotes apoptosis -27 
12 MARCKS actin filament binding 95 NOX4 oxygen sensor -25 
13 SLC6A15 neuronal amino acid 
transport 
94 RGMB coordinate BMP 
signaling 
-18 
14 MIR100HG unknown 80 PRSS21 serine-type endo. 
activity  I 
-18 
15 GBRG1 neurotransmission 75 IGF1R tyrosine kinase activity -18 
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Table 4.1-1b:  Top fifteen over- and down-expressed genes 
 DLKP-SQ vs DLKP-I genelist: 
 Gene symbol Main function Fold change Gene symbol Main function Fold change
 Top 15 over-expressed genes Top 15 down-expressed genes 
01 CDH2 cell adhesion 155 HAPLN1 cell adhesion -179 
02 TTF1 nuclear transcription 
factor 
154 IFITM3 cytokine-mediated 
signalling pathway 
-84 
03 DSG2 calcium ion binding 132 BACE2 aspartic type 
endopeptidase acitivity 
-55 
04 PTPRC T cell activation 120 IGFBP2 IGFR signalling pathway -52 
05 DSG3 calcium ion binding 119 IFITM2 cytok-medi signal. path. -49 
06 CADM2 adherins junct organis 103 ARHGAP18 signal transduction -46 
07 FST BMP signalling pathway 94 STGC3 not known -40 
08 DSC1 homophilic cell adhesion 84 TRIM56 ubiquitin-protein lig act -39 
09 ROBO2 axon guidance 67 APOBEC3B deoxycytid deamin activi -36 
10 ALCAM cell adhesion 74 FAM155A not known -36 
11 hypo prot 
LOC144977 
unknown 70 CLONE=IMAGE
:2369365 
not known -37 
12 DKK1 wnt signalling pathway 69 PSMB8 DNA damage response -32 
13 SLC6A15 neurotrans trans activity 63 IGF1R Insulin recep sign pathw -31 
14 gb:N25883 unknown 63 QPRT NAD metabolic process -30 
15 AW291402 unknown 58 VCAN cell adhesion -28 
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(1) Integrin alpha V 
Integrin alpha V was over-expressed in both the DLKP-SQ vs DLKP-M (3-fold) and DLKP-SQ 
vs DLKP-I (3 fold) genelists.  Previous studies have confirmed the pivotal role of alphaV 
integrins in cell invasion and metastasis317,318.  Integrin alpha V was expressed at higher levels in 
the DLKP-I and DLKP-M clones (figure 4.1-2).   
 
(2) N-cadherin (cadherin 2) 
N-cadherin was over-expressed in the DLKP-SQ vs DLKP-I (155 fold) genelist only.  It is also 
known as neural cadherin and is a classical cadherin from the cadherin superfamily.  
Immunofluorescence was performed on N-cadherin to illustrate the localisation of the protein 
within the cells.  Investigation of N-cadherin expression in the DLKP clones revealed that it was 
overexpressed in the DLKP-I clone only (figure 4.1-4).   
 
 
DLKP-SQ   DLKP-I   DLKP-M 
Figure 4.1-4:  Immunofluorescence cell surface staining of N-cadherin.  DLKP-SQ (A), DLKP-I 
(B) and DLKP-M (C) cells stained with an N-cadherin antibody.  Immunoreactivity is observed in 
invasive DLKP-I cells only.  DLKP-SQ and DLKP-M cells show very weak immunoreactivity.  
Counter stained with propidium iodide.  Original magnification of all photomicrographs, ×400, scale 
bar = 20 μm.   
 
(3) Piccolo 
Piccolo was over-expressed in the DLKP-SQ vs DLKP-M (83 fold) microarray genelist only.  
Piccolo encodes a protein that functions as part of the presynaptic cytoskeletal matrix thought to 
be involved in regulating neurotransmitter release.  Immunofluorescence was performed on 
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piccolo to illustrate the localisation of the protein within the cells.  Strongest expression was 
observed in the DLKP-I clone, with some cells in the DLKP-M population also showing strong 
expression of the protein.   
 
 
Figure 4.1-5:  Immunofluorescence cell surface staining of piccolo.  DLKP parent (A), DLKP-SQ 
(B), DLKP-I (C) and DLKP-M (D) cells stained with a piccolo antibody.  Strongest immunoreactivity 
is observed in the invasive DLKP-I cells with some cells in the DLKP-M population showing some 
immunoreactivity.  DLKP and DLKP-SQ cells show weak immunoreactivity.  Counter stained with 
propidium iodide.  Original magnification of all photomicrographs, ×,400 scale bar = 100μm.   
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Figure 4.1-6:  Expression of SLIT2 and its receptor ROBO2 in the DLKP clones.  (A.) Immunoblot 
showing expression of SLIT2 in the DLKP clones.  SLIT2 migrated at approximately 165 kDa.  α-
tubulin was used as an equal loading control.  (B.) Immunofluorescence cell surface staining of 
ROBO-2.  DLKP parental cells, DLKP-SQ, DLKP-SQ, DLKP-I and DLKP-M cells stained with a 
ROBO-2 antibody.  Immunoreactivity was observed in all of the cells with the DLKP-M cells 
showing the strongest immunoreactivity.  Original magnification of all photomicrographs, ×400, scale 
bar = 50μm.  Results facilitated by Andrew McCann.  This work is currently unpublished.   
 
(4) SLIT2 / ROBO2 
Microarray analysis indicated that ROBO2 is overexpressed in the DLKP-I cells only (table 4.1-
1).  ROBO2 is a receptor for SLIT2, and probably SLIT1, which is thought to act as molecular 
guide in cellular migration during neuronal development.  Western blot analysis confirmed that 
the DLKP-M cells express high levels of SLIT2 and ROBO2, whereas the DLKP parental cells, 
DLKP-SQ and DLKP-I express low levels of SLIT2 (figure 4.1-6).  Using immunofluorescence, 
ROBO2 was detected in all of the clones with the strongest expression observed in the DLKP-M 
cells.   
 
(5) ALCAM 
CD166, also known as activated leukocyte cell adhesion molecule (ALCAM), is a highly 
conserved 110-kDa multidomain, transmembrane type-1 glycoprotein of the immunoglobulin 
super family, which was first described as a CD6 ligand on leukocytes319.  Microarray analysis 
indicated that ALCAM was overexpressed in the DLKP-I cell line relative to the DLKP-SQ cell 
50μm 50μm 50μm 50μm 
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line (table 4.1-1).  Western blot analysis confirmed that the DLKP parental, DLKP-SQ and 
DLKP-M cell lines express low levels of ALCAM whereas the DLKP-I cells expressed high 
levels of this protein (figure 4.1-7).   
 
Figure 4.1-7.  Western blot analysis showing expression of ALCAM in the DLKP clones.  (A.) 
ALCAM migrated at approximately 105 kDa.  ALCAM is clearly overexpressed in the DLKP-I cell 
line.  (B.)  α-tubulin was used as an equal loading control.  Blot facilitated by Andrew McCann.  This 
work is currently unpublished.   
 
(5) OLFM3   
Microarray analysis indicated that olfactomedin 3 (OLFM3) is down-expressed in the DLKP-M 
cell line (table 4.1-1a).  OLFM3 belongs to a family of glycoproteins containing a conserved C 
terminal olfactomedin domain.  OLFM3 may have a role in anoikis-resistance in the DLKP cell 
line as shown in a study carried out in collaboration with Dr. Joanne Keenan and others in this 
laboratory281 (Appendix II).   
 
4.1.7  Expression of MMP-2 and MMP-10 in the DLKP clones 
Since the major enzymes implicated in extracellular matrix remodelling are the matrix metallo 
proteinases (MMPs), the MMP expression profile of the DLKP clones was examined using 
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immunofluorescence studies and zymography.  Since MMP-2 was previously shown to be 
increased in drug resistant DLKP-SQ cells in our laboratory196 and MMP-10 was shown to be 
increased in the DLKP-SQ vs DLKP-M and SQ vs SQ-Mitox microarray genelists, the further 
investigation of the role of these MMPs in DLKP invasion was warranted.   
Using immunofluorescence studies as described in section 2.5.1, MMP-2 was detected in all of 
the cell lines with the the DLKP parent showing similar staining to DLKP-I (figure 4.1-8).  The 
DLKP-SQ clone shows diffuse staining while for the DLKP-I clone, the MMP-2 antigen is 
asymmetrically distributed upon the cell surface, with major concentrations of the enzyme found 
along the lamellopodia.  The DLKP-M clone shows the strongest staining.   
The DLKP parent cells show less MMP-10 staining overall (figure 4.1-9).  The DLKP-I clone 
appears to have the most MMP-10.  Like MMP 2, it appears to be located on the surface and on 
the lamellopodia.  The DLKP-M clone shows less staining than the DLKP-I clone even though 
the zymogram analysis indicates that it has a much higher level of MMP 10 (figure 4.1-2).  It is 
likely that it may be secreted into the conditioned medium by the DLKP-M clone.   
Zymography analysis of MMPs from the conditioned media is illustrated in figure 4.1-2.  This 
shows that the DLKP parent and all of the clones secrete MMP-2 protein.  The levels of MMP-2 
protein detected are similar in both DLKP-SQ and DLKP-M cell lines while the DLKP-I cells 
may produce more latent MMP-2 than the DLKP-SQ and DLKP-M cells.  However, the DLKP-I 
cell line also expressed low levels of active MMP-2 as seen by the presence of a faint lower 
molecular weight band in figure in 4.1-2.  In contrast, DLKP-M appeared to produce more latent 
MMP-10 than the DLKP-SQ and DLKP-I cells.   
 
4.1.7.1  Effect of MMP-2 and MMP-10 blocking antibodies on the in vitro invasiveness of the 
DLKP-I and DLKP-M cell lines 
Following observations that the DLKP-I and DLKP-M cell lines were more invasive than the 
DLKP-SQ cell line and subsequent to the MMP analysis, there were dramatic differences 
observed between the cell lines in their MMP-2 and MMP-10 expression patterns.  These results 
suggested that MMP-2 and MMP-10 expression in DLKP-I and DLKP-M may play a role in the 
increased invasiveness of these cells.  In order to address this question, MMP-2 and MMP-10 
blocking antibodies were employed to investigate their effects, if any, on the invasiveness of the 
DLKP-I and DLKP-M cell lines.   
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The addition of 5μg/ml of MMP-2 antibody saw a significant reduction in the invasiveness of the 
DLKP-I and DLKP-M cell lines (approximately 50-30% respectively).  Cells treated with an IgG 
control antibody for MMP-2 showed no decrease in invasion in comparison to DLKP-I and 
DLKP-M control cells (figures 4.1-10 and 4.1-11) (p < 0.001 for DLKP-I and p < 0.05 for 
DLKP-M).   
 
Figure 4.1-8:  Immunofluorescence cell surface staining of MMP-2 in DLKP clones.  DLKP parent 
(A), DLKP-SQ (B), DLKP-I (C) and DLKP-M (D) cells stained with an MMP-2 antibody which 
detects both the pro- and active forms of human MMP-2.  Immunoreactivity is observed in all of the 
cells with the DLKP parental cells showing similar staining to the DLKP-I cells.  Strongest 
immunoreactivity is observed in the DLKP-M cells.  Counter stained with propidium iodide.  Original 
magnification of all photomicrographs, ×400, scale bar = 100 μm.   
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Figure 4.1-9:  Immunofluorescence cell surface staining of MMP-10 in DLKP clones.  DLKP parent 
(A), DLKP-SQ (B), DLKP-I (C) and DLKP-M (D) cells stained with an MMP-10 antibody which 
detects both the pro- and active forms of human MMP-10. Immunoreactivity is observed in all of the 
cells with the DLKP parental cells showing the weakest staining. Counter stained with propidium 
iodide. Original magnification of all photomicrographs, ×400, scale bar = 100μm.   
 
 
 
 
 
 
 
151 
 
In contrast, the addition of 10μg/ml of MMP-10 antibody had no effect on the invasiveness of 
DLKP-I and DLKP-M cells.  There was a small but variable effect in MMP-10 treated DLKP-I 
cells while there was a highly variable effect in MMP-10 treated DLKP-M cells. 
 
4.1.8  Sequenom analysis of DLKP clones 
The DLKP clones and the cell line DLRP were evaluated for the presence of mutations using 
sequenom technology (section 2.14 and section 1.2.6).  DLRP (see section 2.1) is a poorly 
differentiated squamous cell lung carcinoma which was developed in the National Institute for 
Cellular Biotechnology (NICB)282 within Dublin City University (DCU).   
Analysis of the clones (table 4.1-2) using Sequenom’s mutation panel (section 2.14 and appendix 
I) showed a sequence alteration within the following genes: 
1. the Sema domain of MET (MET_N375S_A1124G), 
2. the p85α regulatory subunit of PI3K3R1 (PIK3R1_M3261_G978ATC) (DLKP, 
DLKP-SQ and DLKP-M clones only), 
3. TP53 (TP53_G245VDA_G734TAC) (all DLKP clones and DLRP) 
4. EGFR (EGFR_V769LMG2305AT) (DLKP-SQ clone only) 
5. IDH1 (IDH1_V1781_G532A) (DLRP only) 
6. NRAS (NRAS_G12SRC_G34ACT) (DLRP only) 
 
Table 4.1-2:  Sequenom Mutation Analysis of DLKP Clones and DLRP 
Mutation DLKP Parent DLKP-SQ DLKP-I DLKP-M DLRP 
EGFR_V769LM_G2305AT G AG G G G 
IDH1_V1781_G532A G G G G AG 
MET_N375S_A1124G AG AG AG G A 
NRAS_G12SRC_G34ACT G G G G GT 
PIK3R1_M3261_G978ATC AG AG G AG G 
TP53_G245VDA_G734TAC AG AG AG AG AG 
 
The results indicate that there may be differential activation of EGFR, Met and PIK3R1 within 
the clones.  
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Figure 4.1-10:  The effect of MMP-2 and MMP-10 blocking antibodies on the in vitro invasion 
activity of DLKP-I.  Within the DLKP-I cell line, invasion is decreased with blocking of MMP 2 
relative to non-treated cells while there is a variable and small effect in MMP-10 treated cells.  After 
48 hours incubation, the invading cells on the underside of the insert were stained with crystal violet 
and allowed to air dry: (A.) untreated; (B.) 5.0 μg/ml of control mouse IgG1 monoclonal antibody; 
(C.) 5.0 μg/ml of MMP 2 monoclonal antibody and (D.) 10.0 μg/ml of MMP 10 monoclonal antibody.  
Magnification, ×200. Scale bar, 200μm Results are presented as the mean +/- standard deviation (SD) 
of three independent experiments.  Statistics:  *** p < 0.005 (unpaired t-test to DLKP-I IgG control).   
***
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Figure 4.1-11:  The effect of MMP-2 and MMP-10 blocking antibodies on the in vitro invasion 
activity of DLKP-M.  Within the DLKP-M cell line, invasion is decreased with blocking of MMP 2 
relative to non-treated cells while there is a highly variable effect in MMP-10 treated cells.  After 48 
hours incubation, the invading cells on the underside of the insert were stained with crystal violet and 
allowed to air dry: (A.) untreated; (B.) 5.0 μg/ml of control mouse IgG1 monoclonal antibody; (C.) 
5.0 μg/ml of MMP 2 monoclonal antibody and (D.) 10.0 μg/ml of MMP 10 monoclonal antibody.  
Magnification, ×200. Scale bar, 200μm.  Results are presented as the mean +/- standard deviation 
(SD) of three independent experiments.  Stats: * p < 0.05 (unpaired t-test to DLKP-M IgG control).  
*
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4.1.8.1  c-Met Alterations in the DLKP clones 
Analysis of the clones showed an insertion in the Sema domain (MET_N375S_A1124G) in the 
DLKP parent, DLKP-SQ and DLKP-I cells.  A missense change was seen in the DLKP-M clone.   
4.1.8.2  TP53 Alterations in the DLKP clones 
Also identified were TP53_G245VDA_G734TAC mutations in all of the DLKP clones and the 
DLRP cell line.   
4.1.8.3  PI3K3R1 alterations in the DLKP clones 
Analysis of the clones showed an insertion in the p85α regulatory subunit of PI3K3R1 
(PIK3R1_M3261_G978ATC).  This alteration occurred in the DLKP, DLKP-SQ and DLKP-M 
clones only.   
4.1.8.4  EGFR alterations in the DLKP clones  
Analysis of the clones showed an insertion within the EGFR receptor in the DLKP-SQ only.   
4.1.9  DLKP clones – investigation of stem cell markers 
Cancer stem cells (CSCs) are cancer cells found within tumours that possess characteristics 
associated with normal stem cells, specifically the ability to give rise to all cell types found in a 
particular cancer sample.  CSCs are therefore tumourigenic (tumour-forming), in contrast to other 
non-tumourigenic cancer cells 320.  CSCs have been isolated and characterised from more than 20 
cancer types321-323 and emerging evidence supports the notion that CSCs are responsible for 
tumour development including tumour initiation, invasion, angiogenesis, therapy resistance and 
recurrence.  Since the parental DLKP contains at least three phenotypically different subclonal 
populations, the possibility of a stem cell model in these cells was investigated with the 
expression of a small panel of markers for embryonic stem cells (figure 4.1-12).  Oct-4 
(POU5F1) and NANOG have been suggested as two of the four major factors that allow the 
reprogramming of adult cells into germ-line competent, induced pluripotent cells.  Oct-4 plays a 
critical role in the development and self-renewal of embryonic stem cells and has been linked to 
oncogenic processes.  NANOG maintains pluripotency of embryonic stem cells and functionally 
blocks differentiation324.  The transcription factor, KLF4 has been demonstrated to be a good 
indicator of stem-like capacity.  The DLKP clones were found to be negative for KLF4 and 
NANOG.  Very low levels of Oct-4 were detected in all the clones.  The result was not visible 
when photographed.  Therefore, no results are shown for this gene.   
155 
 
Myc (c-Myc) is activated upon various mitogenic signals such as Wnt, Shh and EGF (via the 
MAPK/ERK pathway).  By modifying the expression of its target genes, Myc activation results 
in numerous biological effects.  The first to be discovered was its capability to drive cell 
proliferation (upregulates cyclins, downregulates p21), but it also plays a very important role in 
regulating cell growth (upregulates ribosomal RNA and proteins), apoptosis (downregulates Bcl-
2), differentiation and stem cell self-renewal.  c-Myc was present in all of the clones.   
 
 
 
 
Figure 4.1-12:  DLKP parents and clones were negative for Oct-4, KLF4, and pluripotency marker 
NANOG.  Barely detectable levels of Oct-4 were observed, and though not quantifiable, seemed to 
represent similar levels in parent and clones.  RT and NTC are negative controls used to ensure there 
is no contaminating DNA in the reverse transcription reaction or RNA in the PCR reagents.   
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4.2  Establishment of drug resistant invasive DLKP-SQ variants 
4.2.1  Introduction 
The major causes of treatment failure in cancer are the development of multidrug resistance and 
cancer invasion/metastasis.  There is indirect evidence that these two traits may be linked or at 
least often occur together, but it is unclear whether they share any mechanisms228.  Drug 
resistance to chemotherapy in patients is often associated with increased malignancy.  One 
explanation for the link between resistance and malignancy may simply be that resistance 
facilitates cancer progression and invasion.  There is some evidence that the two processes can be 
linked to each other (reviewed in Liang et al., 2002325).  Acquisition of P-gp-mediated multidrug-
resistance does not however, always correlate with observed malignant behavior of lung 
cancer196.  Additionally, many of the model systems used to study the link between drug 
resistance and invasion bypass the earliest events.  Consequently, the critical first step in the 
transition from a preinvasive to an invasive phenotype during the development of drug resistance 
has been less well studied than at later stages.   
To delineate molecular alterations important for this transition, we pulse selected the clone 
DLKP-SQ with mitoxantrone and established isogenic sub-populations, overexpressing BCRP 
and P-gp.  The DLKP-SQ-Mitox-BCRP and DLKP-SQ-Mitox-MDR cell lines overexpress 
BCRP and P-gp respectively and displayed the invasive phenotype after the 6th pulse.  
Microarray analysis was used to search for changes which may be functionally significant in the 
transition from a preinvasive to an invasive phenotype.   
 
4.2.2  Generation of invasive mitoxantrone resistant cell lines 
DLKP-SQ-Mitox-BCRP and DLKP-SQ-Mitox-MDR were previously established by 
mitoxantrone pulsing (chapter 3).  These cell lines were pulsed two more times to generate the 
DLKP-SQ-Mitox-BCRP-6P and DLKP-SQ-Mitox-MDR-6P cell lines as shown in the flow 
diagram in figure 4.2-1.  Invasion was induced in the 6th pulse, which was independent of 
transporter expression (see section 3.1.6).  A stable, higher drug resistant cell population isolate, 
was subsequently isolated from the SQ-Mitox-BCRP-6P cell line.  This new cell population was 
named SQ-Mitox-BCRP-6P-(isolate 2).  Figure 4.2-1 outlines the phenotypes observed during 
mitox treatment.   
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Figure 4.2-1: Flow diagram outlining the generation of the mitoxantrone resistant cell lines.  *These 
eflux pumps were later identified through microarray analysis and revealed to be overexpression of 
BCRP and P-gp in flasks A and B respectively.   
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4.2.3  Morphology of  SQ-Mitox-BCRP cells 
The DLKP-SQ cells are squamous in appearance with distinct cell boundaries.  During the 
development of drug resistance, early changes in cell shape were observed with a spindle-like 
morphology which is commonly associated with increased tumour invasiveness (figure 4.2-2).   
 
4.2.4  Microarray analysis of mitoxantrone resistant cell lines 
Accumulating evidence suggests a tight relationship between chemo-resistance and metastasis.  
Following the development of MDR variants overexpressing BCRP and P-gp with different 
levels of invasion (as described earlier in chapter 3), the gene expression profiles of these cell 
lines were compared using microarray analysis as described in section 2.10.  Such analysis has 
the potential of identifying genes of importance in the metastatic process by identifying 
differentially expressed genes.  These cell lines all share a common genetic background, thus 
studying their genetic differences is simplified because background genetic variation is 
minimised and any significant expression changes may likely represent metastasis associated 
events as opposed to transporter specific changes.   
Figure 4.2-2: Morphological 
appearance of DLKP-SQ-
Mitox-6P cells. The drug 
resistant cells show early 
changes in cell shape with 
irregularity and oblong shapes. 
There is an appearance of 
appendages with a 
multinuclate, light 
nucleoplasm and a granular 
cytoplasm. 
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4.2.4.1  Gene expression differences between drug resistant poorly invasive and invasive lung 
cancer cell lines 
To identify genes involved in the acquisition of an invasive potential during the development of 
drug resistance, the gene expression profiles of poorly invasive DLKP-SQ, SQ-Mitox-BCRP-4P, 
SQ-Mitox-MDR-4P and invasive SQ-Mitox-BCRP-6P and SQ-Mitox-MDR-6P were compared 
using microarray analysis.  The experimental design enabled the identity of genes changing 
between the following comparisons:   
1. SQ-Mitox-BCRP-4P (poorly invasive) versus SQ-Mitox-BCRP-6P (invasive) 
(Genelist 1);  
 (79 genes (1.2 fold); 62 upregulated, 17 downregulated) 
2. SQ-Mitox-MDR-4P (poorly invasive) versus SQ-Mitox-MDR-6P (invasive) 
(Genelist 2);  
 (553 genes (1.2 fold) ; 220 upregulated, 333 downregulated) 
 
Changes in gene expression between DLKP-SQ parental cells and the derived drug resistant cell 
lines were observed using “D-chip” as described in section 2.17.1.  “D-chip” was used to 
generate a list of genes significantly over- or under-expressed with false discovery rates of 0.05, 
with a cut-off value of ± 1.2-fold  change in gene expression.  The top 10 upregulated and 
downregulated genes for both genelists 1 and 2 with a p-value (p) ≤ 0.05 and fold change ≥ 1.2 
are shown in table 4.2-1.   
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Table 4.2-1:  Top ten over- and down-expressed genes on Genelist 1 and Genelist 2 with a p-value (p) ≤ 0.05 and fold 
change ≥ 1.2 in DLKP-SQ-Mitox cell lines.   
SQ-Mitox-BCRP-4P vs SQ-Mitox-BCRP-6P  SQ-Mitox-MDR-4P  vs SQ-Mitox-MDR-6P 
Gene 
symbol 
Fold 
change 
Main function  Gene symbol Fold 
change 
Main function 
Over-expressed 
ADAMTS1 54.1 Metallopeptidase activity  DKK1 9.61 Wnt receptor signalling pathway 
CDH2 13.74 Adherens junction 
organization 
 KIAA0559 
protein 
9.61 unknown 
IGF1R 4.64 Tyrosine kinase activity  ABCC9 7.03 Ion channel binding 
Slit2 4.28 Axon guidance  Slit2 6.52 Axon guidance 
WASH3P 3.36 Arp2/3 complex-mediated 
actin nucleation 
 Neuregulin1 5.77 ErbB signalling pathway 
PRRC2C 3.32 Protein c-terminus binding  FAM46A 5.11 Not known 
SRRM2 3.02 mRNA splicing  NAP1L3 5.03 Nucleosome assembly 
PRRC2C 2.99 Protein c-terminus binding  C5orf23 4.67 unknown 
HELLS4 2.99 Chromatin binding  KCNJ8 4.66 Potassium channel activity 
KRAS 2.75 RAS/MAPK pathway  PDE5A 4.63 Catalytic activity 
Down-expressed 
TTL7 -1.4 Cell differentiation  TIMP2 –3.83 Metalloendopeptidase activity 
THAP10 –1.36 Unknown  cDNA clone 
IMAGE:4811567 
–2.88 Unknown 
CYBRD1 -1.35 Cellular iron ion 
homeostasis 
 CDKN2C -2.67 Cell cycle 
Trim4 -1.34 Zinc ion binding  CGI-146 -2.46 Peptidase activity 
EIF5 -1.34 Translation activity  COL6A1 -2.28 Cell adhesion 
HSPCA -1.31 Molecular chaperone, 
ATPase activity 
 ARL7 -2.21 Cholesterol transport 
ATP1B1 -1.3 Microfilament motor activity  IPS-1 -2.19 inositol biosynthetic process 
SCOC -1.28 Autophagy  ATF5 -2.14 Heat shock protein binding 
CGI-07 -1.25 Protein transport  MT1E -2.07 Zinc ion binding 
EID1 -1.24 Histone acetylation  MT1H -2.05 Zinc ion binding 
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Figure 4.2-3:  Two gene lists were generated - DLKP-SQ-Mitox-BCRP-4P versus DLKP-SQ-Mitox-
BCRP-6P cells (Genelist 1), and DLKP-SQ-Mitox-MDR-4P versus DLKP-SQ-Mitox-MDR-6P cells 
(Genelist 2).  These were used in the search for molecular mechanisms involved in the invasive 
phenotype.  These lists were overlapped to identify common/uncommon genes.  There were 12 genes 
identified as common between the upregulated lists; an overlap of almost 20% on the shorter list.  By 
contrast, only one common gene from the downregulated lists was identified and this was most likely 
an artefact of the analysis. 
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Table 4.2-2:  Up-regulated and Down-regulated genes common to both invasion lists:  SQ-
Mitox-BCRP-4P vs. SQ-Mitox-BCRP-6P and SQ-Mitox-MDR-4P vs. SQ-Mitox-MDR-6P. 
No. Affy ID Description 
Up-regulated: 
01 232797_at CDNA FLJ11397 fis, clone HEMBA1000622/ Integrin alpha V 
02 230130_at SLIT homolog 2 (Drosophila) 
03 224576_at endoplasmic reticulum-golgi intermediate compartment 32 kDa protein 
04 213258_at Tissue factor pathway inhibitor (lipoprotein-associated coagulation 
inhibitor) 
05 210664_s_at tissue factor pathway inhibitor (lipoprotein-associated coagulation 
inhibitor) 
06 209897_s_at SLIT homolog 2 (Drosophila) 
07 209676_at tissue factor pathway inhibitor (lipoprotein-associated coagulation 
inhibitor) 
08 206858_s_at homeo box C6 
09 205433_at butyrylcholinesterase 
10 204602_at dickkopf homolog 1 (Xenopus laevis) 
11 203282_at glucan (1,4-alpha-), branching enzyme 1 (glycogen branching enzyme, 
Andersen disease, glycogen storage disease type IV) 
12 201952_at activated leukocyte cell adhesion molecule/CD166 
Down-regulated:   
13 213428_s_at collagen, type VI, alpha 1 
 
 
4.2.4.2  Ontology analysis of Genelist 1 and 2 
PANTHER analysis, Pathway Studio and GO analyses were carried out on Genelist 1 and 2.  No 
meaningful results were obtained from the latter two procedures.  In contrast, PANTHER 
analysis reavealed common pathways in the two genelists.   
 
(1) Ontology analysis using PANTHER (Protein ANalysis THrough Evolutionary Relationships) 
PANTHER is a unique resource that classifies genes and proteins by their function using 
published scientific experimental evidence and evolutionary relationships abstracted by curators 
with the goal of predicting function, even in the absence of direct experimental evidence (section 
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2.17.4).  PANTHER was used to define a list of enriched pathways that are represented by the list 
of geneslists 1 and 2.   
 
(2) Pathways affected by SQ-Mitox-BCRP-4P versus 6P genelist (identified by PANTHER) 
Ontology analysis of Genelist 1 identified several pathways of interest (table 4.2-3 and figure 
4.2-4):  Ontology analysis of Genelist 2 also identified several interesting pathways (figure 4.2-5 
and table 4.2-5) such as p53 and Wnt signaling pathways.   
 
Table 4.2-3: Pathways affected by SQ-Mitox-BCRP-4P versus 6P genelist (identified by 
PANTHER) 
Category name (Accession) no. 
genes 
% gene hit 
against total 
no. genes 
% gene hit 
against total 
no. pathway 
hits 
Wnt signaling pathway (P00057) 31 10.90% 16.50% 
Inflammation mediated by chemokine and 
cytokine signaling pathway (P00031) 
15 5.30% 8.00% 
Integrin signalling pathway (P00034) 14 4.90% 7.40% 
p53 pathway feedback loops 2 (P04398) 8 2.80% 4.30% 
EGF receptor signaling pathway (P00018) 8 2.80% 4.30% 
Axon guidance mediated by Slit/Robo 
(P00008) 
6 2.10% 3.20% 
Insulin/IGF pathway-protein kinase B 
signaling cascade (P00033) 
6 2.10% 3.20% 
Insulin/IGF pathway-mitogen activated 
protein kinase kinase/MAP kinase 
cascade (P00032) 
6 2.10% 3.20% 
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Figure 4.2-4.  Genes were functionally 
classified based on the PANTHER system 
(http://www.pantherdb.org).  SQ-Mitox-
BCRP-4P (poorly invasive) versus SQ-
Mitox-BCRP-6P (invasive; 79 genes; 62 
upregulated, 17 downregulated).   
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Figure 4.2-5.  Genes were functionally 
classified based on the PANTHER system 
(http://www.pantherdb.org).  SQ-Mitox-
MDR-4P (poorly invasive) versus SQ-
Mitox-MDR-6P (invasive; genelist 2; 553 
genes; 220 upregulated, 333 
downregulated).  Colour codes indicate 
pathways shared with figure 4.2-4.   
166 
 
Table 4.2-4: Top 8 pathways affected by SQ-Mitox-MDR-4P vs 6P genelist (as identified by 
PANTHER) 
Category name (Accession) no. 
genes 
% gene hit 
against total 
no. genes 
% gene hit 
against total 
no. pathway 
hits 
Wnt signaling pathway (P00057) 69 3.70% 8.80% 
p53 pathway (P00059) 49 2.60% 6.30% 
Huntington disease (P00029) 34 1.80% 4.30% 
Integrin signalling pathway (P00034) 31 1.60% 4.00% 
Inflammation mediated by chemokine and 
cytokine signaling pathway (P00031) 31 1.60% 4.00% 
Parkinson disease (P00049) 26 1.40% 3.30% 
p53 pathway feedback loops 2 (P04398) 24 1.30% 3.10% 
Hedgehog signaling pathway (P00025) 24 1.30% 3.10% 
 
4.2.5  Isolation of a new stable, higher drug resistant clone of SQ-Mitox-BCRP-6P 
The DLKP-SQ-Mitox-BCRP and DLKP-SQ-Mitox-MDR cell lines discussed to-date 
overexpress BCRP and P-gp respectively and display the invasive phenotype after the 6th pulse.  
However, this invasive phenotype is only stable directly after the sixth drug pulse and is lost on 
freezing and re-thawing of the cells.  Out of the original population of DLKP-SQ-Mitox-BCRP-
6P cells a sub population was isolated which appeared to be even more resistant and invasive 
than their forebears.  Toxicity assays appeared to confirm this because the new isolates have 
higher IC50 values when treated with mitoxantrone (table 4.2-5) which may account for up to a 
560-fold resistance to this drug relative to the DLKP-SQ parental cell line (or > 4-fold above that 
of the original resistant isolate 1).   
Careful observation of this new, second isolate of BCRP over-expressing cells revealed 
morphological differences, characterised by large numbers of spiky cells which grow in a more 
dispersed manner.  Further investigation of these cells show that indeed, they have higher levels 
of BCRP protein (figure 4.2-6).  In addition, the invasive phenotype within this population of 
cells appears to be stable and is from here on in referred to as SQ-Mitox-BCRP-6P (isolate 2).   
Furthermore, it would also appear that the activity of both MMP-2 and MMP-10 are also 
increased within this new population of DLKP-SQ-Mitox-BCRP-6P cells (figure 4.2-6).   
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MMP-2 
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Figure 4.2-6:  A.  Visual analysis of the level of invasion of DLKP-SQ and SQ-Mitox-BCRP variants. B. The total number of 
invading cells was determined by counting the number of cells per field in 10 random fields, at 200× magnification. The average 
number of cells per field was then multiplied by a factor of 140 (growth area of membrane/field area viewed at 200× magnification 
(calibrated using a microscope graticule)). Error bars represent the standard deviation of triplicate invasion assay experiments (n=3).  
C.  Western blotting analysis (3μg protein) shows upregulation of BCRP protein in the SQ-Mitox-BCRP-6P (Isolate 2) cells. D.  
Zymography analysis showing the presence of increased active MMP2 and MMP10 in the conditioned medium of SQ-Mitox-BCRP-
6P (isolate 2).   
SQ Mitox-BCRPi -  
A. B. 
C. D. 
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Table 4.2-5:  IC50 and fold resistance of all of the DLKP-SQ Mitox resistant variants 
relative to the parental DLKP-SQ cell line. 
CELL LINE IC50 FOLD 
RESISTANCE 
DLKP-SQ 0.08 ng/ml 1 
DLKP-SQ Mitox-BCRP- 4th pulse 16.79 ng/ml 209.8 
DLKP-SQ Mitox-BCRP- 6th pulse (isolate 1) 10.89 ng/ml 134.8 
DLKP-SQ Mitox-BCRP-6th pulse (isolate 2) 44.82 ng/ml 560 
DLKP-SQ Mitox-MDR- 4th pulse 25.59 ng/ml 319.8 
DLKP-SQ Mitox-MDR- 6th pulse 19.35 ng/ml 241.8 
 
4.2.5.1  Increased activity and expression levels of MMP-2 and MMP-10 in SQ-Mitox BCRP- 
6P (isolate 2) cells   
Earlier when describing the role of MMP-2 and MMP-10 in DLKP, it was shown that MMP-2 
but not MMP-10 may be involved in the process of invasion.  To determine if MMP-2 was up-
regulated in the invasive and drug-resistant SQ-Mitox-BCRP-6P (isolate 2) cell population, the 
activity of gelatinases was qualitatively accessed (figure 4.2-6).  Zymographic analysis indicated 
that the proteolytic activity of secreted MMP-2 was remarkably elevated in the isolate 2 cells, 
relative to that of SQ-Mitox-BCRP-4P and parental DLKP-SQ cells.  Thus, the acquisition of 
drug resistance is accompanied by an increased activity of MMP-2 in DLKP-SQ cells.   
MMP-10 was over-expressed in the DLKP-SQ vs DLKP-M microarray gene list and on the 
DLKP-SQ vs SQ-Mitox-BCRP-4P microarray gene list.  Stromolysin zymography (MMP 10) 
indicated that the proteolytic activity of secreted MMP-10 was also remarkably elevated in the 
isolate 2 cells, relative to that of SQ-Mitox-BCRP-4P and parental DLKP-SQ cells (figure 4.2-6).   
 
Effect of MMP 2 blocking antibody on the invasiveness of SQ-Mitox-BCRP-6P cells 
To determine the role of MMPs in SQ-Mitox-BCRP-6P invasion, the invasion potential of SQ-
Mitox-BCRP-6P (isolate 2) cells in the presence of a specific MMP-2 monoclonal antibodies 
were investigated.  As shown in figure 4.2-7, the number of SQ-Mitox-BCRP-6P cells that 
migrated through the extracellular matrix gel (ECM) was moderately decreased by specific 
blocking of MMP-2.  However, there was no significant alteration in the invasiveness of the cells 
treated with the control isotype antibody.  These results support the idea of increased expression 
of MMP2 in SQ-Mitox-BCRP-6P associated with increased invasion.   
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Figure 4.2-7:  SQ-Mitox BCRP-6P cell line: invasion is decreased in MMP 2 treated cells compared 
with non-treated cells.  After 24 hours incubation, the invading cells on the underside of the insert 
were stained with crystal violet and allowed to air dry.  (A.) Untreated; (B.) with the addition of 5.0 
μg/ml of control mouse IgG1 monoclonal antibody; (C.) with the addition of 5.0 μg/ml of MMP 2 
monoclonal antibody. Magnification, ×200. Scale bar, 200μm  (D.)  Invasion assay of MMP-2 
blocking antibody and their effect on SQ-Mitox BCRP-6P cells.  Statistics: * p < 0.05 (unpaired t-test 
to IgG control antibody).   
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4.2.6  Post array analysis and confirmation of selected genes 
Following the identification of genes that were significantly up- or down-regulated from the 
microarray analysis (tables 4.2-1 and 4.2-2), literature searches, immunofluorescence and 
Western blot analysis allowed the confirmation of their expression (as described in section 2.5.2 
and 2.6).  Western blot verification was carried out on ALCAM, IGF1Rβ, integrin alpha V, 
SLIT2/ROBO2 and BCHE confirming the microarray trends (i.e. in this case all up-regulated in 
the SQ-Mitox-BCRP-6P (isolate 2) cell line).  Immunofluorescence studies were performed on 
ALCAM to illustrate the localisation of the protein within the cells.  In contrast, the DLKP-SQ 
and SQ-Mitox-BCRP-4P cell lines expressed low levels of these proteins.  These proteins will be 
discussed further in section 6.3.2.   
 
4.2.6.1  Activated leukocyte cell adhesion molecule (ALCAM) 
Previously ALCAM was shown to be up-regulated in the DLKP-SQ vs DLKP-I microarray gene 
list (table 4.1-1b) and subsequently confirmed to be overexpressed in the DLKP-I cells only.  
Surprisingly, ALCAM was also upregulated in SQ-Mitox Genelists 1 and 2 (table 4.2-2).  A 
progressive up-regulation of ALCAM expression was observed in the cell lysate and on the 
membrane enriched preparation of SQ-Mitox-BCRP-6P (isolate 2) cells (figure 4.2-8).  This up-
regulation occurred in parallel with an increasing level of BCRP (figure 4.2-8).  
Immunofluorescence was performed on ALCAM to illustrate the localisation of the protein 
within the cells.  Immunofluorescence studies confirm the up-regulation of ALCAM on the 
membrane of the BCRP overexpressing cells (figure 4.2-9)   
 
4.2.6.2  Insulin-like growth factor 1 receptor (IGF1R) 
IGF1R was 4.6-fold up-regulated on the SQ-Mitox-BCRP-4P vs SQ-Mitox-BCRP-6P gene list 
(Genelist 1, table 4.2-1).  Western blot analysis confirmed that DLKP-SQ and SQ-Mitox-BCRP-
4P cell lines expressed low levels of IGF1Rβ, whereas the SQ-Mitox-BCRP-6P cell line 
expressed high levels of this protein (figure 4.2-10, A).   
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Figure 4.2-8:  Western blot showing expression of cell adhesion molecule ALCAM in the SQ-Mitox 
cells.  Different levels of ALCAM were expressed in the DLKP-SQ, SQ-Mitox-BCRP-4P and 6P 
(isolate 2), and SQ-Mitox-MDR cells.  A progressive up-regulation of ALCAM expression in the cell 
lysate and on the membrane was observed in SQ-Mitox-BCRP-6P (isolate 2).   
 
172 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.2-9:  Expression of cell adhesion molecule ALCAM in drug sensitive and drug resistant lung cancer 
cell lines.  (A.) DLKP-SQ; (B.) SQ-Mitox-BCRP-4P and (C.) SQ-Mitox-BCRP-6P (isolate 2)).  There are 
different levels of expression amongst the cell lines of the drug transporter BCRP.  A substantial up-
regulation of ALCAM expression is observed in the cell lysate and on the surface membrane of SQ-Mitox-
BCRP- 6P (isolate 2) (C.) Counter stained with propidium iodide. Original magnification of all 
photomicrographs, ×400, scale bar = 50 μm.   
a. 
b. 
c. 
50 μm 
50 μm 
50 μm 
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Figure 4.2-10:  IGF1Rβ, integrin alpha V and N-cadherin expression in SQ-Mitox cells  A. and B.  
Western blot showing a progressive up-regulation of IGF1R and Integrin alpha V expression in drug 
resistant, invasive SQ-Mitox-BCRP- 6P (isolate 2) relative to drug sensitive DLKP-SQ and drug 
resistant poorly invasive SQ-Mitox-BCRP-4P cells.  Insulin-like growth factor I Receptor (IGF1R) 
has been shown to cooperate with integrins to promote tumour cell migration in vitro.  GAPDH and α-
tubulin were used as equal loading controls.  C., D., & E.  Immunofluorescence cell surface staining 
of N-cadherin in drug sensitive (C.) DLKP-SQ and drug resistant lung cancer cell lines (D.) SQ-
Mitox-BCRP-4P and (E.) DLKP-SQ-Mitox-BCRP-6P (isolate 2), white arrows.  Strong 
immunoreactivity is observed in invasive SQ-Mitox-BCRP-6P cells.  SQ-Mitox-BCRP-4P cells show 
very weak immunoreactivity.  Counter stained with propidium iodide. Original magnification of all 
photomicrographs, ×400, scale bar = 20 μm.   
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4.2.6.3  Integrin alpha V   
Previously Integrin alpha V was shown to be up-regulated in the DLKP-SQ vs DLKP-I and 
DLKP-SQ vs DLKP-M microarray gene list and subsequently confirmed by Western Blot (figure 
4.1-2) to be overexpressed in the DLKP-I and DLKP-M cells.  Integrin alpha V was also 
upregulated in SQ-Mitox Genelists 1 and 2 (table 4.2-2).  Integrins are cell surface 
transmembrane glycoproteins involved in the assembly of the actin cytoskeleton as well as in 
modulating signal transduction pathways that control biological and cellular functions including 
cell adhesion, migration, proliferation, cell differentiation and apoptosis326.  ITAGV encodes 
integrin alpha chain V.  Alpha V undergoes post-translational cleavage to yield disulfide-linked 
heavy and light chains, that combine with multiple integrin beta chains to form different 
integrins. 
Western blot analysis confirmed that the DLKP-SQ and SQ-Mitox-BCRP-4P cell lines expressed 
low levels of integrin alpha V, whereas the SQ-Mitox-BCRP-6P cell line expressed high levels of 
this protein (figure 4.2-10, B).   
 
4.2.6.4  N-cadherin   
The cadherin superfamily comprises a large number of cell surface glycoproteins involved in 
Ca2+-dependent cell-cell adhesion.  Cells containing N-cadherin tend to cluster with other N-
cadherin-expressing cells.   
Microarray analysis indicated that N-cadherin is overexpressed in the SQ-Mitox-BCRP-6P cell 
line relative to the SQ-Mitox-BCRP-4P cell line (table 4.2-1).  Immunofluorescence was 
performed on N-cadherin to illustrate the localisation of the protein within the cells.  Figure 4.2-
10 (C – E) confirms that N-cadherin is expressed in the SQ-Mitox-BCRP-6P cell line.  An earlier 
investigation of N-cadherin expression in the DLKP clones also revealed that it was 
overexpressed in the DLKP-I but not the DLKP-M clones (figure 4.1-4).   
 
4.2.6.5  SLIT2/ROBO2 
The SLIT family of proteins consists of three members (SLIT1-3) that signal by binding to one of 
four Roundabout (ROBO1-4) receptors. The SLIT family are large, secreted glycoproteins that 
are subject to proteolytic cleavage resulting in fragments with variable activities.  ROBO1, 
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ROBO2, and ROBO3 are predominantly expressed in the nervous system and SLIT-ROBO 
interactions have been shown to regulate axon repulsion and neuronal outgrowth.   
An up-regulation of SLIT2 expression in the cell lysate was revealed in the BCRP over 
expressing cell lines but not in the SQ-Mitox-MDR cell line.  Interestingly, there was an 
upregulation of SLIT2 in the membrane fraction of the higher drug resistant SQ-Mitox-BCRP-6P 
(isolate-2) invasive cell line (figure 4.2-11, A).   
ROBO2 is a receptor for SLIT2 and is overexpressed in the DLKP-I and DLKP-M cells (figure 
4.1-6).  Further investigation of the expression of ROBO2 in SQ-Mitox cells using 
immunofluorescence revealed that ROBO2 was present in all of the cells to varying extents, with 
the strongest signal in the SQ-Mitox-BCRP-6P (isolate-2) cells (figure 4.2-11, B).   
 
 
 
Figure 4.2-11:  Expression of SLIT2 and its receptor ROBO2 in the SQ-Mitox cells.  (A.) Western 
blot showing expression of SLIT2 in the SQ-Mitox cells.  SLIT2 migrated at approximately 165 kDa.  
GAPDH was used as an equal loading control.  (B.) Immunofluorescence cell surface staining of 
ROBO2:  DLKP-SQ, SQ-Mitox-BCRP-4P, SQ-Mitox-BCRP-6P and SQ-Mitox-MDR cells stained 
with ROBO2 antibody.  Immunoreactivity is observed in all of the cells but the SQ-Mitox-BCRP-6P 
cells show the strongest signal.  Original objective magnification ×400 for SQ and ×200 for all others.   
 
50 μm 100 μm 100 μm 100 μm 
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4.2.7  Effect of ITGAV and BCHE siRNA on proliferation of SQ-Mitox-BCRP-6P cells 
The effect of silencing ITGAV and BCHE protein expression on proliferation was investigated as 
described in section 2.15.  Figure 4.2-12 displays the percentage survival of SQ-Mitox-BCRP-6P 
cells transfected with ITGAV and BCHE siRNAs.  Loss of ITGAV and BCHE did not affect 
proliferation in SQ-Mitox-BCRP-6P cells, indicating they are not essential factors for 
proliferation in these cells.   
 
 
Figure 4.2-12:  Proliferation assays on siRNA-transfected 6P cells indicating that monolayer cell 
growth was not affected by ITGAV or BCRP gene silencing.  Proliferation assay of SQ-Mitox-BCRP-
6P (isolate 2) untreated control, scrambled and transfected with siRNA ITGAV (1) and (2), BCHE (1) 
and (2).  Results graphed as % survival relative to nontreated control (n=3).   
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Figure 4.2-13: ITGAV gene silencing hampers 
SQ-Mitox-BCRP-6P invasiveness. Invasion 
assays of DLKP-SQ-Mitox-BCRP-6P (isolate 2) 
cells (A.) under control conditions; (B.) 
transfected with scrambled siRNA;  (C.) 
transfected with integrin alpha V (1); (D.) 
transfected with integrin alpha V (2).  
Magnification, ×200. Scale bar, 200μm.  (E.) 
Invasion assay of DLKP-SQ-Mitox-BCRP-6P 
(isolate 2) of total number of cells invading post 
siRNA integrin alpha V transfection.  Statistics: 
p ≤ 0.05*, 0.01**, 0.005*** (unpaired t-test to 
scrambled control).   
** 
*
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4.2.7.1  siRNA mediated interference knockdown of ITGAV reduces the invasive capacity of 
SQ-Mitox-BCRP-6P cells 
Integrin alpha V was identified as up-regulated in both Genelist 1 and 2.  To investigate whether 
Integrin alpha V plays a role in DLKP lung cancer invasion, ITGAV-siRNA was used to 
knockdown Integrin alpha V expression in the stable, higher drug resistant SQ-Mitox-BCRP 
overexpressing cell line.  ITGAV knockdown by small interfering (si)RNA reduces the invasion 
of DLKP-Mitox cells (figure 4.2-13).  This preliminary experiment supports the hypothesis that 
increased expression of integrin alpha V plays a role in the aggressive invasive phenotype 
observed in vitro.  Further investigation confirming the knockdown of Integrin alpha V protein 
by Western blot is warranted.   
 
4.2.7.2  siRNA mediated interference knockdown of BCHE reduces the invasive capacity of 
SQ-Mitox-BCRP-6P cells 
Microarray profiling revealed differential expression of BCHE, a secretory butyrylcholinesterase, 
between the SQ-Mitox-BCRP-4P and SQ-Mitox-BCRP-6P cell lines.  BCHE was confirmed by 
Western blot analysis to be abundantly up-regulated in the SQ-Mitox-BCRP-6P (isolate2) 
compared to the parental cell line, DLKP-SQ and its resistant variant, SQ-Mitox-BCRP-4P 
(figure 4.2-14).  Increasing evidence suggests the involvement of cholinesterases in 
tumourigenesis327, 328.  To investigate whether BCHE plays a role in DLKP lung cancer invasion, 
BCHE siRNA was used to knockdown BCHE in the invasive cell line, SQ-Mitox-BCRP-6P.  
BCHE siRNA transfected into SQ-Mitox-BCRP-6P resulted in a significant decrease in invasion 
through matrigel.  Figure 4.2-14 shows a Western blot showing knockdown of BCHE in the SQ-
Mitox-BCRP-6P cell line after BCHE siRNA transfection.   
 
4.2.7.3  IHC analysis of BCHE Expression in Lung Cancer 
Western blot analysis of BCHE showed that it is positively associated with an increase in drug 
resistance and invasion in the SQ-Mitox-BCRP-6P cell line.  BCHE expression in human cancer 
was investigated further (table 4.2-6).  A lung cancer tissue array (TMA) (Biomax, LC817) was 
immunohisto-chemically stained using primary antibodies specific for BCHE.  The array 
contained 16 cases of squamous cell carcinoma, 16 adenocarcinoma, 1 bronchioloalveolar 
carcinoma and 6 small cell carcinoma.  There were single cores per case with matched lymph 
node metastasis for each case, providing 40 cases for analytical interpretation.   
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Figure 4.2-14:  BCHE gene silencing hampers SQ-Mitox-BCRP-6P invasiveness.  Invasion assays of 
DLKP-SQ-Mitox-BCRP-6P (isolate 2) cells.  (A.) Transfected with scrambled siRNA.  (B.) 
Transfected with BCHE, magnification, 200× scale bar 200μm.  (C.) Invasion assay of SQ-Mitox-
BCRP-6P of total number of cells invading post siRNA BCHE transfection.  (D.) Western blot 
showing an increase in BCHE in SQ-Mitox-BCRP-6P relative to SQ-Mitox-BCRP-4P.  Also, a 
Western blot showing knockdown of BCHE at 48 hours post-transfection in SQ-Mitox-BCRP-6P cells 
transfected with two independent siRNAs targeting BCHE relative to scrambled control siRNA 
transfected cells.  GAPDH served as a loading control.  Statistics: p ≤ 0.05*, 0.01**, 0.005*** 
(unpaired t-test to scrambled control).   
 
** **
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Table 4.2-6:  BCHE Immunoreactivity in squamous, adeno and small cell lung tumours from a 
lung cancer tissue array with matched lymph node metastatic tissue.  
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Main numbers indicate BCHE staining intensity score, superscript indicates tumour grade (where 1-3 is equivalent to well-
differentiated, moderately-differentiated or poorly differentiated, respectively).   
Colour coding indicates tumour stage; lilac = Stage II; green = Stage IIIa; red = Stage IIIb.   
Yellow shading indicates the cognate or matched lymph node metastatic tumour, e.g. A1 is matched with E1, A2 is matched 
with E2, etc.   
Tumour diagnosis: A1 – B7: Squamous cell carcinoma; B8 – D4: Adenocarcinoma, except C6: Bronchioloalveolar 
carcinoma; D5 – D10: Small cell carcinoma.  E1 – H10: the corresponding matched lymph node metastatic tisssues to those in 
A1 – D10.   
 
Figure 4.2-15:  Immunohistochemical Analysis of BCHE Expression in a Lung Cancer TMA.  (A.) 
Weak BCHE positive staining is observed in a grade III (high grade, histologically more aggressive) 
squamous cell carcinoma.  (B.) Increased BCHE expression observed in a grade II (histologically less 
aggressive) adenocarcinoma.  (C.) Intense BCHE staining was observed in a number of metastatic 
lung tumours, a representative lymph node metastasis from a squamous tumour is shown.  Original 
magnification of all photomicrographs, ×400.  Scale bar = 100 μM.   
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A total of 80 TMA cores were analysed.  TMA cores were scored semi-quantitatively, according 
to the intensity of the BCHE immunoreactivity observed (weak, moderate, or strong).  Each 
tissue was scored based on the intensity of staining observed and the percentage of cells staining. 
(figure 4.2-15).   
Variable staining was observed in both primary (22/40) and metastatic (26/40) lung tumours.  
Strong staining was observed in 7/40 metastatic lung carcinomas and 2/40 primary tumours.  The 
pattern of staining was granular and was located in both the cell nucleus and cytoplasm of the 
cells.  Interestingly, a higher percentage of cells stained in the primary tumours of the 
adenocarcinomas (9/15) and in the metastatic tissues of the small cell carcinomas (5/6).   
4.3  Summary 
The DLKP clones with various degrees of invasiveness (derived from the same parent) offered a 
unique opportunity to study mechanisms of invasion.  These cell lines provided an ideal in vitro 
model of invasion.  One of the aims of this thesis was to identify genes involved in the 
development of an invasive phenotype in lung cancer cell lines.   
The strategy of deriving isogenic drug resistant cell lines from the DLKP-SQ clone eliminates 
variability due to intrinsic genetic differences between cell lines.  An important point to 
remember when considering the SQ-Mitox analysis is that there are potentially two ways to 
approach this data; (1) one could look at drug resistance and/or (2) look at invasion.  
Theoretically however, any differentially expressed genes identified by the microarray analysis 
of the SQ-Mitox cell lines could relate to drug resistance.  Thus, gene-expression profiles of 
human lung cancer cell lines with differing levels of invasion and drug resistance were analysed 
using microarray analysis.   
The novel cell line model of mitoxantrone resistant lung cancer was developed by pulse selecting 
a clone of DLKP-SQ with mitoxantrone.  In this instance drug resistance developed first, 
followed by invasion.  Induction of invasion was independent of which type of xenobiotic 
transporter was expressed.  Microarray analysis was performed in poorly invasive mitoxantrone 
resistant DLKP-SQ-Mitox-BCRP (4th pulse) and DLKP-SQ-Mitox-P-gp (4th pulse) and 
compared with invasive mitoxantrone resistant DLKP-SQ-Mitox-BCRP (6th pulse) and DLKP-
SQ-Mitox-P-gp (6th pulse).   
182 
 
 
Table 4.2-7:  summarises the findings in this chapter for genes with increased expression in invasive cell 
lines. 
Gene Identified from 
genelist 
SQ vs I SQ vs M× SQ-Mitox-
BCRP-4P vs 6P 
Integrin alpha V SQ vs I 
SQ vs M 
4P vs 6P genelist 1 
and 2  
↑ DLKP-I  ↑ DLKP-M ↑ in 6P vs 4P 
ALCAM Top 15 SQ vs I 
4P vs 6P genelist 1 
and 2 
↑ DLKP-I ↓ DLKP-M ↑ in 6P vs 4P 
SLIT2 SQ vs M 
4P vs 6P genelist 1 
and 2 
low in DLKP-I ↑ DLKP-M ↑ in 6P in the 
membrane vs 4P 
ROBO2 Top 15 SQ vs I 
4P vs 6P genelist 1 
and 2 
↑ DLKP-I ↑ DLKP-M ↑ in 6P vs 4P 
N-cadherin Top 15 SQ vs I 
4P vs 6P genelist 1 
and 2 
↑ DLKP-I absent DLKP-M ↑ in 6P vs 4P 
MMP-2 Not present on DE 
genelists 
↑ DLKP-I ↑ DLKP-M ↑ in 6P vs 4P 
MMP-10 SQ vs I 
SQ vs M 
4P vs 6P genelist 1 
and 2 
↑ DLKP-I ↑ DLKP-M ↑ in 6P vs 4P 
 
Two gene lists were generated – (1) DLKP-SQ-Mitox-BCRP-4P vs DLKP-SQ-Mitox-BCRP-6P 
cells (gene list 1) and (2) DLKP-SQ-Mitox-MDR-4P vs DLKP-SQ-Mitox-MDR-6P cells (gene 
list 2), in search of molecular mechanisms involved in the invasive phenotype.  The genes were 
analysed for over-expression of gene ontology terms in categories assigned by PANTHER 
pathways.  The most significant pathways were related to Wnt signalling, inflammation, integrin 
signalling and p53 pathways – these were common to both gene list 1 and gene list 2.   
A stable, higher drug resistant variant was established from the 6th pulse population of BCRP 
overexpressing cells (SQ-Mitox-BCRP-6P (isolate 2) with a 560-fold resistance to the selecting 
agent).  Western blot and immunofluorescence confirmed the up-regulation of the proteins, 
integrin alpha V, BCHE, ALCAM and SLIT2 (in the membrane) as identified by the microarray 
analysis.  Of particular interest is the identification of the SLIT2 / ROBO2 signaling pathway in 
the invasive, drug resistant 6th pulse.   
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It also appears that the acquisition of drug resistance is accompanied by an increase in activity of 
MMP-2 in DLKP-SQ cells and treatment with an MMP blocking Ab against MMP-2 may 
negatively modulate the invasiveness of drug-resistant SQ-Mitox-BCRP-6P cells.  siRNA 
knockdown experiments also suggest that integrin alpha V plays a role in the aggressive invasive 
phenotype observed in vitro.   
Of particular interest is that the DLKP-SQ clone acquired characteristics common to both the 
DLKP-I and DLKP-M clones.  For example, the DLKP-SQ clone developed an up-regulation of 
the cell adhesion molecules ALCAM and N-cadherin in common with DLKP-I, and the axon 
guidance molecules SLIT2/ROBO2 in common with the DLKP-M clone.  In addition, it also 
acquired the cell surface glycoprotein, integrin alpha V, the metalloproteinases MMP-2 and 
MMP-10 in common with both DLKP-I and DLKP-M (table 4.2-7).  It appears that ALCAM and 
N-cadherin could be a marker for DLKP-I and SLIT2 could be a marker for DLKP-M.   
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CHAPTER 5 
 
Investigation of the effects of MEK inhibitors on drug resistance and invasion in DLKP 
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5.1 MEK inhibitors – effect on drug resistance and invasion 
5.1.1  Introduction 
The mitogen-activated protein kinase (MAPK) signaling pathways involve a family of protein 
kinases that play critical roles in the regulation of diverse cellular activities including cell 
proliferation, survival, differentiation, motility and angiogenesis.  The MAPK pathways (figure 
5.1-1) transduce signals from various extracellular stimuli (growth factors, hormones, cytokines 
and environmental stresses), leading to distinct intracellular responses via a series of 
phosphorylation events and protein-protein interactions329.  These signalling cascades are often 
dysregulated in human cancer cells and targeting MEK as a central kinase of the MAPK pathway 
is currently being tested in clinical trials for its therapeutic potential.  A class of molecular 
targeted compounds called small-molecule protein kinase inhibitors can disrupt such mitogenic 
signalling pathways.  These small molecule inhibitors are moving quickly from bench to 
bedside330,331.   
Dose-limiting side effects are problematic in the use of small molecule inhibitors, and MEK 
inhibitors that sufficiently reduce ERK activation in patients show a low clinical response.  One 
possible reason for the low response to MEK targeting drugs is thought to be the up-regulation of 
counteracting signalling cascades as a direct response to MEK inhibition.  Therefore, 
understanding the biology of cancer cells, cross-talk between intracellular pathways and the 
effects of MEK inhibition on these cells will help to identify new combinatorial approaches that 
are ultimately efficacious for the patient332.   
MAPK pathways have been implicated in acquired tumour resistance following chemotherapy333. 
Previous studies of MAPK signalling pathways in cancer models have shown that the p44/p42 
MAPK cascade is activated by chemotherapeutic agents such as paclitaxel334, cisplatin335 and 
vinblastine336 and is involved in acquired resistance to these drugs.  Hence, the effects of MEK 
inhibitors on the anti-cancer drug resistance of the SQ-Mitox cell lines were investigated.   
Previous studies in the literature have indicated that MEK inhibitors can suppress the 
invasiveness of UM-SCC-1, a squamous cell carcinoma derived from the oral cavity337 and A375 
melanoma cells338.  The differential expression and activation of p44/p42-MAPK among the 
three distinct DLKP clones and the corresponding effects of targeting p44/p42-MAPK on growth 
and survival have not previously been examined.  Thus, an investigation of the MEK/ERK 
inhibitor U0126 and its affects on invasion in the DLKP clones was warranted.   
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5.1.2  Inhibitors used in this study 
U0126 is a mitogen activated protein kinase kinase (MAPKK) inhibitor that inhibits MEK1/2 
(See table 2-2).  It can penetrate cells and selectively inhibit MEK1/2 to inhibit the 
phosphorylation and activation of MAP kinase (Erk1/2 or p42/44 MAPK)339.  It can also 
suppress the activation of AP-1-dependent gene transcription.   
PD98059 can also penetrate cells and selectively inhibit MEK1 to inhibit the phosphorylation 
and activation of MAP kinase (Erk1/2 or  p44/42MAPK)340.  When compared with PD98059, 
U0126 shows a significantly higher affinity for MEK1.  U0126 and PD98059 both bind to this 
enzyme in a mutually exclusive fashion suggesting that they share a common binding site339.   
The benzimidazole ARRY-142886 (AZD6244) has been reported to be a highly potent MEK 
inhibitor341.  AZD6244 is an oral, non-ATP competitive inhibitor and highly specific for 
MEK1/2, a key enzyme in the Ras-Raf-MEK-ERK pathway.  AZD6244 is probably the most 
widely studied MEK inhibitor for clinical use.  For example a Phase II clinical trial is currently 
underway to compare the efficacy of AZD6244 in combination with docetaxel alone in patients 
with KRAS mutation positive non small cell lung cancer patients342.   
 
Figure 5.1-1:  Diagram taken from Ding et al., (2001)343 – Cross-talk between signalling pathways 
and the multidrug resistant protein MDR-1.   
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5.1.3  Effects of MEK inhibitors on anti-cancer drug resistance of SQ-Mitox cells 
The results described in chapter 3 explained the generation of SQ-Mitox-BCRP and SQ-Mitox-
MDR cells, a cell line model of mitoxantrone resistance.  These cell lines over-expressed the 
xenobiotic or drug resistance pumps, BCRP and P-gp.  The association between the expression of 
these ABC transporter proteins and cell signalling pathways has recently generated some 
interest344,345.  The present study has attempted to further clarify the regulatory mechanisms 
underlying ABC transporter protein expression, focusing on P-gp and BCRP and to identify 
inhibitors that specifically target these expression mechanisms.  Prior to testing the effects of 
PD98059 and U0126 on anticancer drug resistance, the appropriate concentration range for each 
inhibitor was established with the aim of finding a concentration which caused approximately 
10% cytotoxicity.   
 
5.1.3.1  Effects of PD98059 and U0126 on cell growth of DLKP-SQ and SQ-Mitox cells 
The cell viability of DLKP-SQ and SQ-Mitox cells following treatment with PD98059 was 
determined by the acid phosphatase assay as described in section 2.2.  Different concentrations of 
inhibitor were used, ranging from 1 μM to 50 μM over a 3-day study period.  Results indicated 
that the growth inhibitory effects of PD98059 on the drug resistant cells are approximately less 
than 10% (≤ 20 μM, figure 5.1-2, top graph).  A concentration of 20 μM PD98059 was thus 
established for subsequent experiments.   
The cell viability of DLKP-SQ and SQ-Mitox cells was also determined by the acid phosphatase 
assay following treatment with U0126.  Different concentrations of inhibitor were used, up to 10 
μM over a 3-day study period.  The growth suppressive effects of U0126 on the SQ-Mitox-MDR 
cells was less than 10% but there was an increase in sensitivity of the parental DLKP-SQ and 
SQ-Mitox-BCRP cells which appeared to plateau at 1 μM (figure 5.1-2, lower graph).  A 
concentration of 10 μM U0126 was thus established for subsequent experiments.   
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Figure 5.1-2:  Effects of PD98059 and U0126 on cell growth.  DLKP-SQ, SQ-Mitox-BCRP and SQ-
Mitox-MDR cells were seeded into 96 well plates and cultured in the absence or presence of PD98059 
and U0126 for 3 days.  Cell survival was determined using the alkaline phosphatase assay and 
presented as percentages relative to those of control cells cultured in the absence of the MEK 
inhibitor.  DMSO was used as a control.  The data shown are the means ± SD of at least 4 wells, and 
are representative of two independent experiments.   
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5.1.3.2  Effects of PD98059 and U0126 on anticancer drug resistance of SQ-Mitox-BCRP cells  
Inhibition of the MAPK kinase pathway can potentially affect the resistant phenotype of cancer 
cell lines346-348.  The efficacy of the MAPK signalling inhibitors, U0126 and PD98059 in 
combination with an anticancer therapeutic such as mitoxantrone was investigated.  The 
cytotoxicity of mitoxantrone was significantly potentiated in the BCRP over-expressing cell line 
after combination treatment with PD98059 and U0126 for 48 hours (figure 5.1-3).  This 
combination of mitoxantrone with MEK inhibitors produced a substantial and pronounced 
reduction in cell survival when compared with treatment with mitoxantrone alone.  Intriguingly, 
the effect plateaued at approximately 20% cell survival at all concentrations tested.  This is an 
important result because it questions the potential for a therapeutic regime to effectively 
eliminate a tumourigenic cell population.   
 
5.1.3.3  Inhibition of MAPK kinase pathway has no effect on BCRP expression levels  
In the previous section results show that the inhibitor PD98059 is capable of decreasing 
anticancer drug resistance in the SQ-Mitox-BCRP cells.  Was PD98059 therefore capable of 
reducing BCRP protein expression?  SQ-Mitox-BCRP cells were exposed to PD98059 at a 
concentration of 20 µM for 24 and 48 hours and BCRP protein expression levels measured by 
Western blot analysis.   
The level of BCRP protein in the SQ- Mitox-BCRP cells was unchanged after treatment with 
PD98059, suggesting that down-regulation of BCRP is not the molecular change in this cell line 
responsible for decreasing its mitoxantrone resistance (figure 5.1-4, A).   
 
5.1.3.4  Effects of PD98059 and U0126 on anticancer drug resistance of SQ-Mitox-MDR cells  
MEK inhibitors reverse drug resistance significantly in cell lines overexpressing BCRP.  Would 
inhibition of the MAPK kinase pathway also affect the resistant phenotype of the SQ-Mitox-
MDR cells?  MAPK signalling inhibitors in combination with mitoxantrone were similarly 
assessed in this cell line.  The results demonstrated that combination treatment with PD98059 but 
not U0126, substantially increased the drug resistance of SQ-Mitox-MDR cells (figure 5.1-5).  
U0126 had a small but insignificant effect on cell survival.   
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Figure 5.1-3:  Effects of PD98059 and U0126 on anticancer drug resistance of SQ-Mitox-BCRP cells.  
SQ-BCRP cells were seeded into 96 well plates and cultured in the absence or presence of PD98059 
and U0126, with and without Mitox for 48 hours.  Cell survival was determined using the alkaline 
phosphatase assay and presented as percentages relative to those of control cells cultured in the 
absence of the MEK inhibitor.  DMSO was used as a control.  The data shown are the means ± SD of 
at least 4 wells, and are representative of three independent experiments.  Statistics: p ≤ 0.05*, 0.01**, 
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Figure 5.1-4:  (A.) PD98059 treatment of SQ-Mitox-BCRP.  SQ-Mitox-BCRP cells were exposed to 
DMSO (controls) and PD98059 at a concentrations 20 µM for 24 and 48 hours.  Lysates were 
prepared for analysis by Western blot to detect BCRP.  (Representative results of two independent 
treatments).  (B.)  PD98059 treatment of SQ-Mitox-MDR.  SQ-Mitox-MDR cells were exposed to 
DMSO and PD98059 at a concentration of 20 µM for 24 and 48 hours.  Lysates were prepared for 
analysis by Western blot to detect P-gp. (Representative results of two independent treatments).   
 
A. 
B. 
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Figure 5.1-5:  Effects of PD98059 and U0126 on anticancer drug resistance of SQ-MDR1 cells.  SQ-
MDR1 cells were seeded into 96 well plates and cultured in the absence or presence of PD98059 and 
U0126, with and without mitoxantrone for two days.  Cell survival was determined using the alkaline 
phosphatase assay and presented as percentages relative to those of control cells cultured in the 
absence of the MEK inhibitor.  DMSO was used as a control.  The data shown are the means ± SD of 
at least 4 wells, and are representative of three independent experiments.  Statistics: p ≤ 0.05*, 0.01**.  
SQ-Mitox-MDR 
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5.1.3.5  Inhibition of MAPK kinase pathway increases P-gp protein expression levels 
PD98059 increased anticancer drug resistance in SQ-Mitox-MDR cells.  Could PD98059 
stimulate P-gp protein expression?  SQ-Mitox-MDR cells were exposed to PD98059 at a 
concentration of 20 µM for 24 and 48 hours.  The expression of P-gp protein expression levels 
was measured by Western blot analysis.  The level of P-gp protein was increased after treatment 
with PD98059, suggesting that PD98059 enhanced the expression of the P-gp protein (figure 5.1-
4, B) and that this might help explain the increase in drug resistance.   
 
5.1.3.6  Effects of Elacridar on anticancer drug resistance on SQ-Mitox- MDR 
The inhibitor PD98059 stimulated P-gp protein expression in the SQ-Mitox-MDR cell line.  Was 
the resistance mechanism in this cell-line mediated through increased P-gp expression and / or 
activity?  The experiment was repeated with a P-gp inhibitor to investigate if suppression of P-gp 
expression ameliorated the effect.  Elacridar is a P-gp inhibitor which is known to inhibit P-gp at 
a concentration of 0.25μM50.  Elacridar was added to the cell culture media in the mitoxantrone 
and PD98059 combination assay.  This had a significant impact on mitoxantrone toxicity, 
substantially reducing cell survival indicating that P-gp is responsible for the enhanced PD98059 
induced drug resistance (figure 5.1-6).  Of note is the background basal level of cell survival.  
Elacridar has the same effect in both the presence and absence of MEK inhibitor.  Even with P-
gp activity ameliorated there are other mechanisms at work responsible for the albeit low level of 
cell survival.   
 
5.1.3.7  Effects of AZD6244 on anticancer drug resistance of SQ-Mitox-BCRP and SQ-Mitox-
MDR1 cells. 
AZD6244 is an oral, non-ATP competitive inhibitor and is highly specific for MEK1/2, a key 
enzyme in the Ras-Raf-MEK-ERK pathway.  AZD6244 is one of the most widely studied MEK 
inhibitors in the clinical setting and thus a suitable candidate to investigate effects on the anti-
cancer drug resistance of the SQ-Mitox cell line.  Preliminary results from a single investigation 
(figure 5.1-7) indicate that there is a small but insignificant increase in anticancer drug resistance 
of SQ-Mitox-MDR after treatment with AZD6244.  In contrast, AZD6244 diminishes the anti-
cancer drug resistance of BCRP over-expressing cells – a similar response to that observed with 
PD98059 and U0126.   
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Figure 5.1-6:  Effects of Elacridar on anticancer drug resistance on SQ-Mitox- MDR.  Previous 
results showed that PD98059 induced a higher level of P-gp expression in the SQ-Mitox-MDR cell 
line.  The presence of inhibitor and mitoxantrone enhances cell survival by approximately 60% 
relative to treatment with mitoxantrone alone.  This enhanced survival could be reversed by the P-gp 
inhibitor, Elacridar.  Elacridar substantially reduces cell survival with all treatments regardless of the 
combinatorial treatments employed.  The data shown are the means ± SD of at least 4 wells, and are 
representative of three independent experiments.   
 
 
 
195 
 
 
 
 
 
Figure 5.1-7:   Effects of AZD6244 on anticancer drug resistance of SQ-Mitox-BCRP and SQ-
Mitox-MDR1 cells.  There is a small but insignificant increase in anticancer drug resistance of SQ-
Mitox-MDR after treatment with AZD6244.  This may question the clinical efficaciousness of such 
inhibitors used in cancer therapy.  The decrease in anticancer drug resistance of SQ-Mitox-BCRP is 
similar to the results observed in treatments with PD98059 and U0126.   
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5.1.3.8  Effects of PD98059 on anticancer drug resistance of DLKP-SQ 
PD98059 decreased anticancer drug resistance in the SQ-Mitox-BCRP cells.  Would it have the 
same effect on the DLKP–SQ parental cell line which contain low levels of BCRP protein (and 
display little mitoxanrone resistance).  Preliminary results from a single investigation indicate 
that there is a small but insignificant decrease in anticancer drug resistance of DLKP-SQ after 
treatment with PD98059 (figure 5.1-8).   
 
 
 
Figure 5.1-8:  Effects of PD98059 on anticancer drug resistance of SQ.  SQ (2000 cells/well) were 
seeded into 96 well plates and cultured in the absence or presence of PD98059 and increasing 
concentrations of mitoxantrone for two days. Cell survival was determined using the alkaline 
phosphatase assay and presented as percentages relative to those of control cells cultured in the 
absence of the MEK inhibitor. DMSO was used as a control.   
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5.1.3.9  Effects of PD98059 on anticancer drug resistance of DLKP-A 
PD98059 up-regulates P-gp expression in the SQ-Mitox-MDR cell line.  Does it have the same 
effect on other DLKP derived, drug resistant P-gp overexpressing cell lines?  DLKP-A is a drug 
resistant variant, which was initially selected by exposure to adriamycin and over-expresses P-gp 
277.  Inhibition of MEK had a small but not statistically significant effect on the drug resistance 
profile of DLKP-A (figure 5.1-9).  These results suggest that the DLKP-A cells may contain a 
different mechanism of regulation of P-gp to the SQ-Mitox cells.   
 
 
 
Figure 5.1-9:  Effects of PD98059 on anticancer drug resistance of DLKP-A.  DLKP-A cells were 
seeded into 96 well plates and cultured in the absence or presence of PD98059 and increasing 
concentrations of epirubicin for 48 hours.  Cell survival was determined using the alkaline 
phosphatase assay and presented as percentages relative to those of control cells cultured in the 
absence of the MEK inhibitor.  DMSO was used as a control.  The data shown are the means +/- SD 
of three independent experiments.   
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5.1.4  Summary of effects of MEK inhibitors on drug resistant DLKP cell lines 
In this section, the effects of signal transduction inhibitors upon multidrug resistance of the 
DLKP cell lines and its drug resistant variants were investigated.  Table 5.1-1 summarises the 
effects of the MEK inhibitors on the drug resistance of the SQ-Mitox and DLKP-A cell lines.   
 
Table 5.1-1:  Summary of Effects of MEK inhibitors on drug resistant DLKP cell lines. 
MEK Inhibitor SQ-MitoxBCRP SQ-Mitox-MDR DLKP-SQ DLKP-A 
PD98059 ++ ++ + + 
U0126 ++ + _ _ 
AZD6244 ns + _ _ 
++ very significant; + significant; ns: not significant 
 
The MEK inhibitor PD98059 diminishes the drug resistance of BCRP over-expressing cells but 
increases the drug resistance of P-gp over-expressing cells.  Western blot analysis reveals that 
PD98059 up-regulates P-gp expression in the SQ-Mitox-MDR cells, while having little effect on 
the expression of BCRP protein levels in the SQ-Mitox-BCRP cell line.  The role that the MAPK 
kinase pathway may play in the regulation of ABC transporter protein expression is a complex 
one and much remains to be elucidated.   
 
5.2  Investigation of the effects of MEK inhibitors on invasion of 
DLKP- cells 
5.2.1  Introduction 
Earlier, DLKP-I and DLKP-M cells were observed to over-express MMP-2 and MMP-10.  The 
MEK/ERK pathway has been implicated in the up-regulated expression of MMPs in tumour 
cells338,347,349,350.  Common transcription factors stimulated by the MAPK effector molecules 
include those of the AP-1 and ETS family.  Many of the MMP gene promoters contain DNA 
binding regions for these transcription factors and therefore activation of the MAPK pathway 
may lead to increased MMP gene transcription.  We therefore examined whether this pathway is 
involved in DLKP cell invasion.  In this section, the MEK inhibitor, U0126 was investigated for 
potential effects on the invasive capacity of DLKP-I and DLKP-M cell lines.   
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5.2.2  Effects of U0126 on cell growth of DLKP-I and DLKP cells 
The cell viability of DLKP-I and DLKP-M cells following treatment with U0126 was determined 
by the acid phosphatase assay.  Different concentrations of inhibitor ranging from 1 μM to 100 
μM were utilised over a 3-day study period.  Results indicated that the growth inhibitory effects 
of U0126 on the clones were less than approximately 20% at ≤ 20 μM (figure 5.2-1).  A 
concentration of 10 μM U0126 was established for subsequent experiments.   
 
5.2.3  Investigation of the effect of U0126 on matrigel invasion of DLKP-I and DLKP-M 
cells 
Matrigel invasion assays were performed to evaluate the effects of the MEK inhibitor, U0126 on 
the invasive capacity of the DLKP clones.  Cells were incubated with U0126 (5 µM and 10 µM) 
for 24 h in transwell inserts with 8 µm pores coated with matrigel.  As shown in figure 5.2-2 and 
5.2-3, the invasion of DLKP-M cells through the matrigel membrane was inhibited by 
approximately 50% after the addition of U0126, while the same treatment did not change the 
matrigel invasion of DLKP-I cells.  These results indicate that the MAPK kinase pathway may be 
a prime candidate involved in DLKP-M invasion but not in DLKP-I invasion.   
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Figure 5.2-1:  Effect of U0126 on DLKP-I and DLKP-M on cell growth and survival.  DLKP-I and 
DLKP-M cells were seeded into 96 well plates and cultured in the absence or presence of U0126 for 3 
days.  Cell survival was determined using the alkaline phosphatase assay and presented as percentages 
relative to those of control cells cultured in the absence of the MEK inhibitor.  DMSO was used as a 
control.  The data shown are the means ± SD of at least 4 wells, and are representative of three 
independent experiments.   
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Figure 5.2-2:  The DLKP-M cell line: invasion is reduced in U0126 treated cells compared with non-
treated cells.  After 24 hours incubation, the invading cells on the underside of the insert were stained 
with crystal violet and allowed to air dry.  (A) Untreated; (B) with the addition of 5.0 μM U0126; (C) 
With the addition of 10 μM U0126.  Magnification, ×200. Scale bar, 200μm.  Results are presented as 
mean +/- standard deviation (SD) of three independent experiments except for the last treatment (10 
μM) where only two mean values were generated.  Statistics: p ≤ 0.01**, (unpaired t-test to untreated 
control).   
 
 
 
** 
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Figure 5.2-3:  The DLKP-I cell line: invasion in U0126 treated cells compared with non-treated cells.  
After 24 hours incubation, the invading cells on the underside of the insert were stained with crystal 
violet and allowed to air dry.  (A.) Untreated; (B.) with the addition of 5.0 μM U0126 and (C) with the 
addition of 10 μM U0126.  Magnification, ×200.  Scale bar, 200μm Results are presented as mean+/- 
standard deviation (SD) of three independent experiments except for the last treatment (10 μM) where 
only two mean values were generated.   
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5.2.4 U0126 treated DLKP-M cells demonstrate different phosphorylation response 
compared to U0126 treated DLKP-I cells 
In the previous section, results show that the MAPK kinase pathway may be involved in DLKP-
M invasion but not in DLKP-I invasion.  Would other signalling pathways also be involved in 
DLKP-I and DLKP-M invasion?  The investigation of other MAPKs and intracellular signaling 
of DLKP-1 and DLKP-M cells under U0126 treatment was investigated using a commercial 
array kit.  A Human Phospho-MAPK array kit was used, which screens for the activation of 28 
kinases including 9 MAPKs.  The array kit allows the recognition of specific phosphorylation 
sites (amino acid residues) related to the activations of the MAPKs and the signaling proteins.  
The human phospho-MAPK array kit provides phosphorylation information of 29 intracellular 
biochemical signalling proteins.  In addition, analyzing multiple pathways simultaneously tests 
for signalling pathway crosstalk.  With this tool, the intracellular signalling patterns in DLKP-I 
and DLKP-M cells treated with U0126 were investigated.  JNK, p38 and p53 were the three 
phosphorylated proteins with most significant changes in the untreated DLKP-I cells compared to 
the untreated DLKP-M cells.   
The JNK stress pathways participate in many different intracellular signalling pathways that 
control a spectrum of cellular processes, including cell growth, differentiation, transformation, or 
apoptosis. JNK binds to and phosphorylates p53.  In most cases, p38-MAPKs are simultaneously 
activated with JNKs. 
The MAPK assay data (figure 5.2-4) shows that before U0126 treatment, DLKP-I cells had 
higher phosphorylated JNK, p38 and p53 than the DLKP-M cells. 
After U0126 treatment, DLKP-M cells showed increased phosphorylation in p53 and slightly 
increased phosphorylation in p38 and JNK, which suggests induced signalling in the p38 and 
JNK pathways by U0126. Interestingly, U0126 treated DLKP-I cells do not present a significant 
increase in any of the intracellular signalling proteins.   
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Figure 5.2-4: The Human Phospho-MAPK array shows the effect of inhibitors on 
specific pathways. All arrays were incubated with 250 μg of lysate. DLKP-I and 
DLKP-M cells were grown overnight on matrigel coated flasks. After 24 hrs, one 
flask of each was treated with 10 μM of the MEK inhibitor U0126 for 1 hour. A 1 
½ hour exposure to film is shown.  This experiment was carried out once.   
 
1.  JNK2, p38δ  2.  JNK pan, p53 3.  HSP27, p38α 4.  JNK2, p38δ 4.  5.  JNK pan, p53  6.  JNK2, p38α  7.  p38γ  8.  JNK pan, p53   
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5.2.5  U0126 inhibits ERK activation in the DLKP-M cell line 
 
To confirm that the pathway inhibitors were hitting their intended targets in DLKP-M and 
DLKP-I cells in the invasion assay, Western blot analysis was carried out under similar 
conditions as in the invasion assay to assess activation of pERK in the MAPK kinase  pathway. 
(figure 5.2-5). U0126 inhibited ERK activation in the DLKP-M cell line.  This data shows that 
the reduction of invasion of DLKP-M in the invasion assay is associated with inhibition of the 
intended targets (MAK kinase pathway).  
  
 
 
 pERK 
 
 tERK 
 
 
Figure 5.2.5:  Western blot analysis of pERK levels in the DLKP-M cell line after treatment with the 
MEK inhibitor U0126 (grown on matrigel). U0126 treatment significantly represses the levels of 
pERK in the DLKP-M cell line. The DLKP-I cell line (untreated) contains less levels of 
phosphorylation of pERK compared to the DLKP-M cell line (untreated).  
 
 
5.2.6  DLKP clones show differential activation of extracellular signal-regulated kinase 
U0126 significantly inhibits invasion in the DLKP-M cell line but has no effect on DLKP 
invasion.  To determine the level of ERK activation in DLKP cells, activation of ERK, as well as 
total levels of expression was assessed using phospho-specific or native antibodies, respectively. 
Western blot analysis reveals that the DLKP-M cells show higher levels of endogenous ERK 
activation compared to the DLKP-I and DLKP parent cells (figure 5.2-6) and this might help 
explain the significant inhibition of DLKP-M invasiveness with the inhibitor, U0126.  
MON    M90min   M90min  MON    I untreated 
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Figure 5.2-6: Expression levels of ERK1/2 and phospho-ERK protein in the DLKP parent and its 
clones. DLKP-SQ and DLKP-M cells showed high levels of endogenous ERK activation compared to 
DLKP-I and DLKP parent (In collaboration with Edel McAuley). 
 
5.2.7  Treatment with a MAP kinase inhibitor inhibits the invasiveness of drug-resistant 
SQ-Mitox-BCRP 
Earlier in this chapter the MEK inhibitor, U0126 was observed to inhibit invasion in the DLKP-
M cells but not the DLKP-I cells.  In addition, in chapter 3 (table 4.2-1)), microarray analysis 
revealed an upregulation of KRAS and IGF1R in the invasive SQ-Mitox-BCRP-6P cells.  As 
KRAS and IGF1R and known to mediate their effects through the MAPK pathway, the effect of 
U0126 on the invasion of SQ-Mitox-BCRP-6P cells was investigated.  SQ-Mitox-BCRP-6P 
(isolate 2) cells were incubated with U0126 (10 µM) for 24 h in transwell inserts with 8 µm pores 
coated with matrigel. As shown in figure 5.2-7, the invasion of SQ-Mitox-BCRP-6P cells 
through the matrigel membrane was inhibited by approximately 50% after the addition of U0126, 
indicating that the MAPK pathway may also be involved in the invasive phenotype of drug 
resistant SQ-Mitox-BCRP. 
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Figure 5.2-7:  The SQ-Mitox-BCRP-6P cell line: invasion in U0126 treated cells compared with non-
treated cells.  After 24 hours incubation, the invading cells on the underside of the insert were stained 
with crystal violet and allowed to air dry. A.  Untreated B. with the addition of 10 μM U0126.  Results 
are  presented as mean+/- standard deviation (SD) of three independent experiments.  Statistics: * p < 
0.05 (unpaired t-test to untreated control).   
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5.3  Summary of Effects of MEK inhibitors on invasive DLKP cell lines 
 
The effects of signal transduction inhibitors upon invasion of the DLKP cell lines and its drug 
resistant variants were investigated. Table 5.2-1 summarises the effects of the MEK inhibitors on 
the invasion of the SQ-Mitox and DLKP clones. Interestingly, the SQ-derived mitoxantrone cells 
show a similar response to the DLKP-M clone. 
 
Table 5.2-1: Summary of effects of MEK inhibitors on invasion of the DLKP cell lines  
MEK Inhibitor SQ-Mitox- 
BCRP- 6P 
DLKP-I DLKP-M 
U0126 + - + 
 
 
5.4  Sequenom analysis of DLKP clones 
The DLKP clones show differential activation of extracellular signal-regulated kinase.  Genetic 
alterations that activate the mitogen-activated protein kinase (MAP kinase) pathway occur 
commonly in cancer. Do the DLKP clones harbour mutations in the signaling pathways which 
would explain the differential activation of extracellular signal-regulated kinase between the 
clones?  Mutation profiling has the potential to quickly identify which signalling pathway(s) have 
been co-opted to drive the proliferation of a specific human tumour type. In chapter 4, the DLKP 
clones were evaluated for the presence of mutations using sequenom technology (table 5.2-2). Of 
particular interest are the genes showing sequence alterations in the DLKP-SQ and/or DLKP-M 
clones only as these clones have higher levels of ERK activation compared to the DLKP-I clone.  
In addition, treatment of the DLKP-M clone and the DLKP-SQ derived mitoxantrone resistant 
cells with a MAP kinase inhibitor inhibited the invasiveness of these cells but had no effect on 
the DLKP-I cells.  Further investigation of the role of EGFR, Met and PIK3R1 genes in the 
DLKP clones is warrented.  The role that the MAPK kinase pathway may play in the invasive 
phenotype of the DLKP clones is a complex one and much remains to be elucidated.   
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Table 5.2-2:  Sequenom Mutation Analysis of DLKP Clones 
Mutation DLKP Parent DLKP-SQ DLKP-I DLKP-M DLRP 
EGFR_V769LM_G2305AT G AG G G G 
IDH1_V1781_G532A G G G G AG 
MET_N375S_A1124G AG AG AG G A 
NRAS_G12SRC_G34ACT G G G G GT 
PIK3R1_M3261_G978ATC AG AG G AG G 
TP53_G245VDA_G734TAC AG AG AG AG AG 
 
 
5.3  Summary   
Drug resistance and invasion were investigated using MEK inhibition. The cell lines used were 
the DLKP clones (DLKP-SQ, DLKP-I and DLKP-M) and the mitoxantrone resistant variants of 
DLKP-SQ (SQ-Mitox-BCRP and SQ-Mitox-MDR).   
Combination treatment with mitoxantrone and/or PD98059/U0126 significantly reversed drug 
resistance in the SQ-Mitox-BCRP cell line with no effect on BCRP protein expression levels.  In 
contrast combination treatment with mitoxantrone and PD98059 increased drug resistance in the 
SQ-Mitox-MDR cell line with an increase in the levels of P-gp protein.   
MEK inhibitor treatment of DLKP-M cells had a considerable effect on its invasiveness while 
having no effect on the DLKP-I cells.  Western blot analysis revealed that the DLKP-M cells 
show higher levels of endogenous ERK activation compared to the DLKP-I and DLKP parent 
cells and this might help explain the significant inhibition of DLKP-M invasiveness with the 
inhibitor, U0126.   
The poorly invasive DLKP-SQ clone had the highest level of phosphorylation of ERK of all the 
clones.  Interestingly, MEK inhibition of the SQ-Mitox-BCRP-6P cells, which are DLKP-SQ 
derived also had a significant effect on its invasiveness.   
The DLKP clones were evaluated for the presence of mutations using sequenom technology and 
sequence alterations were revealed in the EGFR, MET, and PIK3R1 genes.  Generally the results 
indicate that there may be differential activation of EGFR, Met and PIK3R1 within the clones.   
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CHAPTER 6 
 
Discussion 
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6.1  Drug resistance and cancer invasion   
This thesis examined the temporal relationship between the emergence of drug resistance and 
invasiveness in a human carcinoma cell line model of mitoxantrone resistance in order to better 
understand the link between the development of multidrug resistance and cancer metastasis or 
invasion under the confines of the cell culture techniques employed here.   
Almost all types of cancer are characterised by their ability to progress toward increased 
malignancy.  Evolutionary processes are clearly very important because the most crucial problem 
during cancer chemotherapy is the development of resistance by the cancer cells with the 
subsequent ability to acquire in some cases, an aggressive invasiveness or ability to break 
through the normal tissue boundaries and spread to disparate sites throughout the body.  For 
example, most small cell lung carcinomas (SCLCs) are drug sensitive at diagnosis, but any 
recurrence of the disease is usually characterised by an acquired drug resistance.  In contrast, 
other neoplasms such as non small cell lung carcinomas (NSCLCs) are predominantly, 
intrinsically resistant to chemotherapy to start with.  The various cancer phenotypes displayed by 
different tumours contribute to the slow pace of progress with respect to developing more 
effective and specific treatments.   
One of the primary reasons for the difficulty encountered during chemotherapy is the lack of 
understanding at a fundamental level of how cells evolve in response to drug treatment and how 
malignant tissues develop drug resistance.  There is indirect evidence that multidrug resistance 
and invasion/metastasis may be linked or at least, often occur together but it is unclear at this 
time whether they share any mechanisms.  The possibility of a relationship between drug 
resistance and invasion/ metastasis phenotypes has been raised by at least two types of 
observations325 : firstly, some drug resistant tumour cells are more invasive/metastatic relative to 
non-resistant parental cells; secondly, in some cases, secondary (more metastatic) tumours are 
more resistant to chemotherapeutic drugs than their primary counterparts.  In support of these 
ideas, many studies have been performed.  Colone et al.,199 decribed a doxorubicin-selected, 
multidrug-resistant human melanoma line expressing high levels of ABCB1 (P-gp) that showed a 
more invasive phenotype that the parental cell line and knockdown of ABCB1 by siRNA 
substantially reduced the invasiveness of this cell line in vitro.  Reduction of ABCB1 levels by 
siRNA also reduced the migration of MCF-7 breast cancer cells in transwell migration and 
matrigel invasion assays351.  However, in some cases, no correlation was seen between drug 
resistance and cancer invasion/metastasis196,198.   
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DLKP-SQ, a clone of DLKP, was chosen for the establishment of a mitoxantrone resistant cell 
line at the start of this project.  The parental cell line, DLKP has a heterogeneous population of 
cells and was derived from a secondary site of the original tumour.  These cells are very sensitive 
to adriamycin, vincristine, VP-16 and cisplatin282.  In addition, invasion assays have 
demonstrated a low level of invasiveness in the DLKP-SQ clone.  In this way, isogenic drug 
resistant cell lines could be generated from the DLKP-SQ clone which would serve to eliminate 
variability due to intrinsic genetic differences between different cell lines.   
The primary aim of this study was to establish if the resistant and invasive phenotypes emerged 
at the same or at different time points, and to this end the differences in invasion between the 
mitoxantrone resistant SQ cells and poorly invasive SQ parent were monitored during the 
development of drug resistance.  Table 4.2-5 summarises the association between mitoxantrone 
drug resistance and invasion in selected cell lines.  The SQ parent displayed low invasion and 
low drug resistance.  Following successive drug pulsing with mitoxantrone (in both BCRP and P-
gp overexpressing cell lines), cells were isolated from the fourth (4th) pulse population, which 
displayed high drug resistance but low invasiveness, similar to the SQ parent.  In contrast, the 
cells isolated from the sixth (6th) pulse population displayed high invasiveness with similar drug 
resistance to the 4th pulse.  Results indicate that invasion was increased in the 6th pulse cells 
relative to the 4th pulse cells and the original SQ parent for both the SQ-Mitox-BCRP and SQ-
Mitox-MDR cells.  Large standard deviations were observed in these assays which may have 
been due to the instability of the invasive phenotype in these new drug resistant cells.  
Subsequently, a sub-population of stable invasive cells were isolated from the 6th pulse BCRP 
over-expressing cells.  Careful observations of these cells revealed morphological features 
characterised by large numbers of spiky, elongated cells – consistent with the view that this sub-
population of cells were more invasive and more resistant than those observed to date.  Further 
investigations of these cells confirmed they had a higher IC50 and higher levels of BCRP protein.  
This drug resistant, stable invasive cell line has provided an excellent base model for further 
studies.  In addition, this work suggests that future studies to clone or isolate a stable invasive 
sub-population of the P-gp over-expressing cells could also yield further valuable insights into 
the cancer cell phenotype.   
Section 6.2 discusses the characterisation of the resistant phenotype of the mitoxantrone resistant 
SQ cell lines using microarray analysis and proteomic analysis.  Interestingly, induction of 
invasion was independent of the type of transporter expressed.   
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Tumour cells can evade death induced by exposure to drugs through various mechanisms.  The 
most simplistic strategy is to move to an environment that contains a lower concentration of a 
cytotoxic drug.  This is achieved through metastasis by tumour cells.  In the mitoxantrone 
selection, the cells developed the membrane-bound drug efflux pumps, BCRP and P-gp to 
eliminate the drug or its metabolites out of the cell cytoplasm, subsequent drug pulsing initiates 
the next stage of cell survival, i.e. cell cytoskeletal remodelling and movement of cells away 
from local high concentrations of drug.   
Two observations suggested that the emergence of invasion may be independent of the drug 
transporter induced.  The first observation indicated that the 6th pulse SQ-Mitox BCRP over-
expressing variant was significantly more invasive than the 4th pulse SQ-Mitox BCRP over-
expressing variant (figure 3.1-1 and figure 3.1-3).  The second observation showed that the 6th 
pulse SQ-Mitox P-gp overexpressing variant was also significantly more invasive than the 4th 
pulse SQ-Mitox P-gp overexpressing variant (figure 3.1-1 and figure 3.1-3).  Do BCRP and P-gp 
indirectly promote invasion of SQ-Mitox cells?  Are common transcription factor or signalling 
pathways responsible for increased cell invasion (such as switching on MMP genes)?  
Microarray analysis allowed further examination of the impact of mitoxantrone resistance on the 
invasive phenotype in both SQ-Mitox-BCRP and SQ-Mitox-MDR cell lines.  This analysis 
identified genes involved in the invasion process for both BCRP and P-gp overexpressing cell 
lines (see section 4.2).  These cell lines share a common genetic background, i.e. BCRP over-
expression in the case of the SQ-Mitox-BCRP cell lines and P-gp over-expression in the case of 
the SQ-Mitox-MDR cell lines.  Genetic variation is minimised and expression changes most 
likely represent invasion as opposed to BCRP or P-gp transporter specific changes.  
Accumulating evidence suggests that P-gp may promote invasion and metastasis of cancer cells 
in vitro 199,351,352.   
The elevated level of BCRP in the SQ-Mitox-BCRP-6P (isolate 2) cells was associated with 
stable invasion (see section 4.2.4).  Concurrently there was also an elevated expression of the cell 
adhesion molecule ALCAM (figure 4.2-8).  The newly developed DLKP-SQ and SQ-Mitox cell 
lines were thus employed as a model to study the relationship between drug resistance and 
invasion/metastasis (discussed in section 6.3).   
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6.2  Development of MDR- and BCRP-mediated resistant lung cancer 
cell lines 
Multidrug resistance (MDR) is still a major obstacle to cancer chemotherapy.  The establishment 
of drug resistant cancer cell lines in vitro could provide an important model for studying the 
mechanism of MDR and the reversal of resistance.  The establishment of drug resistant cancer 
cell lines in vitro can therefore enhance the screening of chemotherapeutic drugs, improve the 
sensitivity of cancer cells to drugs and provide a model for understanding the molecular basis of 
drug resistance and allow the establishment of reversing strategies to be employed in the fight 
against cancer.  The overcoming of tumour multidrug resistance will allow significant progress to 
be made in chemotherapeutic efficacy.  In vitro drug resistant cell lines have a history of more 
than 20 years as a primary tool for studying the mechanism of tumour multidrug resistance.  
Generally, high-dose drug intermittent induction or increasing drug concentrations are used on 
parental cells to establish these cell lines.  Intermittent high-dose induction is similar to clinically 
periodic chemotherapy, and therefore can simulate the drug resistant phenomena in patients 
following representative treatments.   
The DLKP-SQ Mitox resistant cell lines were successfully established by intermittent high-dose 
Mitox-induced method for four months (see section 3.1).  The resistance index was 210- and 
320-fold for the DLKP-SQ-Mitox-BCRP and DLKP-SQ-Mitox-MDR cell line respectively (table 
3.1-1).  In order to investigate changes in the gene expression pattern during mitoxantone 
selection, microarray analysis was performed in highly resistant DLKP-SQ-Mitox cells (see 
section 3.1.10).  Interestingly, BCRP was the primary over-expressed gene in the DLKP-Mitox-
BCRP cell line and P-gp was the primary over-expressed gene in the DLKP-Mitox-MDR cell 
line (figure 3.1-4).  Induction and overexpression of ABCB1 (MDR1) and ABCG2 (BCRP) were 
demonstrated by microarray analysis (table 3.1-2) and qPCR and Western blot (figure 3.1-4) in 
SQ-Mitox-MDR and SQ-Mitox-BCRP respectively.  The level of mRNA detected in the drug 
resistant cell lines positively correlated with the level of protein detected.  Low levels of BCRP 
were detected in the drug sensitive parental cell line while P-gp protein was not detectable.  
Despite the similar selection strategy, the mechanism of mitoxantrone resistance differs 
significantly between these two cell lines.  Nieth et al.,353, reported that mitoxantrone treatment 
influences the expression of several ABC-transporters but in the end, merely a single extrusion 
pump will be dominant.  Yang et al.,354 showed that P-glycoprotein-mediated multi-drug 
resistance and CDDP-resistance phenotypes can coexist in colon cancer cells with primary 
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resistance to CDDP.  Tegze et al., developed multiple drug resistant cell lines in parallel from 
MCF-7 and MDA-MB-231 breast cancer cells and concluded that heterogeneity caused evolution 
of multiple resistant clones with different resistance characteristics.355.  It is also interesting to 
note that the expression of P-gp did not correlate with resistance in the cell line models, despite 
the development of models with two P-gp substrates (doxorubicin and paclitaxel)355.   
 
6.2.1  Cross-resistance in the DLKP-SQ cell line and its mitoxantrone resistant variants 
To determine if the SQ-Mitox-BCRP and SQ-Mitox- MDR cell lines displayed cross-resistance, 
a panel of drugs that differed in their structure and function were tested.  As observed (table 3.1-
1), the SQ-Mitox-MDR cells demonstrate a “typical” MDR phenotype which has been correlated 
with P-glycoprotein-mediated drug resistance and its associated cross-resistance to taxol, 
epirubicin, vinblastine, irinotecan and VP16.  SQ-Mitox-MDR cells showed neither significant 
cross resistance nor sensitivity to cisplatin or 5-fluorouracil, when compared with the parental 
cell line.   
In contrast, the SQ-Mitox-BCRP cell line exhibited resistance to mitoxantrone and irinotecan but 
not to taxol, epirubicin, vinblastine, VP16 or 5-FU.  The efflux protein BCRP has a more 
selective transport profile than P-gp.  BCRP does not transport taxol, vincristine or verapamil. 
However, irinotecan and its active metabolite SN-38 are substrates of BCRP.   
BCRP can have functional variants, for example, a mutation in its primary sequence leads to an 
amino acid substitution298.  The wild-type BCRP has an arginine (R) at position 482.  Two 
known variants exist; variant R482T which has threonine (T) at position 482 and variant R482G 
where position 482 is occupied by the amino acid glycine (G).  These variations can lead to 
functional changes in BCRP.  Wild type BCRP does not transport the anthracycline, epirubicin, 
where as the R482G variant does transport anthracyclines356.  In this study, the SQ-Mitox-BCRP 
cell line was not resistant to epirubicin, implying that this cell line contains wild-type BCRP.   
 
6.2.2  MDR and BCRP confer drug resistance to Mitoxantrone-selected DLKP-SQ 
siRNA techniques were utilised to confirm that the BCRP and P-gp proteins were contributing to 
the resistant phenotype observed in the SQ-Mitox-BCRP and SQ-Mitox-MDR cells respectively.  
The siRNA investigations were coupled with toxicity assays, with the protein of interests’ effects 
on drug sensitivity ultimately being analysed (see section 3.1.9).  To evaluate if BCRP and 
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MDR1 were conferring resistance to mitoxantrone in the BCRP and P-gp overexpressing cell line 
respectively, cytotoxicity assays were performed in the presence and absence of elacridar, a 
specific inhibitor of BCRP and MDR1.  With the addition of 443nM Elacridar, the BCRP-
mediated and MDR1- mediated resistance to mitoxantrone were reversed (figure 3.1-6).  
Elacridar is a very potent MDR modulator that exerts its MDR reversal effect in nanomolar 
concentrations.  In order to down regulate the genes over-expressed in the resistance cells, highly 
efficacious and target specific siRNA sequences were selected.  An siRNA for kinesin was 
included in this study as a positive control which resulted in 100% knockdown.  Western blot 
analysis confirmed the knockdown of BCRP protein in the SQ-Mitox-BCRP cells and P-gp 
protein in the SQ-Mitox-MDR cells (figure 3.2.7).  Due to the very high level of overexpression 
of BCRP and P-gp respectively in the two resistant variants, only partial knockdown could be 
achieved using siRNAs.  There was a corresponding effect on resistance, which supported a role 
for these pumps in resistance but because complete knockdown was not possible, the results do 
not allow us to determine whether or not these are the only, or even the main, determinants of 
resistance, although the Elacridar data would suggest that this is the case.  Elacridar, however, is 
less specific in its effect than an siRNA would be.   
 
6.2.3  ABCB1 and ABCG2 expression in SQ-Mitox-MDR and SQ-Mitox-BCRP 
There are generally two possibilities for the origin of drug resistance in cells: (1) it is an inherent 
property of the cells, or (2) it may be acquired following exposure to drugs and other xenobiotics.  
The chemotherapeutic drugs may therefore act as gene inducers through activation of xenobiotic 
sensors, or mutagens causing genetic changes which result in MDR cells, or as selective agents, 
eliminating the sensitive cells from the population.  DLKP was established from a primary 
human squamous lung carcinoma and exhibited high levels of cytogenetic variability282.  
Consequently, the potential existed for drug resistant cells to have been selected from a pre-
existing resistant population or to have been acquired following exposure to mitoxantrone.   
Western blot analysis showed that BCRP and P-gp overexpression occurred early on in the drug 
pulsing process (figure 3.1-4).  This posed the question as to whether the drug resistant cells were 
pre-existing in the DLKP-SQ population or arose by gene induction or mutation arising from the 
drug treatment.  During the initial selection process by which eventually the mitoxantrone cell 
lines were derived, the DLKP-SQ clones were grown at high density to approximately 70% 
confluency, prior to the initial drug exposure (see section 3.1).  The initial four hour 
217 
 
mitoxantrone treatment reduced the cell population to approximately 5% and consisting of single, 
dispersed cells.  These cells then grew into colonies and were maintained until they appeared 
healthy.  The cells were then trypsinised and this whole cyclic treatment was repeated five more 
times, generating the replicate SQ-Mitox cell lines (figure 3.1-1).  Selection with the 
mitoxantrone drug could therefore have resulted in the isolation of a cell population that already 
exists in the culture.  This has been demonstrated for other drug resistant models. For example, 
Barr et al., identified cisplatin resistant subpopulations of NSCLC cells with a putative stem-like 
signature357. 
 
6.2.3.1  Gene amplification 
Gene amplification has long been recognised as a major contributor to the increased expression 
of ABCB1 and ABCG2358,359.  Initially it seemed possible that the increased expression of BCRP 
and P-gp in the SQ-Mitox cells might also be due to gene amplification.   
ABCG2 gene amplification was first shown in a study of a few mitoxantrone-selected derivative 
cell lines of MCF-7359 and in Adriamycin-selected MCF- 7/AdVp3000 cells309.  The 
mitoxantrone-sensitive parental cell line MCF-7, had no amplification or chromosome 
translocation of the ABCG2 gene.  It has also been shown that the resistance level to SN-38 in 
colorectal cancer cells positively correlates with ABCG2 gene amplification360, suggesting that 
gene amplification of ABCG2 is not restricted to MCF-7 breast cancer cells.  Rao et al.310 
examined the mechanisms of ABCG2 gene amplification during the stepwise drug selection of 
the glioblastoma cell line SF395.  It was found that double minute chromosomes were 
responsible for ABCG2 gene amplification in the drug resistant SF395 derivative cell lines 
selected with low concentrations of mitoxantrone (50 and 100nM).  However, in the derivative 
cell lines selected with high concentration of mitoxantrone (250 and 500nM), ABCG2 gene 
amplification appears to be due to chromosomal reintegration of the amplicon at multiple 
chromosomes to generate a more stable genotype. 
The amplification of the MDR/ABCB1 chromosomal region has been reported from in vitro 
acquired drug-resistant cell lines from various cancers, including breast361,362, liver363, 
neuroblast364, esophagus 365 and ovary 366,367.  In the present study, the gene copy number of 
ABCG2 and ABCB1 was investigated using qPCR (see section 3.1.12.2).  .  The CT values were 
at the upper limits of detection and as a result there were errors.  The minimum and maximum 
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copy numbers are shown in table 3.1-7.  Future studies should include increasing the 
concentration of the template (gDNA) and using ten replicates instead of four.   
While the DLKP-A cell line277 exhibited a ABCB1 gene copy number of 6, the SQ-Mitox-MDR 
cells exhibited no change in copy number (table 3.1-7).  DLKP-A is a cell line composed of a 
mixture of cells, with respect to their level of resistance to chemotherapeutic drugs and mode of 
resistance to these drugs277.  Increased expression of P-gp in some of the clones of DLKP-A may 
be due to gene amplification.  Surprisingly the DLKP-SQ and the SQ-Mitox-BCRP cells 
exhibited an MDR1 gene copy number of 3.  In summary, the elevated expression of these genes 
cannot be solely explained by gene copy number.   
 
6.2.3.2  Methylation 
The lack of ABCB1 and ABCG2 gene amplification in the SQ-Mitox cell lines suggested that the 
dramatic upregulation of ABCB1 and ABCG2 in these drug-resistant cell lines may be due to the 
loss of transcriptional silencing of these genes.  Epigenetic alterations are potential driving forces 
for acquired chemoresistance368.  A typical epigenetic modification, which is frequently observed 
in tumour cells, is aberrant methylation of cytosine bases (C) located 5′ of a guanine base (G), so 
called CpG dinucleotides 369. Although CpG dinucleotides are generally underrepresented in 
mammalian genomes, they frequently cluster around the transcription start site (TSS) of genes, in 
genomic areas referred to as CpG islands (CGIs)370.   
 
5-aza-2′-deoxycytidine treatment of DLKP-SQ cells 
To further understand the mechanisms leading to this overexpression, two different approaches 
were employed.  Firstly, a direct experiment examining the effects of inhibiting methylation on 
gene expression using 5-aza-2′-deoxycytidine (5-aza-dC) was performed (see section 3.1.12.3).  
This agent has been shown to increase gene expression by inhibiting DNA–methyltransferase I, 
thereby decreasing epigenetic methylation of DNA.  DLKP-SQ and SQ-Mitox cells were treated 
with 1µM 5-aza-dC, and its effects on both BCRP and P-gp protein expression were investigated.  
Treatment with 5-aza-dC did not result in any change in ABCG2 or ABCB1 in the DLKP-SQ or 
SQ-Mitox cell lines, as assessed by Western blot analysis as shown in figure 3.1-11.   
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Methylation analysis 
The second approach to understanding gene over-expression was the use of methylation analysis.  
This was performed for the BCRP promoter as it has only one CpG island and therefore it is 
relatively easy to design primers and probes for a successful investigation.  In contrast, the 
MDR1 promoter has several CpG islands, which make such an analysis more difficult.  The 
methylation status of the BCRP promoter in the DLKP-SQ cell line and its ABCG2 over-
expressing MDR counterpart was investigated using MethylLight technology269.  MethyLight is a 
sodium bisulfite (NaHSO3) dependent, quantitative, fluorescence-based, real-time PCR method 
to sensitively detect and quantify DNA methylation in genomic DNA.  The results indicated that 
the BCRP promoter was unmethylated in both the DLKP-SQ and SQ-Mitox-BCRP cells (see 
section 3.1.12.3).  As expected, the results also illustrated that the primer pair for detection of a 
methylated BCRP gene did not produce a signal (thereby also confirming no DNA methylation).   
Future work examining the methylation state of the MDR1 promoter is also warranted as it is 
probably the most prominent gene involved in drug resistance being transcriptionally regulated 
via CpG island (CGI) promotor methylation.  Epigenetic alterations such as promoter 
demethylation, leading to upregulation of ABCB1 was described in adriamycin-selected CCRF-
CEM cells (CEM-A7R)371 and vincristine-selected KB3-1 cells372.  Baker et al.,373 demonstrated 
the direct epigenetic up-regulation of the MDR1 gene within a single cell cycle, in antiapoptotic, 
bcl2-transfected CCRF-CEM-bcl2 cells, occurring in response to chemotherapeutic drug 
exposure.  To et al.,374 have shown an active CpG island within the proximal ABCG2 promoter 
region, thereby facilitating its transcriptional silencing in aberrantly methylated renal cell 
carcinoma lines.  While Turner et al.,75 demonstrated that ABCG2 expression in multiple 
myeloma patients is regulated in part by promoter methylation, one report documented the 
impact of single-step anticancer drug selection and concomitant ABCG2 expression in 
doxorubicin-selected cancer cells311.  Histone acetylation and deacylation has also been shown to 
possibly regulate ABCG2 promoter activity.  Following drug selection in several cancer cell lines 
and the subsequent overexpression of ABCG2, To et al.,374 observed an increase in acetylated 
histone H3 but a decrease in class I HDACs associated with the ABCG2 promoter.   
 
6.2.4  Other mechanisms of gene regulation 
Regulation of the expression of the major human drug transporter gene ABCB1 is highly 
complex375.  As well as gene amplification and chromosomal tranlocation376, mRNA 
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stabilization377 can also contribute to the elevelated ABCB1 protein levels in highly drug-
resistant cell lines.  Alternative promoter usage378,379 and promoter mutation380,381 also influence 
the transcription of the ABCB1 gene.  Like many TATA-less promoters, the promoter of the 
MDR1 gene contains multiple start sites.  The MDR promoter elements include the GC-box, 
inverted CCAAT element (Y-box), p53 element, AP-1 element, CAAT element, C/EBP element, 
heat shock element (HSE), TCF elements and steroid xenobiotic (SXR elements)381.  The 
inverted CCAAT box can potentially interact with the regulatory protein YB-1 or the 
transcription factor NF-Y.  Previous studies implicated YB-1 as a fundamental regulatory factor 
for the MDR1 gene in human cancers382.   
A large number of studies have suggested that ABCB1 is phosphorylated, however, it is still 
unclear what role phosphorylation plays in regulating ABCB1 function 383,384,385.  In 1987, 
Mellado and Horwitz published the first evidence suggesting that ABCB1 was phosphorylated386.  
Their work showed that phosphorylation of ABCB1 increased when cells were treated with 
cAMP.  Treatment of partially purified ABCB1 with recombinant PKA (i.e., the catalytic 
subunit) results in increased phosphorylation of ABCB1 in vitro386.  It is now apparent that 
ABCB1 is likely phosphorylated by a number of kinases, including PKC and PKA.   
Other mechanisms of drug-induced up-regulation of gene expression have been proposed for the 
BCRP transporter (figure 6.2-1).  The BCRP (ABCG2) promoter also lacks a TATA-box and 
contains a CAAT-box, lots of AP1, AP2 sites and several putative Sp1 sites, which are 
downstream of a putative CpG island.  Thus potential transcriptional control points have been 
identified 79.  The upstream region contains functional oestrogen77 and hypoxia78 response 
elements, consistent with its expression in mammary glands and a role in haemopoietic stem cell 
protection.  Furthermore, ABCG2 expression has been shown to be suppressed by DNA 
methylation75, up-regulated by the aryl hydrocarbon receptor74 and up-regulated by Oct476 (with 
respect to hepatobiliary cancer).  Several other transcription factors, such as nuclear factor-κB 
(NF-κB), hypoxia-inducible factors (HIFs), nuclear factor erythroid 2-related factor 2 (Nrf2), 
peroxisome proliferator-activated receptors (PPARs) and Krüppel-like factor 5 (KLF5), have also 
been recently shown to bind to their response elements in the promoter/enhancer to activate the 
transcription of BCRP70.  BCRP transcription can be influenced by proinflammatory cytokines, 
growth factors, and the homeobox protein MSX2.  Signaling pathways, such as Sonic hedgehog 
(Shh), Notch and RAR/RXR pathways, may also be involved in the transcriptional regulation of 
BCRP.  In addition, promoter methylation and histone acetylation are essential for BCRP 
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Figure 6.2-1:  Putative mechanisms for BCRP overexpression in drug-resistant cells.  A. In drug-
sensitive cells, BCRP transcription is regulated by histone 3 trimethylated at lysine 9 (H3K9me3) and 
the proximal promoter region is reported to be methylated in cells prior to drug selection or treatment.  
Synthesized mRNA is negatively regulated by possible candidate miRs, including miR-519c, miR-32 
8, and miR-520h, which are purported to bind miR response elements in 3’UTR of BCRP mRNA.  
Thus, BCRP expression is transcriptionally and post transcriptionally regulated.  B. BCRP gene 
amplification is observed in some drug selected cancer cells.  Transcription factors become more 
accessible because of histone 3 modifications, including acetylation at lysine 9 and 14 (H3K9ac, 
H3K14ac), methylation at lysine 4 (H3K4me), and phosphorylation at serine 10 (H3S10p).  Multiple 
TSSs are likely used for induction of BCRP.  Demethylation of CpG islands around promoter regions 
may contribute to overexpression of BCRP in response to drugs.  Once BCRP mRNA is synthesised, 
its 3’UTR becomes truncated, resulting in deletion of miR response elements, which in turn increases 
BCRP mRNA stability and levels. M: methylation; A: acetylation; P: phosphorylation.  Taken from  
Nakanishi et al. (2012).   
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transcription, especially for drug-induced BCRP expression.  Wu et al.,  reviews the recent 
research progresses in this field with an emphasis on the roles of transcription factors and 
epigenetics in the transcriptional regulation of BCRP387.   
In addition, phosphorylation has been implicated in the regulation of BCRP, with 
phosphorylation of Thr-362 by Pim-1 kinase affecting the oligomerisation and plasma membrane 
localisation of BCRP, with unknown effects on the substrate specificity of the transporter 388.   
BCRP is also under post-transcriptional regulation by microRNAs.  The miRNAs miR-519c and 
miR-328 decrease the level of ABCG2 mRNA and thus protein by binding to a putative binding 
site located within the 3′ untranslated region.  However, these binding sites are proposed to be 
absent from some drug selected, BRCP over-expressing cell lines389-391.  Similarly, miR-520h has 
also been reported to target BCRP in hematopoietic stem cells during their differentiation into 
progenitor cells392.   
The ABC transporters may also undergo post-transcriptional modifications such as glycosylation.  
A study by Liang et al., showed that glycosylation defects on ABCC1 (also known as MRP1), 
leads to the mislocalization of multidrug transporters in cisplatin-resistant cancer cell lines393.  It 
was also observed that increased levels of glycosylation-defective ABCC1 and ABCC4 are 
associated with resistance to platinum compounds in ovarian carcinoma cell lines394.  
Glycosylation of P-gp occurs on the first extracellular loop, which contains three putative 
glycosylation sites54.  Even though glycosylation of P-gp was not found to be necessary for the 
drug transport activity of P-gp, glycosylation of P-gp was shown to be important for proper 
quality control of P-gp in the endoplasmic reticulum54 and proper transport of P-gp to the plasma 
membrane52.  Similarly, glycosylation might also regulate BCRP transporter levels, as altered 
glycosylation of BCRP results in increased degradation395.  N-linked glycans are thought to be 
crucial regulators of the stability of BCRP in the endoplasmic reticulum395,396.  Studies have 
shown that N-glycosylated wild-type BCRP is degraded in lysosomes, whereas misfolded mutant 
proteins have been shown to undergo ubiquitin-mediated degradation in the proteasome396,397.  
In addition Diop et al., have shown that within BCRP, there is a single residue (N596) which is 
glycosylated and this modification is associated with correct assembly and effective trafficking of 
stable protein to the plasma membrane but is not required for protein function398.   
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6.2.5  Microarray analysis of SQ-Mitox sub variants 
The mitroxantrone selection activated, exclusively and in parallel, a P-gp and a BCRP-related 
resistance mechanism.  There may also be alternate pathways, activated randomly by drug 
exposure.  The aim of the microarray analysis was to identify the differences at the genetic level 
between the mechanisms of resistance amongst the two cell lines (see section 3.1.10).   
Different genes functionally involved in cellular assembly and organisation (including cell 
adhesion and cytoskeleton organisation) were induced or suppressed following exposure to 
mitoxantrone (table 3.1-2).  Cell adhesion has been demonstrated to modulate drug response and 
prevent cell death, implicating the interaction of cell-cell or cell-extracellular matrix as a 
potentially important determinant in the emergence of drug resistance399.  Indeed, a number of 
cell adhesion-related and microtubule related genes, including CD36, KIF1A, MDK and MYH10 
were commonly down-regulated in both BCRP and P-gp over-expressing cell lines.  CD36, 
which is a cell surface molecule, is causally involved in suppressing the stromal remodelling that 
accompanies tumourigenesis400.  MYH10 encodes a member of the myosin superfamily with 
diverse functions including regulation of cytokinesis, cell motility, and cell polarity401.   
KIF1A (Kinesin family member 1A) encodes a protein that is a microtubule-dependent molecular 
motor involved in important intracellular functions such as organelle transport and cell 
division402.  Midkine (MDK) is a heparin-binding molecule involved in the regulation of growth 
and differentiation during embryogenesis, which is overexpressed in most of human malignant 
tumours and may act as an oncoprotein 403.   
The online tool, DAVID was used for the functional annotation analysis using the BP_FAT 
category of Gene Ontology (GO).  Functional annotation analysis of probesets differentially 
expressed using gene ontology (GO) categories were performed for ‘biological process’.  This 
allows for the discovery of over-represented categories of genes.  Firstly, gene expression 
patterns between the DLKP-SQ cells and DLKP-SQ-Mitox-BCRP and DLKP-Mitox-MDR cells 
were compared in a search for common markers and/or molecular mechanisms involved in drug 
action.  A subset of 823 probesets were found to be similarly deregulated in SQ-Mitox-BCRP 
and SQ-Mitox-MDR with respect to the parental DLKP-SQ cell line (figure 3.1-8).  Gene 
ontology analysis revealed that the most significant GO categories were related to the broad 
functional categories of mRNA metabolic processing and RNA splicing.   
In surveying the changes in gene expression which were exclusively differentially expressed 
between DLKP-SQ and DLKP-SQ-Mitox-BCRP, it is clear that the BCRP over-expressing cell 
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line exhibits an altered expression of genes whose products are involved in RNA processing, 
intracellular transport, cellular responses to stress and cell cycle regulation (table 3.1-4).  ABCG2 
may be protecting against the cytotoxic effects of mitoxantrone in this selection, as it does in 
stem cells 404.  Pisco et al.,405 suggested that dynamic non-genetic heterogeneity of clonal cell 
populations continuously produces metastable phenotypic variants (persisters), some of which 
represent stem-like states that confer resistance and that even without genetic mutations, 
Darwinian selection can expand these resistant variants.  This could explain the invariably rapid 
emergence of stem-like resistant cells.  A recent study by Ming Zhuet al., (2012) 406 showed that 
the JNK1/c-jun signaling pathway was also involved in ABCG2-mediated multidrug resistance in 
colon cancer cells.  Meyer et al., (2006)407 reported that EGF increases the expression of ABCG2 
by activation of the mitogen-activated protein kinase cascade via phosphorylation of extracellular 
regulated kinase (ERK)1/2 and c-jun iNH-terminal kinase/stress-activated protein kinase 
(JNK/SAPK) in cytotrophoblasts.  Imai et al., (2009)347 reported that MEK inhibitor could induce 
transcriptional upregulation of endogenous BCRP through the inhibition of the MEK-ERK-RSK 
pathway.  They also suggested BCRP was post-transcriptionally downregulated through the 
inhibition of the MEK-ERK-non-RSK pathway in breast cancer MCF-7 cells.  The cell cycle 
genes cyclin A2 and cyclin-dependent kinase inhibitor 1A have been shown to be 2 fold down-
regulated while genes involved in DNA repair were upregulated (RAD50 homolog, RAD51 
homolog and RecQ protein-like) suggesting that the SQ-Mitox-BCRP cell line can repair DNA 
more effectively than the parental line, consistent with recent studies that suggest that DNA 
repair contributes to general drug resistance408, 409.  Some limited evidence has previously been 
reported on the cell cycle dependence of ABC transporter expression410,411.  However, it has 
never been demonstrated that the functional activity of these transporters correlate with a 
particular phase of the cell cycle.   
Gene ontology analysis revealed that the 649 probesets identified as exclusively, differentially 
expressed in the P-gp overexpressing cell line belonged to the functional categories of chromatin 
modification and organisation, embryonic morphogenesis and negative regulation of gene 
expression (table 3.1-4).  As mitoxantrone is a DNA interchelator and topoismerase poison, it is 
likely that selection for mitoxantrone resistance may result in changes in gene expression within 
the resistant cell lines that alter the drug’s ability to bind to DNA either through slight base 
sequence changes, DNA scaffolding changes or increased metabolic activity within the resistant 
cells.  Several proteins affecting gene expression were identified in the microarray results (results 
not shown).  These included the SWI/SNF family and chromodomain helicase DNA-binding 
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proteins (CHDs).  In recent years, research has indicated that chromatin accessibility or 
epigenetic modifications, play a large role in controlling the endogenous MDR1 expression 
state412.   
Several candidate proteins are involved in the complex regulation of chromatin accessibility 
which can have a profound effect on gene transcription.  The proteins encoded by SMARCA5, 
SMARCC1 and SMARCE1 are members of the SWI/SNF family of proteins.  Members of this 
family are chromatin remodeling proteins, which move, destabilise, eject or restructure 
nucleosomes, thereby changing chromatin structure and adding an extra layer of regulation413.  
Lymphoid-specific helicase is an enzyme that in humans is encoded by the HELLS gene and is 
required for de novo or maintenance DNA methylation.  The chromodomain helicase DNA-
binding proteins (CHDs) are known to affect transcription through their ability to remodel 
chromatin and modulate histone deacetylation.  Chromodomain helicase DNA binding protein 5 
plays a tumour suppressor role in human breast cancer414.  Coactivator-associated arginine 
methyltransferase 1 (CARM1) is a protein arginine methyltransferase that methylates histones 
and transcriptional regulators.  Interestingly, Hajihassan et al., 415 have shown that mitoxantrone 
binds to chromatin with higher affinity compared to DNA, implying that the histone proteins may 
also play an important role in the chromatin-mitoxantrone interaction/accessibility process.   
 
6.2.6  Proteomic analysis of  DLKP-SQ and drug resistant variant SQ-Mitox-BCRP-4P by 
two-dimensional difference in-gel electrophoresis 
Analysis using Decyder in Biological Variation analysis revealed a total of 293 proteins to be 
differentially regulated with p<0.05 and fold differences ranging from 2.55-fold up-regulation to 
-1.9-fold down-regulation (DLKP-SQ versus SQ-Mitox-4th pulse) (see section 3.1.11).  Of the 
130 proteins identified by MALDI-ToF mass spectrometry, 19 were found to be up-regulated and 
9 were down-regulated.  EF1a-like protein and beta-tubulin were over 2-fold higher in the 
mitoxantrone-resistant variant (table: 3.1-5, Up- and Down-Regulated expression) while 
NBLa10058 protein, ARPC2 and Galectin-1 were more than 1.5-fold down-regulated.  Ontology 
analysis through PubMed searches, identified many cellular processes associated with these 
proteins with glycolysis, protein turnover and translational elongation constituting the greatest 
number of protein expression changes (table 3.1-5).   
On the whole, the number of differentially expressed proteins may be underestimated because the 
2D-PAGE approach poorly recovers some proteins416.  The BCRP transporter protein was not 
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detected among the differentially expressed proteins, even though the SQ-Mitox-BCRP cell lines 
have been demonstrated to overexpress BCRP (chapter 3).  However BCRP is a membrane 
protein and 2D-PAGE is known to underrepresent these proteins.   
The primary up-regulated protein was EF1a-like protein.  Western blotting confirmed the 
increase in protein levels of EEF1A1 as a surrogate for EF1a-like protein in SQ-Mitox-BCRP 
cells and DLKP-SQ-parent cells (figure 3.1-9).  No antibodies were available for EF1a-like 
protein at the time of the investigation.  Eukaryotic translation elongation factor 1A (eEF1A) is 
one of the most abundant proteins in cells417.  In advanced vertebrates, a gene family encodes for 
two distinct isoforms, eEF1A1 and eEF1A2302.  The coding region of the eEF1A gene is highly 
conserved throughout eukaryotes.  In humans, the almost identical (92% sequence identity) 
amino-acid sequences of the eEF1A isoforms differ in length only by one additional C-terminal 
amino-acid residue present in the second isoform.  eEF1A belongs to the family of GTP-binding 
proteins and promotes the GTP-dependent binding of aminoacyl-tRNA to the A-site of the 
ribosome during the elongation cycle in protein biosynthesis.  eEF1A1 has been shown to be 
involved in additional non-canonical functions, including actin-binding and bundling, apoptosis, 
nuclear transport, proteasomal-mediated degradation of damaged proteins, heat shock and 
transformation418.  It is known that different signalling pathways, such as the phosphatidylinositol 
3-kinases/Protein Kinase B/mammalian target of rapamycin and the Ras-mitogen-activated 
protein kinase signalling cascades, are involved in the control of the translation apparatus419.  Not 
much is clear about the direct regulation of eEF1A even though several groups have been 
studying phosphorylation and regulation of this elongation factor420.  High levels of eEF1A1 
were associated with pro-survival activity and resistance to chemotherapy 421,422 and down-
regulation of eEF1A1 expression resulted in cell death423.  Overexpression of EF1A mRNA has 
been correlated with increased metastastic potential in mammary adenocarcinoma probably due 
to its interaction with the actin cytoskeleton, an effector in metastasis424 and to have a reduced 
affinity for F-actin 425.   
Western blotting confirmed the decrease in EBP1 protein levels in the SQ-Mitox-BCRP cell lines 
compared to the DLKP-SQ and SQ-Mitox-MDR cell lines (figure 3.1-9).  EBP1 encodes an 
RNA-binding protein that is involved in growth regulation. It is also known as proliferation-
associated protein 2 G4.  This protein is present in pre-ribosomal ribonucleoprotein complexes 
and may be involved in ribosome assembly and the regulation of intermediate and late steps of 
rRNA processing.  This protein can interact with the cytoplasmic domain of the ErbB3 receptor 
227 
 
and may contribute to transducing growth regulatory signals.  This protein is also a 
transcriptional co-repressor of androgen receptor-regulated genes and other cell cycle regulatory 
genes through its interactions with histone deacetylases.  Overexpression of EBP1 inhibits the 
growth of breast cancer cells426.  Ectopic expression of EBP1 in breast cancer cells reduces the 
levels of HER2 protein, HER2 promoter activity and reduces HER2 protein stability427,426.  EBP1 
also interacts with AKT via the PKC pathway to regulate cell survival and suppress apoptosis428.  
There are two different isoforms of EBP1, the longer form p48, suppresses apoptosis whereas the 
shorter from p42 promotes cell differentiation 429.  This suggests that EBP1 has different effects 
on cell growth on survival depending on the expression of its isoforms. 
Groups of functionally related proteins display similar dynamics, for example, CCT2, CCT3 and 
CCT7 showed an increase of 1.2- to 1.5-fold (table 3.1-5).  CCT chaperonin was initially 
identified as a molecular chaperone specifically required for the folding of the cytoskeletal 
proteins tubulin and actin.  In a more recent study searching for CCT substrates, up to 15% of 
cellular proteins were proposed to require the assistance of CCT for correct folding upon 
translation.   
There was a burst of glycolytic activity in the 4th pulse cell population as indicated by the 
changes in the enzymes of the glycolytic pathway exemplified by trisephosphate isomerise 1 
(1.84 fold) and phosphoglycerate mutase (1.76 fold).  Trisephosphate isomerise 1 is a glycolytic 
enzyme which rapidly interconverts dihydroxyacetone phosphate with glyceraldehyde 3-
phosphate, increasing the effectiveness of glycolysis and simplifying its regulation.  Proteins 
involved in the response to stress such as heat shock 70kDa protein also increased (1.7 fold) in 
the 4th pulse cell population.  Heat shock 70kDa (Hsc70, Hsc71, or HspA8) is a member of the 
Hsp70 family.  Hsc70 is constitutively expressed in the cytosol of all eukaryotic cellular 
organisms and performs functions related to normal cellular processes.  Annexin 1 was 1.35 fold 
up-regulated and was consistent with previous results430.  Annexin 1 belongs to a family of 
calcium- and phospholipid-binding proteins which may contribute to drug efflux through 
exocytosis of drug-filled vesicles431.  Galectin-1 (down-regulated), Nbla10058 (down-regulated) 
and Heat Shock 70kDa protein 8 (up-regulated) expression are also consistent with previous 
results in our laboratory430.  Galactin-1 has been described as a small protein with major 
functions 432.  Galectins bind to cell-surface and extracellular matrix glycans and thereby affect a 
variety of cellular processes433.  Nbla10058, also known as PSMB2, has been associated with 
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anthracyclines nuclear transport434, 435.  Heat Shock 70kDa protein 8 is a major cytosolic 
molecular chaperone436.   
FABP5 was also 1.2 fold up-regulated in the 4th pulse cell population.  It is involved in lipid 
metabolism.  FABPs may also modulate cell growth and proliferation, possibly by virtue of their 
ability for lipid ligands, (eg prostaglandins, leukotrienes and fatty acids).  In a proteomic study on 
lung cancer cells to elucidate the mechanisms that determine histological phenotype, Seike et al., 
437 suggested that FABP5 may play an important role in the differentiation of lung cancer.  This 
protein was also shown to be up-regulated in a mitoxantrone resistant pancreatic cell line by 
Sinha et al.,438.  They suggested that mitoxantrone could bind to cellular FABPs and lead to its 
sequestration in cytoplasm, thus inhibiting transfer of mitoxantrone to the nucleus.   
ARPC2 protein, also known as PRO2446, was decreased in the SQ-Mitox-BCRP-4P cells.  This 
gene encodes one of seven subunits of the human Arp2/3 protein complex.  The Arp2/3 protein 
complex has been implicated in the control of actin polymerisation in cells and has been 
conserved through evolution.  The exact role of the protein encoded by this gene, the p34 
subunit, has yet to be determined although it was found to be down-regulated in human gastric 
cancers 439.   
The DNA repair protein XRCC5 (Ku80) was 1.33 fold up-regulated in the SQ-Mitox-BCRP-4P 
cells.  This correlated with the microarray analysis result of a 1.39 fold up-regulation.  
Interestingly a functional anti-invasive antibody, 7B7 generated using the Mia PaCa-2 clone 3 
cell line as an immunogen in our laboratory and directed against the Ku70/Ku80 heterodimer 
demonstrated strong membrane reactivity in the SQ-Mitox-BCRP-6P cells440.   
DSCAML1 was identified as 1.2-fold down-regulated in the SQ-Mitox-BCRP-4P cells (table 
3.1-5).  However, Down Syndrome Cell Adhesion Molecule ( DSCAM) was investigated instead 
as a more likely candidate to provide information because of its role in cell adhesion and cell-cell 
interactions.  Western blotting confirms the decrease in protein levels of DSCAM in SQ-Mitox-
BCRP-4P SQ-Mitox-BCRP-6P cells, compared to DLKP-SQ parent cells (figure 3.1-9).   
Down Syndrome (DS), caused by trisomy 21, is the most common birth defect associated with 
cognative impairment.  It is expressed in the developing nervous system with the highest level of 
expression occurring in the fetal brain.  DSCAM is a member of the Ig superfamily that maps to 
a region in chromosome 21 and is one amongst several genes associated with Down Syndrome 
cognative impairment (figure 6.2-1).  It encodes a 230 kDa type I membrane protein with a large 
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extracellular domain comprising ten C2-type Ig-like domains and six fibronectin type III repeats.  
Human DSCAM is expressed in axonal and dendritic processes of the central and peripheral 
nervous system.  When this gene is over-expressed in the developing fetal central nervous 
system, it leads to Down syndrome.   
 
 
 
 
Figure 6.2-2:  Chromosome 21 from Human Genome Program.  Adapted from the US Human 
Genome Project Information Archive 1990-2003 website at http://web.ornl.gov/sci/techresources 
/Human_Genome/posters/chromosome/chromo21.shtml.   
 
Despite its molecular classification as a cell adhesion molecule, DSCAM is recognised for its 
physiological role in “self-avoidance” in Drosophila and mammals.  Self-avoidance involves the 
repulsion of processes from the same cell during axon branching and the prevention of clumping 
of cells of the same subtype during the development of structures with well-defined anatomies 
such as the mammalian retina.  In this way, self-avoidance counteracts cell adhesion, which knits 
cells together441.   
Garrett 441 et al., pointed out, that in neurodevelopmental processes, the phenomenon of not 
adhering is often viewed as the passive alternative to adhesion, and that in some cases this may 
be true.  However, it is becoming increasingly clear that active signaling pathways are involved 
in preventing adhesion between cells441.  The same principal may apply to cancer.  A lung cancer 
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tissue array (Biomax, LC817) was immune-histochemically stained using primary antibodies 
specific for DSCAM (figure 3.1-10 and table 3.1-6).  Variable membrane staining was observed 
in a number of squamous carcinomas and adenocarcinomas but in contrast, lung small cell 
carcinomas did not show any staining.  Interestingly, in metastatic tumours from small cell 
carcinomas, weak staining was observed in 3/6 even though the primary tumours were negative.  
Interestingly, the work of Sato et al., 307, illustrated in a genome-wide association study, a SNP in 
the DSCAM gene which was associated significantly with shortened overall survival.   
The proteomics data supports the concept that MDR development requires several adjustments 
by cancer cells in order to prevent chemotherapeutic drug-induced damage, and thus provides 
further insights into the complex mechanisms of mitoxantrone chemoresistance.  In particular, 
this data highlights the role of various proteins involved in a myiad of processes including but not 
confined to glycolysis, protein turnover and translational elongation, as well as the BCRP protein 
itself, a key component in the cellular efflux of xenobiotics.  This information may be useful as it 
may lead to the development of new functional tests for the investigation of the mechanisms 
responsible for MDR.   
 
6.2.7  miRNA Expression Analysis of DLKP-SQ, SQ-Mitox-BCRP-4P and SQ-Mitox-MDR-
4P   
MicroRNAs (miRs) are small non-coding, endogenous, single stranded RNAs that regulate gene 
expression (see section 1.2.4).  By regulating the gene expression at a posttranscriptional level, 
miRs have a large impact on a wide variety of pathways, including those pathways related to 
cancer development.  Several research groups have shown that the expression of miRNAs in 
chemoresistant cancer cells and their parental chemosensitive ones are different442,443.  The 
objective of this section was to investigate how the miRNA profile is altered in the SQ-Mitox-
BCRP and SQ-Mitox-MDR cell lines (see section 3.1.13).   
miRNA lists with significant changes in expression (p < 0.05) in each cell line compared to the 
drug sensitive parental cell line, DLKP-SQ were generated (table 3.1-10 and table 3.1-11).  Four 
miRs were significantly different in the SQ-Mitox-BCRP cell line.  There were two upregulated 
miRs (miR-218 and miR-27*) and two downregulated miRs (miR-639 and miR-335*).  Four 
miRs were also significantly different in the SQ-Mitox-MDR cell line.  There was one 
upregulated miR (miR-342-3p) and three downregulated miRs (miR-935, miR-524 and miR-
550).   
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miR218 was the most highly upregulated miRNA in the SQ-Mitox-BCRP cells (table 3.1-10).  A 
down-regulation of miR-218 has been reported as tumour suppressive miRNA in several kinds of 
tumours, including gastric cancer444,445, lung cancer446, cervical cancer447, head and neck 
cancer284 and prostate cancer448.  miR-218, along with miR-585, has been found to be silenced by 
DNA methylation in oral squamous cell carcinoma449.  It is also downregulated in 
nasopharyngeal carcinoma, with artificially-induced expression serving to slow tumour 
growth450.  miR-218 has also been found to have tumour suppressing qualities in bladder cancer 
cells451.  One study reported that miR-218 was a potent activator of Wnt signaling, contributed to 
osteoblastogenesis, and facilitated the metastasis of breast cancer cells into the bone452.   
There are two genes that code for mature miR-218. miR-218-1 is located on chromosome 
4p15.31, and miR-218-2 is located on chromosome 5p34451.  The gene code for mature miR-218-
1 is located within the intron 15 of slit homologue 2 (SLIT2), a tumour suppressor gene.  
Interestingly, Western blot analysis also shows an upregulation of the SLIT2 protein in the BCRP 
over-expressing cell line (figure 4.2-11).  miR218-1 expression may be under the control of the 
SLIT2 promoter254.  ROBO2 was also present in all of the BCRP over-expressing cells to varying 
extents (figure 4.2-11).  Tie et al.,445 have suggested that there may be a Slit-miR-218-Robo1 
regulatory circuit whose disruption may contribute to gastric cancer metastasis.  Further 
investigation of the role of miR218 and SLIT2 in BCRP-mediated drug resistance is warrented.   
The second upregulated miRNA was miR27a*.  miR27a* is located at chromosome 19 and is 
known to regulate components involved in numerous types of cancer, including breast453 and 
ovarian454.  miR-27* is an activator of the Wnt signalling pathway, affecting the differentiation of 
mesenchymal stem cells into osteoblasts455.  Expression levels of miR-27* are positively 
correlated with beta-catenin455 a key protein in Wnt signaling.  miR-27* has been found to target 
and inhibit gene expression of the adenomatous polyposis coli (APC) protein, enabling it to 
regulate osteoblast differentiation455.  Inhibition of miR-27* by antisense molecules decreases 
cell proliferation456.  Antisense RNA directed against miR-27a* has been shown to decrease the 
percentage of cells in S phase whilst also increasing those in the G2-M phase457.   
Interestingly an experiment in doxorubicin-resistant ovarian cancer cell lines showed 
downregulation of P-gp was mediated by antagonizing miR-451 and miR-27a*458.  
Downregulation of miR-27a* resulted in a decrease of P-gp expression in oesophageal squamous 
carcinoma and in gastric cancer cells459,460.  After transfection of miR-27a inhibitor, Li et al.,214 
reported a downregulation of P-gp and an increased sensitivity to paclitaxel in the paclitaxel-
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resistant ovarian cancer cell line (A2780/Taxol) gastric cancer cells.  Previous studies in this 
laboratory showed that miR27a* was increased in the adriamcyin resistant cell line, DLKP-A 
compared to the DLKP parent461.   
miR335 was 8 fold downregulated in the SQ-Mitox-BCRP cells compared to the DLKP-SQ cells.  
miR-335, which is transcribed from the genomic region chromosome 7q32.2, has been reported 
to be differentially expressed in benign and malignant tumours462 and  regulates Rb1 and controls 
cell proliferation in a p53- dependent manner463.  It participates in the development of breast 
cancer464 and regulates growth and invasion of malignant cells465.  Other research reports that 
miR-335 might function as a metastasis suppressor in gastric cancer by targeting Bcl-2 and SP1, 
and could be further developed as a potential prognostic factor466.  Yan et al.,467  suggested that 
hsa-miR-335 is involved in regulating target genes in several oncogenic signal-pathways, such as 
p53, MAPK, TGF-b, Wnt, ERbB, mTOR, Toll-like receptor and focal adhesion.  Finally Peng et 
al.,468 suggested that miR-335 was downregulated in a majority of primary gallbladder carcinoma 
patients and may be associated with the aggressive tumour behaviours.   
There was one upregulated miR (miR-342-3p) and three downregulated miRs (miR-935, miR-
524 and miR-550) in the SQ-Mitox-MDR cell line.  Cittelly et al., suggest that miR-342 regulates 
tamoxifen response in breast tumor cell lines by regulating the expression of genes involved in 
tamoxifen mediated tumor cell apoptosis and cell cycle progression469 and has also been found to 
be aberrantly expressed in prostate cancer470.  miR-550 has been found to be differentially 
expressed in the transformation of gastritis into MALT lymphoma471  . In addition, miR-550 is 
differentially expressed in childhood acute lymphoblastic leukemia472 and has been shown to 
promote the migration and invasion of hepatocellular carcinoma473.  The function of miR-935 
and miR-524-3P is unknown.   
This thesis reports the establishment of novel cell lines with resistance to mitoxantrone while 
over-expressing BCRP and P-gp pumps.  These events coincide with early events in the drug 
pulsing and selection processes.  The strategy of deriving isogenic drug resistant cell lines from 
one cell line eliminates variability due to intrinsic genetic differences between cell lines.  The 
cause of the early upregulation of the BCRP and P-g transporters seen in these investigations 
remains to be elucidated.   
The expression profiling approach outlined here was successful in identifying differentially 
expressed genes which may contribute to P-gp and BCRP-mediated resistance.  The over-
expression of a particular ABC transporter during drug selection also appears to depend on a 
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multitude of factors which include but are not limited to the cell type, the selection regimen, the 
drug used for selection pressure as well as the concentrations utilised.  These factors suggest that 
a number of ABC transporters in addition to ABCB1 should be evaluated following drug 
selection.   
The establishment of multi-drug resistant cell lines from DLKP-SQ-Mitox has provided a 
powerful tool for further study of the cancer multi-drug resistant phenotype.  This model allows 
detailed studies on mechanisms of cross-resistance and the direct investigation of drug resistance 
(e.g. by siRNA knockdown).  In addition, these cell lines may prove to be useful models for the 
study of new modulators of resistance aimed at improving the outcome of acquired drug 
resistance.  The conclusions from these investigations remain to be validated in human tumour 
biopsies.   
 
6.3  Establishment of drug resistant invasive DLKP-SQ variants 
Several publications have suggested an association between advanced malignancy and drug 
resistance in many cancers196.  In this thesis, lung cancer invasion potential in vitro was 
investigated using drug-sensitive cell lines and their MDR variants – the results indicate MDR 
variants possess an enhanced invasive capacity.   
Resistance to chemotherapy drugs is a major problem in cancer treatment.  Scientific advances 
made in the last two decades have resulted in the identification of genes and molecular signalling 
pathways that contribute to drug resistance.  However, to further complicate our understanding of 
drug resistance, patients given chemotherapy gradually develop mutations or metabolic 
potentiation and adaptation which leads to tumour progression and metastatic changes, making 
treatment difficult for such patients.   
Previous studies196 show that exposure of the human lung carcinoma cell line, DLKP to 
mitoxantrone, an anthracenedione, can result in not only an MDR phenotype but also enhanced 
cell invasion in vitro.  Array technology can help answer increasingly complex questions and 
allow for more intricate experiments to be performed.  Arrays can infer the probable functions of 
new genes based on similarities in expression patterns with those of known genes.  This can aid 
the understanding of how genes and their products coordinate and interrelate, and speed the 
identification of genes involved in the development of various diseases.   
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Expression array data have led to crucial insights into fundamental cancer biology, including the 
mechanisms of tumourigenesis, metastasis, and drug resistance474.  They have also had enormous 
clinical impact, e.g., several cancers can now be fractionated into therapeutic subsets with unique 
prognostic outcomes based on their molecular phenotypes475-481.   
The primary aims within this section of the thesis were to establish an in vitro model of 
mitoxantrone resistance and to identify changes in gene expression associated with the transition 
from pre-invasive to an invasive phenotype.  DLKP-SQ, a clone of DLKP was chosen for the 
establishment of a mitoxantrone resistant cell line in order to eliminate variability due to intrinsic 
genetic differences between cell lines (chapter 3).   
Four sub-populations displaying differences in invasion were further analysed to characterise the 
in vitro invasive phenotype.  DLKP-SQ-Mitox-BCRP-4P and DLKP-SQ-Mitox-MDR-4P were 
characterised as poorly invasive and DLKP-SQ-Mitox-BCRP-6P and DLKP-SQ-Mitox-MDR-6P 
were characterised as invasive (chapter 4.2).   
Matsuo and colleagues482 reported that increased expression of MDR-1 in tumour tissue obtained 
at initial cytoreduction surgery is associated with increased risk of developing brain metastases in 
women with epithelial ovarian, fallopian tube, or peritoneal cancer.  Consistent with these 
observations, our results indicated that BCRP and P-gp were over-expressed in the 4th pulse cell 
population, followed by the appearance of the invasive phenotype in the 6th pulse cell population.  
These results suggest a strong relationship between drug resistance and metastasis (figure 4.2-1).   
 
6.3.1  Microarray analysis of SQ-Mitox sub variants 
In order to investigate changes in gene expression pattern during the transition from a pre-
invasive to an invasive phenotype during the development of drug resistance, microarray analysis 
was performed in poorly invasive mitoxantrone resistant DLKP-SQ-Mitox-BCRP (4th pulse) and 
DLKP-SQ-Mitox-P-gp (4th pulse) and invasive mitoxantrone resistant DLKP-SQ-Mitox-BCRP 
(6th pulse) and DLKP-SQ-Mitox-P-gp (6th pulse) (see section 4.2.4).   
Two gene lists were generated - DLKP-SQ-Mitox-BCRP-4P versus DLKP-SQ-Mitox-BCRP-6P 
cells (Genelist 1) and DLKP-SQ-Mitox-MDR-4P versus DLKP-SQ-Mitox-MDR-6P cells 
(Genelist 2), in search of molecular mechanisms involved in the invasive phenotype.   
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6.3.1.1  Genes related to invasion and specific to SQ-Mitox-BCRP-4P vs 6P  
In identifying genes changing between SQ-Mitox-BCRP-4P (poorly invasive) versus SQ-Mitox-
BCRP-6P (invasive) (Genelist 1), a comparison of the two cell lines resulted in a list of 79 genes 
being up- or down-regulated (1.2 fold) in SQ-Mitox-BCRP-6P (62 genes up-regulated and 17 
genes down-regulated).  The top 10 over-expressed and under-expressed genes are shown in table 
4.2-1.   
The top over-expressed gene was ADAMTS1.  ADAMTS1 is a disintegrin and metalloproteinase 
with thrombospondin motifs.  The expression of this gene may be associated with various 
inflammatory processes as well as development of cancer cachexia483.  While elevated 
ADAMTS1 has been shown to promote pro-tumourigenic changes, other studies depict it as a 
tumour suppressor484. 
N-cadherin was expressed at higher levels in the SQ-Mitox-BCRP-in 6P compared to the DLKP-
SQ and SQ-Mitox-BCRP-4P cell lines (figure 4.2-10).  Cadherins (named for "calcium-
dependent adhesion") are a class of type-1 transmembrane proteins.  They play important roles in 
cell adhesion, forming adherens junctions to bind cells within tissues together.  They are 
dependent on calcium (Ca2+) ions to function.  Cells containing specific cadherin subtypes tend 
to cluster together to the exclusion of other types, both in cell culture and during development485.  
For example, cells containing N-cadherin tend to cluster with other N-cadherin-expressing cells 
and bind cells within tissues together.   
Cadherin switching (i.e. E-cadherin to N-cadherin) associated with epithelial-mesenchymal 
transition (EMT) is implicated in the transition from benign tumours to invasive, malignant 
cancer and the subsequent metastatic dissemination of tumour cells486.  Ectopic expression of N-
cadherin increases tumour cell motility, implicating cadherin switching in the regulation of cell 
behaviour146,487.   
Microarray analysis showed that the kras gene may be up-regulated in the SQ-Mitox-BCRP-6P 
cells.  Interestingly, oncogenic K-ras is sufficient to upregulate N-cadherin expression in 
pancreatic ductal cells suggesting that K-ras may play an active role in cadherin switching in 
pancreatic cancer488.   
The under-expressed gene list consisted of low fold changes.  In mammals, the HSP90 family 
consists of four major types, two cytosolic isoforms, the heat-inducible HSP90a encoded by gene 
HSP90AA1 and HSP90AA2 and the constitutively-expressed HSP90b encoded by HSP90AB1.  
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Recent studies suggest that HSP90AA1 but not HSP90AA2 is expressed extracellularly and 
involved in cancer cell invasiveness489.   
 
6.3.1.2  Genes related to invasion and specific to SQ-Mitox-MDR-4P vs 6P  
Comparison of SQ-Mitox-MDR-6P to SQ-Mitox-MDR-4P resulted in a list of 533 genes.  That 
is, the expression of 533 genes was up- or down-regulated (1.2 fold) in SQ-Mitox-MDR-6P (220 
genes up-regulated and 333 genes down-regulated).  The top 10 over-expressed and under-
expressed genes are shown in table 4.2-1.   
Different genes involved in signaling were induced or suppressed in the transition to the invasive 
phenotype (table 4.2-1).  The primary over-expressed gene was DKK1 (9.6-fold over-expressed).  
Although Dickkopf-1 (DKK1) is known to be a negative regulator of the Wnt/β-catenin pathway, 
it has been recently found to be upregulated in cancers490.  NRG1 (5.77-fold over-expressed) is 
one of four proteins in the neuregulin family that act on the EGFR family of receptors.  The 
neuregulins are cell-cell signaling proteins that are ligands for receptor tyrosine kinases of the 
ErbB family.  Through their interaction with ERBB receptors, NRG1 isoforms induce the growth 
and differentiation of epithelial, neuronal, and glial cells.  There is evidence that NRG1 is a 
tumour suppressor gene491.  Tissue inhibitor of metalloproteinase-2 (TIMP2), was the primary 
suppressed gene (reduced 3.8-fold).  Matrix metalloproteinases (MMP) have also been 
implicated in multiple stages of cancer metastasis.  TIMP-2 plays an important role in regulating 
MMP-2 activity492.   
 
6.3.1.3  Comparison of genelist 1 and 2 
Gene expression patterns between the BCRP cell lines (Genelist 1) and MDR cell lines (Genelist 
2) were compared with each other to search for molecular mechanisms involved in the invasive 
phenotype.  These lists contained both well and poorly annotated genes.  Several of the annotated 
genes can be related to invasion, cell survival, motility and apoptosis.  The possibility that some 
of the unanotated genes are also relevant to cancer invasion awaits further investigation.   
These lists were overlapped to identify common and uncommon genes (figure 4.2-3).  Twelve 
genes were identified as common between the upregulated genes.  Different genes involved in 
cell adhesion, axon guidance and wnt signaling were induced in the transition from the pre-
invasive to invasive phenotype.   
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6.3.1.4  PANTHER analysis of microarray gene lists 
The classification of genes was determined by the web program PANTHER493,494.  PANTHER 
pathway analysis revealed that the most significant pathways were related to Wnt signalling, 
inflammation, integrin signalling and p53 in both Genelist 1 and Genelist 2 (see section 4.2.3.2).   
Abberations in the Wnt signalling pathway have been linked to many human cancers 495-496.  Wnt 
signalling is important for cell migration, invasion, adhesion and survival.  The Wnt signaling 
pathway is also strongly implicated as a stem cell regulator497.  Three Wnt signaling pathways 
have been characterised: (1) the canonical Wnt pathway, (2) the noncanonical planar cell polarity 
pathway, and (3) the noncanonical Wnt/calcium pathway.  Wnt proteins are secreted 
glycoproteins that bind to the N-terminal extra-cellular cysteine-rich domain of the plasma 
membrane located Frizzled (Fz) receptor family of G-protein coupled receptors, which passes the 
biological signal to the protein Dishevelled inside the cell.  The canonical Wnt pathway leads to 
regulation of gene transcription, the noncanonical planar cell polarity pathway regulates the 
cytoskeleton and is responsible for the shape of the cell, and the noncanonical Wnt/calcium 
pathway regulates calcium inside the cell498 - 499.   
PANTHER pathway analysis is generally useful in assisting in the interpretation of microarray 
analysis.  It has allowed the enrichment of pathways that were represented by Genelists 1 and 2.  
However, many of the pathways as indicated by PANTHER may have been based on only one 
gene for example, SLIT2.  Despite this, it did give an indication of the pathways represented on 
both gene lists.   
The results indicate that chronic treatment with anticancer agents leads to the acquisition of drug-
resistance in DLKP cells.  Importantly, along with the acquisition of drug resistance, there is also 
a marked increase in the expression and activity of MMP-2 and integrin alpha V.   
In summary, this model provides a unique in vitro representation of an invasive, drug resistant 
lung carcinoma.  If the critical alterations of tumour cells after treatment with chemotherapeutic 
drugs can be understood, it may enable the determination of the key molecules and signaling 
pathways involved (table 6.3-1).   
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Table 6.3-1:  Key protein expression changes in each cell line 
Protein SQ parent SQ-Mitox-4P SQ-Mitox-6P 
(Isolate 2) 
Mitoxantrone IC50 0.08 ng/ml 16.79 ng/ml 44.82 ng/ml 
BCRP low present high 
ALCAM absent trace high 
IGF1Rβ low low high 
Integrin alpha V absent present high 
MMP2 low present high 
MMP10 low present high 
SLIT2 low high high 
ROBO2 low low high 
BCHE low low high 
 
6.3.2  Confirmation of array results 
6.3.2.1  Role of integrin alpha V expression 
The initial step of tumour metastasis is a movement of invasive tumour cells migrating through 
the basement membrane, which implicates major roles for cell adhesion and migration as well as 
proteolysis of the extracellular matrix (ECM).  This step involves many molecules including 
matrix metalloproteinases (MMPs) and integrins 500 501 502 503 504 505 506 507 508 509 510.  Cell–cell 
adhesion is a prerequisite for the maintenance of epithelial integrity and is thus often altered 
during carcinogenesis and particularly during the metastatic process.  As the primary linkage 
between a cell and the ECM, integrins have an essential role in the invasion process.  Indeed, 
changes in the expression and/or function of integrins have been implicated in all steps of tumour 
progression, including detachment of tumour cells from the primary site, migration through the 
basement membrane, invasion of the ECM, intravasation into the blood stream, dissemination 
through the circulation, extravasation into distant target organs, and formation of the secondary 
lesions 155 511 512 513 514.  Some integrins, especially αVβ3, seem to promote tumour progression 
and metastasis515.  Blaheta et al., 516 reported that chemoresistance induces enhanced adhesion of 
neuroblastoma cells by down-regulating NCAM surface expression.  In recent years, cell 
adhesion-mediated drug resistance (CAM-DR) has become an active area of investigation in the 
study of tumour drug resistance 517,518519.  In the present work, siRNAs directed against the 
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mRNA of the αV chain of integrin alpha V obtained a significant reduction in invasion of the 
SQ-Mitox-BCRP-6P cell population (figure 4.2.13).   
 
6.3.2.2  Role of BCHE expression 
Microarray profiling revealed differential expression of a secretory butyrylcholinesterase, BCHE, 
between the SQ-Mitox-BCRP-4P and SQ-Mitox-BCRP-6P cell line.  There is increasing 
evidence that suggests the involvement of cholinesterases in tumourigenesis327, 328.   
BCHE protein was differentially expressed in subpopulations of the DLKP lung cancer cell line 
displaying distinct invasive phenotypes (figure 4.2-14).  Mitoxantrone drug pulsing of the least 
invasive subpopulation induced an upregulation of the BCHE protein.  BCHE knockdown by 
small interfering RNA (siRNA) reduces the invasion of DLKP-SQ-Mitox.  Immuno-
histochemical analysis indicated that decreased BCHE expression is associated with higher grade 
lung cancer (table 4.2-6 and figure 4.2-15).  The observed intense BCHE staining in metastatic 
tumours needs to be investigated further to establish its role in lung cancer invasion and drug 
resistance.   
 
6.3.2.3  Role of ALCAM expression 
Immunofluorescence and Western blot analysis has revealed a higher level of expression of 
ALCAM in the stable, invasive BCRP over-expressing variant, with lower levels in the DLKP-
SQ parental cell line and DLKP-SQ-BCRP-4P (figure 4.2-8 and figure 4.2-9).  ALCAM mediates 
cell–cell adhesion through homophilic and heterophilic protein–protein interactions and is 
thought to be involved in cell migration and guided outgrowth in neurogenesis, in hematopoiesis, 
and in immune responses520,521.   
ALCAM is a member of a subfamily of immunoglobulin receptors with 5-immunoglobulin-like 
domains.  It is a type 1 transmembrane molecule, with an extracellular domain of 500 amino 
acids, a transmembrane domain of 22 amino acids and a short cytoplasmic domain of 34 amino 
acids522.  It is mainly found in the spleen, placenta, and liver.  ALCAM was also identified on 
thymic epithelial cells and activated leukocytes, fibroblasts, neurones, pancreatic acinar and islet 
cells, and bone marrow523.   
Its functions have been studied in detail with regard to T-cell biology where the co-stimulatory 
role of ALCAM in T-cell activation suggests an involvement in the immunological response to 
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tumour cells524.  Altered ALCAM expression has also been associated with the differentiation 
state and progression in melanoma525, prostate526,527, colorectal528, and breast cancers523.  
ALCAM is up-regulated in some of these cancers and down-regulated in others and the major 
functions of this cell adhesion molecule in cancer remain poorly understood522.   
ALCAM increased with increased BCRP expression in the present studies but it was barely 
detectable in the Pgp over-expressing cell lines.  Presently there are no reports in the published 
literature of an ALCAM association with BCRP.  In pancreatic cancer cells, a reduced ALCAM 
expression has been shown to be associated with chemoresistance529.   
ALCAM is a membrane protein, confirmed in these studies by the presence of ALCAM in the 
membrane preparations.  Indeed, the stable invasive BCRP over-expressing variant has a higher 
membranous expression of ALCAM (figure 4.2-8).  This would suggest that it is the 
membranous expression or localisation of ALCAM which is more significant for invasion in the 
SQ-Mitox cells.  Ishiguro et al., 530, found membranous expression in NSCLC and its localisation 
in the membrane was associated with decreased overall survival.   
Although ALCAM has been implicated in different cancers, it is as yet unclear how ALCAM 
contributes to metastasis.  ALCAM expression may be necessary for motility and invasiveness in 
the SQ-Mitox-BCRP- invasive 6P cell line.  One likely way in which ALCAM could promote an 
invasive phenotype is through regulation of matrix metalloproteinases (MMPs).  MMPs are zinc-
dependent proteinases whose expression has been implicated in processes such as tissue 
remodeling and cancer metastasis531.  MMP-2, a 72 kDa protein also called gelatinase A, is the 
most abundant of the MMPs.  Activation of MMP-2, and the additional gelatinase family protein 
MMP-9, allows degradation of type IV collagen which is a primary component of basement 
membranes.  MMPs are synthesised as pro-enzymes that must be processed to their active form 
by proteolytic cleavage.  Pro-MMP-2 is recruited from the extracellular milieu and processed by 
a complex consisting of Type I MMP (MT1-MMP/MMP-14) and tissue inhibitor of 
metalloproteinase-2 (TIMP-2); this process is known to require full-length ALCAM532.  MMP-2 
levels in the SQ-Mitox-BCRP-6P cell line were assayed using gelatin zymography and western 
bloting, where pro-MMP-2 appears as a 72 kDa band, and active MMP-2 appears as a ∼64 kDa 
band.   
Functional reports indicate a functional link between ALCAM and cadherins, another major 
family of cell adhesion molecules.  The cadherins have been known to link to the actin 
cytoskeleton via their intracellular binding partners, the catenins533.  Interestingly, N-cadherin 
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was expressed at higher levels in the SQ-Mitox-BCRP-in 6P compared to the DLKP-SQ and SQ-
Mitox-BCRP-4P cell lines (figure 4.2-10).  Jannie et al. 534, suggest a mechanism by which 
ALCAM might differentially enhance or decrease invasiveness in uveal melanoma cells, 
depending on the type of cadherin adhesion complexes present in tissues surrounding the primary 
tumour, and on the cadherin status of the tumour cells themselves.   
 
6.3.2.4  Role of MMP-2 expression 
The MMP family is comprised of more than 25 members that are divided into 5 groups based on 
their target substrates: (1) collagenase, (2) stromelysin, (3) gelatinase, (4) matrilysin and (5) 
membrane type (MT)-MMP8.  Although MMPs are secreted by most tumour cells, gelatinases, 
including MMP-2 (gelatinase A; Mr 72KDa) and MMP-9 (gelatinase B; Mr 92KDa), have been 
implicated as critical enzymes in the invasion of cells into secondary sites.  Liang et al.,196 
reported that anticancer drug-selected lung carcinoma cell variants showed enhanced in vitro 
invasive abilities through up-regulation of MMPs.  Song et al., 535 reported that advanced 
malignancy due to acquired drug resistance is responsible for the progressive invasiveness of 
leukemia cell via MMP-2.  The level of MMP-2 in the stable, drug-resistant SQ-Mitox-BCRP-6P 
cell variant was evaluated.  While there was no change in the stable, drug-resistant SQ-Mitox-
BCRP-4P cell variants, the 6th pulse cell variant of the SQ-Mitox-BCRP demonstrated a 
significant increase in the expression and gelatinolytic activity of MMP-2 as well as in its 
invasiveness.   
To confirm the precise role of MMP-2 on SQ-Mitox-BCRP-6P cell invasiveness, invasion assays 
of these cells were performed in the presence of a specific anti-MMP-2 monoclonal antibody.  As 
shown in figure 4.2-7, the number of SQ-Mitox-BCRP 6th pulse cells that migrated through the 
ECM gel was significantly decreased by specific blocking of MMP-2.  However, there was no 
significant alteration in the invasiveness of the cells treated with the control isotype antibody.  
Taken together, these findings clearly indicate that the enhanced invasiveness of drug-resistant 
SQ-Mitox-BCRP 6th pulse cell variants is associated with an increased level of MMP-2.  The 
incomplete suppression of invasiveness in this assay suggests that other factors, such as 
regulation by other MMPs and integrins, may also be involved in the invasiveness of drug-
resistant cancer cell variants.   
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6.3.2.5  Role of MAPK kinase pathway in SQ-Mitox-BCRP-6P invasion 
IGF-1R was identified as a gene potentially involved in invasion in Genelist 1.  I The insulin-like 
growth factors (IGF) and their receptors play pivotal roles in cellular signaling transduction and 
regulation of cell growth, differentiation, apoptosis, transformation and other important 
progresses.  IGF1R mainly engages in the Ras/mitogen-activated protein kinase (MAPK) and the 
phosphoinositide 3-kinase/protein kinase B (PI3K/AKT) pathways, with significant cross-talk 
with the epidermal growth factor receptor (EGFR) pathway also in evidence536,537.   
Increased IGF-1R expression has been previously linked with tumour invasion538.  Former 
investigations in this lab (Pierce, A., PhD thesis, 2006279) previously demonstrated that 
decreasing IGF-1R expression reduces the in vitro invasiveness of the DLKP drug resistant 
variants.  Additionally, KRAS was shown to be 2.75-fold up-regulated in the DLKP-SQ-Mitox-
BCRP-6P cells relative to the SQ-Mitox-BCRP-4P cells.  Activated KRAS engages multiple 
effector pathways, notably the RAF-mitogen-activated protein kinase, phosphoinositide-3-kinase 
(PI3K).  ERK was shown to be activated in the DLKP clones (section 5.2.7).  The poorly 
invasive DLKP-SQ clone had the highest level of phosphorylation of ERK of all the clones when 
grown on plastic.  Genetic factors may require the cooperation of another genetic event to 
manifest the invasive phenotype.  For example the DLKP-SQ clone contains low levels of 
integrin αV and MMP-2 and the DLKP-M and DLKP-I clones contain high levels of these 
proteins (figure 4.1-2 and 4.2-6).  Experiments with MEK inhibitors showed that invasion of the 
SQ-derived SQ-Mitox-BCRP-6P and DLKP-M cell lines was reduced when the MAPK kinase 
inhibitor, U0126 was added to the invasion assay suggesting that the MEK/ERK  pathway 
contributes to cell invasion in these cells (section 5.2).   
 
6.4  Characterisation of clonal subpopulations of DLKP 
The DLKP parental population has been shown to contain at least 3 phenotypically different 
clonal subpopulations281, 280.  On prolonged subculture, SQ and M can each interconvert with I, 
but SQ and M do not interconvert.  Of the three, M-type cells are the most invasive, I-type cells 
are slightly less invasive, wherease SQ-type cells are the least invasive in vitro.   
Scientific concepts are fashioned by the experimental models used and molecular biologists, 
working on cancer cell lines or transformed cells often tend to consider their cell lines as a 
homogeneous population.  However, pathologists confronted with real tumours have a different 
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view and recognise the heterogeneity of cancers539.  In the clinical setting, the primary obstacle to 
the success of therapy is the heterogeneous composition of tumours, where highly metastatic 
cells can escape from the effect of therapeutic agents or are metabolically enhanced and can 
eliminate or degrade a xenobiotic with ease.  Invading tumour cells appear to have lost the 
control mechanisms which prevent normal cells from invading neighbouring tissues at 
inappropriate times and places.  Thus, the fundamental difference between normal and malignant 
cells is one of regulation.  The differences must lie in the proteins that start, stop or maintain the 
invasion programme at times and places that are inappropriate for non-malignant cells.  A major 
goal is to understand what signals and signal transduction pathways are perpetually activated or 
deregulated in malignant invasion540.  The DLKP cell lines with differing levels of invasiveness 
(derived from the same parent) offer a unique opportunity to study tumour heterogeneity (figure 
4.1-1).   
The adherence properties of the DLKP clones to a number of ECM proteins and their invasion 
potential were assayed to determine what roles individual tumour subpopulations may play in the 
progression of malignant disease figure 4.1-2).  Microarray analysis was used to search for 
differences between the three distinct clonal subpopulations, DLKP-SQ, DLKP-I and DLKP-M 
(aee section 4.1.6).   
 
6.4.1  Adhesion and invasion assays of DLKP clones 
The adherence properties of DLKP clones to a number of ECM proteins were found to differ 
from each other (figure 4.1-2).  Of the three cell lines investigated, the highest level of adhesion 
was observed through fibronectin and vitronectin (as observed in in vitro binding assays) for the 
DLKP-M and DLKP-I clones.  The increased adhesion to vitronectin could be explained by the 
increased expression of integrin αV in the DLKP-I and DLKP-M clones (figure 4.1-2).  The 
alpha-V integrins are receptors for a variety of molecules associated with the extracellular matrix 
including vitronectin, cytotactin, fibronectin, fibrinogen, laminin, matrix metalloproteinase-2, 
osteopontin, osteomodulin, prothrombin, thrombospondin and vWF.  Integrin alpha V is 
expressed at higher levels in the DLKP-I and DLKP-M clones (figure 4.1-2).  Interestingly, the 
DLKP-I and DLKP-M populations also displayed increased invasion through matrigel compared 
to the DLKP-SQ clone (figure 4.1-1).  There were no significant differences in attachment to 
laminin among the clones.  Nor did any of the clones adhere to collagen IV or collagen V.   
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6.4.2  Expression of MMP-2 and MMP-10 in the DLKP clones 
The acquired ability of tumour cells to migrate and invade through the extracellular matrix 
between tissues has long been accepted as a hallmark of metastatic potential.  Numerous signal 
transduction pathways and a wide variety of protein classes have been implicated as important 
players in cell migration and/or invasion.  For example, matrix-metalloproteinases (MMPs) have 
been implicated in the degradation of components of the basal lamina, that is presumably 
required for the movement of cells through the extracellular matrix.  The contribution of the 
MMPs to cell invasion in the clones was investigated to determine if they played a role in the 
process.  The levels of MMP-2 and MMP-10 were evaluated in the DLKP clones.  The DLKP-I 
and DLKP-M clones demonstrated a significant increase in the expression and gelatinolytic 
activity of MMP-2 and MMP-10 (figure 4.1-2).   
To confirm and illucidate the role of MMP-2 in DLKP-I and DLKP-M invasiveness, an invasion 
assay of these cells was performed in the presence of a specific anti-MMP-2 monoclonal 
antibody.  As shown in figures 4.1-10 and 4.1-11, the number of DLKP-I and DLKP-M cells that 
migrated through the ECM gel was significantly decreased by blocking antibodies directed 
towards MMP-2.  There was no significant alteration in the invasiveness of the cells treated with 
non-specific, control isotype antibody.  These findings indicate that the invasiveness of DLKP-I 
and DLKP-M cell variants is associated with increased levels of MMP-2.  The incomplete 
suppression of invasiveness in this assay suggests that other molecules (other MMPs and 
integrins) may also be involved in determining the invasive phenotype.   
Matrix metalloproteinase 10 (MMP-10, stromelysin-2) is a secreted metalloproteinase which 
functions in skeletal development, wound healing, and vascular remodelling.  Its over-expression 
is implicated in lung tumourigenesis and general tumour progression.  To investigate the role if 
any of MMP-10 on DLKP-I and DLKP-M invasiveness, the invasion assay of these cells was 
repeated in the presence of a specific anti-MMP-10 monoclonal antibody (figure 4.1-10 and 4.1-
11).  Results were negative, there was no effect on invasion.  MMP-10 is up-regulated in human 
non-small cell lung carcinoma (NSCLC), where it is associated with poor clinical outcome541.  In 
addition, MMP-10 was identified as a major downstream effector of two NSCLC oncogenes, 
Kras and PKCι542,543.  Silencing of MMP-10 expression in lung cancer cells blocks anchorage-
independent growth and invasion542.  Silencing of MMP-10 expression also suppresses the 
enhanced self-renewal and tumourigenic properties of a subpopulation of lung cancer cells with 
stemlike characteristics as described by Justilien et al., 2012544  Genetic loss of Mmp10 
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suppresses tumourigenesis and tumour growth in mouse models of oncogenic Kras-mediated 
lung adenocarcinoma543.   
 
6.4.3  Microarray analysis of DLKP clones 
In order to investigate changes in gene expression patterns between the clones, hierarchical 
clustering was performed on the data derived from the microarray analysis of poorly invasive 
DLKP-SQ and invasive DLKP-I and DLKP-M clones (see section 4.1.6).   
In hierarchical clustering, genes with similar expression patterns are grouped together and are 
connected by a series of branches to form a diagram which is called a clustering tree (or 
dendrogram).  All of the samples used in the experiment were run in triplicate, and all three 
replicates of a particular sample were expected to cluster together.  These clusters were expected 
to be significantly different from those of each cell line.  This was not the case for one of the sets 
of samples (figure 4.1-13).  DLKP-I did not behave as expected and did not cluster with its 
replicates.  Two of the DLKP-I samples clustered with the DLKP-SQ samples and one clustered 
with the DLKP-M sample (figure 4.1-3).   
This was a surprising result as all biological replicates were treated in the same way prior to 
RNA extraction and microarray processing.  Due to the sensitivity of microarray analysis, all cell 
culture conditions including media, incubation and cell number were kept the same for all 
samples.  Despite this, it is clear that some event occurred that brought about ‘drift’ in the genetic 
profile.  Previous studies from this laboratory proposed that the DLKP-I clones could possibly 
undergo interconversions to either DLKP-SQ and/or DLKP-M cells280.  It is possible that over a 
number of passages a different sub-population of DLKP-I could have inadvertently been 
selected.   
6.4.3.1  Genes changing between DLKP-SQ (poorly invasive) vs DLKP-M (invasive) 
Following the clustering analysis results, studies were continued to identify genes changing 
between DLKP-SQ (poorly invasive) vs DLKP-M (invasive).  This comparison resulted in a list 
of 2746 genes.  That is, the expression of 2746 genes was up- or down-regulated in DLKP-M 
relative to the DLKP-SQ clones (1753 genes up-regulated and 993 genes down-regulated).  The 
primary 15 over-expressed and under-expressed genes are shown in table 4.1-1a.   
The primary over-expressed gene was Vgll3.  Mammalian Vgll3 is related to the transcriptional 
cofactor Vestigial (Vg), originally described in Drosophila melanogaster.  Drosophila Vestigial is 
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involved in determining cell fate in the developing fly wing and muscle.  In mammals, there are 
four highly conserved “vestigial-like” genes.  Previous reports have suggested that members of 
this protein family are associated with muscle development and function.  For example, Vgll3 has 
been reported to be expressed in developing muscle tissues of the mouse embryo545.  Further 
investigation into the role of Vgll3 in DLKP lung cancer invasion is warranted.   
The second over-expressed gene was Piccolo.  Piccolo is a neuronal synaptic vesicle protein.  
The protein encoded by this gene is part of the presynaptic cytoskeletal matrix, which is involved 
in establishing active synaptic zones and in synaptic vesicle trafficking.  A role for PCLO gene in 
calcium sensing has also been suggested546, but a role in cancer has not been previously reported.  
Piccolo is a very large protein (520kDa)547 548.  Genes encoding extremely large proteins are 
reported to have low expression and are late in DNA replication timing.  As a result the mutation 
rate is higher and it has been suggested that such potentially spurious genes that have been 
nominated as cancer associated genes in the recently published cancer genome studies are false 
positives548.  Immunofluorescence staining showed strongest expression in the DLKP-I clone, 
with some cells in the DLKP-M population showing less expression of the protein, despite the 
fact that this gene is not present on the DLKP-SQ vs I genelist (figure 4.1-5).   
The primary down-expressed gene was Olfactomedin 3.  Olfactomedin 3, encodes an 
olfactomedin domain-containing protein and was previously studied in this laboratory281.  High 
expression of OLFM3 was confirmed at the RNA level by qRT-PCR in DLKP-SQ and at the 
protein level by Western blotting.  Little or no OLFM3 was detected in the other two clones 
(DLKP-M and DLKP-I).  Anoikis is a form of programmed cell death which is induced by 
anchorage-dependent cells detaching from the surrounding extracellular matrix and OLFM3 was 
shown to contribute to anoikis-resistance in the clones.  This is the first instance of OLFM3 being 
linked with anoikis resistance in a human cancer cell line281 (Appendix II).   
In surveying genes which were differentially expressed between DLKP-SQ and DLKP-M, it is 
clear that the DLKP-M cell line exhibits altered expression of genes whose products are involved 
in cell adhesion and signalling.  For example the gene CADM2 is over-expressed in both the 
DLKP-I and DLKP-M genelists.  This gene encodes a member of the synaptic cell adhesion 
molecule 1 (SynCAM) family which belongs to the immunoglobulin (Ig) superfamily.  Recent 
studies suggest that cell adhesion molecules (CADM), might serve as tumour suppressors549,550.  
For example He et al., 551 suggested that CADM2 might be involved in the maintenance of cell 
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polarity and adhesion in renal cell carcinoma and that it may serve as a tumour suppressor gene 
by inducing apoptosis and inhibiting tumour growth both in vitro and in vivo.   
The large extracellular matrix proteoglycan, versican (VCAN) was 28 fold down-expressed in 
the DLKP-M clone compared to DLKP-SQ.  The role of versican in cell adhesion, migration, and 
proliferation is extensively studied.  Versican is often considered an anti-adhesive molecule552.   
 
6.4.3.2  Genes changing between DLKP-SQ (poorly invasive) vs DLKP-I (invasive) 
Despite the clustering analysis results, studies were continued using the remaining two DLKP-I 
replicates to identify genes changing between DLKP-SQ (poorly invasive) vs DLKP-I (invasive).  
Comparison of DLKP-SQ (baseline) to DLKP-I (experiment) resulted in a list of 1319 genes.  
That is, the expression of 1319 genes was up- or down-regulated in DLKP-I relative to DLKP-
SQ clones (490 genes up-regulated and 829 genes down-regulated).  The primary 15 over-
expressed and under-expressed genes are shown in table 4.1-1b.   
The primary over-expressed gene was N-cadherin.  Interestingly, this gene was also over-
expressed in the mitoxantrone resistant DLKP-SQ.  Cadherins (named for "calcium-dependent 
adhesion") play important roles in cell adhesion, forming adherens junctions to bind cells 
together within tissues.  It has been observed that cells containing a specific cadherin subtype 
tend to cluster together to the exclusion of other types, both in cell culture and during 
development 485.  Immunofluorescence staining showed that N-cadherin is expressed in the 
DLKP-I clone only (figure 4.1-4).  N-cadherin is associated with a more aggressive behavior of 
cell lines and tumours, such as invasion146,553.   
The second over-expressed gene in the DLKP-I genelist was thyroid transcription factor 1 
(TTF1).  This gene was also over-expressed in the DLKP-M genelist.  Thyroid transcription 
factor-1 is a protein that regulates transcription of genes specific for the thyroid, lung, and 
diencephalon.  For lung cancers, adenocarcinomas are usually positive, while squamous cell 
carcinomas and large cell carcinomas are rarely positive. Small cell carcinomas (of any primary 
site) are usually positive554,555. 
Desmosomes are cell-cell junctions between epithelial, myocardial, and certain other cell types.  
The desmogleins are a family of cadherins associated with desmosomes consisting of proteins 
DSG1, DSG2, DSG3, and DSG4.  Three of these four desmogleins (DSG 1, 2 and 3) are up-
regulated in the DLKP-I genelist but are not present on the DLKP-M genelist.  DSG3 (98 fold 
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over-expressed) is a calcium-binding transmembrane glycoprotein component of desmosomes in 
vertebrate epithelial cells and has recently been shown to be upregulated in squamous cell 
carcinoma (SCC)556.  It has been identified as a good tumour-specific marker for clinical staging 
of cervical sentinel lymph nodes in head and neck squamous-cell carcinoma557.  In addition, 
DSG2 (93 fold over-expressed) has been shown to interact wth desmcollin-1558 which is 84.3 
fold over-expressed.  These desmosomal family members, along with the desmogleins, are found 
primarily in epithelial cells where they constitute the adhesive proteins of the desmosome cell-
cell junction and are required for cell adhesion and desmosome formation.  The desmoglein gene 
family members are located in a cluster on chromosome 18559.  However, little else is known 
about their biological function in cancer and further investigation of the role of the desmoglein 
family in DLKP-I invasion is warranted.   
ROBO2, an axon guidance receptor, is over-expressed in the DLKP-I cell lines.  ROBO2 is a 
receptor for SLIT2 and these molecules are known to function in axon guidance and cell 
migration.  Both of these proteins were shown to be over-expressed in the SQ-Mitox-BCRP-6P 
cell line.  In addition, ALCAM, which was discussed earlier in this chapter is also over-expressed 
in the DLKP-I and DLKP-M cells.  ALCAM and ROBO2 are both membrane proteins while 
SLIT2 is both a membrane and secreted protein, suggesting the importance of interactions 
between tumour cells and their microenvironment in the development of invasion.   
The primary down-expressed gene in both the DLKP-I and DLKP-M genelists was hyaluronan 
and proteoglycan link protein 1 (HAPLN1).  The function of HAPLN1 is to link proteoglycans to 
hyaluronic acid thus participating in the architecture of the extracellular matrix560.  Interestingly, 
this gene was previously found to be up-regulated in aggressive melanoma561 and is often up-
regulated in highly metastatic cell lines or aggressive human tumours562,563.  The expression of 
HAPLN1 in the DLKP-SQ parental cell line should be confirmed.   
The second down-expressed gene in the DLKP-I genelist was interferon-induced transmembrane 
protein 3.  Interferon-induced transmembrane proteins (IFITM) are a family of transmembrane 
proteins that contain two α helical domains.  To date, there are five IFITMs (IFITM1, IFITM2, 
IFITM3, IFITM5 and IFITM10) that are all clustered on chromosome 11 with less than 2 kb next 
to each fragment.  IFITMs have diverse roles, including the control of cell proliferation, 
promotion of homotypic cell adhesion, protection against viral infection, promotion of bone 
matrix maturation and mineralisation, and mediating germ cell development564,565.  Recent 
studies identified possible roles of IFITM genes in carcinogenesis.  For example, the IFITM1 and 
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IFITM3 genes were shown to be expressed at higher levels in astrocytoma cells than in normal 
astrocytes in mice566.  In addition, IFITM3 expression has been suggested as a preferential 
marker for ulcerative colitis-associated colon cancer and has been found to be up-regulated in 
gastric cancer, colorectal tumours, glioma and breast cancer567-570.  IFITM3 is transcribed in most 
tissues and highly interferon-inducible.   
The third down-expressed gene in the DLKP-I genelist was BACE2.  This gene codes for the 
enzyme beta-secretase-2.  BACE2 is a close homolog of BACE1 which is a protease known to be 
an important enzyme involved in the cellular pathways that some believe lead to Alzheimer's 
disease.  The physiological function and role of BACE2 in Alzheimer's disease is unknown and it 
has not been reported in cancer.  Western blot analysis showed this protein to be down-expressed 
in the DLKP-I and DLKP-M cells (Edel McAuley, unpublished results).   
 
6.4.4  Microarray lists from DLKP-SQ (Mitoxantrone) and SQ vs. M and SQ vs I clones 
An important point to ponder when considering the SQ-Mitox analysis is that there are 
potentially two ways to approach this data: look at drug resistance and/or invasion.  Theoretically 
however, any differentially expressed genes identified by the microarray analysis of the SQ-
Mitox cell lines could relate solely to drug resistance.  The DLKP clones with differing levels of 
invasiveness (derived from the same parent) also offer a unique opportunity to study mechanisms 
of invasion.  These cell lines provide an in vitro model of invasion.  One of the aims of this thesis 
was to identify genes involved in the development of an invasive phenotype in lung cancer cell 
lines.   
SQ-Mitox-4P cells may be pre-disposed to an invasive phenotype, already having some of the 
genes necessary for invasion ‘switched on’.  They may require only the up regulation of some 
key genes to push the phenotype into a highly-invasive one.  The genes most highly up-regulated 
in the SQ-Mitox-BCRP-4P versus 6P and SQ-Mitox-MDR-4P versus 6P genelists may be part of 
a group of genes essential for invasion.  It is significant that three of the primary twelve probesets 
over-expressed in the SQ-Mitox-BCRP and SQ-Mitox-MDR 4P versus 6P genelist (N-cadherin, 
ALCAM and SLIT2) were also differentially expressed in the SQ vs I genelists.  In addition, 
integrin alpha V and MMP10 were differentially expressed in the SQ-Mitox 4P vs 6P genelists 
and confirmed as overexpressed in the DLKP-I and DLKP-M clones.  Indeed, N-cadherin 
expression seems to be associated with the DLKP-I clone only and SLIT2 appears to be 
associated with the DLKP-M cell lines.    
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Interestingly the differentially expressed proteins identified in this chapter are all heavily N-
glycosylated and studies have shown that N-glycosylation is a key regulator of various aspects of 
tumourigenesis571.  For example diverse sALCAM forms have been reported in different tissues.  
A glycosylated 96 kDa form consisting of most of the extracellular domain has been described in 
epithelial ovarian cancer sera and cells572 and in epithelial cells573.  A 60 kDa isoform has been 
reported in conditioned media of thyroid cancer cells as the result from alternative cleavages and 
related glycosylation patterns574,575.  N-glycosylation impacts cell adhesion and cytoskeletal 
dynamics and studies have shown that the N-glycosylation state of N-cadherin impacts the 
intrinsic kinetics of cadherin-mediated intercellular binding576.  In addition although integrin-
mediated adhesion to ECM proteins is based on the interaction of specific amino-acid residues, 
the strength of binding may be modulated by various factors including glycosylation of 
integrins577.   
 
6.4.5  Investigation of stem cell markers in DLKP clones  
Putative cancer stem cells (CSCs) have been identified in many cancers, often by markers 
associated with normal stem cells.  This is similar with the situation in lung cancer where the 
accumulated data on side population cells, CD133, CD166, CD44 and ALDH1 are beginning to 
clarify the true phenotype of the lung cancer stem cell.  However, the results presented in this 
thesis argue against the cancer stem cell model operating in the DLKP cell line.  The expression 
of a small panel of markers for embryonic stem cells was investigated and DLKP clones were 
found to be negative for KLF4 and NANOG.  Very low levels of Oct-4 were seen and c-Myc was 
present in all of the clones.  Myc is a potent oncogene that can promote tumourigenesis in a wide 
range of tissues578,579.  c-Myc functions as a master transcriptional regulator of a wide  number of 
target genes that execute various cellular responses, including cell cycle progression, cell 
differentiation, angiogenesis and apoptosis.  It will be critical to determine which cancers follow 
a stem cell model and which cancers do not, so therapies designed to target rare subpopulations 
of cells are appropriately tested in patients whose disease is driven by many diverse cancer cells.   
 
6.4.6  Sequenom analysis of DLKP clones 
Mutation profiling has the potential to quickly identify which signalling pathway(s) have been 
co-opted to drive the proliferation of a specific human tumour type.  DLKP clones and the cell 
line DLRP282 were evaluated for the presence of mutations using sequenome technology (see 
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table 4.1-2).  This mutation panel was designed to look at point mutations.  By altering just one 
amino acid, the entire peptide may change, thereby changing the entire protein.  However in this 
study, in some cases there were two allele insertions and in these cases the mutation is 
heterozygous.  This could lead to the nucleotides’still being read in triplets, but in different 
frames.   
Results showed a two allele insertion within the Sema domain (MET_N375S_A1124G).  This 
heterozygous mutation was notably seen in the DLKP parent, DLKP-SQ and DLKP-I.  A 
missense change was seen in the DLKP-M clone.  The MET receptor tyrosine kinase and its 
cognitive ligand the hepatocyte growth factor (HGF)/scatter factor, play a major role in tumour 
development.  Krishnaswamy et al.,580 showed the majority of the MET mutations to be germline 
in lung cancer.  MET mutation N375S was detected in a high proportion of East Asian samples 
and was correlated to the incidence of squamous cell carcinoma.  The MET-N375S mutation 
seems to confer resistance to MET inhibition580.  However, Shieh et al., 581 suggested that the c-
Met-N375S sequence variant was not associated with lung cancer susceptibility and prognosis.   
There were TP53_G245VDA_G734TAC mutations present in all of the DLKP clones and the 
DLRP cell line.  The tumour suppressor gene TP53 is frequently mutated in human cancers 582.  
Abnormality of the TP53 gene is one of the most significant events in lung cancers and plays an 
important role in the tumourigenesis of lung epithelial cells.  TP53 is mutated in 80% to 100% of 
small cell lung cancers (SCLC) and 50% to 80% of non-SCLC (NSCLC)583.  TP53 gene 
mutations can occur in association with EGFR and KRAS mutations584.   
Analysis of the clones showed an AG insertion within the EGFR receptor in the DLKP-SQ only.  
The DLKP-SQ clone also has the highest levels of phosphorylation of the pERK and so further 
investigation of this pathway in the clones would be of interest.   
 
6.5  Investigation of the effects of MEK inhibitors on drug resistance 
and invasion in DLKP 
6.5.1  Effects of MEK inhibitors on drug resistance in DLKP 
Molecular targeted therapies are of recent interest for the treatment of cancer585, 586.  These agents 
can disrupt tumourigenesis by specifically targeting molecular signals regulating cellular 
proliferation and/or enhancing apoptosis.  Molecular targeted therapies may overcome 
mechanisms by which cancer cells resist traditional cytotoxic chemotherapeutic agents.  A class 
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of molecular targeted compounds called small-molecule protein kinase inhibitors can disrupt 
mitogenic signaling pathways.  Mitogen-activated protein kinase pathways are conserved 
signaling pathways that enable cells to respond to external stresses and stimuli.  The MAPK 
family includes Jun amino-terminal kinases (JNK1/2/3), p38 proteins, the extracellular signal–
related kinases (p44/p42-MAPK or ERK1/2), and ERK5 587.  The extra-cellular signal-regulated 
(ERK), mitogen-activated protein kinase (p42/p44 MAPK) pathway is a target that has received 
significant attention588.   
The p44/p42-MAPK pathway can be activated through G-protein–coupled receptors or receptor 
tyrosine kinases.  Signals travel through the small oncogenic G-protein Ras and ultimately to Raf 
(or MEK kinase), which then activates the downstream signaling proteins MEK1/2 (MAPK/ERK 
kinase or MAP kinase kinase) and ERK1/2 (p44/p42-MAP kinase).  Activated ERK1/2 control a 
diverse range of cellular processes through their many substrates (>160) that are located in 
cellular membranes, the cytoplasm and nucleus.  Many of these are transcription factors that are 
important in cellular proliferation, differentiation, survival, angiogenesis and migration.   
The association between the expression of ABC transporter proteins and cell growth signaling 
has recently generated some interest589.  Among the complex signaling networks, mitogen-
activated protein kinase (MAPK) pathways have been implicated in acquired tumour resistance 
to chemotherapy333.  Previous studies of MAPK signaling pathways in cancer models have 
shown that the p44/p42 MAPK cascade is activated by chemotherapeutic agents such as 
paclitaxel334, cisplatin335, and vinblastine336 and is involved in acquired resistance to these 
drugs590.  In one study, drug-resistant neuroblastoma cells generated from doxorubicin or MDL 
28842 demonstrated decreased ERK activation and nuclear translocation590.  The authors 
speculated that ERK down-regulation slowed cell cycle progression, affording drug-resistant 
cells an opportunity to repair drug-induced damage.  This implies that inhibiting ERK may grant 
neuroblastoma cells protection from cytotoxic agents, although this has not been confirmed590.   
Despite demonstrating in vitro activity, major in vivo limitations were identified for the early first 
generation MEK inhibitors, PD098059340 and U0126339 due to their rapid turnover rate.  
Although both compounds were deemed unsuitable for clinical consideration due to their 
pharmaceutical properties, they have proven to be invaluable tools for investigating the 
Ras/MAPK pathway.  In this study, we examined the effects of these signal transduction 
inhibitors, upon the expression levels of P-gp and BCRP and find that PD98059 up-regulates P-
gp expression in the SQ-Mitox–MDR cells and that PD98059 and U0126 diminish the anti-
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cancer drug resistance of BCRP, while having no effect on the expression of BCRP protein levels 
in SQ-Mitox-BCRP cells.   
P-gp, BCRP and pMEK expression levels were analysed in DLKP-SQ-Mitox-MDR and DLKP-
SQ-Mitox-BCRP cell lines treated with or without the specific inhibitor of MEK, PD09059 and 
the inhibitor of ERK, U0126.  The PNP assay was used to determine the susceptibility of SQ-
Mitox-MDR and SQ-Mitox-BCRP to mitoxantrone, treated with or without PD98059 and 
U0126.  The cytotoxicity of mitoxantrone was found to be significantly potentiated by PD98059 
and U0126 in DLKP-SQ-Mitox-BCRP.  The cytotoxicity of mitoxantrone was found to be 
significantly decreased by PD98059 but unchanged by U0126 in DLKP-SQ-Mitox-MDR.   
 
Table 6.5-1:  Summary of Effects of MEK inhibitors on drug resistant DLKP cell lines. 
MEK Inhibitor SQ-MitoxBCRP SQ-Mitox-MDR DLKP-SQ DLKP-A 
PD98059 ++ ++ + + 
U0126 ++ + _ _ 
AZD6244 ns + _ _ 
++ very significant; + significant; ns: not significant 
 
Despite the fact that the cytotoxicity of mitoxantrone was found to be significantly potentiated by 
PD98059 and U0126 in DLKP-SQ-Mitox-BCRP,  Western blot analysis revealed that there was 
no change in BCRP protein expression.  This would suggest that up-regulation of BCRP is not 
the only molecular change in this cell line compared to the parental cell line.  There are other 
lines of evidence to support this argument.  Previous studies in this laboratory591 showed that the 
IC50 of epirubicin alone was 40nM and in combination with elacridar, this reduced to 28nM.  
This suggests that DLKP-Sq/Mitox-BCRP contains another resistance mechanism.  In addition, 
inhibition of BCRP with elacridar increased the toxicity of dasatinib in DLKP-Sq/Mitox-BCRP 
to beyond that of the parental cell-line.  Src kinase, one of the targets for dasatinib, is upstream of 
the Raf-MEK pathway and up-regulation of BCRP as a response to mitoxantrone may also up-
regulate p-src, a target of dasatinib, thus making the resistant BCRP expressing DLKP-Sq/Mitox 
more sensitive to dasatinib.  It has been shown by others that inhibition of the mitogen-activated 
protein kinase pathway results in the down-regulation of P-gp346, BCRP347, MRP1 and MRP3348.  
In the case of BCRP positive cells, there are mixed reports of MEK inhibitors transcriptionally 
upregulating BCRP but simultaneously enhancing its protein degradation347.  Lin et al.,348 
254 
 
showed that MEK inhibitors reduced MRP1 as well as MRP3 expression in hepatocellular 
carcinoma.   
Table 6.5-2 provides a list of well-known and novel signaling pathway inhibitors that alter P-gp 
function in drug-resistant cells.  Many of these pathways (e.g., Ras/MAPK, JNK, p38 MAPK, 
protein kinase A- and PKC-related proteins, and PI3K) involve cell proliferation status, mediate 
apoptotic signaling, or generate the stress response.  To our knowledge, this is the first report that 
inhibition of a signaling pathway can increase P-gp expression.   
There are only two reports in the literature of a down-regulation of the ERK1/ERK2 proteins 
resulting in an increase in P-glycoprotein-mediated multidrug resistance.  Wartenberg et al.,411 
found that UO126 induced upregulation of P-glycoprotein as well as HIF-1 under control 
conditions that was even more increased under conditions of hyperthermia.  These results point 
towards the notion that inactivation of JNK as well as ERK1,2 are a prerequisite for the induction 
of a MDR phenotype in multicellular prostate tumour spheroids and that active JNK as well as 
ERK1,2 may be involved in negative regulation the mdr-1 and HIF-1 genes.  They previously 
demonstrated that in small tumour spheroids that are drug sensitive and devoid of P-glycoprotein 
expression a high level of endogenous JNK and ERK1,2 activity occurs, whereas only minor 
activation of p38 was observed.  Also, Yan et al.,592 reported a down-regulation of ERK 1/2 
activity in P-glycoprotein-mediated multidrug resistant hepatocellular carcinoma cells.   
There are a variety of mechanisms by which this could occur.  In the first case, the ERK1/2 
cascade is involved in the phosphorylation of a number of proteins, including transcription 
factors involved in determining cell survival and death593.  Studies on the role of signal crosstalk 
in the transcriptional control of ABCB1 indicate that ABCB1 is a target of the Ras/Raf signalling 
pathway594.  PD098059 could therefore reverse changes in drug resistance mediated by this 
pathway directly.  Alternatively, there may be direct cross-talk between the ERK1/2 signalling 
cascade and MDR-1 function i.e. that activation of the ERK1/2 either directly or indirectly 
affects the activity of the MDR-1 protein, by changing its phosphorylation state for example.  In 
a minireview by Callaghan et al., 2014595 they discuss the implications of the phosphorylation of 
the P-gp protein.  The protein has of numerous PKC consensus motifs within in the linker region.  
Moreover, it has been demonstrated that P-gp is phosphorylated by PKC at several of these 
motifs within the linker region.  A number of studies examined the phosphorylation status of P-
gp in cell lines selected for drug resistance and suggested that it played a key role in the resistant 
phenotype595,596.   
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It is feasible that the effects of PD98059 are by an alternative unknown mechanism. However, 
these would still be linked to MDR-1 expression.  The fact that PD098059 could increase drug 
resistance and that the alternative MEK inhibitor U0126 had no significant effect indicates that 
there may be an additional targets for this chemical.  This is substantiated by evidence that 
PD098059 can interact with other cellular targets such as the aryl hydrocarbon receptor and 
inhibit other signalling cascades such as those mediated by ERK 5 and the COX1/2 pathways for 
instance597.  In addition, Zuber et al., 598 report that in a genome-wide survey of Ras 
transformation targets, PD098059 treatment of cells has effects on 61 Ras targetted genes, 
blocking down-regulation of 36 genes and up-regulation of 25 targets.   
Increased MEK hyperphosphorylation has been reported in p-gp over-expressing cells.  Increased 
P-MEK levels have been reported after treatment with other MEK inhibitors, such as CI-1040 
and AZD6244; therefore, MEK phosphorylation appears to be a common response to MEK 
inhibitors and may be due to interference with the feedback regulation of the Ras-Raf-MEK-ERK 
pathway599.  The increase in MEK phosphorylation may overwhelm the ability of the MEK 
inhibitor to suppress P-ERK, thus allowing reactivation of the targeted pathway, thereby inducing 
P-gp.  
Further investigation of the role of the MAPK kinase pathway in the SQ-Mitox-MDR and SQ-
Mitox-BCRP cells is warrented.  The regulatory mechanisms underlying the expression of ABC 
transporters, including P-gp and BCRP, still remain to be clarified.   
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Table 6.5-2: Selection of novel compounds and inhibitors found to reverse P-gp 
MDR by altering signal transduction (Adapted from Callaghan et al., 2014595) 
Compound Probable Pathway or Target Reference 
FTI-277,U0126 & 17AAG MAPK/ERK, HSP90 Katayama et al., 2007346 
REM JNK1/2 Choi et al., 2013600 
SC-51089 Prostaglandin E2 receptor Pekcec et al., 2009601 
PHII-7idarubicin derivative JNK phosphorylation Peng et al., 2013602 
siRNA Bile extract Wnt/β-catenin Shen et al., 2013603 
PEITC (phenethyl isothiocyanate) PI3K-Akt Tang et al., 2013604 
Dioscin NF-kB Wang et al., 2013605 
Parthenolide NF-kB and Hsp70 Xin et al., 2013606 
Procyanidin NF-kB and MAPK/ERK Zhao et al., 2013607 
 
 
6.5.2  Effects of MEK inhibitors on invasion in DLKP  
 
MEK Inhibitor DLKP-I DLKP-M SQ-Mitox-BCRP-6P 
U0126 - ++ ++ 
 
Previous studies in the literature have indicated that PD98059 and U0126 suppresses the 
invasiveness of squamous cell carcinoma 337 and melanoma cells338.  Could these inhibitors affect 
the invasion of the DLKP clones?  The role of MAPK kinase signalling in cell invasion was 
investigated using the MEK1/2 inhibitor U0126.  U0126 showed no effect on invasion of DLKP-
I under the conditions tested.  The effect on cell invasion of DLKP-M was very evident, with 
U0126 inhibiting invasion by approximately 50% at 5 and 10 µM.  Data shown as the mean ± 3 
experiments.  The inhibitor, U0126 had no effect on proliferation at the concentrations tested.  
The p44/p42 MAPK pathway intermediate ERK was subsequently shown to be expressed in all 
three DLKP clone types.  However, the DLKP-SQ and DLKP-M cells showed high levels of 
endogenous ERK activation compared to DLKP-I and DLKP parent (figure 5.2-5).  Interestingly, 
microarray results for the SQ vs M clones showed a 1.63-fold change in DLKP-M for MAPK1.   
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Post-translational modifications are important processes in the regulation of protein activity.  One 
of the primary and reversible protein modifications is phosphorylation.  It is estimated that nearly 
30% of all the proteins in a eukaryotic cell are transiently phosphorylated and by inference under 
dynamic control.  The phosphorylation patterns of proteins within a cell are determined by the 
sum of all the protein kinases active at that point in time.  These protein kinases are themselves 
also under active dynamic control and are principally involved in signalling pathways which are 
responsible for diverse processes such as those involved in angiogenesis, apoptosis, cell 
migration and cell cycle control.  It is easy to appreciate that dysregulation at any point in this 
system could upset the normal homeostatic mechanisms within a cell and lead to a series of 
molecular events culminating in a malignant phenotype.   
Dysregulation of normal protein kinase activity may simply occur by a mutation that renders the 
kinase constitutively active (or a phosphatase inactive or a combination of reversal activities).  
Sequenom analysis for example revealed mutations in EGFR, Met and PIK3R1 which may help 
explain the higher levels of ERK activation and effects of the MEK inhibitors on the invasiveness 
of the DLKP-M cell line.   
However, it is not possible to relate regulation through phosphorylation to levels of mRNA 
(microarray results).  Therefore, the investigation of MAPKs and intracellular signaling of 
DLKP-1 and DLKP-M cells under U0126 treatment was extended using a commercial array kit 
(Human Phospho-MAPK array kit), which screens for the activation of 28 kinases including 9 
MAPKs.  The array kit allows the recognition of specific phosphorylation sites (amino acid 
residues) related to the activations of MAPKs and signaling proteins.  JNK, p38 and p53 were the 
three phosphorylated proteins with the most significant changes in untreated DLKP-I cells 
compared to the untreated DLKP-M cells.  The JNK stress pathways participate in many 
different intracellular signalling pathways that control a spectrum of cellular processes, including 
cell growth, differentiation, transformation, or apoptosis.  Particularly relevant to this study is the 
connection between JNK, p53 and p38.  JNK binds to and phosphorylates p53 and in most cases, 
p38-MAPKs are simultaneously activated with JNKs.   
Following U0126 treatment, DLKP-M cells showed increased phosphorylation in p53 and 
slightly increased phosphorylation in p38 and JNK, which suggests induced signaling in the p38 
and JNK pathways.  Interestingly, U0126 treated DLKP-I cells do not present a significant 
increase in any of the intracellular signalling proteins.   
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Results from this study have demonstrated that MEK inhibitor treatment of DLKP-M had a 
considerable effect on its invasiveness.  The resistance of DLKP-I cells to MEK inhibition in the 
cell invasion assay indicates the MAPK targeted treatment may be unsuccessful against this 
subtype within a heterogeneous DLKP tumour.  MAPK plays a major role in inducing proteolytic 
enzymes that degrade the basemant membrane, enhancing cell migration, initiating several pro-
survival genes and maintaining growth.  Activated MAPK pathways have been detected in many 
tumours including breast, lung, colon and kidney, implicating it in tumour progression and 
metastasis608.  Understanding the differences in DLKP type MAPK expression/activity, MAPK 
signaling and the functional response to MEK activity may help to further elucidate the 
phenotype and behavioural traits of DLKP.   
These experiments suggest that the DLKP cell line does not adopt a hierarchy consisting of a 
minor subpopulation of tumourigenic cells and a majority population of non-tumourigenic cells.  
Markers were successfully identified that robustly distinguish the invasive DLKP-I and DLKP-M 
clones from the examination of genes which were over-expressed in the microarray results for 
both the DLKP clones and the mitoxantrone resistant DLKP-SQ cell lines.  All of the clones had 
the capacity to grow in vivo (unpublished results).  The phenotypically distinct and poorly 
invasive DLKP-SQ cell line (in vitro) had the capacity to form tumours in vivo.  This suggests 
that the poorly invasive DLKP-SQ cell line appeared to undergo reversible changes in vivo.  
Thus, tumourigenic capacity is not restricted to a small subpopulation of the DLKP cell line but 
is shared among all three of the DLKP-SQ, DLKP-I and DLKP-M clones.   
While the morphology of each of the clones is stable, the DLKP-I clone did not cluster well – 
two clustered with DLKP-SQ and one clustered with the DLKP-M clones.  The Sequenom data 
indicated that there might be important mutational differences while the experiments with MEK 
inhibitors indicate pathway activation at a post DNA level.  The clones, being from the same 
tumour may interconvert609.  As Floor et al.,539 pointed out, hallmarks are often interpreted as 
applying to a canonic cancer cell, or equally to all cells within a cancer.  In their article, they 
discuss the separate concepts of causes, oncogenic events, signal transduction programs, and 
hallmarks.  They argue that there is no unimodal relation between these concepts but a complex 
network of interrelations that vary in different cells, between cells, and at different times in any 
given cell.   
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6.6  Summary and Conclusions 
An overview of the current state of research in the field is presented in Chapter 1.   
Chapter 2 presents details of materials and methods used to generate the data from the numerous 
studies described herein.   
Chapter 3 characterises the resistant phenotype of mitoxantrone resistant lung cancer cell lines 
and describes the establishment of two novel cell lines resistant to mitoxantrone, one 
overexpressing the BCRP and the other the P-gp efflux pumps.  Resistance occurred early on in 
the drug pulsing process.  These cell lines were selected in an identical manner in the same study 
using the same source of DLKP-SQ cells.  The strategy of deriving isogenic drug resistant cell 
lines from one cell line is a method that can reduce variability due to intrinsic genetic differences 
between cell lines.  The establishment of multi-drug resistant DLKP-SQ-Mitox cell lines has 
provided a powerful tool for further study of multi-drug resistant phenotypes.  It is anticipated 
that these cell lines will continue to be useful models for the study of new modulators and 
markers of resistance, ultimately aimed at improving the outcome for patient acquired drug 
resistance that is often observed in the clinical setting.   
Chapter 4 describes the molecular characterisation of morphologically and behaviourly distinct 
populations of the lung cancer cell line DLKP using mRNA expression microarray analysis.  
DLKP-SQ and its BCRP- and P-gp–overexpressing, mitoxantrone resistant variant were used to 
investigate lung cancer drug resistance and invasion potential in vitro.   
Chapter 5 describes the effect of MEK inhibitors on DLKP drug resistance and invasion.  The 
association between the expression of ABC transporter proteins and cell signalling pathways was 
first explored.  Inhibition of MEK with the MEK inhibitor PD98059 led to an up-regulation of P-
gp expression in SQ-Mitox suggesting a role for the MAPK kinase pathway in regulation of P-
gp.  There is a need for caution in the use of such inhibitors as co-therapeutic options designed to 
reverse multidrug resistance in cancer because cancer cell survival may be increased under 
certain conditions.  The MAPK kinase pathway may also play a role in DLKP invasion.   
 
6.6.1  Development of P-gp- and BCRP-mediated mitoxantrone resistant cell lines.   
1. Two mitoxantrone resistant variants of the DLKP-SQ cell line were established one 
with P-glycoprotein (SQ-Mitox-MDR-4th pulse) and one with BCRP (SQ-Mitox-
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BCRP-4th pulse) overexpression.  These two cell lines were selected from the same 
cell population and under identical conditions.   
2. Over-expression of P-gp and BCRP was revealed by microarray analysis and was 
confirmed by RT-PCR and Western blotting.   
3. SQ-Mitox-MDR-4th pulse cells – cross resistance profiling showed resistance to: 
mitoxantrone (320×); taxol (303×); epirubicin (179×); vinblastine (128×); 
irinotecan (5.8×); and VP-16 (1727×), but displayed no significant resistance to 
cisplatin (0.79×) or 5-FU (1.74×).  SQ-Mitox-BCRP-4th pulse cells – cross 
resistance profiling showed resistance to mitoxantrone (210×) and irinotecan 
(4.03×) but displayed no significant resistance to taxol (0.67×), epirubicin (1.34×), 
vinblastine (1.07×), cisplatin (0.63×) VP-16 (1.25×) or 5-FU (2.25×).   
4. When P-gp was silenced in SQ-Mitox-MDR cells and BCRP was silenced in SQ-
Mitox-BCRP cells, an increase in sensitivity to mitoxantrone was observed across 
all concentrations.  Because of the very high level of overexpression of BCRP and 
P-gp respectively in the two resistant variants, only partial knockdown could be 
achieved using siRNAs.  There was a corresponding effect on resistance, which 
supported a role for these pumps in resistance, but because complete knockdown 
was not possible, the results do not allow us to determine whether or not these are 
the only, or even the main, determinants of resistance, although the Elacridar data 
would suggest that this is the case.  Elacridar, however, is less specific in its effect 
than an siRNA would be.   
5. Western blots confirmed that P-gp siRNAs and BCRP siRNAs reduced the 
expression of P-gp and BCRP respectively in the cell lines.  A reduced amount of 
the protein was observed with both siRNAs for BCRP and P-gp.  In contrast, with 
the addition of 443 nM Elacridar, both ABCG2-mediated and ABCB1- mediated 
resistance to mitoxantrone was reversed.   
6. Microarray analysis was performed in DLKP-SQ-Mitox-BCRP (4th pulse) and 
DLKP-SQ-Mitox-P-gp (4th pulse).  Functional annotation analysis of probesets 
exclusively differentially expressed in the BCRP overexpressing cell line revealed 
that the most significant GO categories were related to RNA processing, cellular 
response to stress and cell cycle.  Functional annotation analysis of genes 
261 
 
exclusively and differentially expressed in the P-gp overexpressing cell line 
revealed that the most significant GO categories were related to chromatin 
organisation and modification and embryonic morphogenesis.   
7. Gene copy number analysis revealed no alterations in either the BCRP or P-gp copy 
number.   
8. 5-azacytidine treatment of the DLKP-SQ, SQ-Mitox-BCRP and SQ-Mitox-MDR 
cells had no effect on BCRP or P-gp protein expression.  DNA methylation analysis 
of the BCRP over-expressing cell line revealed that the promoter of BCRP was 
unmethylated in both the DLKP-SQ and SQ-Mitox-BCRP cells.   
9. miRNA analysis identified 4 miRNAs with differential expression relating to 
mitoxantrone and/or BCRP expression in the SQ-Mitox-BCRP cell line. The 
miRNAs were involved in tumour suppression, cell proliferation and Wnt 
signalling.  miRNA analysis identified 4 miRNAs (of unknown function) with 
differential expression relating to mitoxantrone and/or P-gp expression in the SQ-
Mitox-MDR cell line.   
10. Proteomic analysis identified 28 proteins with differential expression relating to 
mitoxantrone exposure.  The majority are involved in glycolysis, protein turnover 
and translational elongation.  DSCAM protein was investigated.  Intense 
immunoreactivity was observed in squamous and adenocarcinoma and where 
immunoreactivity was observed in the primary tumour, staining was also observed 
in matched metastatic tumours in the same patients.  Small cell carcinomas did not 
show any staining.  Interestingly, in metastatic tumours from small cell carcinomas, 
weak staining was observed in 3/6 even though the primary tumours were negative.   
 
In summary, overexpression of P-gp, and BCRP, play an important role in drug resistance in SQ-
Mitox cells.  The combination of microarray and proteomic techniques and suitable in vitro 
models presents an excellent setting for dissecting the processes and players involved in drug 
resistance.  These sublines may also prove to be useful models for the study of new modulators 
of resistance aimed at improving the outcome of acquired drug resistance.   
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6.6.2  Establishment of drug resistant invasive DLKP-SQ variants  
Many of the model systems used to study the link between drug resistance and invasion bypass 
the earliest events.  Consequently, the critical first step in the transition from a preinvasive to an 
invasive phenotype during the development of drug resistance is less well studied than later 
stages.  DLKP-SQ-Mitox-BCRP and DLKP-SQ-Mitox-MDR were previously established by 
mitoxantrone pulsing.  These cell lines were pulsed two more times to generate the DLKP-SQ-
Mitox-BCRP-6P and DLKP-SQ-Mitox-MDR-6P cell lines.  A stable, higher drug resistant cell 
population, DLKP-SQ-Mitox-BCRP-6P (isolate 2) was subsequently isolated from the DLKP-
SQ-Mitox-BCRP-6P cell line.   
1. The SQ parent displayed low invasion and low drug resistance.   
2. Successive drug pulsing (in both BCRP and MDR1 overexpressing cell lines) 
isolated the 4th pulse cell population, which displayed high drug resistance but low 
invasion, similar to the SQ parent.   
3. The 6th pulse cell population displayed high invasion and similar resistance to the 
4th pulse cell population.  The invasive phenotype was lost upon freezing and 
thawing.   
4. A sub-population (6th pulse) of the BCRP over-expressing cells was subsequently 
isolated.  Careful observation of these cells revealed morphological differences, 
characterised by large numbers of spiky, elongated cells.  This sub-population of 
cells was believed to be more invasive and more resistant than those observed to 
date.  Further investigation of these cells showed that indeed, they did have a higher 
IC50 and higher levels of BCRP protein.   
5. Microarray analysis gave two gene lists – DLKP-SQ-Mitox-BCRP-4P versus 
DLKP-SQ-Mitox-BCRP-6P cells (Genelist 1) and DLKP-SQ-Mitox-MDR-4P 
versus DLKP-SQ-Mitox-MDR-6P cells (Genelist 2).  PANTHER pathway analysis 
revealed that the most significant pathways were related to Wnt signalling, 
inflammation, integrin signalling and p53 pathways in both Genelist 1 and Genelist 
2.  Twelve genes were identified as common between the up-regulated gene lists.  
Different genes functionally involved in cell adhesion, axon guidance and wnt 
signaling were induced during the transition from the pre-invasive to the invasive 
phenotype.   
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6. Western blot and immunofluorescence validation confirmed the upregulation (in 
the SQ-Mitox-BCRP- 4P versus SQ-Mitox-BCRP-6P cell lines) of the proteins, 
integrin alpha V, BCHE, ALCAM, N-cadherin.  Of particular interest is the 
identification of the SLIT2/ROBO2 signaling pathway in the invasive, drug 
resistant 6th pulse cell line.  The cell adhesion molecule, ALCAM increased with 
increased BCRP expression and was barely detectable in the Pgp over-expressing 
cell lines.   
7. The acquisition of drug resistance is accompanied by an increased activity of 
MMP-2 in DLKP-SQ cells and treatment with an MMP blocking antibody against 
MMP-2 inhibits the invasiveness of drug-resistant SQ-Mitox-BCRP-6P cells.   
8. siRNA knockdown experiments suggest that integrin alpha V plays a role in the 
invasive phenotype observed in vitro.   
9. Treatment with a MAP kinase inhibitor, U0126, inhibits the invasiveness of drug-
resistant SQ-Mitox-BCRP-invasive-6P and the DLKP-M cells, suggesting a role for 
the MAPK kinase pathway in these cell lines.  Western blot analysis revealed that 
the DLKP-M cells showed higher levels of endogenous ERK activation compared 
to the DLKP-I and DLKP parent cells and this might help explain the significant 
inhibition of DLKP-M invasiveness with the inhibitor, U0126.   
 
In summary, mitoxantrone treatment can increase invasiveness of the surviving DLKP cells.  An 
important question concerns exactly what mechanisms link mitoxantrone resistance to cell 
invasion, i.e. what events are triggered by mitoxantrone treatment that lead to increased cell 
invasion and metastasis?  The occurrence of an elevated invasive capability and an acquired 
multiple drug resistance in the SQ-Mitox-BCRP cells suggest strong links between drug 
resistance and invasion.  Future work should focus on whether a common transcription factor 
exists to turn on multiple sets of genes.  It is plausible that proteins that act as drug sensors such 
as those of the nuclear receptor family could act to initiate the first events that result in gene 
transcription and may ultimately be responsible for mitoxantrone resistance.  The activation of 
BCRP genes and those responsible for increased cell invasion, e.g. MMP genes would be 
amongst a series of events leading to the resistant/invasive phenotype.   
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6.6.3  Characterisation of clonal subpopulations of DLKP 
Heterogeneity within tumours may signify the existence of sub-populations with different and 
inherent invasive / metastatic and drug resistance potentials143.  The DLKP cell line contains at 
least three morphologically distinct subpopulations with different levels of invasiveness.  
Microarray analysis was used to generate gene lists that were specific to an invasive phenotype, 
in order to identify genetic markers for invasion.   
1. The DLKP-I and DLKP-M cells exhibit higher adhesiveness to fibronectin and 
vitronectin.   
2. Seven genes were shown to be differentially expressed in the invasive DLKP-M 
and DLKP-I and poorly invasive DLKP-SQ cells.  These included integrin αV, 
SLIT2/ROBO2, ALCAM, piccolo, MMP-2 (from previous studies) and MMP-10.   
3. Western blotting showed that: 
a. Expression of ALCAM was undetectable in the DLKP-SQ cells, low 
in DLKP-M cells and highly expressed in the DLKP-I cells. 
b. Expression of SLIT2 was undetectable in the DLKP-SQ and DLKP-I 
cells but highly expressed in the DLKP-M cells.   
c. Expression of integrin αV was undetectable in the DLKP-SQ but 
highly expressed in the DLKP-I and DLKP-M cells.   
4. Immunofluorescence demonstrated that:   
a. ROBO2 was detected in all of the clones with strongest expression in 
the DLKP-M cells.   
b. N-cadherin is overexpressed in the DLKP-I clone only.   
c. MMP-2 and MMP-10 was detected in all of the cell lines.   
d. Piccolo was highly expressed in the DLKP-I cells with some cells in 
the DLKP-M population also showing strong expression of the 
protein.   
5. The DLKP-I and DLKP-M cells expressed high levels of MMP-2 and MMP-10 
whereas the parental cells did not, as detected by zymography. 
6. In the DLKP-I and DLKP-M cell line, invasion is decreased with blocking of 
MMP-2 with no effect in MMP-10 treated cells. 
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7. Cell adhesion molecules such as ALCAM and N-cadherin may be associated with 
DLKP-I while axon guidance molecule SLIT2, with DLKP-M.  These proteins may 
be possible markers which are capable of distinguishing between the clones.   
 
6.6.4  MEK inhibitors and anti-cancer drug resistance of SQ-Mitox cells 
Cancer often arises when normal cellular growth goes awry due to defects in critical signal 
transduction pathways.  A growing number of inhibitors that target specific components of these 
pathways are in clinical use, but the success of these agents has been limited by the resistance to 
inhibitor therapy that ultimately develops.   
Combination treatment with (1) mitoxantrone and PD98059 and (2) mitoxantrone and U0126, 
significantly reversed drug resistance in the SQ-Mitox-BCRP cell line.  However, inhibition of 
the MAPK kinase pathway had no effect on BCRP expression levels, suggesting that down-
regulation of BCRP is not the only molecular change in this cell line responsible for increasing 
its mitoxantrone sensitivity.   
In contrast, combination treatement with (1) mitoxantrone and PD98059, but not (2) 
mitoxantrone and U0126, significantly increased drug resistance in the SQ-Mitox-MDR cell line.  
That is, the inclusion of the small molecule inhibitors significantly enhanced the survivability of 
the cell line when co-treated with mitoxantrone.  The level of P-gp protein was increased after 
treatment with PD98059, suggesting that PD98059 enhanced the expression of the P-gp protein.  
Supression of P-gp with the P-gp inhibitor elacridar, ameliorated the effect, confirming that P-gp 
was responsible for the enhanced PD98059 induced drug resistance.   
Inhibition of MEK had a small but not statistically significant effect on the drug resistance profile 
of DLKP-A.  DLKP-A cells may contain a different mechanism of regulation of P-gp to the SQ-
Mitox cells as also suggested by the copy number assay results with a copy number of 6 for 
MDR1, a far higher number than that exhibited by the other cell lines.   
The complexity of cell signaling pathways has profound implications on our understanding of 
tumour cell behavior and on our ability to use this knowledge for better treatmemts in the clinical 
setting.  Cancer cells undergo multiple genetic changes, and continuously evolve in response to 
selective pressures.  Even if an activated pathway can be blocked by an inhibitor (e.g. as in the 
case of SQ-Mitox-MDR cells treated with PD98059), tumour cells may evade the inhibitor by 
activating other pathways.  Care must therefore be used in the interpretation of experiments with 
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inhibitors, as is the case with all other pharmacological tools.  It will always be more appropriate 
to conduct experiments with at least two pharmacologically distinct inhibitors where possible and 
to confirm the results with other cell types.   
 
6.6.5  Investigation of the effects of MEK inhibitors on invasion of DLKP 
MEK inhibitor treatment of DLKP-M had a considerable effect on its invasiveness.  The 
resistance of DLKP-I cells to MEK inhibition in the cell invasion assay indicates the MAPK 
targeted treatment may be unsuccessful against this subtype within a heterogeneous DLKP 
tumour.  During tumour development and progression, aberrations in cellular behaviour are 
strongly correlated with alterations in kinase expression and/or activity.  The identification of 
novel kinase targets which may play a pivotal role in the progression of DLKP cancer invasion 
may offer new therapeutic vantage points.  Functional evaluation of the DLKP-I and DLKP-M 
clones, using immunoblotting to validate the Sequenom analysis as well as assessment of 
response to kinase inhibitor treatment will be carried out explain how cancer cells metastasize.   
 
6.6.6  Conclusions 
The work presented in this thesis has a very wide scope and as we have seen, throws up further 
questions as to the mechanism of action with respect to the molecular events that contribute 
towards resistance and metastasis.  Cancer is caused by genetic changes in genes which results in 
defects to regulatory circuits which give cancer cells survival and growth advantages.  As a 
result, populations of tumour cells can display variability in their phenotypes with the ability to 
be able to adapt and become resistant to therapeutics allowing them to invade into tissues and 
metastase to others.  The mitoxantrone resistant cell line model demonstrates that the same parent 
cell line treated with the same chemotherapy agent can lead to the development of two different 
mechanisms of resistance.  This demonstrates that individual cells within a cancer, even though 
initially clonally derived from one or a small population to begin with, can exhibit high levels of 
heterogeneity with respect to drug resistance.  Even if tumours are initially not resistant to a 
specific anticancer treatment, this heterogeneity with selective pressure imposed by potent 
anticancer drugs can result in overgrowth of drug-resistant variants with the rapid acquisition of 
drug resistance.  Clinically, this heterogeneity has been associated with poor prognosis and 
treatment resistance in cancer patients.  Understanding this heterogeneity is central to the 
development of targeted, cancer-preventative and-therapeutic interventions.  The DLKP cell line 
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is a good example of this heterogeneity.  The genes ALCAM, SLIT2 and N-cadherin have been 
identified as potential biomarkers capable of distinguishing between the clones.  Their protein 
products may serve as quantitative markers in future studies of the DLKP cells and may be used 
more effectively to study aspects of the tumourigenic process with a clearer understanding of 
how information obtained from these cells may be applied in vivo.   
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Appendix I: Sequenom Mutation Panel 
 Gene  AA Change    Gene  AA Change    Gene   AA Change 
1. AKT1 E17K 58. CTNNB1 I35N/S/T 115. HRAS G12S/R/C/D/A/V 
2. AKT1 E49K 59. CTNNB1 H36P/R/Y 116. HRAS G13S/R/C 
3. AKT1 G173R 60. CTNNB1 S37A/P/T/C/F/Y 117. HRAS Q61H/H/Q/K/L/P/R 
4. AKT1 K179M 61. CTNNB1 T41A/P/S/I/N/S 118. HRAS E62G 
5. AKT2 E17K 62. CTNNB1 S45A/P/T/C/F/Y 119. IDH1 G70D 
6. AKT2 G175R 63. DDR2 R105S 120. IDH1 R132C/G/S/H/L 
7. AKT3 E17K 64. DDR2 N456S 121. IDH1 V178I 
8. AKT3 G171R 65. DDR2 T533K 122. IDH2 R172G/W/M/K/S 
9. ALK L560F 66. EGFR V689M 123. KIT M552L 
10. ALK A877S 67. EGFR N700D 124. KIT Y553N 
11.  ALK D1091N 68. EGFR E709A/V/G/K/Q 125. KIT W557G/R/R 
12. ALK M1166R 69. EGFR G719A/D/C/S/R 126. KIT K558N/R 
13. ALK I1171N 70. EGFR S720T/P 127. KIT V559A/D/G/I 
14. ALK F1174C/S/L/L/I/V 71. EGFR D761N/Y 128. KIT V560D/A 
15. ALK F1245C/L/V/I 72. EGFR V769L/M 129. KIT G565R 
16. ALK R1275Q/L 73. EGFR T783A 130. KIT N566D 
17. APC R1114X 74. EGFR A839T 131. KIT Y568D 
18.  APC E1306X 75. EGFR K846R 132. KIT V569G 
19. APC E1338X 76. EGFR L858M/R 133. KIT P573L 
20. APC Q1367X 77. EGFR L861Q/R 134. KIT F584S 
21. APC E1379X 78. EGFR G863D 135. KIT L576P 
22. APC Q1429X 79. EGFR H870R 136. KIT E561K 
23. APC R1450X 80. EGFR E884K 137. KIT K642E 
24. BRAF R444Q 81. ERBB2 S310F/Y 138. KIT V654A 
25. BRAF R462I 82. ERBB2 L755S 139. KIT T670I 
26. BRAF I463S 83. ERBB2 G776S/V 140. KIT D716N 
27. BRAF G464E/V/A/R 84. ERBB2 D769H 141. KIT D816E/H/N/Y/G/V/A 
28. BRAF G466R/E/V/A 85. ERBB2 V777A/L/M 142. KIT D820E/E/H/Y/A/G/ 
29. BRAF G469A/E/R/V 86. ERBB2 V842I 143. KIT N822K/N/K/Y/H 
30. BRAF V471F 87. ERBB2 H878Y 144. KIT Y823D/N 
31. BRAF Y472S 88. FBXO4 S8R 145. KRAS G12D/A/V/S/R/C 
32. BRAF E586K 89. FBXO4 S12L 146. KRAS G13D/A/V/S/R/C/ 
33. BRAF D587A/E 90. FBXO4 L23Q 147. KRAS L19F/F 
34. BRAF I592M/V 91. FBXO4 P76T 148. KRAS Q22K 
35. BRAF D594E/V/G 92. FBXW7 R465C/H/L 149. KRAS T58I 
36. BRAF F595L/L/L/S 93. FBXW7 R479G/Q/L 150. KRAS A59T/G/E 
37. BRAF G596R 94. FBXW7 R505C/S/H/L/P 151. KRAS G60D 
38. BRAF L597R/R/Q/V 95. FBXW7 S582L 152. KRAS Q61E/K/X/H/H/Q/L/P/R 
39.  BRAF T599I 96. FGFR1 S125L 153. KRAS A146P/T 
40. BRAF V600E/A/G/L/M 97. FGFR1 P252T 154. MAP2K1 F53C/S 
41. BRAF K601E/N/N 98. FGFR2 S252W 155. MAP2K1 Q56P 
42. BRAF S605N 99. FGFR2 Y375C 156. MAP2K1 K57N 
43. BRAF G615R 100. FGFR2 N549K/K 157. MAP2K1 P124L/T/S 
44. CDK4 R24C/H 101. FGFR3 R248C 158. MAP2K1 E203K/Q 
45. CDKN1B P117S 102. FGFR3 S249C 159. MAP2K2 E207K/Q 
46. CDKN2A R58X 103. FGFR3 G370C 160. MAP2K2 R388Q 
47. CDKN2A E61X 104. FGFR3 S371C 161. MAP3K13 P373S 
48. CDKN2A E69X 105. FGFR3 Y373C 162. MAP3K13 S694L 
49. CDKN2A R80X 106. FGFR3 G380R 163. MAP3K13 R880C 
50. CDKN2A H83Y 107. FGFR3 A391E 164. MAP3K13 A882S 
51. CDKN2A E88X 108. FGFR3 K650E/Q/M/T 165. MET E168D 
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 Gene  AA Change    Gene  AA Change    Gene   AA Change 
52. CTNNB1 A13T 109. FGFR3 G697C 166. MET N375S 
53. CTNNB1 A21T 110. GNA11 Q209L/P 167. MET R970C 
54.  CTNNB1 V22A 111. GNA11 R183C 168. MET T1010I 
55. CTNNB1 D32A/G/V/H/N/Y 112. GNAS R201H/S/C 169. MET H1112R/L/Y 
56. CTNNB1 S33A/P/T 113. GNAS Q227H/L/R 170. MET H1124D 
57. CTNNB1 G34E/V/A/R/R 114. GNAQ Q209L/P/R 171. MET M1131T 
172. MET Y1248C/H/D 210. PIK3CA M1004I 248. SMARCD D391H 
173. MET Y1253D 211. PIK3CA G1007R 249. SMARCD Q504X 
174. MET M1268T 212. PIK3CA Y1021C/H/N 250. SOS1 R248H 
175. MLH1 V384D 213. PIK3CA R1023Q 251. SOS1 R688Q 
176. MYC P57S 214. PIK3CA T1025A/S/I/T 252. SOS1 H888Q 
177. MYC T58A 215. PIK3CA A1035T/V 253. SRC Q531X 
178. NCOR1 R108X 216. PIK3CA M1043I/I/I/V 254. STK11 Q37X 
179. NCOR1 Q313X 217. PIK3CA A1046V 255. STK11 Q170X 
180. NCOR1 E379X 218. PIK3CA H1047R/L/Y 256. STK11 D194N/Y/V 
181. NCOR1 I1422S 219. PIK3CA G1049R 257. STK11 G196V 
182. NCOR1 Q1792X 220. PIK3CA I1058F 258. STK11 E199X/K 
183. NRAS G12D/A/V/S/R/C 221. PIK3CA H1065L 259. STK11 P281L 
184. NRAS G13D/A/V/S/R/C 222. PIK3R1 M326I 260. STK11 W332X 
185. NRAS A18T 223. PIK3R1 G376R 261. STK11 F354L 
186. NRAS Q61E/K/X/H/H/Q/R/P/L 224. PIK3R1 D560Y 262. TBX3 Y163X 
187. PDGFRA V561D 225. PIK3R1 N564D 263. TBX3 W197X 
188. PDGFRA N659K/Y 226. PTEN R130L/P/Q/X 264. TP53 V143A 
189. PDGFRA D842Y/N/V 227. PTEN R173C/H 265. TP53 R175H/P/L 
190. PDGFRA D846Y 228. PTEN R233X 266. TP53 C176F 
191. PDGFRA Y849C 229. PTEN R335X 267. TP53 I195S 
192. PDGFRA D1071N 230. PTPN11 A72D/V/T 268. TP53 R196X 
193. PHLPP2 L1016S 231. PTPN11 E69K 269. TP53 R213X/L 
194. PIK3CA R38H 232. PTPN11 E76A/G/V/Q/K 270. TP53 Y220C/S/H/N 
195. PIK3CA Q60K 233. RB1 E137X 271. TP53 Y234H/N/D/C 
196. PIK3CA R88Q 234. RB1 L199X 272. TP53 M237I 
197. PIK3CA K111N 235. RB1 R320X 273. TP53 G245D/A/S/C/R 
198. PIK3CA G118D 236. RB1 R358X 274. TP53 R248Q/P/L/W/G 
199. PIK3CA N345K 237. RB1 R455X 275. TP53 R273C/H/P/L/S 
200. PIK3CA S405F 238. RB1 R552X 276. TP53 D281G/H/Y 
201. PIK3CA E418K 239. RB1 R556X 277. TP53 R282W 
202. PIK3CA C420R 240. RB1 R579X 278. TP53 R306X 
203. PIK3CA E453K 241. RB1 C706F 279. VHL P81S 
204. PIK3CA P539R 242. RB1 E748X 280. VHL L85P 
205. PIK3CA E542K/Q/V/G 243. RET C634R/W/Y 281. VHL L89H 
206. PIK3CA E545D/K/Q/A/V/G 244. RET A664D 282. VHL L158Q/V 
207. PIK3CA Q546H/E/K/L/P/R 245. RET E768D 283. VHL R161X 
208. PIK3CA C901F 246. RET M918T 284. VHL R167W 
209. PIK3CA F909L/L 247. SMARCD Q539X    
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Appendix II: Research Article 
Olfactomedin III expression contributes to anoikis-resistance in clonal variants of a human lung 
squamous carcinoma cell line.   
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Three clonal subpopulations of DLKP, a poorly differentiated squamous lung carcinoma cell line,
display striking differences in ability to survive in suspension (anoikis resistance). DLKP-SQ is
anoikis resistant (7.5% anoikis at 24 h). In contrast, DLKP-M and DLKP-I are sensitive to anoikis
(49.2% and 42.6% respectively). DLKP-I shows increased apoptosis consistently over all time
points tested while DLKP-M appear to slow down metabolically and perhaps delays onset of anoi-
kis by undergoing autophagy. Expression microarray analysis identified pronounced differential
expression of Olfactomedin 3 (OLFM3) between the clones. High expression of OLFM3 was con-
firmed at the RNA level by qRT-PCR in DLKP-SQ and at the protein level by Western blotting
(within the cell and secreted). Little or no OLFM3 was detected in the other two clones (DLKP-
M and DLKP-I). Following siRNA knockdown of OLFM3 in DLKP-SQ, anoikis was increased 2.8-
fold to 21% which was intermediate between the anoikis levels in DLKP-SQ and DLKP-M or
DLKP-I. This knockdown correlated with increased apoptosis in suspension but not in attached
culture conditions. Addition of recombinant OLFM3 reduced anoikis in DLKP-I. This is the first in-
stance of OLFM3 being linked with anoikis resistance in a human cancer cell line.
© 2012 Elsevier Inc. All rights reserved.
Keywords:
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Introduction
Cellular heterogeneity within tumours could provide protection
against a changing environment, such as exposure to hypoxia or
chemotherapeutic drugs or the opportunity for invasion to a
more suitable site. Subpopulations can arise by mutation or by al-
terations in the differentiation state, such as epithelial to mesen-
chymal and mesenchymal to epithelial transitions (EMT–MET) or
by differentiating cancer stem cells [1]. Lung cancer, although
the most preventable cancer, kills more people than the next top
three cancers (breast, prostate and colon) [2]. Lung cancer is
heterogeneous, consisting of two main groups: small cell lung
cancer and non-small cell lung cancer (adenocarcinoma, large
cell lung cancer and squamous cell carcinoma) and even within
these groups there is morphological, functional, genetic as well
as proteomic heterogeneity [3–5]. Subpopulations have been
found to have differences in their drug resistance profiles and /or
in their invasive potential [6,7] and this can impact critically on
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treatment [8]. Understanding the biology of these subpopulations
and how they interact may provide opportunities to improve
treatment or produce new diagnostic markers.
In previous work in our laboratory, three subpopulations
(DLKP-SQ, DLKP-M and DLKP-I) of a poorly differentiated squa-
mous lung carcinoma line, DLKP, were isolated and characterised
with respect to epithelial, mesenchymal and other lung differenti-
ation markers [4]. In this paper, we explore differences in anoikis-
resistance between these clonal subpopulations, and investigate
the role of Olfactomedin-3 in regulation of anoikis-resistance.
Materials and methods
Chemicals
All chemicals (unless otherwise stated), FBS, glutamine and cell
culture media were obtained from Sigma (Poole, UK). Recombi-
nant OLFM3 (cat. H00118427-P01) was obtained from Abnova
(Taiwan).
Cell lines
DLKP is a poorly differentiated human squamous carcinoma cell line
established in this laboratory [9] from which the three subclones
DLKP-SQ, DLKP-M and DLKP-I were isolated [4]. DLKP-SQ is
squamous-like, DLKP-M is mesenchymal cell-like and DLKP-I ex-
hibits an intermediate morphology. DLKP variants were maintained
in DMEM/Hams F12 (1:1) supplemented with 5% FBS and 1% L-
glutamine. MCF-7, SKBR3 and RPMI-2650 were obtained from the
ATCC. RPMI-2650tx was previously obtained by continuous expo-
sure to taxol [10]. MCF-7 and SKBR3 were maintained in RPMI-
1640 supplemented with 10% FBS and 1% L-glutamine. RPMI-2650
and RPMI-2650txl were maintained in MEM supplemented with
5% FBS and 1% L-glutamine, 1% sodium pyruvate and 1% NEAA. All
cell lines were mycoplasma negative. A frozen cell pellet of 2×106
cells of DLKP and variants was submitted to LGC Limited
(Middlesex, UK) for DNA fingerprinting. A database search of over
3000 cell lines showed no match with DLKP indicating that it was
unique and the sub-cloneswere confirmed to be derived fromDLKP.
qRT-PCR for OLFM3
Total RNA extracted from cell lysates (MirVana miRNA Isolation
Kit, cat AM1560, Applied Biosystems) were quantified using the
Nanodrop (ND-1000 spectrophotometer), reverse-transcribed
using (High capacity RNA-to-cDNA kit, cat 4387406, Ambion)
and requantified using the Nanodrop. TaqMan gene expression
experiments were performed in 20 μl reactions containing 10 μl
of TaqMan® Fast Universal Master Mix (2X), No AmpErase®
UNG, 9 μl of cDNA template (80 ng) and 1 μl of TaqMan gene ex-
pression assay (20x). The following thermal cycling specifications
were performed on the ABI 7500 Fast Real-Time PCR system (Ap-
plied Biosystems) 20 s at 95 °C and 40 cycles each for 3 s at 95 °C
and 30 s at 60 °C. Expression values were calculated using the
comparative threshold cycle (Ct) method. Briefly, this technique
uses the formula 2-delta deltaCt to calculate the expression of target
genes normalised to a calibrator sample [11]. Glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) was selected as the endoge-
nous control.
SiRNA transfection
Transfection assays were carried out with NeoFX transfection re-
agent (siPORT NeoFX, AM4511, Ambion Inc) and olfactomedin 3
validated siRNAs S26707, Ambion Inc (OLFM3(1)) and S26708,
Ambion Inc (OLFM3(2)) with scrambled control 2 (AM4613, Ap-
plied Biosystems) in OptiMEM medium (Gibco™) [12]. Cells in
log phase of growth were fed prior to setting up transfection at
the following conditions: 2×105 cells per well (in 1 ml for trans-
fection) and 2 ul NeoFX. Cells were fed after overnight exposure
to transfection with 2 ml fresh medium. The cells were allowed
to grow for three days at 37 °C and 5%CO2, over which time, micro-
scopic observations were used to look for changes in morphology
and to assess the efficiency of transfection (by looking at the
growth in kinesin control (KIF-II, Ambion, Inc). At 72 h the cells
were trypsinized, counted and anoikis assays were set up. A dupli-
cate plate was washed in PBS A and lysed with 2D lysis buffer for
protein analysis.
Western blotting
Western blotting was performed on cell lysates. Samples with 20–
30 μg of protein per well, were separated on a 12% SDS gel [13].
After Western blotting [14], blots with primary antibodies
(OLFM3 (Santa Cruz, Germany), Caspase-3 and FAK (BD, Europe,
cat 610322 and 610087), phospho-FAK and phospho-PAX (Cell
Signalling Cat 8556, 2541) or alpha-tubulin, LC3 (Sigma, cat
T6199) were incubated overnight at 4 °C. Secondary antibodies
conjugated to horse-radish peroxidase (Sigma, Poole, UK) were
detected by enhanced chemiluminesence (Luminol, Santa Cruz,
CA, USA).
Anoikis assays
The base of wells in a 24-well tissue culture plate (Costar, Cat
3524) were coated with 200 μl of poly-2-hydroxyethyl methacry-
late (poly-HEMA, 12 mg/ml dissolved in 95% ethanol, Sigma
P3932) and allowed to dry overnight. Coating was repeated. Im-
mediately before use, the coated wells were washed twice with
sterile PBS A. A 1 ml volume of cell suspension at 1x10E5 cells/
ml was added to control (no poly-HEMA) and coated wells (3
per assay). The cells were incubated for specified times at 37 °C
and 5% CO2. Three hour prior to the end of the assay, 100 μl
Almar Blue (Serotec BUF012B), an indicator dye was added. Meta-
bolically active cells convert Almar Blue (resazurin) to a fluores-
cent and colormetric indicator (resorufin). Colour development
was measured on a Bio-Tek plate reader at 570 nm with reference
wavelength of 600 nm. Alternatively at the end of the incubation,
cell viability was assessed by trypan blue exclusion dye of cells
growing in poly-HEMA coated plates. Apoptosis (Guava Nexin
cat 4500–0450) and Cell cycle analysis (Guava Cell cycle reagent
4500-0220) were assessed on a bench top flow cytometer
(Guava EasyCyte Instrument).
Collection of conditioned media
Cells were grown in 175 cm2 flasks until about 40–50% confluent.
Following extensive washing with fresh medium (no serum), cells
were grown for 72 h to generate conditioned medium (CM). The
CM was removed and centrifuged at 1000 rpm for 5 min, filter-
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sterilised through a 0.22 μm low-protein binding filter and con-
centrated (to 10x of the starting volume of the CM) in a Vivaspin
concentrator (Vivaspin-20, cat Vs2012) with a 5 kDa cut-off and
the retentate was filter-sterilised.
Statistics
Statistics were carried out using the Student t-test assuming a
two-tailed distribution and two samples of unequal variance.
Values of p<0.05 were considered as statistically significant.
Results
Anoikis resistance in DLKP clones
The presence of ‘floaters’ (viable cells that are suspended in the
medium without the need for attachment to a surface) in sub-
confluent flasks of DLKP-SQ, suggest that either DLKP-SQ or a sub-
population of the clone could be resistant to anoikis. These floating
cells if placed in a fresh flask attach and grow in the same fashion
as DLKP-SQ. In contrast, DLKP-M and DLKP-I have very few
floaters, and most of the cells floating were dead. As a result of
these observations, the three clones were tested individually for
anoikis resistance (Fig. 1). Microscopically, DLKP-SQ in suspension
consists mostly of single cells, not forming clumps. DLKP-M and
DLKP-I had very few loose single cells and formed aggregates
which became more tightly clumped with time (Fig. 1F). When
cells were grown for prolonged periods in polyhema-coated flasks
(up to 10 passages), DLKP-SQ continued to grow with no lag-
phase, the percentage viability remained high and when seeded
in normal flasks, the cells attached and grew with the same mor-
phology as the original DLKP-SQ. DLKP-M and DLKP-I, on the
other hand, struggled and after three days showed only 42% and
56% viability respectively (data not shown).
Anoikis was measured by monitoring cell counts of attached
and suspended cells, cell growth and viability in suspension and
the Almar Blue assay (a measure of the metabolic activity of
cells). After 24 h in suspension, DLKP-SQ undergo only 7.5% cell
death as measured by viable cell counts and Almar Blue measure-
ments (Figs. 1A and B) and with no significant changes in cell via-
bility (Fig. 1E). At 48 h, although there is a slight reduction in
growth for suspension cells compared to attached cells and
Almar Blue measurement, there is no change in viability. While
Annexin V staining suggest some apoptosis is occurring (Fig. 2A),
DLKP-SQ is the only clone that continues to grow in suspension
(Fig. 1D). These results suggest that no significant adaptation is re-
quired to survive anoikis conditions and that the bulk DLKP-SQ
population rather than a sub-population is anoikis resistant.
The clones, DLKP-I and DLKP-M, showed 42–50% anoikis by
Almar Blue measurement and show similar morphology under
anoikis conditions but variations in viable cell counts suggest dif-
ferent mechanisms.
DLKP-I maintained in suspension show a continuous loss of via-
ble cell numbers and viability (Figs. 1A, D–E) over time which is
reflected in the metabolic state of the cells (Figs. 1B–C) and corre-
lates with increased apoptosis. Annexin V staining revealed DLKP-
I cells to be more susceptible to apoptosis under normal attached
conditions (at 13%, higher than DLKP-SQ or DLKP-M at 6% and 8%
respectively). In suspension, there was a significant (2.8-fold)
increase in apoptosis in DLKP-I, with 33% of the cells being apopto-
tic at 24 and 48 h (Fig. 2B). Procaspase-3 levels were reduced in
DLKP-I in suspension due to cleavage, indicating apoptosis
(Fig. 2C). In addition there is a loss of phosphorylated FAK and
phosphorylated Paxillin when DLKP-I are maintained in suspension
(Fig. 2C).
For DLKP-M, there was a lag phase between the loss of meta-
bolic activity and the reduction in viable cell number (Figs. 1A–
C). While there was a slight increase in annexin V staining
(Fig. 2B) this was not significant.
We analysed cell cycle progression to see if this could explain
the lag phase. For the clones, cell cycle analysis revealed some
changes between the clones under attached conditions, notably
for DLKP-I, there was a higher proportion of cells in the G2/M
phase than the other clones. However at 24 h, comparison of sus-
pension cells to attached cells for each of the clones showed no
significant differences, suggesting for this time point, cell cycle
analysis was not a determining factor in the lag phase for DLKP-
M (Fig. 2A). At 48 h, there was a more distinct increase in the pro-
portion of DLKP-M cells in G0/G1 arrest (Fig. 2A).
At 24 h, an increase in the ratio the LC3-II to LC3-I peptides of
the autophagymarker LC3 was observed (Fig. 2C). This in conjunc-
tion with the Almar Blue measurements and viable cell counts
suggests that DLKP-M may be undergoing autophagy under anoi-
kis conditions during the first 24 h.
Olfactomedin 3 in DLKP clones
Microarray analysis of the three clones of DLKP (Helena Joyce and
Padraig Doolan, unpublished results) shows that one of the most
highly differentially expressed mRNA among the clones was olfacto-
medin 3. The levels of OLFM3 in DLKP-I were 6% of those in DLKP-SQ
(p-value <0.002) and in DLKP-M were less than 1% of those in
DLKP-SQ (p-value<0.003)(Fig. 3A). Other members of the olfacto-
medin family (OLFM1, 2 and 4) were not differentially or highly
expressed in the three clones at the mRNA level from microarray
studies. Quantitative RT-PCR was carried out on the clones
(Fig. 3B) using GAPDH as the internal control (shown not to be dif-
ferentially expressed on the mRNA level in microarray results).
OLFM3 was shown to be highly expressed in the DLKP-SQ compared
to the two clones DLKP-M and DLKP-I. The levels of OLFM3 in DLKP-I
were 3.6% of those in DLKP-SQ (p-value 2x10E-13) and in DLKP-M,
were less than 1% of those in DLKP-SQ (p-value<2x10E-12).
Western blotting demonstrated high levels of OLFM3 protein
in the DLKP-SQ cells, with little or no expression in the other
two clones (Fig. 3C). Densitometry of Western blots for OLFM3
using alpha-tubulin as the loading control (shown not to be differ-
entially regulated at least at transcript level in the microarray
data) revealed DLKP-M and DLKP-I to express 1.3% and 1.2% of
the OLFM3 expressed in DLKP-SQ (p-values <0.005) (Fig. 3D).
OLFM3 is a secreted protein and may be present in the condi-
tioned media (CM). Western blotting showed expression of
OLFM3 in DLKP-SQ CM and none in DLKP-M or DLKP-I (Fig. 3E).
There was little or no alpha- tubulin in the CM, indicating a lack
of intracellular contaminants.
RNAi downregulation of Olfactomedin 3 in DLKP-SQ
Two validated siRNAs targeting OLFM3 were selected (OLFM3(1)
and OLFM3(2)) and DLKP-SQ in log phase of growth were
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Fig. 1 – Effect of anoikis conditions on cell growth, Almar blue measurements, viability and morphological differences in DLKP
clones (DLKP-SQ, DLKP-I and DLKP-M). (A) Anoikis measured as the percentage of cell death when grown in polyhema-coated wells
over a 24 hour period (n=4) compared to control cells in untreated wells. B and C show the results of Almar Blue measurements at
24-hour and 48-hour in polyhema-coated versus control plates respectively. * or ** indicates a p-value of <0.05 or <0.01 comparing
DLKP-SQ to either of the other two clones; ph indicates in polyhema-coated wells. D shows the Viable cell number of the cells in the
polyhema-coated plates while E shows the viability of those cells. (F) Morphological differences between DLKP clones viewed under
200× magnification at 24 h and 48 h.
596 E X P E R I M E N T A L C E L L R E S E A R C H 3 1 8 ( 2 0 1 2 ) 5 9 3 – 6 0 2
transfected with OLFM3 siRNA (kinesin siRNA (positive) or scram-
bled siRNA (negative) were used as controls). Microscopically,
transfection of kinesin siRNA was seen to reduce growth as would
be expected (by 90%, data not shown) indicating good siRNA trans-
fection conditions. Therewas nomorphological change in the DLKP-
SQ as visualised microscopically following OLFM3 siRNA transfec-
tion, suggesting that OLFM3was not a decisive factor in determining
the morphological differences between DLKP-SQ and the other
clones. At 72 h, cells counts (using trypan blue dye exclusion to
look at viable cell numbers) showed no significant change in the
total viable cell counts of siRNA-treated DLKP-SQ cells.
Knockdown of OLFM3 in DLKP-SQ had a significant impact on
anoikis resistance (Fig. 4A), resulting in a 2.8-fold increase in anoi-
kis compared to the scrambled control which was significant for
both siRNAs (p<0.01 and p<0.05 for OLFM3(1) and OLFM3(2) re-
spectively). Analysis of the protein levels of OLFM3 lysates in trans-
fected samples showed that levels of OLFM3were reduced by about
80% in the siRNA transfected cells (Figs. 4B and D). The level of
anoikis in DLKP-SQ transfected cells was not as high as that seen
with DLKP-M or DLKP-I suggesting that other factors may be having
an impact on anoikis resistance, or that the remaining levels of
OLFM3 are sufficient to maintain some level of anoikis resistance.
Loss of OLFM3 correlates with increased annexin V staining
(Fig. 4D) suggesting anoikis may be occurring by apoptosis.
There was no significant change in cell cycle profiles on loss of
OLFM3 following siRNA transfection (data not shown).
Effect of recombinant OLFM3 on Anoikis sensitive clones
As OLFM3 appears to have a protective role against anoikis in
DLKP-SQ, recombinant OLFM3 was tested on DLKP-I and DLKP-M
anoikis sensitive cell lines. Recombinant OLFM3 at 1 ng/ml re-
duced anoikis in DLKP-I significantly (p<0.001) by 1.9-fold but
not in DLKP-M, supporting a protective role for OLFM3 in apopto-
sis (Fig. 5). It is interesting to note that DLKP-I is the intermediate
clonal type in the interconversion of the DLKP clones. It appears to
Fig. 2 – Effect of growth under anoikis conditions on cell cycle and apoptosis. (A) Cell cycle analysis on DLKP clones comparing
attached versus suspension cells at 24 h and 48 h. (B) Apoptosis in DLKP clones as measured by Annexin-V staining in attached
versus suspension cells at 24 h. * indicates a p-value of <0.05 DLKP-I in suspension to DLKP-I attached. For all experiments, results
are the average of at least 3 separate repeats. (C) Western blotting of selected proteins in DLKP clones either attached (att) or in
suspension (sus).
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retain OLFM3 sensitivity without producing it, while DLKP-M not
only does not produce OLFM3 but has lost sensitivity to it.
Expression of OLFM3 in other anoikis resistant cell lines
We looked at expression of OLFM3 in number of cancer cell lines
with different anoikis resistance levels (Fig. 6). In the nasal carci-
noma, the anoikis-sensitive parent RPMI-2650 expressed little or
no OLFM3 but the taxol-resistant variant which was anoikis-
resistant expressed OLFM3. In breast cell lines, anoikis-resistant
SKBR-3 express OLFM3 while anoikis-sensitive MCF-7 does not.
These results together with the results for SQ-CM and recombi-
nant OLFM3 suggest that OLFM3 expression may have a role in
anoikis resistance.
Discussion
In this work, the presence and possible role in anoikis of Olfacto-
medin 3 was investigated in clones of a poorly differentiated
squamous lung carcinoma cell line. Affymetrix expression micro-
array studies in our laboratory showing OLFM3 to be one of the
most highly differentially expressed mRNAs between the DLKP
clones DLKP-SQ (high) and DLKP-M and DLKP-I (both low) were
confirmed by qRT-PCR. Western blotting confirmed the presence
of OLFM3 at the protein level in DLKP-SQ while the two other
clones had little or no expression of OLFM3.
SiRNA knockdown of OLFM3 showed no effect on total viable
cell growth or in morphology in the siRNA-transfected DLKP-SQ
compared to the parental DLKP-SQ. Knockdown of OLFM3
resulted in increased anoikis (which is a form of cell death result-
ing from a disruption in the ECM signals). Knockdown of OLFM3
did not alter cell cycle but showed increased apoptosis as mea-
sured by annexin V expression (Fig. 4D). While the knockdown
of OLFM3 was significant as detected by Western blotting
(Fig. 4), the level of anoikis in the siRNA-transfected cells was
still less than that observed in the DLKP-M or DLKP-I cells, sug-
gesting that reduction in OLFM3 levels was not sufficiently com-
plete for the time period or that other factors are involved in
anoikis resistance in DLKP-SQ compared to DLKP-M and DLKP-I.
Fig. 3 – Expression of OLFM3. (A) Normalised signal intensity for OLFM species from microarrays. Standard t-test with p-value
<0.003 compared to DLKP-SQ for DLKP-I or DLKP-M. OLFMl1 refers to OLFM-like 1. (B) Relative quantitation of OLFM3 compared to
DLKP-SQ and normalised to GAPDH by qRT-PCR. Results are the average and standard deviation for three biological repeats.
Standard t-test with p-value <2x10E-12 compared to DLKP-SQ for DLKP-I or DLKP-M. (C) Protein expression of OLFM3 and alpha
tubulin as loading control in DLKP clones with (D) densitometry normalised to alpha tubulin. Results are the average and standard
deviation for four biological repeats. ** represents Student t-test with p-value <0.002 for DLKP-SQ compared to DLKP-M and
DLKP-I. (E) Western blot of OLFM3 in conditioned medium from DLKP clones. Image shows average blots from three biological
repeats. A typical Western blot for OLFM3 in DLKP-SQ (labelled DLKP-SQ con) and control alpha tubulin is shown.
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When recombinant OLFM3 was added to DLKP-I cells in suspen-
sion, anoikis was significantly reduced (Fig. 5). This is the first
time, to our knowledge, that OLFM3 has been linked with anoikis
resistance.
Olfactomedin 3 belongs to a family of glycoproteins containing
a conserved C terminal olfactomedin domain, with four main
groups OLFM1 to OLFM4 and at least 13 isoforms in mammals
[15,16]. Identified first in the olfactory neuroepithelium of the
bull frog in the 1990s [17], olfactomedins have been found in di-
verse species ranging from C. elegans to humans. The fact that
the olfactomedins have been identified only in multicellular or-
ganisms suggests that they play a role in cell–cell interaction and
signalling. Olfactomedins are involved in normal development
and are associated with several diseases including open-angle
glaucoma and cancer [18–22]. OLFM1 and 3 are expressed mainly
in the brain, OLFM2 in the pancreas and prostate, and OLFM4 in
the bone marrow, small intestine, colon and prostate [15]. Al-
though originally identified in neural tissue, OLFM3 expression
has been reported in the lung and spinal cord [23–25] and com-
mercially available OLFM3 antibodies have been shown to stain
lung cancer tissue. Lung cancers have also been observed to ex-
press OLFM1 and OLFM4 [19,22]. In this study, we also observed
OLFM3 expression in lung as well as breast and nasal cancer cell
lines that were anoikis resistant. None of the other olfactomedin
proteins were differentially regulated at the mRNA level and sub-
sequently were not investigated.
OLFM3, first identified in rat eye tissue and named optimedin
[24] is a very conserved protein. OLFM3 forms homodimers (N-
terminal important) and heterodimers (C-terminal important)
with other olfactomedin domain containing proteins. OLFM3 is
often localised to the Golgi and is a secreted protein. In mouse
lens, the Pax6 transcription factor directly targets OLFM3 expres-
sion [25]. However, while Pax6 was detected in our microarray
studies, the mRNA levels were slightly lower in DLKP-SQ than in
DLKP-I or DLKP-M.
Olfactomedin 3 is known to interact with myocilin, a protein
with cytoskeletal function and is associated with hereditary
juvenile-onset open-angle glaucoma [26]. Microarray analysis
showed very low levels of myocilin mRNA to be expressed in the
clones and no difference was seen in the expression levels.
Fig. 4 – Effect of siRNA knockdown on anoikis in DLKP-SQ cells. After siRNA transfection and growth for 72 h, cells were trypsinised
and set up under anoikis conditions, allowed to grow for a further 24 h and then counted. Samples were taken for Western blotting
at 72 h. (A) Effect of siRNA knock-down on anoikis in DLKP-SQ asmeasured using Almar blue assay. (B)Western blotting for OLFM3
expression of siRNA-transfected DLKP-SQ and (C) Densitometry of Western blot. (D) Apoptosis assay as measured by Annexin V
staining. Results are the average of at least 3 separate experiments. ** denotes Student t-test with a p-value of <0.005 compared to
the scrambled control.
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From the literature, it has been previously found that OLFM3
increased growth rate [27], and modulated cytoskeletal organisa-
tion, cell adhesion and migration [15]. Expression of OLFM3 in
PC cells increased expression of N-cadherin, alpha-catenin and
beta-catenin [27]. When Lee and Tomerav [27] knocked down ex-
pression of N-cadherin in OptH cells, the decreased levels of N-
cadherin led to beta-catenin destabilisation, reduced formation
of aggregates and increased the number of single cells in culture.
Interestingly, for DLKP-SQ which express OLFM3 but not N-
cadherin (unpublished), the cells readily grow as single cells in
suspension.
While the functions of OLFM3 are mostly unknown, several of
the other olfactomedin proteins show similarities to the effects
seen with DLKP-SQ. Both OLFM1 and OLFM4 have been implicated
in apoptosis. Mutations in OLFM1 [28] and silencing of OLFM1
resulted in increased apoptosis [29]. OLFM4 may have differing
roles depending on the tissue, being antiapoptotic in gastric can-
cers [30] and growth promoting in pancreas and lung cancer
cells [31,21]. Recently, OLFM4 in prostate cancer, suppressed
growth and metastasis and exerted a negative impact on autop-
hagy through interactions with Cathepsin D and stromal-derived
factor 1 [31].
The mechanism by which OLFM3 may regulate anoikis in
DLKP-SQ is currently being investigated. Anoikis, meaning ‘home-
lessness’ in Greek, describes the induction of programmed cell
death due to inappropriate expression of or loss of cell surface at-
tachment to the extracellular matrix, and as such, provides a
mechanism for preventing dissemination of cancer cells. There
are two major cell death pathways involved in anoikis, apoptosis
and autophagy [32]. Apoptosis from the literature appears as the
main mechanism of anoikis with autophagy becoming important
where apoptosis is blocked as a means of cell death. In autophagy,
macromolecules and organelles especially mitochondria are
targeted for degradation by lysozymal proteins to recycle
nutrients within the cell. As such, autophagy may be a self-
conservation response in times of stress. If the stress is excessive,
autophagy can lead to cell death and there is extensive cross-talk
between the two processes [32].
Mechanisms of anoikis resistance include augmentation of
anti-apoptotic signals (such as Bcl-2 or Bcl-Xl [33]) or dampening
of extracellular signals. Reducing extracellular signals occur at sev-
eral levels, through cell surface receptors (such as integrins, cad-
herins and IGF-IR [34–37]), through the signalling cascades
emanating from those receptors (such as the PI3K/Akt and ERK
signalling pathways) and through the signalling molecules con-
necting receptors to pathways (such as Src family kinases and
FAK [38]). EMT has been linked to suppression of anoikis via de-
pletion of E-cadherin and expression N-cadherin to protect cells
against anoikis [39,40].
It is possible that the activity of OLFM3 in reducing anoikis in
DLKP-SQ is related to intracellular interaction with apoptotic ma-
chinery within the cell. For example, OLFM4 was found to interact
with and inhibit the apoptosis promoting factor GRIM-19 [41]. Al-
ternatively, secreted OLFM3 may interact with cell surface recep-
tors or secreted proteins to prevent anoikis signalling. Secreted
OLFM1 interacts with the Wnt signalling system through WIF-1
to regulate apoptosis through a variety of mechanisms [42].
In the clones, phosphorylated FAK is low in DLKP-SQ and
DLKP-M suggesting reduced sensitivity to extracellular anoikis
signals (Fig. 2C). In DLKP-I, the high levels of phosphorylated
FAK in attached cells, are lost when the cells are maintained in
suspension together with a loss of phosphorylated Paxillin
(Fig. 2C), suggesting that integrin signalling through FAK is active
and a source of anoikis signalling in DLKP-I.
There are several interacting proteins that have been previous-
ly identified to bind to OLFM3 including N-cadherin, Pax and Myoc
[27,23,24]. Interestingly, N-cadherin is the only one of the above
connectors that is significantly differentially regulated at the
Fig. 5 – Effect of recombinant OLFM3 on DLKP-I and DLKP-M.
Results are the average of at least 3 separate experiments.
** denotes Student t-test with a p-value of <0.001 compared to
DLKP-I.
Fig. 6 – Correlation of expression of OLFM3 in anoikis resistant
and anoikis sensitive pairs. Results for anoikis are the average
of at least 3 separate experiments. Western blots shown are
representative of three separate repeats with alpha tubulin
being used as the loading control.
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mRNA level in the DLKP-clones, being up in DLKP-I and low or ab-
sent in DLKP-M and DLKP-SQ respectively (also in protein levels as
determined by Western blotting (data not shown)).
Given that recombinant OLFM3 was able to reduce anoikis in
DLKP-I but not back to the levels of DLKP-SQ and that loss of
OLFM3 did not increase anoikis in DLKP-SQ to levels seen in the
anoikis sensitive clones, suggests that other factors are involved
in anoikis resistance in addition to OLFM3. Further, that FAK is
not significantly affected by DLKP-SQ between attached and sus-
pended cells supports more than one mechanism of anoikis resis-
tance. This is not surprising as changes in apoptosis and/or
autophagy may result in anoikis resistance. For apoptosis, many
sets of molecules interact at the cell surface, inducing different
downstream signalling cascades that lead to intracellular machin-
ery controlling apoptosis [43]. In addition, the signalling mole-
cules connecting the cytoskeleton and cytoplasm to the
extracellular matrix can exhibit extensive cross-talk between the
different signalling pathways [44].
Whether the expression of OLFM3 is a common mechanism is
uncertain. Limited analysis has shown some correlation in breast
cell lines with expression detected in the anoikis resistant SKBR3
but not in the anoikis sensitive MCF-7. Similarly OLFM3 was shown
to be expressed in the anoikis resistant nasal cell line RPMI-2650-
Txl variant while not in the anoikis sensitive parent, RPMI-2650.
Recently, both OLFM1 and OLFM4 expression have been linked
to early stage lung cancer, while OLFM4 expression has also been
implicated in early stages of gastric, colon and breast cancer
[19–21]. It may be that expression of OLFM3 in DLKP-SQ reflects
an early stage cancer.
In conclusion, this paper shows that expression of OLFM3 con-
tributes to the increased anoikis resistance of DLKP-SQ and reduces
anoikis in DLKP-I by reducing apoptosis. These results suggest that
OLFM3 expression may have a role in anoikis resistance.
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